{"meta":{"query_hash":"60e1f68fa11d","filters":{"venue":"Lung Cancer"},"cohort_total":361,"direct_labels_cover":0,"predictions_cover":361,"exported":361,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/60e1f68fa11d","api":"https://metacan.xera.ac/api/v1/cohort?venue=Lung+Cancer"},"results":[{"id":"W1499085340","doi":"10.1002/9781118468791.ch12","title":"Staging of the Mediastinum","year":2014,"lang":"en","type":"other","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Mediastinoscopy; Mediastinum; Medicine; Lung cancer staging; Radiology; Lung cancer; Stage (stratigraphy); Mediastinal lymph node; Lymph node; Modalities; Cancer; Pathology; Metastasis; Internal medicine","score_opus":0.00740995929479451,"score_gpt":0.29900963663890606,"score_spread":0.2915996773441116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1499085340","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00071481225,0.027345328,0.00003458226,0.0034395517,0.0031945892,0.0010840372,0.0001656432,0.00011420203,0.96390724],"genre_scores_gemma":[0.039058276,0.0025113467,0.00012512687,0.0011990628,0.0018883982,0.00027466714,0.000018428149,0.00043108463,0.9544936],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99918616,0.000019397536,0.00014391814,0.00021283976,0.00027775258,0.00015994192],"domain_scores_gemma":[0.9992192,0.000026838146,0.00020029974,0.00046720027,0.000028828772,0.00005767443],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000042903717,0.00016956056,0.00037510687,0.000056302368,0.000016719174,0.0000039697684,0.00010628064,0.000116911055,0.0051569594],"category_scores_gemma":[0.000013718271,0.000096724325,0.00014185224,0.00009670059,0.00006376833,0.0000052937066,0.00004382986,0.0001305895,0.000016391126],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011104805,0.000038614937,0.07779323,0.00084011327,0.00040809246,0.0000028763961,0.00007239615,0.0000021481403,0.000011330151,0.00009718434,0.91763234,0.0030905926],"study_design_scores_gemma":[0.0009991077,0.00003438624,0.016548231,0.0051994678,0.000952516,0.00000195014,0.000007762564,0.00003252109,0.0005685691,0.000007522922,0.9755203,0.00012765494],"about_ca_topic_score_codex":0.0012273525,"about_ca_topic_score_gemma":0.0005498708,"teacher_disagreement_score":0.061245,"about_ca_system_score_codex":0.00023803244,"about_ca_system_score_gemma":0.00020389324,"threshold_uncertainty_score":0.99575245},"labels":[],"label_agreement":null},{"id":"W1500680442","doi":"10.1002/9781118468791.ch7","title":"Detection and Treatment of Preneoplastic Lesions","year":2014,"lang":"en","type":"other","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Lung cancer; Medicine; Radiology; Natural history; Lung; Biopsy; Cancer; Disease; Pathology; Internal medicine","score_opus":0.010573428309209548,"score_gpt":0.29656285781861874,"score_spread":0.2859894295094092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1500680442","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.046532415,0.27218002,0.0008375235,0.0014522868,0.0047982587,0.006588424,0.0007451244,0.0006435721,0.6662224],"genre_scores_gemma":[0.3643266,0.04430132,0.00020438655,0.00009001493,0.0012638762,0.00096801337,0.00004329807,0.00040869933,0.5883938],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99940705,0.000012139408,0.000116974894,0.00024039416,0.000108546505,0.000114876726],"domain_scores_gemma":[0.99954724,0.000031304513,0.000112800284,0.0002113151,0.000017754186,0.000079587],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000010694866,0.00018079065,0.00039989618,0.000104650004,0.000018021325,0.000004004522,0.00001670094,0.00013459756,0.0010781443],"category_scores_gemma":[0.0000040560367,0.0001273688,0.000073814444,0.00005083508,0.000037214428,0.0000058583173,0.000007924189,0.00003374656,0.000008322562],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040969846,0.0013004865,0.13390453,0.0041511757,0.00510954,0.0000452162,0.0004739716,0.000023548313,0.00060661376,0.00014497901,0.3623251,0.49150515],"study_design_scores_gemma":[0.0040036924,0.001434111,0.027553301,0.0030773159,0.0035003521,0.000015693478,0.000008127965,0.00022010932,0.0023730756,0.0000064489727,0.9575652,0.00024260579],"about_ca_topic_score_codex":0.0021308374,"about_ca_topic_score_gemma":0.0034299258,"teacher_disagreement_score":0.59524006,"about_ca_system_score_codex":0.00034897428,"about_ca_system_score_gemma":0.000083580075,"threshold_uncertainty_score":0.999835},"labels":[],"label_agreement":null},{"id":"W1529488333","doi":"10.1016/j.lungcan.2013.11.006","title":"Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer","year":2013,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Cetuximab; Medicine; Internal medicine; Oncology; Lung cancer; Hazard ratio; Chemotherapy; Odds ratio; Meta-analysis; Randomized controlled trial; Proportional hazards model; Confidence interval; Cancer; Colorectal cancer","score_opus":0.10246975773111995,"score_gpt":0.409869584780272,"score_spread":0.3073998270491521,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1529488333","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83837557,0.10589757,0.005433723,0.0030249343,0.00063004467,0.017817792,0.028104201,0.000055779205,0.00066041143],"genre_scores_gemma":[0.95995474,0.008043635,0.00903852,0.00090777,0.0002455622,0.0138132,0.0051886323,0.00009714288,0.002710782],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9968321,0.00015461931,0.001523452,0.00069643214,0.00046112176,0.00033227788],"domain_scores_gemma":[0.9955372,0.0014210027,0.0013515601,0.0011013456,0.00042676815,0.00016212465],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004827449,0.00042505295,0.0050933314,0.00026233672,0.00007551917,0.000026952186,0.00028917688,0.00012815771,0.005637684],"category_scores_gemma":[0.00012993759,0.00026482457,0.0019338372,0.00044065213,0.00008143257,0.00015773087,0.00006661679,0.00007470619,0.0000022567017],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030712496,0.001704845,0.0025495936,0.00047733923,0.92188865,0.000003817667,0.008188181,0.011166924,0.0018221275,0.000016567494,0.0059268405,0.015542592],"study_design_scores_gemma":[0.20834629,0.00044962112,0.0005645051,0.00008876685,0.7470544,2.3073554e-7,0.00022138035,0.021663094,0.019763075,0.000044279634,0.0015352682,0.00026908188],"about_ca_topic_score_codex":0.034257535,"about_ca_topic_score_gemma":0.003344045,"teacher_disagreement_score":0.17763379,"about_ca_system_score_codex":0.00056790083,"about_ca_system_score_gemma":0.0008248953,"threshold_uncertainty_score":0.9999804},"labels":[],"label_agreement":null},{"id":"W1550684373","doi":"10.1016/j.lungcan.2015.04.007","title":"The incidence and clinical impact of bone metastases in non-small cell lung cancer","year":2015,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Bone health and treatments","field":"Medicine","cited_by":117,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"","keywords":"Medicine; Lung cancer; Spinal cord compression; Internal medicine; Incidence (geometry); Bone metastasis; Oncology; Retrospective cohort study; Cohort; Radiation therapy; Surgery; Cancer; Metastasis; Spinal cord","score_opus":0.03881720652294452,"score_gpt":0.42509689147911367,"score_spread":0.38627968495616916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1550684373","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95356464,0.044679202,0.0000066297034,0.00057997165,0.0002367095,0.0005013526,0.00003981922,0.000008196563,0.00038348456],"genre_scores_gemma":[0.9927977,0.0060115713,0.00013618798,0.0002657339,0.00008192895,0.00009192425,0.000004147858,0.000013892195,0.00059692096],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989225,0.000063068146,0.0003773337,0.00019321985,0.00016738726,0.00027646564],"domain_scores_gemma":[0.9990744,0.00016865975,0.0001465775,0.00021664193,0.000097784374,0.0002959456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044437026,0.000118802236,0.0003669175,0.000041914467,0.00003706892,0.000007729998,0.000046876354,0.00006727737,0.00003183042],"category_scores_gemma":[0.0000858784,0.00006949429,0.00007874443,0.00014888558,0.000083037725,0.000048343332,0.000038112208,0.00018873866,0.0000017614386],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046788002,0.00010378682,0.9884228,0.00012829648,0.000104835155,0.00003399035,0.00024989975,0.0000210568,0.000029832709,0.000003038128,0.0045392136,0.0058953688],"study_design_scores_gemma":[0.004129228,0.00033300632,0.9919873,0.000315728,0.0003271011,0.000008604677,0.00005534163,0.0020262883,0.00018299479,0.000014035696,0.00053889875,0.00008145644],"about_ca_topic_score_codex":0.038022924,"about_ca_topic_score_gemma":0.0118997255,"teacher_disagreement_score":0.03923306,"about_ca_system_score_codex":0.00031572467,"about_ca_system_score_gemma":0.0010692369,"threshold_uncertainty_score":0.96838295},"labels":[],"label_agreement":null},{"id":"W1679349094","doi":"10.1016/j.lungcan.2015.07.001","title":"Low muscle mass is associated with chemotherapy-induced haematological toxicity in advanced non-small cell lung cancer","year":2015,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Gemcitabine; Vinorelbine; Toxicity; Common Terminology Criteria for Adverse Events; Chemotherapy; Lung cancer; Internal medicine; Lean body mass; Chemotherapy regimen; Regimen; Oncology; Gastroenterology; Surgery; Urology; Cisplatin","score_opus":0.03323948792599945,"score_gpt":0.3422419903377314,"score_spread":0.30900250241173194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1679349094","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98785937,0.0014512704,0.00019968729,0.006603482,0.00033955427,0.00096327276,0.000023619365,0.000106576445,0.0024531777],"genre_scores_gemma":[0.9862883,0.0003917825,0.0008534432,0.010785556,0.00017020866,0.0003490596,0.000013055749,0.000046582212,0.0011020084],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99829537,0.000053963846,0.0003379302,0.0004230076,0.00033840784,0.00055134506],"domain_scores_gemma":[0.99899405,0.000046767425,0.00016810368,0.00024064897,0.00021060483,0.00033985006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024770235,0.00023096791,0.0005705897,0.0001027427,0.00006582514,0.000017748025,0.00010972429,0.000210536,0.0004698709],"category_scores_gemma":[0.0000322355,0.0001885817,0.000060015038,0.00042149768,0.000037677244,0.000083830986,0.000020574831,0.00045832107,0.0000060448147],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012599786,0.0008893703,0.92862004,0.001633738,0.00014252207,0.0003121938,0.0046028174,0.00021759806,0.039335243,0.000023972665,0.01884185,0.0041206777],"study_design_scores_gemma":[0.06823885,0.0011868807,0.58353907,0.012261944,0.00043326136,0.00003551977,0.0017711563,0.05172512,0.26982665,0.00018914341,0.008826326,0.0019661023],"about_ca_topic_score_codex":0.00059032644,"about_ca_topic_score_gemma":0.001065804,"teacher_disagreement_score":0.345081,"about_ca_system_score_codex":0.0011393367,"about_ca_system_score_gemma":0.0006394754,"threshold_uncertainty_score":0.7690139},"labels":[],"label_agreement":null},{"id":"W177387553","doi":"10.1016/j.lungcan.2012.10.017","title":"18F-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography fused imaging in malignant mesothelioma patients","year":2012,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Hôpital Notre-Dame","funders":"","keywords":"Medicine; Mesothelioma; Positron emission tomography; Radiology; Peritoneal mesothelioma; Extrapleural Pneumonectomy; Pleural disease; PET-CT; Positron emission; Thoracoscopy; Nuclear medicine; Lung cancer; Pneumonectomy; Respiratory disease; Pathology; Lung; Internal medicine","score_opus":0.005173032213293872,"score_gpt":0.25715114180126025,"score_spread":0.2519781095879664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W177387553","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856382,0.012401798,0.000021424083,0.00025035732,0.00041699788,0.00048749722,0.00006582876,0.000076150885,0.00064176833],"genre_scores_gemma":[0.997965,0.00015320526,0.00034386246,0.0008304035,0.00024602222,0.00008810428,0.0001979386,0.0000388491,0.00013665674],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984361,0.000047842976,0.0002905254,0.00030846152,0.0004286912,0.0004883948],"domain_scores_gemma":[0.9992824,0.000027412354,0.00009091656,0.00023231759,0.000033852863,0.00033307614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008957372,0.00023712216,0.00024559812,0.00030511266,0.00008200478,0.000016740645,0.000094741146,0.000053558124,0.00037138682],"category_scores_gemma":[0.000008558724,0.00019661746,0.00017521206,0.0004451131,0.000060688693,0.00024390014,0.00006599402,0.00012592238,0.000017161921],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037761626,0.0008022682,0.9768556,0.00009739403,0.000053729276,0.000015768925,0.00014898204,0.0000078166295,0.011607062,0.000018224542,0.0020645075,0.007951051],"study_design_scores_gemma":[0.0019613358,0.00006461378,0.98641866,0.0004367062,0.00014134622,0.00000606853,0.000025292866,0.00034696813,0.008657586,0.00002127147,0.0016828339,0.0002373089],"about_ca_topic_score_codex":0.0002602836,"about_ca_topic_score_gemma":0.000009496385,"teacher_disagreement_score":0.012326781,"about_ca_system_score_codex":0.00023132785,"about_ca_system_score_gemma":0.00003426605,"threshold_uncertainty_score":0.8017827},"labels":[],"label_agreement":null},{"id":"W1881422607","doi":"10.1016/j.lungcan.2015.06.009","title":"IL1B gene polymorphisms, age and the risk of non-small cell lung cancer in a Chinese population","year":2015,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Immune Response and Inflammation","field":"Immunology and Microbiology","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Ministry of Science and Technology; Ministry of Health, British Columbia; Fudan University; Research and Development; National Natural Science Foundation of China; National Science Foundation","keywords":"Medicine; Lung cancer; Oncology; Chinese population; Internal medicine; Gene; Genetics; Genotype; Biology","score_opus":0.006080338920320681,"score_gpt":0.25174813654559786,"score_spread":0.24566779762527718,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1881422607","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9493431,0.049136665,0.00007023338,0.00023492718,0.00051790616,0.0003530442,0.000026036088,0.000011435149,0.00030666945],"genre_scores_gemma":[0.99583995,0.0023124104,0.000025965652,0.000066370216,0.000055508335,0.00009659468,0.000036747053,0.000011935385,0.0015545083],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99913436,0.00024546648,0.00026245663,0.00014849145,0.000032550342,0.00017668476],"domain_scores_gemma":[0.99949163,0.000074365555,0.00019303702,0.00018289701,0.000044930846,0.000013109093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038871088,0.000121107885,0.00024283623,0.0000848058,0.00006310094,0.000008000516,0.000102621445,0.00013569315,0.000093380695],"category_scores_gemma":[0.000041587784,0.000079394544,0.0000467103,0.00014080296,0.00008941707,0.000079155354,0.00005013958,0.00017860137,0.0000047060953],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021361692,0.000042729942,0.77352166,0.00007241694,0.00020689683,0.0000056861704,0.00803696,0.0011849041,0.20793612,0.00008795205,0.0012121436,0.0055563482],"study_design_scores_gemma":[0.0066646007,0.000036900932,0.9548421,0.000097265394,0.00017546842,0.0000059924328,0.00010170582,0.0023862352,0.0345663,0.000105151405,0.00082828925,0.00019001482],"about_ca_topic_score_codex":0.02353351,"about_ca_topic_score_gemma":0.0023774947,"teacher_disagreement_score":0.18132041,"about_ca_system_score_codex":0.00009362575,"about_ca_system_score_gemma":0.00009034623,"threshold_uncertainty_score":0.98296887},"labels":[],"label_agreement":null},{"id":"W1920342986","doi":"10.1016/j.lungcan.2015.07.004","title":"Temporal trends in the incidence and relative survival of non-small cell lung cancer in Canada: A population-based study","year":2015,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Incidence (geometry); Lung cancer; Relative survival; Population; Cancer; Demography; Oncology; Internal medicine; Cancer registry; Environmental health","score_opus":0.021763515646647368,"score_gpt":0.34458078962022687,"score_spread":0.3228172739735795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1920342986","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994846,0.0022886212,0.000021664993,0.00088652916,0.00021232535,0.00075155863,0.00006797088,0.000005393136,0.0009199574],"genre_scores_gemma":[0.99894714,0.000016309199,0.00006266425,0.00017967462,0.000047778507,0.00032837124,0.000029264414,0.000014241417,0.0003745663],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988824,0.00008983526,0.00028813013,0.00023247354,0.0003198255,0.00018731676],"domain_scores_gemma":[0.99942666,0.00009012679,0.00012548675,0.00018641938,0.0000895031,0.000081810314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020531371,0.00013878426,0.00029547297,0.00014124908,0.000033190787,0.000007935963,0.0000759553,0.00003623533,0.000048560658],"category_scores_gemma":[0.000017672803,0.0000976264,0.000024691268,0.00052166975,0.000017982595,0.000077827295,0.000017028351,0.00015836488,9.97312e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010588061,0.0001401984,0.9896511,0.00005448969,0.000059503054,0.000042825835,0.006299097,0.0024411804,0.0000072169446,0.0000084297135,0.0003407328,0.0008493564],"study_design_scores_gemma":[0.0038285458,0.00010609449,0.98624533,0.00017839117,0.0002624769,6.040879e-7,0.002646291,0.0065735015,0.000017106848,0.000006279315,0.00003632029,0.000099071316],"about_ca_topic_score_codex":0.9772679,"about_ca_topic_score_gemma":0.9930572,"teacher_disagreement_score":0.015789263,"about_ca_system_score_codex":0.001960125,"about_ca_system_score_gemma":0.0029055865,"threshold_uncertainty_score":0.51543856},"labels":[],"label_agreement":null},{"id":"W1934286911","doi":"10.1016/j.lungcan.2015.09.004","title":"Analysis of serum protein levels of angiogenic factors and their soluble receptors as markers of response to cediranib in the NCIC CTG BR.24 clinical trial","year":2015,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; Princess Margaret Cancer Centre; Queen's University; Ottawa Hospital","funders":"Canadian Cancer Society Research Institute; Cancer Care Ontario; Cancer Research Institute","keywords":"Medicine; Internal medicine; Biomarker; Oncology; Proportional hazards model; Vascular endothelial growth factor; Gastroenterology; VEGF receptors","score_opus":0.07367530118651305,"score_gpt":0.4186572175267875,"score_spread":0.3449819163402744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1934286911","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961835,0.0008329162,0.00001652964,0.00085125066,0.00031478403,0.001361968,0.00020468565,0.0000068368727,0.00022752228],"genre_scores_gemma":[0.9988763,0.000025722404,0.00010048194,0.00010297255,0.000048813603,0.00008991053,0.000010011295,0.000013105953,0.0007327202],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984815,0.00029321233,0.00056420837,0.00022314164,0.0002754853,0.00016242352],"domain_scores_gemma":[0.99887997,0.00030296887,0.00022800906,0.00031872932,0.00015146,0.00011886006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011115205,0.00013293597,0.00060174783,0.00027972335,0.000019859302,0.0000050176395,0.00010635892,0.000089585024,0.00017020444],"category_scores_gemma":[0.00040040212,0.00007784594,0.00024773757,0.00094047573,0.000096784875,0.00004794696,0.000029731778,0.00009395897,4.835846e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10364232,0.0006980331,0.8537857,0.00016127792,0.0072560385,0.000007449038,0.020966418,0.00020756798,0.004490941,0.000040051633,0.0025157772,0.0062284227],"study_design_scores_gemma":[0.03570247,0.004365156,0.9359218,0.00036346997,0.005212455,0.0000017812863,0.0066196523,0.0002488188,0.008633332,0.000052104122,0.0026610654,0.0002179065],"about_ca_topic_score_codex":0.001859849,"about_ca_topic_score_gemma":0.0008524902,"teacher_disagreement_score":0.08213609,"about_ca_system_score_codex":0.00015478628,"about_ca_system_score_gemma":0.00066266616,"threshold_uncertainty_score":0.31744656},"labels":[],"label_agreement":null},{"id":"W1944068990","doi":"10.1016/j.lungcan.2014.07.013","title":"Interval lung cancers not detected on screening chest X-rays: How are they different?","year":2014,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brock University","funders":"National Cancer Institute","keywords":"Medicine; Lung cancer; Cancer; National Lung Screening Trial; Stage (stratigraphy); Lung; Internal medicine; Oncology; Radiology; Lung cancer screening","score_opus":0.019618729451306795,"score_gpt":0.291492737576781,"score_spread":0.27187400812547424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1944068990","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9817275,0.0016748466,0.0006351494,0.0116622215,0.0012552293,0.0009211266,0.00008186967,0.00025644063,0.0017856493],"genre_scores_gemma":[0.99392253,0.00045937524,0.00015865391,0.0023451962,0.0010326782,0.0005734681,0.00003186575,0.00008177919,0.0013944813],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99810153,0.000071187234,0.00023345159,0.00060574414,0.00046719692,0.00052087073],"domain_scores_gemma":[0.9987305,0.00013978242,0.00019482497,0.00054939266,0.00011310362,0.00027243968],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00010070754,0.00039281553,0.0005716905,0.00011818691,0.00014566026,0.00007443069,0.00016469014,0.00013489912,0.00027794257],"category_scores_gemma":[0.000069245514,0.00028737527,0.00022492142,0.00013086955,0.000055318742,0.00008752039,0.000059118076,0.00033307596,0.000011762799],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012030147,0.00032308028,0.9251162,0.00088731933,0.0015082709,0.00006310775,0.0010171378,0.00047306775,0.0014265025,0.00020652445,0.022311725,0.04546405],"study_design_scores_gemma":[0.0056386907,0.0006227226,0.95319855,0.0039607347,0.0010306628,0.00000832458,0.00017080817,0.01058926,0.013147488,0.0000119894075,0.011109068,0.00051167596],"about_ca_topic_score_codex":0.001485623,"about_ca_topic_score_gemma":0.0034486996,"teacher_disagreement_score":0.044952374,"about_ca_system_score_codex":0.0019214214,"about_ca_system_score_gemma":0.000104199695,"threshold_uncertainty_score":0.99995786},"labels":[],"label_agreement":null},{"id":"W1964109435","doi":"10.1016/j.lungcan.2008.06.017","title":"Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer","year":2008,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cégep de Lévis; Jewish General Hospital","funders":"","keywords":"Medicine; Oncology; Internal medicine; Phase (matter); Lung cancer","score_opus":0.05241453114756632,"score_gpt":0.41515913076825106,"score_spread":0.3627445996206847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1964109435","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9537352,0.0372139,0.000054788903,0.0016290533,0.0005189994,0.004508893,0.00029914046,0.000087128996,0.0019529496],"genre_scores_gemma":[0.9586671,0.006373022,0.00016895647,0.0009095723,0.00088194193,0.0030658694,0.000023972936,0.00009649511,0.029813044],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974651,0.000063065614,0.0005445996,0.000627747,0.00060895295,0.0006905656],"domain_scores_gemma":[0.99822813,0.00016253797,0.00022224561,0.0005738962,0.0005730034,0.00024016213],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00025593967,0.00036023944,0.0008291137,0.00018653102,0.0003639745,0.000011583382,0.00025539423,0.00010289132,0.0015527942],"category_scores_gemma":[0.00006166672,0.0002932863,0.0002017655,0.00038270548,0.00016517047,0.00010506746,0.00012981771,0.00033775406,0.000003029482],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027405024,0.0261126,0.2835897,0.006710022,0.008038104,0.0004390685,0.063553505,0.00041313746,0.097286426,0.00008519739,0.45539126,0.030975966],"study_design_scores_gemma":[0.29751587,0.07927776,0.05875899,0.0024275263,0.0031667056,0.00008314291,0.008247995,0.0074808914,0.3048629,0.00013012708,0.23522817,0.0028199463],"about_ca_topic_score_codex":0.0042956495,"about_ca_topic_score_gemma":0.0021496466,"teacher_disagreement_score":0.27011085,"about_ca_system_score_codex":0.000636255,"about_ca_system_score_gemma":0.0011432853,"threshold_uncertainty_score":0.9999519},"labels":[],"label_agreement":null},{"id":"W1965250671","doi":"10.1016/j.lungcan.2012.05.091","title":"Cyto-histologic agreement in pathologic subtyping of non small cell lung carcinoma: Review of 602 fine needle aspirates with follow-up surgical specimens over a nine year period and analysis of factors underlying failure to subtype","year":2012,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; Terry Fox Foundation","keywords":"Subtyping; Medicine; Lung cancer; Immunohistochemistry; Pathology; Carcinoma; Lung; Targeted therapy; Oncology; Internal medicine; Cancer","score_opus":0.02731344183904456,"score_gpt":0.30117816090950206,"score_spread":0.2738647190704575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965250671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9326002,0.06604135,0.000017695555,0.00020894794,0.000062182524,0.00070355996,0.000056845867,0.0000066377315,0.00030258237],"genre_scores_gemma":[0.99662113,0.0026552123,0.00034352383,0.000078262776,0.000025250016,0.000073601805,0.000052113573,0.000017240925,0.00013365895],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99859273,0.00005320398,0.0004817473,0.00030921272,0.0002532311,0.00030988964],"domain_scores_gemma":[0.9990613,0.00007187194,0.00030976403,0.00030373817,0.00012243338,0.00013093113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022319134,0.00023605248,0.0010859305,0.00026972833,0.000024821518,0.0000041663307,0.00007064443,0.000081793696,0.0006860559],"category_scores_gemma":[0.000020554304,0.00016003461,0.00017513278,0.00084168854,0.00005899448,0.0000501395,0.000056748373,0.00011284431,5.2904744e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020454904,0.00026434616,0.99234164,0.0036996154,0.0005045669,0.000036297817,0.0013222427,0.00006223617,0.0011328666,0.000014298675,0.00025748086,0.00015987447],"study_design_scores_gemma":[0.002570566,0.00059871125,0.9860997,0.0030438316,0.0038283742,0.0000044318426,0.00039153337,0.00010518672,0.0029918863,4.378751e-7,0.00018711716,0.00017822921],"about_ca_topic_score_codex":0.001675229,"about_ca_topic_score_gemma":0.0017274782,"teacher_disagreement_score":0.06402094,"about_ca_system_score_codex":0.0004115326,"about_ca_system_score_gemma":0.00011108845,"threshold_uncertainty_score":0.7511831},"labels":[],"label_agreement":null},{"id":"W1965527358","doi":"10.1016/s0169-5002(01)00397-x","title":"Potential of 5-aza-2′-deoxycytidine (Decitabine) a potent inhibitor of DNA methylation for therapy of advanced non-small cell lung cancer","year":2001,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":89,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Decitabine; Epigenetics; DNA methylation; Lung cancer; Medicine; Carcinogenesis; Deoxycytidine; Cancer research; Methylation; Epigenetic therapy; Cancer; Oncology; Gene; Biology; Internal medicine; Gene expression; Genetics; Gemcitabine","score_opus":0.008718673126525666,"score_gpt":0.2836352383365898,"score_spread":0.27491656521006413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965527358","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94916177,0.027754173,0.021640277,0.000075185635,0.00039584003,0.0006942447,0.00013561506,0.000004363982,0.00013853227],"genre_scores_gemma":[0.9842992,0.0126839895,0.0021131847,0.000026901978,0.000330363,0.0001429456,0.00008952657,0.000035253885,0.00027867395],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99880177,0.000035032117,0.00047285625,0.0003010744,0.00017691798,0.00021236908],"domain_scores_gemma":[0.9987761,0.000020346526,0.00044138887,0.0002765848,0.00043215798,0.000053445983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001798603,0.00017420526,0.00030084891,0.00007390962,0.000034366396,0.000004568345,0.00013820818,0.00016304861,0.000034139695],"category_scores_gemma":[0.000022084054,0.00016430598,0.0001902477,0.00015082327,0.00004657967,0.000007034395,0.000040547093,0.00005220313,8.314152e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005569303,0.000104307095,0.009097094,0.0001924976,0.000105451,2.5613093e-7,0.000116966556,0.011411749,0.9656854,0.000007578858,0.00011056977,0.012611181],"study_design_scores_gemma":[0.0021172026,0.0003416665,0.011267271,0.00007531962,0.000076462056,2.0086681e-7,0.000037538637,0.0027897207,0.9814067,0.000040976814,0.0016775856,0.00016937863],"about_ca_topic_score_codex":0.00022503232,"about_ca_topic_score_gemma":0.0001007247,"teacher_disagreement_score":0.035137393,"about_ca_system_score_codex":0.000037871614,"about_ca_system_score_gemma":0.00017122345,"threshold_uncertainty_score":0.67002034},"labels":[],"label_agreement":null},{"id":"W1966226479","doi":"10.1016/s0169-5002(00)80174-9","title":"Is there a role for maintenance chemotherapy in patients treated for non-small cell lung cancer (NSCLC) stage IIIB and IV?","year":2000,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University","funders":"","keywords":"Medicine; Stage (stratigraphy); Oncology; Chemotherapy; Internal medicine; non-small cell lung cancer (NSCLC); Lung cancer","score_opus":0.0073079127568988255,"score_gpt":0.29998126115390294,"score_spread":0.2926733483970041,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966226479","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9839777,0.006140985,0.00011883795,0.001229142,0.00013021256,0.0040102806,0.0010310418,0.000039952993,0.0033218742],"genre_scores_gemma":[0.93448466,0.0026903627,0.00061525847,0.002497438,0.00018283202,0.003954125,0.00012395694,0.00009862374,0.05535277],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987417,0.000009810455,0.00025042484,0.00044316414,0.00012067902,0.0004342463],"domain_scores_gemma":[0.99939543,0.00003918675,0.000090474125,0.00022246219,0.0001326554,0.00011976353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000048735757,0.00024984434,0.00035879572,0.00006716278,0.00010107523,0.000025526422,0.00007152452,0.00010762954,0.0008603674],"category_scores_gemma":[0.0000037478985,0.00019929351,0.000106284744,0.00015576897,0.00003450743,0.00008695425,0.000008115983,0.00008746246,0.0000016193608],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025547296,0.0005079526,0.9163458,0.0008550911,0.0005190563,0.0000041594,0.005010385,0.00008713795,0.00043223667,0.000019493376,0.01451565,0.059148323],"study_design_scores_gemma":[0.074948415,0.0011775602,0.73605096,0.0019419483,0.0015020177,0.0000013337037,0.0004038302,0.024460923,0.0074419384,0.000072586256,0.15111521,0.0008832875],"about_ca_topic_score_codex":0.0025838371,"about_ca_topic_score_gemma":0.0009301201,"teacher_disagreement_score":0.18029484,"about_ca_system_score_codex":0.00056481163,"about_ca_system_score_gemma":0.0002561484,"threshold_uncertainty_score":0.942042},"labels":[],"label_agreement":null},{"id":"W1966804257","doi":"10.1016/j.lungcan.2003.08.024","title":"Women’s susceptibility to tobacco carcinogens","year":2003,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Smoking Behavior and Cessation","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Cancer Institute","keywords":"Medicine; Odds ratio; Lung cancer; Confidence interval; Demography; Logistic regression; Smoking history; Incidence (geometry); Cohort; Tobacco control; Cohort study; Relative risk; Public health; Internal medicine; Pathology","score_opus":0.024848849269004603,"score_gpt":0.3287624544172703,"score_spread":0.3039136051482657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966804257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995123,0.000091443464,0.00006096161,0.0003154396,0.00047781362,0.00026465053,0.0000072789694,0.00004864685,0.0036107278],"genre_scores_gemma":[0.99629015,0.000008894717,0.00005703328,0.0009608872,0.0001087472,0.00015822997,0.000003668832,0.0000129401415,0.0023994318],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992814,0.00001980719,0.00010271295,0.00019668833,0.00018124422,0.00021813416],"domain_scores_gemma":[0.9995024,0.000009197311,0.000018388973,0.0002553737,0.00007066848,0.00014396895],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00014031961,0.00007598096,0.00012489827,0.000040755316,0.000040837414,0.000009422496,0.000031722207,0.000050347357,0.0027728735],"category_scores_gemma":[0.000049376555,0.00006764114,0.00003571495,0.0001644225,0.000013675288,0.000028572007,0.000007809159,0.00008402153,0.000010788461],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029249633,0.000035761124,0.9888126,0.000020547355,0.000012870204,0.0000042404417,0.0011290709,0.000008878375,0.0038426865,0.00009210823,0.003214175,0.0027977966],"study_design_scores_gemma":[0.00044830155,0.00006143805,0.9766045,0.000027331645,0.000057212543,0.0000042051724,0.00031785324,0.0000029666974,0.008890824,0.000016638753,0.013476462,0.000092228955],"about_ca_topic_score_codex":0.00023113747,"about_ca_topic_score_gemma":0.00010814792,"teacher_disagreement_score":0.012208079,"about_ca_system_score_codex":0.00077808293,"about_ca_system_score_gemma":0.000118191034,"threshold_uncertainty_score":0.9981387},"labels":[],"label_agreement":null},{"id":"W1966930108","doi":"10.1016/s0169-5002(03)00283-6","title":"Histology-related variation in the treatment and survival of patients with lung carcinoma in Canada","year":2003,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Regional Cancer Foundation; Health Canada","funders":"","keywords":"Medicine; Lung cancer; Chemotherapy; Radiation therapy; Stage (stratigraphy); Internal medicine; Survival rate; Relative survival; Oncology; Cancer; Carcinoma; Small-cell carcinoma; Surgery; Cancer registry","score_opus":0.005651231004388065,"score_gpt":0.23508689627475934,"score_spread":0.2294356652703713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966930108","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99515927,0.0030220805,9.730974e-7,0.00036874902,0.00015137918,0.00056038826,0.00001824421,0.0000022820877,0.0007166308],"genre_scores_gemma":[0.999411,0.00024891665,0.000012145807,0.00009927804,0.000007012097,0.00015807484,0.000013843829,0.000007881671,0.00004184084],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99934137,0.000063073894,0.00016419627,0.0001608903,0.00013214276,0.0001383354],"domain_scores_gemma":[0.99967885,0.0000605446,0.000063150415,0.0001347278,0.00003174668,0.000030974217],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005558397,0.000098607714,0.00021577405,0.00004311346,0.000017759674,0.0000022781528,0.000022989341,0.000030158793,0.00005577959],"category_scores_gemma":[0.0000063363423,0.00005781117,0.000014348028,0.00015452069,0.000018600895,0.000021880156,0.00000250504,0.000054160722,8.879983e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009654086,0.0002271163,0.9973976,0.00004332888,0.00008078649,0.000019476556,0.0012793917,0.000085848755,0.000001983477,0.00024281774,0.00013304917,0.00039206492],"study_design_scores_gemma":[0.005036746,0.00019776367,0.993778,0.0000740394,0.0001690565,0.0000013292587,0.00008417306,0.00014434913,0.000035132605,0.0000073062347,0.0004159338,0.000056166988],"about_ca_topic_score_codex":0.7742624,"about_ca_topic_score_gemma":0.9179021,"teacher_disagreement_score":0.14363967,"about_ca_system_score_codex":0.0029551003,"about_ca_system_score_gemma":0.00074268715,"threshold_uncertainty_score":0.7727484},"labels":[],"label_agreement":null},{"id":"W1968673033","doi":"10.1016/s0169-5002(99)00132-4","title":"An estimate of the cost of conducting phase II trials in lung cancer","year":2000,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Medicine; Gemcitabine; Docetaxel; Clinical trial; Lung cancer; Pharmacy; Oncology; Cancer; Internal medicine; Intensive care medicine; Family medicine","score_opus":0.10718475209156585,"score_gpt":0.5220729525916058,"score_spread":0.41488820050003994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968673033","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9791249,0.014703635,0.0000071089066,0.0024792352,0.00041191105,0.0015681944,0.00019768445,0.000023403018,0.0014839313],"genre_scores_gemma":[0.9949632,0.0026744932,0.00010161882,0.00020322857,0.00044411176,0.0004257397,0.000005493361,0.00002935489,0.0011527304],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978974,0.00024401449,0.00071129855,0.00028287046,0.0004899166,0.00037451787],"domain_scores_gemma":[0.99879956,0.00018969028,0.0002813551,0.0004482797,0.0001843015,0.000096806056],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012057057,0.00016989809,0.0008937479,0.00009966815,0.00010567443,0.0000077915065,0.00021389121,0.00006722829,0.0024953724],"category_scores_gemma":[0.00034113444,0.000110485234,0.00014541498,0.00050193636,0.00022464394,0.00013160208,0.000062970474,0.00026862507,6.574489e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064169113,0.0017100835,0.44628015,0.0049841283,0.0019663605,0.00005768683,0.016042922,0.008005714,0.19631018,0.00020621771,0.027884614,0.29013503],"study_design_scores_gemma":[0.084720545,0.0029184544,0.13541134,0.018153828,0.0042461758,0.0000421555,0.0028163732,0.07794104,0.6310063,0.00015190516,0.041021388,0.0015705284],"about_ca_topic_score_codex":0.0064614443,"about_ca_topic_score_gemma":0.0015891549,"teacher_disagreement_score":0.4346961,"about_ca_system_score_codex":0.0004913081,"about_ca_system_score_gemma":0.00065230456,"threshold_uncertainty_score":0.9984165},"labels":[],"label_agreement":null},{"id":"W1969713662","doi":"10.1016/j.lungcan.2011.05.012","title":"Mesothelioma at era of helical tomotherapy: Results of two institutions in combining chemotherapy, surgery and radiotherapy","year":2011,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"Royal College of Physicians and Surgeons of Canada","keywords":"Tomotherapy; Medicine; Radiation therapy; Chemotherapy; Mesothelioma; Oncology; General surgery; Radiology; Internal medicine; Pathology","score_opus":0.03445576827368732,"score_gpt":0.32202801683707605,"score_spread":0.2875722485633887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969713662","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933669,0.004882571,0.000026840715,0.00038536178,0.00006313897,0.00018411687,0.0000809001,0.0000117282025,0.0009984298],"genre_scores_gemma":[0.99638623,0.0023643156,0.0005237383,0.00048212,0.00004008666,0.000023138966,0.00001722221,0.000014010804,0.00014912202],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99927413,0.000022980958,0.00028300777,0.00015635608,0.00014908762,0.0001144433],"domain_scores_gemma":[0.9996249,0.00006260542,0.0000935428,0.00013653102,0.000015654932,0.000066765424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000093950955,0.00009368175,0.00027121181,0.000081147475,0.00002278525,0.0000014042436,0.000034412267,0.000040536186,0.00041336956],"category_scores_gemma":[0.000009655074,0.00007923254,0.00006491448,0.00013779514,0.0001796222,0.000048615646,0.000013608931,0.00006265791,7.5441153e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029393532,0.00036846724,0.973276,0.000110482426,0.00011193047,0.000007268943,0.0012329138,0.000018001925,0.014360715,0.00025564563,0.00049424515,0.006824965],"study_design_scores_gemma":[0.0039768335,0.00011253351,0.9781431,0.000375323,0.00003208203,0.000008867017,0.000025056563,0.0002043124,0.016119977,0.00006524677,0.00084099727,0.00009566628],"about_ca_topic_score_codex":0.0010925062,"about_ca_topic_score_gemma":0.00012981129,"teacher_disagreement_score":0.0067292987,"about_ca_system_score_codex":0.00011345495,"about_ca_system_score_gemma":0.00008200401,"threshold_uncertainty_score":0.45261067},"labels":[],"label_agreement":null},{"id":"W1970151900","doi":"10.1016/s0169-5002(00)80603-0","title":"Prognostic significance of BAG-1 expression in non-small cell lung cancer","year":2000,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Heat shock proteins research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dr. H. Bliss Murphy Cancer Centre; Memorial University of Newfoundland","funders":"","keywords":"Medicine; Lung cancer; Oncology; Internal medicine; Expression (computer science)","score_opus":0.008902687794944778,"score_gpt":0.298233672332086,"score_spread":0.2893309845371412,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970151900","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98733985,0.008444023,0.00027314777,0.0001097948,0.00008184117,0.0009829812,0.000050097347,0.000008550113,0.0027097214],"genre_scores_gemma":[0.9907615,0.0021731,0.0005285988,0.000089520516,0.00020257202,0.000992444,0.00002052388,0.000037111706,0.005194593],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985682,0.000085405845,0.00026019703,0.00044487804,0.00021375695,0.00042758515],"domain_scores_gemma":[0.9993625,0.000018637604,0.000054092463,0.00037541677,0.00008413587,0.00010519857],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00015873581,0.00016551999,0.00019536534,0.000056510846,0.000042184038,0.000012518216,0.0002837123,0.00017748863,0.0009982116],"category_scores_gemma":[0.000027948012,0.00015566961,0.000061219915,0.00020018031,0.00006067861,0.0000055079604,0.0000789633,0.00018534095,0.000005578555],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013968603,0.00008088836,0.08673818,0.00035522826,0.000016063712,0.0000065721574,0.0001309932,0.002468017,0.90113646,5.4138224e-7,0.002084462,0.006842887],"study_design_scores_gemma":[0.00073005905,0.00008350898,0.016393868,0.0003074116,0.000014366716,6.3837507e-7,0.00001595845,0.0020341503,0.97303563,0.000002712437,0.007167986,0.00021372434],"about_ca_topic_score_codex":0.0011859026,"about_ca_topic_score_gemma":0.00066734344,"teacher_disagreement_score":0.07189913,"about_ca_system_score_codex":0.00009429259,"about_ca_system_score_gemma":0.0003916696,"threshold_uncertainty_score":0.999915},"labels":[],"label_agreement":null},{"id":"W1970574485","doi":"10.1016/j.lungcan.2015.04.006","title":"Prophylactic cranial irradiation (PCI). Still a no-brainer?","year":2015,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Princess Margaret Cancer Centre; Sunnybrook Health Science Centre","funders":"Sunnybrook Foundation","keywords":"Prophylactic cranial irradiation; Conventional PCI; Medicine; Intensive care medicine; Medical physics; Surgery; Radiology; Internal medicine","score_opus":0.03641837392901453,"score_gpt":0.38552492142454425,"score_spread":0.3491065474955297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970574485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7937963,0.029358333,0.00045435206,0.049794815,0.006551763,0.0054781823,0.00012608079,0.0008686143,0.11357156],"genre_scores_gemma":[0.9840754,0.0001390916,0.00035045092,0.0010095858,0.002128055,0.00034069223,0.000011953959,0.000039985916,0.011904733],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99841124,0.000045415163,0.00018395497,0.00030515817,0.0006651751,0.00038907118],"domain_scores_gemma":[0.99879897,0.00004305568,0.00006733704,0.0002876048,0.00050266995,0.00030033695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022227771,0.00015960465,0.00027191767,0.00009812434,0.000055611094,0.000029661092,0.00009468497,0.00006707441,0.00028542455],"category_scores_gemma":[0.00057934446,0.00012521325,0.00006350357,0.0002732752,0.00008654573,0.0001512647,0.00006300572,0.00024531203,0.00018265207],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006557249,0.00055640156,0.25552,0.003582067,0.001154835,0.00041374215,0.01181047,0.0003735742,0.012103548,0.00069381774,0.6711272,0.036107115],"study_design_scores_gemma":[0.024918143,0.0030472085,0.18358815,0.00079801166,0.0011906942,0.00012249187,0.00066998386,0.023962138,0.00154175,0.0005141214,0.7583519,0.0012953934],"about_ca_topic_score_codex":0.00090102333,"about_ca_topic_score_gemma":0.0001489465,"teacher_disagreement_score":0.19027916,"about_ca_system_score_codex":0.0010637802,"about_ca_system_score_gemma":0.00089168345,"threshold_uncertainty_score":0.5106048},"labels":[],"label_agreement":null},{"id":"W1971754811","doi":"10.1016/j.lungcan.2005.05.028","title":"Acquisition of fluorescence and reflectance spectra during routine bronchoscopy examinations using the ClearVu Elite™ device: Pilot study","year":2005,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Photodynamic Therapy Research Studies","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Bronchoscopy; Lung cancer; Carcinoma in situ; Radiology; Lung; Population; Pathology; Carcinoma; Nuclear medicine; Internal medicine","score_opus":0.029500268182809507,"score_gpt":0.38617791242534527,"score_spread":0.3566776442425358,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971754811","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99299407,0.0049805786,0.00007243154,0.00081961916,0.00004288513,0.0008025899,0.000010279821,0.000031233754,0.00024632527],"genre_scores_gemma":[0.9974891,0.0012190606,0.0006233993,0.00009218118,0.00023777886,0.00005424028,0.0000013291968,0.000018719207,0.00026422445],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99892277,0.00006953006,0.00020849869,0.00023303444,0.00032543187,0.00024075428],"domain_scores_gemma":[0.99940693,0.00006582349,0.00008314236,0.00026290174,0.00012893643,0.000052238964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023903426,0.000118111515,0.00020666183,0.00007236718,0.00020305639,0.000016460084,0.000093179915,0.000018064475,0.000087697044],"category_scores_gemma":[0.000042668325,0.000086299595,0.00001857923,0.0002881601,0.0001306106,0.00011362379,0.000060580394,0.00018709013,8.814667e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048089668,0.00026869582,0.044143587,0.00014662973,0.0001665983,0.0000056771005,0.0026845813,0.00006263963,0.95053494,0.000028033424,0.000040378953,0.0014373579],"study_design_scores_gemma":[0.0021791593,0.0007446159,0.9481038,0.00044725442,0.00016721392,0.000016752203,0.0011629219,0.008964579,0.03801644,0.000009868087,0.000053151824,0.00013425933],"about_ca_topic_score_codex":0.00048899394,"about_ca_topic_score_gemma":0.00076568004,"teacher_disagreement_score":0.9125185,"about_ca_system_score_codex":0.00037941907,"about_ca_system_score_gemma":0.00007309269,"threshold_uncertainty_score":0.35191953},"labels":[],"label_agreement":null},{"id":"W1972272153","doi":"10.1016/j.lungcan.2014.04.014","title":"Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05)","year":2014,"lang":"en","type":"article","venue":"Lung Cancer","topic":"MicroRNA in disease regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mach-Gaensslen Foundation of Canada","keywords":"Medicine; Erlotinib; Internal medicine; Oncology; Bevacizumab; Clinical endpoint; Lung cancer; Chemotherapy; Clinical trial; Cancer; Epidermal growth factor receptor","score_opus":0.003084220057585393,"score_gpt":0.25172074226016494,"score_spread":0.24863652220257956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972272153","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960027,0.00086348463,0.0015341934,0.00008775907,0.00014749053,0.0011698772,0.0000351561,0.00003716724,0.00012217813],"genre_scores_gemma":[0.9958408,0.000011763958,0.0027281565,0.00026201838,0.00011129977,0.00021768534,0.00065269985,0.000089852925,0.00008576375],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981849,0.00008230878,0.00035247934,0.0006612173,0.00027482415,0.00044423155],"domain_scores_gemma":[0.9990013,0.000027672202,0.0003259,0.00040551953,0.00011500004,0.00012455434],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017480234,0.00030572145,0.00025335557,0.000060830636,0.00014938237,0.000029999588,0.00017433793,0.00019221165,0.000031222822],"category_scores_gemma":[0.000076537275,0.00028259397,0.00007993827,0.00018009725,0.000050818817,0.00001465888,0.000059652688,0.00012409547,0.0000016066327],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009116184,0.00009995319,0.3612967,0.00012920765,0.000029005616,0.0000011819043,0.00007277914,0.0024551593,0.62309605,5.404704e-7,0.0005228167,0.011384985],"study_design_scores_gemma":[0.01707282,0.0005403041,0.16540271,0.0008757177,0.000061232015,0.0000022199588,0.000020954705,0.011793988,0.80074835,0.000005050705,0.002498961,0.0009777049],"about_ca_topic_score_codex":0.000029572388,"about_ca_topic_score_gemma":0.00007333236,"teacher_disagreement_score":0.19589399,"about_ca_system_score_codex":0.0003026527,"about_ca_system_score_gemma":0.00013943652,"threshold_uncertainty_score":0.9999626},"labels":[],"label_agreement":null},{"id":"W1974498632","doi":"10.1016/s0169-5002(03)00300-3","title":"Induction treatment before surgery for non-small cell lung cancer","year":2003,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Stage (stratigraphy); Induction chemotherapy; Radiation therapy; Clinical trial; Disease; Chemotherapy; Randomized controlled trial; Lung cancer; Surgery; Standard of care; Oncology; Cancer; Internal medicine","score_opus":0.04540205712742559,"score_gpt":0.36755930025658906,"score_spread":0.3221572431291635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974498632","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002805838,0.98677325,0.00003070785,0.0002949186,0.0041595157,0.0068252548,0.0007482372,0.00008461691,0.00080288644],"genre_scores_gemma":[0.000058227906,0.9558378,0.00018134071,0.00025390755,0.0023645188,0.027558181,0.00073041295,0.0002584521,0.012757175],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996844,0.00007136409,0.0008626574,0.0011122753,0.00031382113,0.0007958664],"domain_scores_gemma":[0.99787706,0.00021287402,0.0006315014,0.00075165386,0.00019252731,0.00033439838],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016205998,0.0010048908,0.003169649,0.00030751666,0.00017774261,0.00005313285,0.000121860845,0.0005997006,0.0005937388],"category_scores_gemma":[0.000011426537,0.00070504687,0.0017278545,0.00042877998,0.00004568497,0.000076985,0.000027944827,0.0002984984,0.000016277727],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000049090657,0.0005347181,0.0073306924,0.06674134,0.0031319049,0.00004492222,0.0001883503,0.0000060596017,3.2276432e-7,0.0000129813525,0.06918621,0.8527734],"study_design_scores_gemma":[0.0015713259,0.00025273042,0.0001575615,0.030372316,0.020512577,0.000024870495,0.000011175294,0.00003100399,0.00004078802,0.0000029690582,0.9464653,0.000557375],"about_ca_topic_score_codex":0.0016809509,"about_ca_topic_score_gemma":0.0010120551,"teacher_disagreement_score":0.8772791,"about_ca_system_score_codex":0.009428688,"about_ca_system_score_gemma":0.003794608,"threshold_uncertainty_score":0.9995401},"labels":[],"label_agreement":null},{"id":"W1976487567","doi":"10.1016/j.lungcan.2012.02.019","title":"Emphysema detected on computed tomography and risk of lung cancer: A systematic review and meta-analysis","year":2012,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":101,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Lung cancer; Meta-analysis; Odds ratio; Cochrane Library; Lung cancer screening; Internal medicine; Lung; Radiology","score_opus":0.04412811388537274,"score_gpt":0.38101351988535676,"score_spread":0.336885405999984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976487567","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005437063,0.9906071,0.000014634596,0.000069073736,0.00006665979,0.007254152,0.0018205416,0.0000463474,0.00006711249],"genre_scores_gemma":[0.00030855346,0.99588543,0.000055451,0.00009401853,0.00010399455,0.0029815973,0.000117493284,0.00009144718,0.00036203384],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99551797,0.0009987465,0.0012723524,0.0008703977,0.0008088228,0.0005317333],"domain_scores_gemma":[0.99624366,0.00048010098,0.0012765317,0.0011482806,0.00037283005,0.00047862393],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00065210933,0.00077200274,0.010825484,0.0008547161,0.00009867424,0.000028210898,0.00025267564,0.00025304,0.0008725162],"category_scores_gemma":[0.00010262395,0.0005009993,0.0027968548,0.0023551423,0.00021069577,0.000078117046,0.00017287258,0.0006495679,0.0000026696052],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013508038,0.000053545766,0.0009962354,0.729207,0.2614598,0.000011247885,0.00002392293,0.0000010267386,8.415201e-8,0.000006838542,0.00015227897,0.008074537],"study_design_scores_gemma":[0.00027280548,0.000029860821,0.0015287509,0.115561426,0.8785551,0.00001938542,0.000004049715,0.00023763087,4.7603697e-7,0.0000013473774,0.0034329528,0.0003561673],"about_ca_topic_score_codex":0.0010420505,"about_ca_topic_score_gemma":0.00019532039,"teacher_disagreement_score":0.61709535,"about_ca_system_score_codex":0.000565752,"about_ca_system_score_gemma":0.00046551318,"threshold_uncertainty_score":0.9997442},"labels":[],"label_agreement":null},{"id":"W1977749101","doi":"10.1016/j.lungcan.2004.07.040","title":"Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer","year":2004,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Lung cancer; Stage (stratigraphy); Univariate analysis; Carboplatin; Multivariate analysis; Performance status; Chemotherapy; Population; Histology; Cancer; Gastroenterology; Oncology; Cisplatin","score_opus":0.015688345930696318,"score_gpt":0.3198114188996633,"score_spread":0.304123072968967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1977749101","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845021,0.009451302,0.00090872555,0.0015430878,0.0003404039,0.0020332697,0.00032651407,0.00004947116,0.0008451316],"genre_scores_gemma":[0.9946329,0.0005345236,0.0002599327,0.0006874033,0.00017117942,0.00095328066,0.00008843612,0.00006844427,0.0026039039],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988668,0.000016018097,0.00024101412,0.00030657748,0.0002027018,0.00036688245],"domain_scores_gemma":[0.99895084,0.00012780556,0.00026225825,0.00026334275,0.00029500682,0.00010071899],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000084217594,0.00025030205,0.00038897526,0.000058302805,0.00016090128,0.000017075985,0.000112921596,0.0000916123,0.00024206411],"category_scores_gemma":[0.000016094455,0.00014220287,0.00013622736,0.0002762539,0.000051730218,0.00008931672,0.000013817775,0.0001612312,2.9595472e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002432196,0.0023938422,0.78322047,0.0021533452,0.011379005,0.00001867418,0.048721224,0.01885689,0.09145847,0.00011295574,0.010822608,0.028430339],"study_design_scores_gemma":[0.05589565,0.0027728034,0.6095937,0.004151645,0.00516372,0.000002256843,0.002773231,0.0014231114,0.30765727,0.0001307086,0.009280374,0.001155543],"about_ca_topic_score_codex":0.000650982,"about_ca_topic_score_gemma":0.0039502,"teacher_disagreement_score":0.21619882,"about_ca_system_score_codex":0.0007220696,"about_ca_system_score_gemma":0.0009308152,"threshold_uncertainty_score":0.57988644},"labels":[],"label_agreement":null},{"id":"W1982407179","doi":"10.1016/s0169-5002(03)00355-6","title":"Early combined treatment with carboplatin and the MMP inhibitor, prinomastat, prolongs survival and reduces systemic metastasis in an aggressive orthotopic lung cancer model","year":2003,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Protease and Inhibitor Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"Bristol-Myers Squibb","keywords":"Carboplatin; Medicine; Lung cancer; Metastasis; Matrix metalloproteinase inhibitor; Chemotherapy; Matrix metalloproteinase; Internal medicine; Cancer; Combination therapy; Oncology; Cisplatin","score_opus":0.008950563754020943,"score_gpt":0.2611626431329394,"score_spread":0.2522120793789185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982407179","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9770843,0.02144338,0.00009527614,0.00008572479,0.000104267434,0.0010366448,0.000042281736,0.0000090738995,0.0000990828],"genre_scores_gemma":[0.99705327,0.0014593699,0.00013497708,0.000049626473,0.00007813968,0.0010097842,0.000012280683,0.000025262952,0.00017728921],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988676,0.00016400011,0.00018224986,0.0004168758,0.000120575445,0.00024874244],"domain_scores_gemma":[0.9994824,0.000009936355,0.00014983366,0.00021728736,0.000055839904,0.00008468672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014351119,0.0002188996,0.0002621322,0.000032908367,0.00009324462,0.000044617533,0.0000679121,0.00009328488,0.0000042991583],"category_scores_gemma":[0.00000903388,0.00013778814,0.000031887223,0.00007326422,0.00010066682,0.000015927131,0.000033467288,0.00008438886,5.739486e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036409826,0.0002404476,0.13487323,0.0003861943,0.00093428575,0.00007276035,0.0043586823,0.0017783483,0.84533876,0.0027023016,0.00007914135,0.0055948533],"study_design_scores_gemma":[0.014204058,0.0014253055,0.0021376547,0.00058903144,0.0005100537,0.000050523926,0.0005618314,0.013519209,0.9659419,0.00016239352,0.00014594663,0.00075208064],"about_ca_topic_score_codex":0.00084858976,"about_ca_topic_score_gemma":0.0011823913,"teacher_disagreement_score":0.13273558,"about_ca_system_score_codex":0.00007380898,"about_ca_system_score_gemma":0.00021724423,"threshold_uncertainty_score":0.56188375},"labels":[],"label_agreement":null},{"id":"W1983913656","doi":"10.1016/j.lungcan.2005.02.011","title":"Asian ethnicity and adenocarcinoma histology continues to predict response to gefitinib in patients treated for advanced non-small cell carcinoma of the lung in North America","year":2005,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Gefitinib; Medicine; Histology; Adenocarcinoma; Ethnic group; Internal medicine; Oncology; Carcinoma; Lung; Cancer; Epidermal growth factor receptor; Anthropology","score_opus":0.0075751153579548735,"score_gpt":0.28768857319094115,"score_spread":0.2801134578329863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983913656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932261,0.001202492,0.000034758945,0.002145271,0.0001106848,0.0026749293,0.00025528987,0.0000121493085,0.00033831905],"genre_scores_gemma":[0.9966706,0.000016515289,0.0006251612,0.0008905972,0.000041036434,0.0007480749,0.000030678788,0.000025979745,0.0009513339],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998827,0.000067772766,0.0003347918,0.00034404112,0.000119744494,0.00030665254],"domain_scores_gemma":[0.99928874,0.00008918966,0.000112279326,0.00026051566,0.000117127456,0.00013214308],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000067148794,0.00016910832,0.00037904398,0.00017833796,0.00004444313,0.0000045243,0.00009675301,0.000065453736,0.000016455666],"category_scores_gemma":[0.00007426437,0.00013064746,0.000056529698,0.00039738812,0.000046856432,0.000045177552,0.000045573102,0.00010970599,7.52818e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034220836,0.00019521332,0.980652,0.000093342605,0.000030205416,0.0000046964988,0.0070013935,0.0002669588,0.00039728673,9.886672e-7,0.0010355256,0.006900306],"study_design_scores_gemma":[0.0066287005,0.0007220039,0.9884638,0.0001388882,0.00016178824,8.6319363e-7,0.00019477283,0.00029784284,0.0010825059,5.8487274e-7,0.0021890684,0.00011913853],"about_ca_topic_score_codex":0.0016564138,"about_ca_topic_score_gemma":0.010423052,"teacher_disagreement_score":0.008766638,"about_ca_system_score_codex":0.0007437204,"about_ca_system_score_gemma":0.0002226013,"threshold_uncertainty_score":0.58163077},"labels":[],"label_agreement":null},{"id":"W1983936911","doi":"10.1016/j.lungcan.2004.12.004","title":"Does the incidence and outcome of brain metastases in locally advanced non-small cell lung cancer justify prophylactic cranial irradiation or early detection?","year":2005,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Radiation therapy; Prophylactic cranial irradiation; Chemotherapy; Incidence (geometry); Lung cancer; Stage (stratigraphy); Surgery; Oncology; Brain metastasis; Internal medicine; Cancer; Metastasis","score_opus":0.010715695218175135,"score_gpt":0.311923990686607,"score_spread":0.30120829546843186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983936911","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898471,0.003687356,0.0007114283,0.003966138,0.00030349818,0.0013595411,0.00006735435,0.00002190107,0.00003565671],"genre_scores_gemma":[0.9959152,0.00039318437,0.001449406,0.0007607323,0.00023271565,0.00044084477,0.000004015246,0.000028049231,0.00077587593],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986305,0.00008937061,0.0004086197,0.00033612354,0.000261686,0.0002736487],"domain_scores_gemma":[0.9991151,0.00022153948,0.0002108017,0.00025963006,0.00009801071,0.00009492829],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002678949,0.0002122207,0.0003780498,0.00010375944,0.000087797416,0.000024432036,0.00008579617,0.000069109774,0.00018055878],"category_scores_gemma":[0.00008952518,0.000106684056,0.00007323522,0.0002690486,0.00007864509,0.00016946039,0.000035733792,0.00022253259,0.0000016289665],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033743542,0.00052581786,0.7597442,0.0024667876,0.00042538773,0.00011676817,0.0036934104,0.008875084,0.018637782,0.000042602365,0.00020118742,0.2018966],"study_design_scores_gemma":[0.008739401,0.0007016073,0.94948184,0.00053412776,0.0015045964,0.00002261735,0.00036792716,0.017448317,0.01921466,0.000019404653,0.0015747101,0.00039081505],"about_ca_topic_score_codex":0.004885448,"about_ca_topic_score_gemma":0.01801502,"teacher_disagreement_score":0.20150578,"about_ca_system_score_codex":0.00036673053,"about_ca_system_score_gemma":0.0002556912,"threshold_uncertainty_score":0.9999036},"labels":[],"label_agreement":null},{"id":"W1984146948","doi":"10.1016/j.lungcan.2012.04.014","title":"National survey of the medical treatment status for non-small cell lung cancer (NSCLC) in China","year":2012,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":114,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"BC Cancer Agency; National Comprehensive Cancer Network","keywords":"Medicine; Docetaxel; Gefitinib; Erlotinib; Pemetrexed; Oncology; Internal medicine; Gemcitabine; Lung cancer; Guideline; Chemotherapy; Cancer; Epidermal growth factor receptor; Cisplatin; Pathology","score_opus":0.02256977514883364,"score_gpt":0.37233941694808714,"score_spread":0.3497696417992535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984146948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97523355,0.013251941,0.00016302847,0.0014868671,0.0013401327,0.0020194913,0.0010596705,0.000017293618,0.0054280018],"genre_scores_gemma":[0.9940268,0.00088685617,0.00015624786,0.00035167902,0.00032624317,0.0012354564,0.00011848535,0.000029698464,0.0028685625],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99864644,0.000050460934,0.00028052562,0.00020008521,0.00041374174,0.00040872747],"domain_scores_gemma":[0.99919206,0.00014407269,0.00012153691,0.0001830205,0.00017183577,0.0001875028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023846191,0.00016665758,0.0002879029,0.00006834161,0.0000637717,0.000006518632,0.00008675917,0.000096944204,0.0005002286],"category_scores_gemma":[0.00006914358,0.000103559614,0.00010857833,0.0002531196,0.000049623683,0.000064448235,0.000025756584,0.000102669444,0.0000013590547],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015309517,0.0005121109,0.9887219,0.000188821,0.00031382163,0.0000012052996,0.0018747705,0.00014411073,0.00010259433,0.000068639616,0.0045730695,0.0033458497],"study_design_scores_gemma":[0.004872843,0.00007683302,0.98708904,0.0002782248,0.0003965781,0.0000018262369,0.00003722945,0.0025859335,0.0011972145,0.000007492998,0.003345149,0.00011162614],"about_ca_topic_score_codex":0.025586698,"about_ca_topic_score_gemma":0.01674967,"teacher_disagreement_score":0.018793197,"about_ca_system_score_codex":0.0015806688,"about_ca_system_score_gemma":0.002610499,"threshold_uncertainty_score":0.980902},"labels":[],"label_agreement":null},{"id":"W1986187845","doi":"10.1016/j.lungcan.2012.10.006","title":"VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: Pooled analysis of SAKK19/05 and NTR528","year":2012,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung; Universitair Medisch Centrum Groningen; Maastricht Universitair Medisch Centrum; Institute for Oil Sands Innovation, University of Alberta; Universiteit Maastricht; Inselspital, Universitätsspital Bern","keywords":"Erlotinib; Medicine; Bevacizumab; Internal medicine; Lung cancer; Oncology; Hazard ratio; Gefitinib; Confidence interval; Proportional hazards model; Chemotherapy; Log-rank test; Cancer; Epidermal growth factor receptor","score_opus":0.00779591278885484,"score_gpt":0.28823118241143075,"score_spread":0.2804352696225759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986187845","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99091846,0.005290324,0.00013688269,0.000368925,0.00004900786,0.0027636953,0.00030389658,0.000016177355,0.00015262913],"genre_scores_gemma":[0.99706894,0.00026978418,0.0005260419,0.00020131866,0.00005508257,0.0015525533,0.0001613855,0.00003417811,0.0001307003],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99886286,0.000022125727,0.00025412018,0.00031331117,0.00020594404,0.00034162082],"domain_scores_gemma":[0.99916553,0.0001344898,0.00018648611,0.00022575661,0.00017326254,0.00011448803],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007214206,0.0002436874,0.00047554815,0.00014908002,0.00012986634,0.000027956388,0.000059816768,0.000064091066,0.000019301586],"category_scores_gemma":[0.000013985407,0.00014110401,0.00005732083,0.00062208774,0.00009368262,0.00012466505,0.000013964847,0.00009987672,9.312588e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011925129,0.00046599322,0.98841333,0.0005222335,0.0021165598,0.0000040596974,0.004287347,0.00074699725,0.000032408632,0.000009547536,0.00010289372,0.0021060854],"study_design_scores_gemma":[0.010907337,0.001001706,0.96445346,0.0005072144,0.01882435,0.0000021708697,0.0002838856,0.0032629617,0.00021172065,0.0000010714685,0.00034426153,0.00019988303],"about_ca_topic_score_codex":0.00199463,"about_ca_topic_score_gemma":0.0044482243,"teacher_disagreement_score":0.023959924,"about_ca_system_score_codex":0.00020721425,"about_ca_system_score_gemma":0.00023968838,"threshold_uncertainty_score":0.5754055},"labels":[],"label_agreement":null},{"id":"W1986783484","doi":"10.1016/s0169-5002(00)00240-3","title":"Using treatment interruptions to palliate the toxicity from concurrent chemoradiation for limited small cell lung cancer decreases survival and disease control","year":2001,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Western University","funders":"","keywords":"Medicine; Etoposide; Internal medicine; Epirubicin; Toxicity; Population; Gastroenterology; Cyclophosphamide; Radiation therapy; Chemotherapy; Mucositis; Vincristine; Progressive disease; Cancer; Oncology; Surgery; Urology","score_opus":0.08057751619949674,"score_gpt":0.4081317458969609,"score_spread":0.32755422969746417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986783484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95284116,0.027967753,0.005533316,0.008754552,0.000556647,0.0030498158,0.0011711781,0.000057422818,0.00006815026],"genre_scores_gemma":[0.98983735,0.005423707,0.00015107343,0.0010120204,0.0008551147,0.0021428782,0.000066737986,0.000036814956,0.00047432072],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99859184,0.000070591435,0.00023889479,0.00042511418,0.00024874305,0.00042481258],"domain_scores_gemma":[0.9986025,0.00032396778,0.00009618022,0.00026887056,0.00021412437,0.0004943639],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010550518,0.00024960877,0.00038803226,0.00006840308,0.0002596977,0.000059517413,0.000092717455,0.000043764067,0.00011166955],"category_scores_gemma":[0.00017894186,0.00016969121,0.00012495084,0.00017917316,0.000080987375,0.000064610154,0.00005320015,0.000101810685,0.0000011239925],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039650532,0.00044197537,0.9620095,0.00044014095,0.001512478,0.000026877535,0.0018475283,0.0024036698,0.0077629904,0.000054907305,0.0043964135,0.015138451],"study_design_scores_gemma":[0.025837505,0.00080949574,0.5778208,0.0018458173,0.0075121955,0.0000031928746,0.00080527586,0.35199225,0.004577672,0.00007835261,0.02777395,0.0009434783],"about_ca_topic_score_codex":0.008988618,"about_ca_topic_score_gemma":0.0061976076,"teacher_disagreement_score":0.3841887,"about_ca_system_score_codex":0.0015971143,"about_ca_system_score_gemma":0.00054094865,"threshold_uncertainty_score":0.9976106},"labels":[],"label_agreement":null},{"id":"W1987622504","doi":"10.1016/j.lungcan.2011.05.027","title":"ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity","year":2011,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Toronto General Hospital","funders":"Pfizer","keywords":"Crizotinib; Medicine; Anaplastic lymphoma kinase; ALK inhibitor; Lung cancer; Internal medicine; Oncology; Chemotherapy; Fluorescence in situ hybridization; Adenocarcinoma; Tyrosine-kinase inhibitor; Fusion gene; Cancer; Cancer research; Gene; Biology","score_opus":0.02078302751036611,"score_gpt":0.3394637568106692,"score_spread":0.3186807293003031,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987622504","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922377,0.003703718,0.00020635399,0.00038790973,0.00017560954,0.0015396781,0.0006269487,0.00007503405,0.0010470428],"genre_scores_gemma":[0.99497026,0.0004451638,0.001069146,0.00035381777,0.00032933184,0.0010931788,0.00011266344,0.00005293255,0.0015734781],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989651,0.00002293371,0.0001328842,0.00043109013,0.00015291016,0.00029512658],"domain_scores_gemma":[0.99921834,0.000040314513,0.000097373886,0.00021541094,0.00019934471,0.00022921788],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000039663366,0.00023577981,0.00030178967,0.00007790973,0.00020464328,0.000020977257,0.000037328242,0.00008575642,0.00018443969],"category_scores_gemma":[0.0000086128275,0.00016897447,0.00005173925,0.0001455939,0.00007617149,0.00023785881,0.00001978833,0.00008904327,5.5610406e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024151955,0.0024193814,0.6932236,0.0012285688,0.0046929684,0.001091713,0.013033144,0.00005604789,0.08950775,0.00023188883,0.007465551,0.16289745],"study_design_scores_gemma":[0.022239823,0.006323893,0.54283214,0.0018360204,0.010708514,0.00026127324,0.00062096864,0.0051085637,0.40523183,0.000031554726,0.003626667,0.0011787546],"about_ca_topic_score_codex":0.014574489,"about_ca_topic_score_gemma":0.003972298,"teacher_disagreement_score":0.31572407,"about_ca_system_score_codex":0.00048494965,"about_ca_system_score_gemma":0.00032120914,"threshold_uncertainty_score":0.9919875},"labels":[],"label_agreement":null},{"id":"W1987756569","doi":"10.1016/s0169-5002(03)00148-x","title":"Patterns of initial management of lung cancer in the Republic of Ireland: a population-based observational study","year":2003,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Observational study; Lung cancer; Population; General surgery; Demography; Intensive care medicine; Oncology; Internal medicine; Environmental health","score_opus":0.043261292114015505,"score_gpt":0.41295802667273485,"score_spread":0.3696967345587193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987756569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962249,0.0007523966,0.00011824423,0.00051830296,0.00016723346,0.0011764829,0.00014602041,0.0000062738704,0.0008901935],"genre_scores_gemma":[0.99887097,0.000050253577,0.00011987362,0.00017583626,0.000030242045,0.00047332956,0.0000590954,0.0000114116765,0.00020898001],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99890333,0.000065857836,0.00039321015,0.00015603293,0.000365998,0.00011555552],"domain_scores_gemma":[0.99933696,0.00006157413,0.0002072663,0.00023785817,0.00013238775,0.00002395737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016394074,0.00009592187,0.00023651026,0.00010269229,0.000026831025,0.000004007949,0.000071584946,0.000030312374,0.00043031957],"category_scores_gemma":[0.000013755591,0.0000677386,0.00006178719,0.0003204103,0.000014536275,0.00005191814,0.0000087164,0.00006390285,8.8146535e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000081529965,0.0005821483,0.9932709,0.00047374898,0.00045301768,0.000007853026,0.0013609721,0.001535458,0.000015403562,0.0012534932,0.00014698866,0.0008184977],"study_design_scores_gemma":[0.0032813402,0.00010443197,0.99393296,0.00044381781,0.00067799905,5.35499e-7,0.0006327723,0.0005982493,0.00014361831,0.0000299889,0.000095861345,0.000058414516],"about_ca_topic_score_codex":0.007170387,"about_ca_topic_score_gemma":0.0017196923,"teacher_disagreement_score":0.005450695,"about_ca_system_score_codex":0.0002089518,"about_ca_system_score_gemma":0.00025540497,"threshold_uncertainty_score":0.99944097},"labels":[],"label_agreement":null},{"id":"W1988539479","doi":"10.1016/j.lungcan.2007.01.007","title":"Lung cancer in systemic lupus erythematosus","year":2007,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Systemic Lupus Erythematosus Research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; McGill University; McGill University Health Centre","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Cancer Institute","keywords":"Medicine; Cancer; Lung cancer; Lung; Systemic lupus erythematosus; Lupus erythematosus; Dermatology; Oncology; Internal medicine; Immunology; Antibody; Disease","score_opus":0.01606062311865448,"score_gpt":0.3507504158093458,"score_spread":0.3346897926906913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988539479","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9235172,0.06190471,0.00035703674,0.0006999498,0.0023425843,0.0017758377,0.000026442242,0.00016691882,0.009209269],"genre_scores_gemma":[0.97999483,0.0017599028,0.00009313118,0.00027137186,0.00087707554,0.0005083287,0.000006808511,0.000106814085,0.016381746],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.9965448,0.000075278294,0.0007646472,0.00060367864,0.0009227337,0.0010888783],"domain_scores_gemma":[0.99835205,0.00020895632,0.00017186228,0.0006763372,0.0002372606,0.0003535482],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011092055,0.000324703,0.0007478599,0.0004922471,0.00007648028,0.000032178377,0.00026933668,0.0002630307,0.0010379046],"category_scores_gemma":[0.00010463481,0.00027399385,0.00015233121,0.00090556534,0.000089237794,0.00012343217,0.00010080127,0.00053338596,0.0000531436],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042200575,0.0000699484,0.9697948,0.0046677543,0.00019202236,0.00052459084,0.0024894977,0.00007248969,0.006852733,0.00021216543,0.01290966,0.0017923375],"study_design_scores_gemma":[0.09894349,0.0008674843,0.22710317,0.18661802,0.0031728062,0.2568513,0.026542561,0.08875708,0.04796344,0.0003313557,0.054958813,0.007890507],"about_ca_topic_score_codex":0.0019603425,"about_ca_topic_score_gemma":0.0021499742,"teacher_disagreement_score":0.74269164,"about_ca_system_score_codex":0.0027262587,"about_ca_system_score_gemma":0.0006755837,"threshold_uncertainty_score":0.9999712},"labels":[],"label_agreement":null},{"id":"W1989531033","doi":"10.1016/j.lungcan.2011.05.009","title":"Mini Nutritional Assessment (MNA) and biochemical markers of cachexia in metastatic lung cancer patients: Interrelations and associations with prognosis","year":2011,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"China Academy of Building Research","keywords":"Medicine; Internal medicine; Adiponectin; Cachexia; Leptin; Gastroenterology; Lung cancer; Cancer; Ghrelin; Context (archaeology); Oncology; Insulin; Obesity; Insulin resistance; Hormone","score_opus":0.03305584892285819,"score_gpt":0.3659825178433134,"score_spread":0.33292666892045525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989531033","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937828,0.0025081334,0.00009597127,0.0019043529,0.00007211371,0.0007236381,0.0001981366,0.000014339778,0.00070051715],"genre_scores_gemma":[0.99203205,0.00049799326,0.00652536,0.0003382755,0.000025082949,0.00045624966,0.00006807517,0.000011933022,0.00004499148],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99920493,0.000034651046,0.0002580889,0.00017524729,0.00017566452,0.00015140293],"domain_scores_gemma":[0.9995218,0.00006189958,0.000120421784,0.000057316516,0.00013913307,0.00009946303],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000106709645,0.00009109384,0.00021637283,0.000130579,0.000048286543,0.000006271701,0.00002305784,0.000044126366,0.00020324452],"category_scores_gemma":[0.000021882744,0.00008041678,0.000021195161,0.00018223815,0.00007959438,0.0000790775,0.000017355527,0.00015770052,1.01760925e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001134736,0.00033011785,0.9956765,0.00056062435,0.00012800329,0.0000015675124,0.0006793933,5.9336446e-7,0.00010307072,0.00023160208,0.0018937975,0.00028123034],"study_design_scores_gemma":[0.002926875,0.00011322146,0.9933653,0.0011710475,0.00026023985,0.0000020927585,0.00020630177,0.0014955439,0.00019672932,0.00005714307,0.000115485076,0.00009002203],"about_ca_topic_score_codex":0.00069952407,"about_ca_topic_score_gemma":0.00036418144,"teacher_disagreement_score":0.0064293887,"about_ca_system_score_codex":0.00029341792,"about_ca_system_score_gemma":0.00018116465,"threshold_uncertainty_score":0.3279301},"labels":[],"label_agreement":null},{"id":"W1991781559","doi":"10.1016/j.lungcan.2011.05.004","title":"Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer","year":2011,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Sunitinib; Internal medicine; Clinical endpoint; Lung cancer; Oncology; Nausea; Maintenance therapy; Chemotherapy; Adverse effect; Carboplatin; Phases of clinical research; Surgery; Cancer; Clinical trial; Cisplatin","score_opus":0.02031515920557238,"score_gpt":0.3429522428959205,"score_spread":0.32263708369034816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1991781559","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921337,0.0012473131,0.00010711275,0.000061139035,0.00021629347,0.003973906,0.00010412726,0.000031150874,0.002125273],"genre_scores_gemma":[0.9938412,0.00045207067,0.00076352805,0.00044359997,0.00003317869,0.0016146952,0.000030965697,0.00006553844,0.0027552696],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983536,0.000045023386,0.00043221773,0.00043042187,0.0003331444,0.00040559474],"domain_scores_gemma":[0.9987828,0.00003480906,0.0002691799,0.00039077393,0.0003733603,0.00014906857],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00007502304,0.00030310778,0.00055100536,0.00015569355,0.00009088431,0.000007825014,0.00014019103,0.000044183253,0.00093192334],"category_scores_gemma":[0.000011011335,0.00019394212,0.000057609643,0.00046908288,0.000061995575,0.00014944663,0.000033415818,0.00017598615,0.0000019049472],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024322411,0.02982466,0.84290415,0.0006212129,0.0021908071,0.00023733193,0.04585049,0.00044626245,0.00037481575,0.000025201023,0.00075517374,0.05244747],"study_design_scores_gemma":[0.3425542,0.06918052,0.5601113,0.0034982879,0.0041265595,0.0000067031524,0.0092531415,0.0010467197,0.0076439297,0.000026384669,0.001339521,0.0012126977],"about_ca_topic_score_codex":0.006671943,"about_ca_topic_score_gemma":0.0049943295,"teacher_disagreement_score":0.31823182,"about_ca_system_score_codex":0.00039427902,"about_ca_system_score_gemma":0.0008284396,"threshold_uncertainty_score":0.99998134},"labels":[],"label_agreement":null},{"id":"W1993982225","doi":"10.1016/j.lungcan.2008.10.002","title":"Improved survival from lung cancer in British Columbia compared to Scotland—Are different treatment rates the whole story?","year":2008,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"BC Cancer Agency","keywords":"Medicine; Internal medicine; Lung cancer; Hazard ratio; Proportional hazards model; Multivariate analysis; Life expectancy; Surgery; Confidence interval; Population","score_opus":0.016353814824862152,"score_gpt":0.32141116587109064,"score_spread":0.3050573510462285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1993982225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9806263,0.012044088,0.000021159713,0.0029398787,0.0010074027,0.0017188699,0.0013545371,0.00006587826,0.00022189508],"genre_scores_gemma":[0.98424387,0.0012661207,0.000037906404,0.0006383941,0.0004661517,0.001840415,0.00017393786,0.00004918673,0.011284047],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985206,0.00007564737,0.000265732,0.0004726444,0.00026107332,0.00040426213],"domain_scores_gemma":[0.999135,0.000089497604,0.00010229486,0.00035459382,0.000109779954,0.00020881175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000039602477,0.00021792643,0.0005404275,0.000041766514,0.00032861414,0.000099674755,0.00012127262,0.00007453094,0.0007753937],"category_scores_gemma":[0.000013735172,0.00019765936,0.00011723076,0.0002284794,0.00007061529,0.00007189792,0.00003822141,0.00016544851,0.0000060439925],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011609149,0.0002999989,0.966887,0.000035663103,0.0006915816,0.00009758797,0.002415334,0.00020629326,0.00081451354,5.6861273e-7,0.024771873,0.0036634726],"study_design_scores_gemma":[0.005384728,0.000110482884,0.9835404,0.00046818177,0.00053273205,0.0000069976504,0.00057412137,0.0016914683,0.000225393,0.000003465416,0.007227223,0.00023478575],"about_ca_topic_score_codex":0.36576128,"about_ca_topic_score_gemma":0.82215613,"teacher_disagreement_score":0.45639485,"about_ca_system_score_codex":0.002216137,"about_ca_system_score_gemma":0.00040478192,"threshold_uncertainty_score":0.8490017},"labels":[],"label_agreement":null},{"id":"W1998005130","doi":"10.1016/j.lungcan.2014.09.016","title":"Referral patterns in advanced non-small cell lung cancer: Impact on delivery of treatment and survival in a contemporary population based cohort","year":2014,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"BC Cancer Agency","keywords":"Medicine; Cohort; Referral; Oncology; Lung cancer; Population; Internal medicine; Cohort study; Cancer; Gerontology; Family medicine; Environmental health","score_opus":0.018891360673866275,"score_gpt":0.32253025293221255,"score_spread":0.3036388922583463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998005130","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947521,0.0026833238,0.00001180492,0.00026760963,0.00022315752,0.001305518,0.00013280772,0.000017532835,0.0006061553],"genre_scores_gemma":[0.99733543,0.0014142353,0.000040856678,0.00019983268,0.00008694583,0.00067781867,0.00012895575,0.000034847486,0.00008106836],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986923,0.00007787963,0.00036780248,0.00042243936,0.00016726607,0.00027234986],"domain_scores_gemma":[0.999287,0.00011285186,0.00015868153,0.0002742859,0.00004630075,0.00012086049],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013512715,0.00027376207,0.00063507695,0.00018483661,0.000023422564,0.0000093021345,0.00004546187,0.00009456429,0.00007075267],"category_scores_gemma":[0.0000054887823,0.00020654604,0.00010389778,0.00015151815,0.000015419486,0.000071333605,0.000014376916,0.00011308723,4.537392e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00096608204,0.00038334183,0.99040765,0.00038724675,0.00012168376,0.000016695329,0.00024922992,0.0036357734,0.00023965535,0.000004029314,0.00009305956,0.0034955523],"study_design_scores_gemma":[0.0091225635,0.0009534446,0.9738833,0.0015546767,0.00017487766,5.1874923e-7,0.000029543015,0.012326687,0.001726825,0.0000020728967,0.00004883953,0.0001766841],"about_ca_topic_score_codex":0.10024447,"about_ca_topic_score_gemma":0.020715889,"teacher_disagreement_score":0.07952858,"about_ca_system_score_codex":0.003045416,"about_ca_system_score_gemma":0.00038866888,"threshold_uncertainty_score":0.9971535},"labels":[],"label_agreement":null},{"id":"W1998447850","doi":"10.1016/j.lungcan.2009.03.030","title":"Lung cancer screening using low-dose computed tomography in at-risk individuals: The Toronto experience","year":2009,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Lung cancer screening; Lung cancer; Nodule (geology); Stage (stratigraphy); Radiology; Cancer; Nuclear medicine; Internal medicine","score_opus":0.017731119485595973,"score_gpt":0.3445140233105349,"score_spread":0.3267829038249389,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998447850","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91719395,0.0788986,0.0002465613,0.0014566474,0.000507664,0.0010792906,0.000062697654,0.000082696366,0.00047189192],"genre_scores_gemma":[0.9921377,0.0036433223,0.0009719418,0.0022059053,0.00046264564,0.00042415745,0.000015379357,0.00003472487,0.00010422691],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978825,0.00008576494,0.00039551314,0.00056441536,0.00049111026,0.00058073667],"domain_scores_gemma":[0.99893945,0.00008631587,0.00020538272,0.0004983101,0.00008644177,0.0001840707],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018465768,0.00032445957,0.0004538258,0.000091434034,0.00028302692,0.00005644183,0.00021123886,0.00011343569,0.0005638881],"category_scores_gemma":[0.000014010967,0.00022986796,0.00017941756,0.0004970629,0.000086808155,0.00022795402,0.00008296063,0.00024181718,0.0000010728386],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016640867,0.00020534625,0.9659927,0.00007232865,0.00029187594,0.000038781352,0.005381828,0.0022416778,0.00020556543,0.00003521797,0.0029383528,0.022429943],"study_design_scores_gemma":[0.0035566913,0.000105176856,0.96736276,0.001977605,0.00057746633,0.000011577847,0.00037399557,0.0215165,0.001425036,0.000012088245,0.0027228286,0.00035828463],"about_ca_topic_score_codex":0.024908021,"about_ca_topic_score_gemma":0.010930018,"teacher_disagreement_score":0.075255275,"about_ca_system_score_codex":0.0023275323,"about_ca_system_score_gemma":0.00018970635,"threshold_uncertainty_score":0.9815852},"labels":[],"label_agreement":null},{"id":"W1998469340","doi":"10.1016/j.lungcan.2014.01.020","title":"Clinically relevant determinants of body composition, function and nutritional status as mortality predictors in lung cancer patients","year":2014,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Body Composition Measurement Techniques","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"McGill University","keywords":"Medicine; Bioelectrical impedance analysis; Sarcopenia; Cachexia; Lung cancer; Intensive care medicine; Malnutrition; Quality of life (healthcare); Anthropometry; Clinical Practice; Cancer; Physical therapy; Internal medicine; Body mass index","score_opus":0.03263241219288492,"score_gpt":0.4028540895371105,"score_spread":0.37022167734422556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998469340","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05821594,0.93694776,0.000099259014,0.000029786397,0.0007209865,0.0030418816,0.0006396934,0.00010727234,0.00019742959],"genre_scores_gemma":[0.045533027,0.95208496,0.00016661904,0.00017463058,0.0003278069,0.00096148293,0.0006447432,0.00006724258,0.000039472252],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962632,0.00028863776,0.0016677948,0.00062823173,0.00079028297,0.00036185738],"domain_scores_gemma":[0.9978177,0.00014564535,0.00096085045,0.00038047074,0.000481401,0.00021394182],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00051194476,0.00042858213,0.0018720481,0.00030038203,0.00006307951,0.000019473766,0.00012205228,0.00043407813,0.00019820251],"category_scores_gemma":[0.000081728205,0.00037944806,0.00028093718,0.00028334843,0.00015003857,0.000120098695,0.00007257175,0.00055651227,0.0000018424154],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002890965,0.00059877586,0.9073378,0.044445816,0.00045982053,0.000007814664,0.000027466389,7.469724e-7,0.000030829706,0.000037318696,0.0024057305,0.044358775],"study_design_scores_gemma":[0.004985594,0.001284019,0.66959137,0.17615129,0.008954087,0.00001625345,0.0000037939249,0.00045593415,0.000065391985,0.00011758104,0.13742009,0.0009546168],"about_ca_topic_score_codex":0.0005643271,"about_ca_topic_score_gemma":0.0001296073,"teacher_disagreement_score":0.23774645,"about_ca_system_score_codex":0.0009396331,"about_ca_system_score_gemma":0.00077192654,"threshold_uncertainty_score":0.9998658},"labels":[],"label_agreement":null},{"id":"W1999448758","doi":"10.1016/j.lungcan.2012.06.002","title":"Rising incidence of adenocarcinoma of the lung in Canada","year":2012,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Public Health Agency of Canada","funders":"","keywords":"Adenocarcinoma; Medicine; Incidence (geometry); Lung cancer; Cohort; Small-cell carcinoma; Cancer; Oncology; Internal medicine; Adenocarcinoma of the lung; Cohort study; Carcinoma; Demography","score_opus":0.02995053333884998,"score_gpt":0.32370334262935885,"score_spread":0.29375280929050884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1999448758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.974636,0.023048023,0.000019659044,0.00037318768,0.00037048588,0.00017851866,0.000009441159,0.0000032009434,0.0013614448],"genre_scores_gemma":[0.9991484,0.00006905856,0.00009533565,0.00047484285,0.000109433335,0.000011113089,5.975515e-7,0.000007777744,0.000083432795],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989545,0.000028956862,0.00026471837,0.00009984755,0.00039051205,0.00026148534],"domain_scores_gemma":[0.9994296,0.0000406889,0.00014113988,0.00024029322,0.00007644399,0.000071824805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001691228,0.00008017391,0.00022656257,0.00003304767,0.000023212202,0.0000016763453,0.0001365424,0.000034236436,0.0001256715],"category_scores_gemma":[0.00006809866,0.00005809523,0.000046691042,0.0003186025,0.00004379224,0.000100475285,0.000056961715,0.0001503126,2.4887035e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004512802,0.000007264876,0.99464864,0.00014004248,0.00001826548,0.0000036332974,0.00045359932,0.00014866801,0.0011614233,0.000066419045,0.0027086153,0.00059829693],"study_design_scores_gemma":[0.00029210877,0.00001015455,0.9884937,0.00079072086,0.000067207664,0.000011374542,0.00036199676,0.0006856841,0.009014994,0.000005766874,0.0002068259,0.000059478993],"about_ca_topic_score_codex":0.928052,"about_ca_topic_score_gemma":0.74882483,"teacher_disagreement_score":0.17922714,"about_ca_system_score_codex":0.0009401334,"about_ca_system_score_gemma":0.0014777906,"threshold_uncertainty_score":0.2621537},"labels":[],"label_agreement":null},{"id":"W2000030988","doi":"10.1016/j.lungcan.2010.07.005","title":"Uptake and tolerance of adjuvant chemotherapy in early stage NSCLC patients in Alberta, Canada","year":2010,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; Alberta Health Services","funders":"","keywords":"Medicine; Chemotherapy; Internal medicine; Stage (stratigraphy); Lung cancer; Clinical trial; Cancer; Population; Oncology; Surgery","score_opus":0.004274299695362077,"score_gpt":0.2545818721247282,"score_spread":0.25030757242936613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000030988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967457,0.00072931143,2.412803e-7,0.0010295616,0.00029996422,0.00042840667,0.000036859834,0.0000033214003,0.0007266569],"genre_scores_gemma":[0.9981089,0.0005093781,0.00004508424,0.00059067266,0.0000418773,0.000104671606,0.0000070447145,0.000016258422,0.00057606335],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991936,0.0000077939285,0.0002181321,0.00021288893,0.00017517405,0.00019239265],"domain_scores_gemma":[0.99960566,0.000034049615,0.000064799904,0.00017835488,0.000040621726,0.000076546115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00003893088,0.00011580973,0.000280594,0.000047002934,0.000011430133,0.000004640271,0.00004336147,0.000051255043,0.00014787025],"category_scores_gemma":[0.000010884149,0.00009650922,0.000021681613,0.00012136718,0.000027524107,0.00004348713,0.000010816002,0.00014639912,3.47566e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013495058,0.00015137275,0.98872507,0.00010223677,0.000028456974,0.000010934988,0.000610574,0.000009385324,0.0000959241,0.000040375373,0.0006162788,0.009474439],"study_design_scores_gemma":[0.004598168,0.000073469586,0.9869896,0.00028633696,0.000018740911,3.898749e-7,0.000014081332,0.00014605702,0.0013924282,0.0000035413232,0.006389731,0.000087462875],"about_ca_topic_score_codex":0.93471104,"about_ca_topic_score_gemma":0.9879833,"teacher_disagreement_score":0.05327225,"about_ca_system_score_codex":0.00032248197,"about_ca_system_score_gemma":0.0003899524,"threshold_uncertainty_score":0.39355317},"labels":[],"label_agreement":null},{"id":"W2000715692","doi":"10.1016/s0169-5002(05)80908-0","title":"P-415 Occupational distribution, incidence and survival rates of malignant mesothelioma in Nova Scotia, Canada 1990–2002","year":2005,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Nova scotia; Medicine; Mesothelioma; Incidence (geometry); Nova (rocket); Distribution (mathematics); Demography; Geography; Pathology; Archaeology","score_opus":0.01148010091261293,"score_gpt":0.2924919957574463,"score_spread":0.28101189484483335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000715692","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99485373,0.0029381874,0.000024697369,0.0010920475,0.0001029729,0.00014581307,0.00063915906,0.0000052978157,0.00019807405],"genre_scores_gemma":[0.99880785,0.00010718133,0.00009214419,0.00032726064,0.00011026406,0.000010465054,0.00016740788,0.0000070992805,0.00037033917],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991673,0.000016125041,0.00020901342,0.0001631213,0.00030482395,0.00013962062],"domain_scores_gemma":[0.9996839,0.00004521274,0.00005990286,0.00008810315,0.000035760175,0.00008712447],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00006008389,0.00009382003,0.00015830758,0.000030641728,0.000023735389,0.0000041811777,0.00004020233,0.000028823562,0.0009913169],"category_scores_gemma":[0.000029043074,0.000081558646,0.000021979138,0.0001319674,0.00007163987,0.000075336255,0.000025664012,0.00005071055,0.0000048005927],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018623237,0.000065470515,0.9913915,0.000074631935,0.000024632109,0.000008618516,0.000021804803,0.00030818855,0.0009204211,0.00014985153,0.0059793545,0.0008693297],"study_design_scores_gemma":[0.0005814748,0.000021772596,0.99438655,0.00015394292,0.000037417994,0.0000058368832,0.000022915083,0.0009217892,0.0020312208,0.000008426582,0.0017413961,0.00008725419],"about_ca_topic_score_codex":0.44927236,"about_ca_topic_score_gemma":0.6525313,"teacher_disagreement_score":0.20325898,"about_ca_system_score_codex":0.0003664272,"about_ca_system_score_gemma":0.00039810527,"threshold_uncertainty_score":0.9999219},"labels":[],"label_agreement":null},{"id":"W2000856265","doi":"10.1016/s0169-5002(99)00093-8","title":"Exposure to environmental tobacco smoke and the risk of lung cancer: a meta-analysis","year":2000,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Smoking Behavior and Cessation","field":"Medicine","cited_by":175,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut National de la Recherche Scientifique; McGill University","funders":"Health Canada","keywords":"Medicine; Relative risk; Lung cancer; Meta-analysis; Tobacco smoke; Confidence interval; Confounding; Cohort study; Cohort; Cancer; Demography; Internal medicine; Environmental health","score_opus":0.056858556199907685,"score_gpt":0.37662433203467754,"score_spread":0.31976577583476984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000856265","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0068049007,0.9906744,0.000007180018,0.000117762494,0.00012997274,0.0012672329,0.0008161423,0.00001455964,0.00016785756],"genre_scores_gemma":[0.014943449,0.9818737,0.00001119175,0.00015421043,0.00017968685,0.0012624245,0.000102085054,0.00003982188,0.0014334242],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99813855,0.00021035352,0.0005502019,0.00043742347,0.00046375935,0.00019973735],"domain_scores_gemma":[0.99875945,0.00011643174,0.00040564765,0.00059894094,0.000018860188,0.000100661986],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003425659,0.00034820256,0.0028738,0.00019791244,0.00007966573,0.000021321011,0.0001512729,0.0002071472,0.0046452666],"category_scores_gemma":[0.000011688882,0.00019113578,0.0018171729,0.00048221336,0.00009758427,0.00003410597,0.000046285142,0.00035248397,0.0000010198069],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010297809,0.000056034263,0.11359322,0.0025875298,0.17950203,0.000006891733,0.0006674716,0.0000778078,3.18132e-7,0.000007576367,0.0010605083,0.7023376],"study_design_scores_gemma":[0.0004664414,0.000024475752,0.008554576,0.0004884411,0.77599823,0.000004152729,0.000018130722,0.0000094029165,0.0000019943839,7.181678e-7,0.21425693,0.00017650779],"about_ca_topic_score_codex":0.0034136,"about_ca_topic_score_gemma":0.00023921575,"teacher_disagreement_score":0.70216113,"about_ca_system_score_codex":0.00032751303,"about_ca_system_score_gemma":0.00013534512,"threshold_uncertainty_score":0.99626464},"labels":[],"label_agreement":null},{"id":"W2001550450","doi":"10.1016/j.lungcan.2011.07.004","title":"Lung cancer associated venous thromboembolic disease: A comprehensive review","year":2011,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université de Montréal; Hôpital Notre-Dame","funders":"","keywords":"Medicine; Lung cancer; Cancer; Thrombosis; Disease; Venous thrombosis; Risk factor; Internal medicine; Incidence (geometry); Oncology; Intensive care medicine","score_opus":0.056645546334832146,"score_gpt":0.397982378862458,"score_spread":0.34133683252762587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2001550450","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000012666274,0.98669666,0.0000031556967,0.00048233126,0.0018977878,0.0071527627,0.0006372045,0.00027188074,0.0028455753],"genre_scores_gemma":[0.000009238426,0.9840412,0.000018507571,0.0056711817,0.00095720467,0.0063507496,0.0006506616,0.00030618216,0.0019950436],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956082,0.00028432716,0.0011945148,0.0011915945,0.0006767328,0.0010445944],"domain_scores_gemma":[0.99653363,0.00010831396,0.0010499962,0.0012701534,0.00039255008,0.0006453516],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00023020254,0.0011327002,0.006947695,0.00025826966,0.00021165781,0.000047620026,0.00053255283,0.00040435715,0.005333078],"category_scores_gemma":[0.00009025535,0.00091243844,0.0014971447,0.0008461337,0.00012803606,0.000107695196,0.00031129055,0.0008699436,0.00014326164],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00000909667,0.0007532147,0.00010485264,0.31756106,0.00541996,0.00014462753,0.00010401799,0.0000010446498,9.830842e-8,0.00017670094,0.3069968,0.36872855],"study_design_scores_gemma":[0.00037428967,0.000056965004,0.0015037964,0.2776756,0.03763675,0.00000653411,0.0000031139152,0.000011854961,9.4769305e-8,0.000006216245,0.68210423,0.0006205221],"about_ca_topic_score_codex":0.0016800166,"about_ca_topic_score_gemma":0.00013596217,"teacher_disagreement_score":0.37510747,"about_ca_system_score_codex":0.001953771,"about_ca_system_score_gemma":0.0018828236,"threshold_uncertainty_score":0.9993326},"labels":[],"label_agreement":null},{"id":"W2004018927","doi":"10.1016/j.lungcan.2011.12.003","title":"Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: A real-world cost-effectiveness analysis","year":2012,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency; Ministry of Health; Canadian Centre for Applied Research in Cancer Control","funders":"BC Cancer Agency","keywords":"Erlotinib; Medicine; Lung cancer; Internal medicine; Oncology; Cost-effectiveness analysis; Cohort; Survival analysis; Erlotinib Hydrochloride; Cost effectiveness; Univariate analysis; Population; Cancer; Multivariate analysis; Epidermal growth factor receptor","score_opus":0.028621419008751803,"score_gpt":0.41023038328219824,"score_spread":0.3816089642734464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004018927","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95399016,0.024640456,0.0014847962,0.00025617421,0.0010475033,0.010607048,0.0028568006,0.0000985001,0.0050185416],"genre_scores_gemma":[0.9699473,0.0036785698,0.0012663405,0.00009735775,0.0005033175,0.011756474,0.0006988927,0.000080519,0.011971223],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980433,0.000054984685,0.00048608246,0.00051710044,0.00025673702,0.0006417683],"domain_scores_gemma":[0.9980386,0.00025710987,0.00036876733,0.00047448045,0.0005403764,0.00032070559],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000097527365,0.00041670335,0.0011044352,0.0003281207,0.00016545792,0.000014423687,0.00009406031,0.00011037847,0.0003276368],"category_scores_gemma":[0.0000151033255,0.00029830672,0.00048068466,0.0010052508,0.00006208136,0.00015656701,0.000024668763,0.000088585344,0.0000027803003],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034844447,0.0019049436,0.9306322,0.0027660418,0.010604169,0.000021213045,0.014157476,0.004775846,0.0019126118,0.0000536911,0.000516811,0.02917059],"study_design_scores_gemma":[0.053938877,0.0061159665,0.5570798,0.0027819332,0.15638955,0.000009216252,0.00909798,0.0064530754,0.16984323,0.000009768819,0.036510468,0.0017701295],"about_ca_topic_score_codex":0.013091286,"about_ca_topic_score_gemma":0.020063587,"teacher_disagreement_score":0.37355235,"about_ca_system_score_codex":0.0029606353,"about_ca_system_score_gemma":0.0010590844,"threshold_uncertainty_score":0.9999469},"labels":[],"label_agreement":null},{"id":"W2004298772","doi":"10.1016/j.lungcan.2011.09.003","title":"Lung cancer histologies associated with emphysema on computed tomography","year":2011,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University; Jewish General Hospital","funders":"Jewish General Hospital","keywords":"Medicine; Lung cancer; COPD; Adenocarcinoma; Odds ratio; Internal medicine; Squamous carcinoma; Lung cancer screening; Pulmonology; Small-cell carcinoma; Cancer; Radiology; Carcinoma; Oncology","score_opus":0.022944144480351387,"score_gpt":0.29865045225307646,"score_spread":0.2757063077727251,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004298772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9603042,0.018513508,0.000050820614,0.0021475991,0.0011762051,0.0012855475,0.00013347936,0.0004716481,0.015917003],"genre_scores_gemma":[0.9951082,0.0007114884,0.00020481652,0.0017531071,0.00017962519,0.00085286784,0.000040263585,0.000055247063,0.0010943773],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984612,0.000038888567,0.00022252025,0.00048858614,0.00035183545,0.0004370074],"domain_scores_gemma":[0.99904245,0.000068890346,0.00016779832,0.00038212634,0.0001762013,0.0001625581],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000060106988,0.00031142755,0.0004974759,0.00014522563,0.00011852154,0.00001685883,0.000119322896,0.00012390205,0.0007956382],"category_scores_gemma":[0.000013047791,0.0002162103,0.00015373276,0.0004252749,0.00011360489,0.00007314224,0.000030593314,0.00020080972,0.0000062963854],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005650137,0.00064251426,0.9450476,0.00018238701,0.0021259387,0.00013875678,0.0010533135,0.000058056004,0.00003474338,0.00026615645,0.046858985,0.0030265169],"study_design_scores_gemma":[0.0039115343,0.0007692453,0.9847916,0.002304875,0.0015194466,0.0000056693084,0.000052071853,0.00055310095,0.0032119774,0.000024653154,0.002469804,0.00038604706],"about_ca_topic_score_codex":0.0030764604,"about_ca_topic_score_gemma":0.0017574854,"teacher_disagreement_score":0.04438918,"about_ca_system_score_codex":0.0013512401,"about_ca_system_score_gemma":0.0002534995,"threshold_uncertainty_score":0.88168},"labels":[],"label_agreement":null},{"id":"W2004469331","doi":"10.1016/j.lungcan.2008.02.002","title":"Brief report: Retrospective review of efficacy of erlotinib or gefitinib compared to docetaxel as subsequent line therapy in advanced non-small cell lung cancer (NSCLC) following failure of platinum-based chemotherapy","year":2008,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Erlotinib; Docetaxel; Gefitinib; Oncology; Chemotherapy; Lung cancer; Internal medicine; non-small cell lung cancer (NSCLC); Cancer; Epidermal growth factor receptor","score_opus":0.02022896833383872,"score_gpt":0.35836567103033284,"score_spread":0.3381367026964941,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004469331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95946336,0.03343601,0.00019407172,0.0012665231,0.00025913253,0.004123937,0.00017782797,0.000038035923,0.0010411139],"genre_scores_gemma":[0.97975355,0.013630773,0.003191875,0.0014792999,0.00011747792,0.00071984925,0.00010849412,0.0000834381,0.00091526797],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99715203,0.000054359174,0.0012424081,0.00059172756,0.00056855974,0.00039090635],"domain_scores_gemma":[0.99759173,0.00013792179,0.00090190425,0.00064375415,0.0005540841,0.00017061908],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002238905,0.00038250416,0.001474751,0.00019578192,0.000059737773,0.0000045518127,0.0001782266,0.00011430909,0.0005837996],"category_scores_gemma":[0.00009796244,0.00030209738,0.00038279465,0.00096241524,0.000084641564,0.00008458665,0.000019150038,0.0002252929,7.695438e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0074659092,0.0029175475,0.8671415,0.012810647,0.0025128047,0.0007252159,0.013071477,0.004432695,0.077295355,0.000026243953,0.0041795755,0.0074210316],"study_design_scores_gemma":[0.06527852,0.0025284102,0.5637925,0.066835806,0.0018754955,0.000068822126,0.00035110948,0.000995108,0.29103455,0.000008280636,0.0061745183,0.0010568526],"about_ca_topic_score_codex":0.003573274,"about_ca_topic_score_gemma":0.0008409918,"teacher_disagreement_score":0.303349,"about_ca_system_score_codex":0.0007550097,"about_ca_system_score_gemma":0.0022549287,"threshold_uncertainty_score":0.99994314},"labels":[],"label_agreement":null},{"id":"W2006129790","doi":"10.1016/j.lungcan.2006.05.009","title":"Syndrome of inappropriate antidiuretic hormone secretion (SIADH) in patients with limited stage small cell lung cancer","year":2006,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Saskatchewan Cancer Agency; University of Saskatchewan","funders":"Vanderbilt University","keywords":"Medicine; Stage (stratigraphy); Antidiuretic; Syndrome of inappropriate antidiuretic hormone secretion; Internal medicine; Performance status; Gastroenterology; Cancer; Statistical significance; Pleural effusion; Lung cancer; Surgery; Hormone","score_opus":0.007191848446745408,"score_gpt":0.26870471296888465,"score_spread":0.26151286452213923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006129790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99329156,0.004017319,0.00003714981,0.000238371,0.00010207009,0.0014439237,0.00009356306,0.000054076252,0.0007219915],"genre_scores_gemma":[0.99601287,0.0005277997,0.00024454232,0.00006836733,0.00005311489,0.00021418379,0.00007280118,0.00006624601,0.0027400532],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979306,0.000071755865,0.00038833803,0.0004347994,0.0006104926,0.0005640067],"domain_scores_gemma":[0.99903446,0.00003721465,0.00021539403,0.00035082066,0.0002360693,0.00012606433],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000081335864,0.0002532199,0.00047578488,0.00028579237,0.00003815582,0.000015131074,0.00013943043,0.000025951551,0.00016243834],"category_scores_gemma":[0.000024373689,0.00020068637,0.000057085294,0.0006812778,0.000109155335,0.00014934155,0.0000626508,0.00036707285,0.0000022409736],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012671003,0.0004058257,0.9861802,0.0012229049,0.000049411447,0.0005649661,0.00006655811,0.0009661906,0.00861574,0.000021493302,0.0004453101,0.00019431204],"study_design_scores_gemma":[0.0069101094,0.0008098981,0.9801105,0.00066497334,0.00012986215,0.000015403804,0.000029683946,0.001648698,0.008911058,0.000010396123,0.0005066677,0.00025270513],"about_ca_topic_score_codex":0.004171701,"about_ca_topic_score_gemma":0.0010632472,"teacher_disagreement_score":0.0060696444,"about_ca_system_score_codex":0.00039233745,"about_ca_system_score_gemma":0.00023861742,"threshold_uncertainty_score":0.81837523},"labels":[],"label_agreement":null},{"id":"W2006472996","doi":"10.1016/j.lungcan.2010.01.012","title":"Population-based patterns and cost of management of metastatic non-small cell lung cancer after completion of chemotherapy until death","year":2010,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Medicine; Chemotherapy; Lung cancer; Medical prescription; Population; Cancer registry; Total cost; Average cost; Cancer; Emergency medicine; Medical record; Intensive care medicine; Internal medicine","score_opus":0.010535648217525272,"score_gpt":0.3217445640135893,"score_spread":0.311208915796064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006472996","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99476427,0.0010507595,0.0020557945,0.0002202071,0.00018676533,0.001038342,0.0003132682,0.00000890678,0.00036167543],"genre_scores_gemma":[0.9962553,0.000327955,0.0024117474,0.00018531893,0.000034096487,0.00033968597,0.00008095722,0.000024808292,0.00034015262],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991757,0.000012310267,0.00029794374,0.0001874457,0.00019158765,0.0001350096],"domain_scores_gemma":[0.9993413,0.000026259668,0.00022152545,0.00021687224,0.00013426757,0.000059780978],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005823231,0.00013457268,0.00033199528,0.00008867079,0.000023250908,0.000004696927,0.00004573158,0.000037625574,0.0004913525],"category_scores_gemma":[0.0000012823806,0.00011215404,0.00007016004,0.00011176792,0.000032765704,0.000036742385,0.000012332886,0.0000716526,1.752975e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018967858,0.00020184043,0.9893858,0.0028542269,0.0004911033,0.000003884755,0.00041957418,0.00029780326,0.0026199664,0.00005844173,0.000099414385,0.0033782574],"study_design_scores_gemma":[0.003802068,0.00006765847,0.9791389,0.0007158187,0.0015284405,6.2656164e-7,0.00005714393,0.0044466206,0.009950937,0.000009956069,0.00018037546,0.000101419355],"about_ca_topic_score_codex":0.0094134845,"about_ca_topic_score_gemma":0.0018445185,"teacher_disagreement_score":0.010246874,"about_ca_system_score_codex":0.0001080273,"about_ca_system_score_gemma":0.00010231606,"threshold_uncertainty_score":0.9971829},"labels":[],"label_agreement":null},{"id":"W2006888413","doi":"10.1016/j.lungcan.2005.11.006","title":"Targeting colloidal particulates to thoracic lymph nodes","year":2006,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lymphatic System and Diseases","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network; University of Toronto","funders":"University of Toronto","keywords":"Lymphatic system; Lymph; Medicine; Pathology; Clearance; Anatomy","score_opus":0.00886427457805322,"score_gpt":0.32012398770829753,"score_spread":0.3112597131302443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006888413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98649764,0.005657029,0.00018080708,0.0010767758,0.00030315973,0.00034913942,0.000015299867,0.00010952966,0.005810611],"genre_scores_gemma":[0.9938269,0.000011856389,0.000383819,0.0007047218,0.000751954,0.00014724767,0.000014733171,0.00002021495,0.004138551],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991258,0.000020708145,0.0001962131,0.00019415261,0.00021211675,0.00025102543],"domain_scores_gemma":[0.9995546,0.000038891074,0.00004088485,0.0001447628,0.000075681965,0.00014523078],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007372196,0.00010908187,0.00019663599,0.000042815816,0.00006886861,0.000028424485,0.000043361604,0.0000381804,0.0003873699],"category_scores_gemma":[0.00005265168,0.00008525796,0.000060389553,0.00017471358,0.000018764536,0.000045807377,0.000020742209,0.000007946344,0.0000716163],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000107366526,0.00007257067,0.9589767,0.00028559184,0.00004448759,0.00002582261,0.00012178073,0.0008342145,0.017552583,0.00011109579,0.021176899,0.00069088006],"study_design_scores_gemma":[0.0027597686,0.000058576406,0.9375411,0.0013485622,0.00075011665,0.000035923706,0.0004305508,0.007497383,0.03849284,0.00020388924,0.010299267,0.0005819908],"about_ca_topic_score_codex":0.0010700399,"about_ca_topic_score_gemma":0.000025650561,"teacher_disagreement_score":0.021435576,"about_ca_system_score_codex":0.00018885639,"about_ca_system_score_gemma":0.00015291179,"threshold_uncertainty_score":0.42414287},"labels":[],"label_agreement":null},{"id":"W2007240877","doi":"10.1016/j.lungcan.2013.05.007","title":"Clinical evaluation of microRNA expression profiling in non small cell lung cancer","year":2013,"lang":"en","type":"article","venue":"Lung Cancer","topic":"MicroRNA in disease regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":198,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"National and Kapodistrian University of Athens","keywords":"microRNA; Lung cancer; Pathogenesis; Gene expression profiling; Medicine; Cancer; Fold change; Gene expression; Cancer research; Pathological; Molecular biology; Pathology; Gene; Biology; Internal medicine; Genetics","score_opus":0.019094468253357384,"score_gpt":0.34699834123570766,"score_spread":0.3279038729823503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007240877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888177,0.009232618,0.0003124527,0.000048438094,0.00030221927,0.0009266653,0.000016758526,0.0000051694465,0.00033800144],"genre_scores_gemma":[0.99772364,0.00041134236,0.0008138599,0.00006692514,0.0002788875,0.0004291644,0.0000672102,0.000022250413,0.00018670753],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99879444,0.00013647298,0.00037176075,0.0003355099,0.00017847469,0.0001833218],"domain_scores_gemma":[0.99917907,0.000010968804,0.00020697732,0.00027058483,0.00027361617,0.00005880707],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004112248,0.00011995966,0.00015188639,0.000041300227,0.000023250816,0.000010594799,0.00012630831,0.00018226949,0.00025493457],"category_scores_gemma":[0.000038980026,0.00011420354,0.000079000245,0.00008039669,0.000032802807,0.000007703627,0.000069527014,0.00008960492,0.000002699059],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003342876,0.000048526228,0.18588652,0.00012894627,0.000017491868,1.3406691e-7,0.000038331542,0.0016480411,0.8067069,4.458988e-7,0.001813182,0.0036780469],"study_design_scores_gemma":[0.0011316097,0.00002064158,0.13708943,0.00020579764,0.00008196651,1.931347e-7,0.000020676182,0.028018286,0.8330902,0.000009909825,0.0001868639,0.00014444852],"about_ca_topic_score_codex":0.0003666909,"about_ca_topic_score_gemma":0.00014866484,"teacher_disagreement_score":0.048797075,"about_ca_system_score_codex":0.000103879145,"about_ca_system_score_gemma":0.00029169177,"threshold_uncertainty_score":0.4657085},"labels":[],"label_agreement":null},{"id":"W2009395127","doi":"10.1016/j.lungcan.2012.06.011","title":"Cediranib in patients with malignant mesothelioma: A phase II trial of the University of Chicago Phase II Consortium","year":2012,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute","keywords":"Medicine; Internal medicine; Clinical endpoint; Regimen; Gastroenterology; Progressive disease; Dosing; Chemotherapy; Phases of clinical research; Oncology; Surgery; Randomized controlled trial","score_opus":0.009072014609089915,"score_gpt":0.26735822757912303,"score_spread":0.2582862129700331,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009395127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982454,0.00029794764,0.0000039506253,0.00013664286,0.00012637957,0.00051036605,0.00027241503,0.0000047817243,0.00040208123],"genre_scores_gemma":[0.9994482,0.000019801675,0.000023860395,0.00006738423,0.00005417947,0.000004097989,0.000024048892,0.0000067421997,0.0003517122],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994009,0.000023106633,0.00012519008,0.000092478105,0.00023655876,0.00012175809],"domain_scores_gemma":[0.9996541,0.000011975948,0.00010415928,0.00013999996,0.000019800653,0.00006995691],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000045515233,0.00007344166,0.00016638871,0.00003277772,0.00005885938,5.096756e-7,0.00005562603,0.000029233057,0.000534182],"category_scores_gemma":[0.000008598567,0.000046986388,0.000056685338,0.000116150455,0.00012590195,0.000059575043,0.0000472532,0.00004930602,9.4035056e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0824291,0.011696137,0.8999899,0.00011495571,0.00013218496,0.000002414398,0.0008966731,0.000013230793,0.0022308058,0.00007247191,0.0008400005,0.0015821381],"study_design_scores_gemma":[0.18196243,0.0030582242,0.8090855,0.00026459072,0.0004599306,5.7305533e-7,0.000102378195,0.000051964354,0.0027525118,0.000004760981,0.0021518534,0.00010532653],"about_ca_topic_score_codex":0.00017218819,"about_ca_topic_score_gemma":0.000021604264,"teacher_disagreement_score":0.09953333,"about_ca_system_score_codex":0.00008198312,"about_ca_system_score_gemma":0.00006854105,"threshold_uncertainty_score":0.58489186},"labels":[],"label_agreement":null},{"id":"W2009482902","doi":"10.1016/j.lungcan.2006.04.007","title":"Risk of lung cancer following nonmalignant respiratory conditions: Evidence from two case-control studies in Montreal, Canada","year":2006,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal; Institut National de la Recherche Scientifique; McGill University; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Lung cancer; Odds ratio; Context (archaeology); Respiratory disease; Asthma; Internal medicine; Pneumonia; Case-control study; Cancer; Confounding; Population; Risk factor; Lung; Environmental health","score_opus":0.024214358865067356,"score_gpt":0.36603021768674476,"score_spread":0.3418158588216774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009482902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7421809,0.25449497,0.000011755237,0.0003052495,0.00045655525,0.0008800252,0.0015234249,0.000019801539,0.00012733268],"genre_scores_gemma":[0.9961403,0.001884938,0.000029184432,0.0002493235,0.00058553176,0.0006679941,0.00001752451,0.00004216333,0.00038302093],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99724674,0.000249998,0.00061123766,0.0005861887,0.00073104206,0.0005747855],"domain_scores_gemma":[0.99794996,0.0008264985,0.00024359561,0.0004944037,0.00030384742,0.00018169028],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003240309,0.00028544923,0.0007180713,0.00017188505,0.00015850656,0.000013157505,0.0001540512,0.00007467929,0.00045880873],"category_scores_gemma":[0.00030658438,0.00025835822,0.00017546753,0.00042371007,0.00019140937,0.00022286706,0.000071252325,0.00036145456,0.0000014553423],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030035473,0.000057800895,0.9722402,0.00055470504,0.0010797518,0.0064148353,0.00029657458,0.005048393,0.0017152741,0.000008456907,0.011141342,0.0011423134],"study_design_scores_gemma":[0.004972334,0.000029846171,0.97586036,0.0036054298,0.0015869549,0.000023082295,0.0006928612,0.011774941,0.0008409495,0.00009177896,0.00021107563,0.00031039215],"about_ca_topic_score_codex":0.982367,"about_ca_topic_score_gemma":0.98352826,"teacher_disagreement_score":0.25395942,"about_ca_system_score_codex":0.0043956423,"about_ca_system_score_gemma":0.0028976102,"threshold_uncertainty_score":0.9999869},"labels":[],"label_agreement":null},{"id":"W2012290550","doi":"10.1016/s0169-5002(00)80349-9","title":"Concurrent chemo- (cisplatin and etoposide) radiation for stage III non-small cell lung cancer: Lack of correlation of p53 expression to treatment response","year":2000,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Medicine; Etoposide; Oncology; Cisplatin; Lung cancer; Internal medicine; Stage (stratigraphy); Radiation therapy; Correlation; Cancer research; Chemotherapy; Biology","score_opus":0.028126937392692876,"score_gpt":0.391023161995535,"score_spread":0.3628962246028421,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012290550","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98476636,0.010089015,0.0006272333,0.0007167703,0.00019811039,0.002821632,0.00032281803,0.000020600497,0.00043743517],"genre_scores_gemma":[0.9833872,0.005122955,0.00043235393,0.00009050326,0.00015216279,0.00094679126,0.00003574146,0.000032406002,0.009799899],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986259,0.000052835403,0.0003968265,0.00034084934,0.0003019648,0.00028167453],"domain_scores_gemma":[0.99896437,0.0002602982,0.00019095684,0.00024018,0.00019354103,0.00015067816],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023865614,0.00019675674,0.00047796627,0.00012023239,0.00007846465,0.0000087453045,0.00006248686,0.00008425851,0.00035605297],"category_scores_gemma":[0.00005020893,0.0001618974,0.00008486008,0.00018272492,0.00006242026,0.000072915056,0.000033029064,0.00009164835,0.0000010569335],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025478937,0.0005902769,0.21398717,0.005639911,0.0006919138,0.000010648405,0.031263493,0.012872325,0.5179862,0.00002962491,0.021762732,0.16968682],"study_design_scores_gemma":[0.02005637,0.0025144017,0.1189368,0.0027216384,0.0008155599,0.0000016927835,0.0005263044,0.05043338,0.77917296,0.000004193222,0.024390446,0.00042624798],"about_ca_topic_score_codex":0.002128898,"about_ca_topic_score_gemma":0.00029215644,"teacher_disagreement_score":0.2611868,"about_ca_system_score_codex":0.0011914107,"about_ca_system_score_gemma":0.00050122297,"threshold_uncertainty_score":0.66019845},"labels":[],"label_agreement":null},{"id":"W2015739947","doi":"10.1016/j.lungcan.2013.07.012","title":"Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial)","year":2013,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital","funders":"National Cancer Institute; Eli Lilly and Company","keywords":"Vinorelbine; Gemcitabine; Medicine; Cisplatin; Oncology; Lung cancer; Internal medicine; Randomized controlled trial; Chemotherapy","score_opus":0.014542369910559483,"score_gpt":0.34099801955339265,"score_spread":0.3264556496428332,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015739947","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96381366,0.0034281786,0.0043704095,0.00073530216,0.0011756286,0.023343384,0.0022038806,0.0001086698,0.0008208982],"genre_scores_gemma":[0.9646069,0.0008383359,0.0037568107,0.00020063925,0.00069688854,0.016094118,0.001908709,0.00020217126,0.011695443],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99401104,0.00017405378,0.0028743052,0.001241513,0.00070028764,0.0009987799],"domain_scores_gemma":[0.99404234,0.0009570157,0.002373141,0.0011852361,0.0009223842,0.0005198766],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006351333,0.0010060414,0.005744218,0.0010050408,0.00022820073,0.00007339393,0.00043852726,0.00030646406,0.0037095102],"category_scores_gemma":[0.00015537231,0.00072194485,0.001329411,0.0014068185,0.00035401955,0.0004032539,0.000108994194,0.00033550052,0.000008584655],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.924952,0.0010768786,0.00071468524,0.0013178021,0.018187666,0.000018844075,0.002178513,0.043623377,0.0034809709,0.00004696416,0.0029436052,0.0014587527],"study_design_scores_gemma":[0.72970575,0.0023063507,0.00022940108,0.00063246925,0.03402539,0.0000037264763,0.0003354164,0.2301152,0.0018327989,0.0000071126315,0.00020218054,0.00060421746],"about_ca_topic_score_codex":0.017769985,"about_ca_topic_score_gemma":0.009690159,"teacher_disagreement_score":0.1952462,"about_ca_system_score_codex":0.0031000015,"about_ca_system_score_gemma":0.0035759418,"threshold_uncertainty_score":0.99952316},"labels":[],"label_agreement":null},{"id":"W2017143209","doi":"10.1016/j.lungcan.2012.11.018","title":"Human papilloma virus genome is rare in North American non-small cell lung carcinoma patients","year":2012,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cervical Cancer and HPV Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; Ontario Institute for Cancer Research","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Human papilloma virus; Lung; Carcinoma; Virus; Genome; Oncology; Pathology; Cancer research; Internal medicine; Virology; Cancer; Gene; Biology; Cervical cancer; Genetics","score_opus":0.017812179469169135,"score_gpt":0.31493750048465374,"score_spread":0.2971253210154846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017143209","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9826365,0.0034001477,0.0000047916865,0.00014091928,0.00017710663,0.0007370153,0.000107482025,0.000029329138,0.012766707],"genre_scores_gemma":[0.99558955,0.00018554379,0.000033424763,0.0016810567,0.0006477565,0.00020849094,0.0000795632,0.00005726455,0.0015173574],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99794984,0.000040457675,0.0003049968,0.00036775516,0.00046074166,0.0008762163],"domain_scores_gemma":[0.99884367,0.000021064983,0.0000877423,0.0004079541,0.00016170477,0.00047784913],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00010027651,0.00022974622,0.00042934006,0.00017637148,0.00010209551,0.00002061605,0.00018805664,0.00006662321,0.0040108245],"category_scores_gemma":[0.000009147095,0.00020496303,0.000113462556,0.000625079,0.000092216025,0.00010212961,0.00013130262,0.00042906925,0.000056087883],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013864429,0.00026078,0.98688227,0.0004152393,0.000032930275,0.000015762194,0.0024083012,0.000003508267,0.0006603376,0.0000019438933,0.0022028643,0.006977415],"study_design_scores_gemma":[0.0022094464,0.00019115926,0.9900996,0.000016660388,0.00006493174,7.9314077e-7,0.000083752355,0.00011056106,0.0010018201,8.393293e-7,0.005981837,0.00023857452],"about_ca_topic_score_codex":0.009344103,"about_ca_topic_score_gemma":0.0070967083,"teacher_disagreement_score":0.01295304,"about_ca_system_score_codex":0.00083016953,"about_ca_system_score_gemma":0.00016429072,"threshold_uncertainty_score":0.99725276},"labels":[],"label_agreement":null},{"id":"W2017922297","doi":"10.1016/s0169-5002(03)00138-7","title":"Genetic alterations of lung adenocarcinoma in relation to smoking and ethnicity","year":2003,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Plant Disease Resistance and Genetics","field":"Agricultural and Biological Sciences","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Adenocarcinoma; Lung cancer; Medicine; Lung; Oncology; Incidence (geometry); Ethnic group; Internal medicine; Adenocarcinoma of the lung; Pathology; Cancer","score_opus":0.014958719896782387,"score_gpt":0.2580034833160323,"score_spread":0.2430447634192499,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017922297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99346083,0.0058788224,0.000016452208,0.00019088965,0.00003671052,0.000119153156,0.000030348905,0.000004849093,0.00026194227],"genre_scores_gemma":[0.9994264,0.0002760254,0.00008224418,0.00011503848,0.000028459835,0.000015344449,0.0000042646966,3.723521e-7,0.00005181954],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99958295,0.00003214098,0.00010108348,0.000114177914,0.00007267335,0.000096985365],"domain_scores_gemma":[0.99985725,0.000034130495,0.00002568357,0.000022797743,0.000017749697,0.000042408807],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000047815938,0.000044663324,0.00006609662,0.000009500097,0.000039672745,0.0000094034785,0.00003299604,0.000031912892,0.00006214309],"category_scores_gemma":[0.000014750014,0.000021346388,0.000014098522,0.00016425653,0.000009988436,0.000027267157,0.000008444889,0.000034163575,3.858979e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000007750268,0.000010543888,0.96643084,0.00001308821,0.0000050711587,0.0000014903025,0.0001164182,0.00037299766,0.030482128,0.00017054267,0.00018617752,0.0022029502],"study_design_scores_gemma":[0.000053357533,0.000013383818,0.9977445,0.000038522707,0.000011631921,5.999556e-7,0.000022863687,0.00041376325,0.0010525287,0.00010591109,0.00048760194,0.000055305325],"about_ca_topic_score_codex":0.00020184716,"about_ca_topic_score_gemma":0.0024679338,"teacher_disagreement_score":0.031313688,"about_ca_system_score_codex":0.000023649656,"about_ca_system_score_gemma":0.000009065468,"threshold_uncertainty_score":0.1377165},"labels":[],"label_agreement":null},{"id":"W2019407271","doi":"10.1016/j.lungcan.2004.08.016","title":"Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer","year":2004,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":134,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Vinorelbine; Chemotherapy; Lung cancer; Internal medicine; Surgery; Cohort; Cancer; Oncology; Cisplatin","score_opus":0.02556108665151988,"score_gpt":0.36827560822227706,"score_spread":0.34271452157075716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019407271","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00054497266,0.99044687,0.000024888961,0.0009137906,0.00055461156,0.0053751227,0.000410035,0.00006644953,0.0016632413],"genre_scores_gemma":[0.0007586897,0.9867735,0.00040572626,0.0013160531,0.00055121066,0.0068433736,0.0002095126,0.0002500693,0.0028918951],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967605,0.00006684911,0.0007272574,0.0012091585,0.00044110836,0.0007951554],"domain_scores_gemma":[0.99817216,0.000080967715,0.00045701332,0.0007498982,0.0002517895,0.00028814463],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00010300114,0.0010507074,0.0030938978,0.00023275652,0.000097928525,0.00005799213,0.00029189847,0.00037903807,0.0008771375],"category_scores_gemma":[0.0000040654513,0.00069838425,0.0004546467,0.0006499589,0.00010526097,0.000097071716,0.000056335663,0.0008046993,0.000030663647],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053030526,0.0017031172,0.027897386,0.21358064,0.0039869933,0.001046135,0.0027446887,0.0003599286,0.0000059268946,0.000047982343,0.0067627095,0.7413342],"study_design_scores_gemma":[0.01052352,0.00067232567,0.0046429783,0.3887958,0.0063725985,0.000063023734,0.00006369366,0.00011787702,0.00009889965,0.0000021156523,0.5871523,0.0014948868],"about_ca_topic_score_codex":0.006334802,"about_ca_topic_score_gemma":0.004652547,"teacher_disagreement_score":0.7398393,"about_ca_system_score_codex":0.007189518,"about_ca_system_score_gemma":0.0041099,"threshold_uncertainty_score":0.9995467},"labels":[],"label_agreement":null},{"id":"W2022580888","doi":"10.1016/s0169-5002(03)00228-9","title":"The impact of regional nodal radiotherapy (dose/volume) on regional progression and survival in unresectable non-small cell lung cancer: an analysis of RTOG data","year":2003,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Red Cross Society","funders":"","keywords":"Medicine; Radiation therapy; Hilum (anatomy); NODAL; Lung cancer; Cancer; Oncology; Internal medicine; Radiology","score_opus":0.028996414512802944,"score_gpt":0.3789804832824597,"score_spread":0.34998406876965676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022580888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9676621,0.03013502,0.000024068611,0.00068309496,0.00014149498,0.00071354967,0.00020100195,0.000010442797,0.00042922926],"genre_scores_gemma":[0.98195124,0.016988583,0.00021147483,0.0000856394,0.00012314231,0.00016410703,0.00014173199,0.00003359206,0.00030046978],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998104,0.00014304422,0.000393163,0.0005448299,0.00045751515,0.00035750074],"domain_scores_gemma":[0.99838364,0.00018704505,0.00027988554,0.00085765583,0.00013274065,0.00015901074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004318781,0.00024689498,0.00064934324,0.0002157966,0.00009598065,0.000022916649,0.00023532973,0.00010235483,0.00024689242],"category_scores_gemma":[0.000015944046,0.00015433604,0.00017084276,0.0007032671,0.0001355076,0.000113123366,0.000039024053,0.00017996639,1.585148e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009057873,0.000799112,0.9843317,0.00016180989,0.0018855404,0.000010642422,0.0004686316,0.0035030416,0.00057350815,0.00007898444,0.0048121456,0.0024690465],"study_design_scores_gemma":[0.004918761,0.00080972846,0.9330577,0.00066004426,0.0014135593,0.0000031916293,0.00010637801,0.056486364,0.00083623256,0.00000806831,0.0014930399,0.00020689412],"about_ca_topic_score_codex":0.017233906,"about_ca_topic_score_gemma":0.006953726,"teacher_disagreement_score":0.052983325,"about_ca_system_score_codex":0.00087875273,"about_ca_system_score_gemma":0.0008567771,"threshold_uncertainty_score":0.98931044},"labels":[],"label_agreement":null},{"id":"W2022747660","doi":"10.1016/j.lungcan.2006.10.021","title":"Impact of hemoglobin levels on outcomes of adjuvant chemotherapy in resected non-small cell lung cancer: The JBR.10 trial experience","year":2006,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Erythropoietin and Anemia Treatment","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Vinorelbine; Internal medicine; Adverse effect; Anemia; Adjuvant; Lung cancer; Oncology; Chemotherapy; Hemoglobin; Cisplatin; Gastroenterology","score_opus":0.017849420176140628,"score_gpt":0.3537547577835715,"score_spread":0.3359053376074309,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022747660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934044,0.0022848076,0.000005895866,0.0008095518,0.00024221896,0.0011575087,0.00007518104,0.000018204608,0.0020022194],"genre_scores_gemma":[0.9944355,0.00041510878,0.00008946606,0.00016120278,0.00020096732,0.00022139453,0.000009488536,0.000029668068,0.0044372124],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99857473,0.000046520927,0.00045674667,0.0002831381,0.0003187717,0.00032009653],"domain_scores_gemma":[0.99909484,0.00011631342,0.00023334027,0.0004045602,0.00009137619,0.000059560083],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00009391607,0.00023761435,0.00060063234,0.000083982704,0.000036329027,0.0000068671607,0.00015383048,0.00010338953,0.0010241838],"category_scores_gemma":[0.000018902318,0.00013743888,0.00023550281,0.00029071028,0.00011591005,0.000030128502,0.000022025177,0.00017246646,0.000001379251],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012301354,0.0011737262,0.9197182,0.0002483816,0.00022345297,0.000023684388,0.0030272729,0.0005649029,0.04735592,0.000012356111,0.013097344,0.0022534255],"study_design_scores_gemma":[0.051972263,0.00097281585,0.81606656,0.0005972495,0.00012413332,0.0000019652541,0.00025266738,0.00054714107,0.12896816,0.000006590506,0.0002878843,0.00020253874],"about_ca_topic_score_codex":0.018865515,"about_ca_topic_score_gemma":0.0010823355,"teacher_disagreement_score":0.1036516,"about_ca_system_score_codex":0.00062524056,"about_ca_system_score_gemma":0.00042711268,"threshold_uncertainty_score":0.999889},"labels":[],"label_agreement":null},{"id":"W2025267040","doi":"10.1016/j.lungcan.2013.06.023","title":"What constitutes best supportive care in the treatment of advanced non-small cell lung cancer patients?—Results from the lung cancer economics and outcomes research (LUCEOR) study","year":2013,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Lung cancer; Clinical trial; Cancer; Disease; Internal medicine; Physical therapy","score_opus":0.020265612033253267,"score_gpt":0.37654256354529836,"score_spread":0.3562769515120451,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025267040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9460937,0.04176589,0.0000010463257,0.002256386,0.0008826443,0.0068615098,0.0012487416,0.000013432635,0.00087667105],"genre_scores_gemma":[0.96057004,0.03160091,0.000045457982,0.00035629654,0.00019207534,0.00584422,0.00018316365,0.000040871066,0.0011669665],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977426,0.00015070623,0.000593037,0.00064896815,0.00034304213,0.0005216591],"domain_scores_gemma":[0.9978203,0.0006647094,0.00026347773,0.0006052438,0.0005082823,0.00013799295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014894365,0.00036719305,0.0006053384,0.00011740622,0.00028397574,0.00014048607,0.0002361252,0.00009784231,0.00020421135],"category_scores_gemma":[0.000027853006,0.00020467164,0.00011632285,0.00026637525,0.00023422718,0.00037470929,0.000067996276,0.00023855866,0.0000035426333],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028523293,0.0010885176,0.88686967,0.00010476918,0.0008523849,0.0000101448095,0.09436808,0.000661207,0.000022456148,0.000009210494,0.0015438079,0.014184547],"study_design_scores_gemma":[0.017903402,0.0011519291,0.87694937,0.000748354,0.0020424216,5.337864e-7,0.09603917,0.0008031193,0.0007490499,0.000012657087,0.003261018,0.00033895037],"about_ca_topic_score_codex":0.09895635,"about_ca_topic_score_gemma":0.056073755,"teacher_disagreement_score":0.04288259,"about_ca_system_score_codex":0.001747376,"about_ca_system_score_gemma":0.0010266993,"threshold_uncertainty_score":0.96115047},"labels":[],"label_agreement":null},{"id":"W2025575316","doi":"10.1016/j.lungcan.2007.07.006","title":"Systematic review of baseline low-dose CT lung cancer screening","year":2007,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Cancer Care Ontario","funders":"","keywords":"Medicine; Lung cancer; Lung cancer screening; Stage (stratigraphy); Predictive value; Clinical trial; Randomized controlled trial; Cancer; Oncology; Internal medicine; Intensive care medicine","score_opus":0.037610699726108913,"score_gpt":0.41769251457685586,"score_spread":0.38008181485074694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025575316","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000020190414,0.9890409,0.00010300983,0.00029091825,0.0008835402,0.008476506,0.00047088903,0.000085880514,0.00064632826],"genre_scores_gemma":[0.000007973549,0.9890886,0.00023325197,0.0016219754,0.000866687,0.005571944,0.00033204776,0.00020281742,0.0020746917],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9947381,0.00028241883,0.0024385685,0.0008855728,0.0009836222,0.00067170785],"domain_scores_gemma":[0.9956831,0.0005156321,0.0017284731,0.0013104214,0.00040742345,0.0003550012],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011927156,0.00095258886,0.007227628,0.00032471996,0.00007937222,0.00002282662,0.00034378696,0.00022665352,0.0017383563],"category_scores_gemma":[0.00022442309,0.0006420785,0.0016776074,0.00095135666,0.00007473835,0.00008339087,0.00010876831,0.00058414356,0.000021286343],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015045233,0.00013973501,0.00015683977,0.847026,0.0040363516,0.00017047307,0.00001935831,0.000001932519,1.092862e-7,0.000015378706,0.016963875,0.13145493],"study_design_scores_gemma":[0.0006858328,0.000041340336,0.000011319274,0.75573075,0.045487028,0.00006953088,0.0000036912502,0.00006514982,0.000003880174,2.2417007e-7,0.19749962,0.00040164802],"about_ca_topic_score_codex":0.0010715636,"about_ca_topic_score_gemma":0.00009148009,"teacher_disagreement_score":0.18053575,"about_ca_system_score_codex":0.0025802916,"about_ca_system_score_gemma":0.0015882037,"threshold_uncertainty_score":0.99960303},"labels":[],"label_agreement":null},{"id":"W2026319709","doi":"10.1016/s0169-5002(00)00135-5","title":"The influence of gemcitabine and cisplatin schedule on response and survival in advanced non-small cell lung cancer","year":2000,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Eli Lilly (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Gemcitabine; Medicine; Cisplatin; Proportional hazards model; Lung cancer; Internal medicine; Oncology; Retrospective cohort study; Carboplatin; Logistic regression; Chemotherapy; Toxicity","score_opus":0.005698174636181947,"score_gpt":0.3125502786399122,"score_spread":0.30685210400373025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026319709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875303,0.00906335,0.0000031231752,0.0013038528,0.000093668634,0.0006527159,0.000048640675,0.000013654088,0.001290704],"genre_scores_gemma":[0.99151486,0.0038606315,0.00017226189,0.00026515208,0.000043096043,0.00026460717,0.000003778382,0.0000220534,0.0038535658],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99903953,0.00005075535,0.00023414553,0.00027266511,0.00016238338,0.00024049403],"domain_scores_gemma":[0.99931246,0.0002290388,0.00007468138,0.00022400903,0.00006730158,0.00009249348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017123947,0.00015585107,0.00024601916,0.00006335283,0.00010636707,0.000016022595,0.000057003457,0.000057734767,0.00011052353],"category_scores_gemma":[0.000030723175,0.000109090695,0.000027659868,0.00020365305,0.00009434863,0.00007732972,0.000019882034,0.0001517284,0.0000011735455],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071617626,0.00019632338,0.9205688,0.0004792274,0.00023644381,0.000037999554,0.003719891,0.011451892,0.019014427,0.00010974991,0.00034915633,0.036674283],"study_design_scores_gemma":[0.0048518814,0.00022570443,0.9874357,0.0006598599,0.00021174592,0.000002876404,0.00015853172,0.0018433018,0.002468229,0.000014322516,0.0019823904,0.00014547106],"about_ca_topic_score_codex":0.0012405684,"about_ca_topic_score_gemma":0.0013000298,"teacher_disagreement_score":0.06686684,"about_ca_system_score_codex":0.00020654457,"about_ca_system_score_gemma":0.00027863067,"threshold_uncertainty_score":0.44485894},"labels":[],"label_agreement":null},{"id":"W2030607022","doi":"10.1016/j.lungcan.2005.08.013","title":"Twenty-year secular changes in sex specific lung cancer incidence rates in an urban Chinese population","year":2005,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Memorial University of Newfoundland","funders":"Prevent Cancer Foundation","keywords":"Medicine; Poisson regression; Incidence (geometry); Lung cancer; Demography; Population; Cancer registry; Cancer; Cohort; Cohort study; Rate ratio; Cohort effect; Epidemiology; Internal medicine; Environmental health","score_opus":0.0286345065994595,"score_gpt":0.36918787538413966,"score_spread":0.3405533687846802,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030607022","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9773965,0.019297779,0.000023308256,0.0017769189,0.00031284947,0.000592334,0.000018975757,0.000059223312,0.00052213477],"genre_scores_gemma":[0.9945409,0.0017132406,0.00032334073,0.0012682204,0.0013585304,0.00021518633,0.000053589978,0.000038164835,0.000488812],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99803364,0.00007307263,0.00036800036,0.00053379446,0.00047908432,0.0005123934],"domain_scores_gemma":[0.99924856,0.00002503063,0.00011894669,0.00035112153,0.000089470675,0.00016684702],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00031573905,0.00026413516,0.00043015534,0.00025978815,0.0000634559,0.00004659238,0.00017926992,0.00014711426,0.0009965664],"category_scores_gemma":[0.000029467139,0.0002410727,0.00005779774,0.0007405963,0.00003841066,0.00049393513,0.00005160801,0.00036043194,0.000009201778],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020694894,0.00004386663,0.9864743,0.00009409403,0.000017979062,0.000058068556,0.0015432608,0.0029648507,0.0023332406,0.000037043374,0.0019566626,0.0042696865],"study_design_scores_gemma":[0.001439715,0.000065865854,0.97408676,0.0009012427,0.000036768954,0.000009718387,0.0002584526,0.019492656,0.00094206363,0.000026677235,0.0024342353,0.00030582995],"about_ca_topic_score_codex":0.010639078,"about_ca_topic_score_gemma":0.07355213,"teacher_disagreement_score":0.06291306,"about_ca_system_score_codex":0.0014068163,"about_ca_system_score_gemma":0.00013972327,"threshold_uncertainty_score":0.9999167},"labels":[],"label_agreement":null},{"id":"W2032371685","doi":"10.1016/j.lungcan.2005.06.010","title":"Taxanes as first-line therapy for advanced non-small cell lung cancer: A systematic review and practice guideline","year":2005,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":101,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; Cancer Care Ontario","funders":"European Society for Medical Oncology","keywords":"Docetaxel; Taxane; Medicine; Oncology; Vinorelbine; Gemcitabine; Internal medicine; Lung cancer; Cisplatin; Paclitaxel; Guideline; Chemotherapy; Regimen; Cancer; Breast cancer; Pathology","score_opus":0.030239857460425346,"score_gpt":0.4431672683192456,"score_spread":0.41292741085882023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032371685","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000011313567,0.96914077,0.00032373195,0.0043715346,0.0005178992,0.023736943,0.00058894715,0.0000907888,0.0012282863],"genre_scores_gemma":[0.0000017212934,0.94927895,0.0032828078,0.0071141724,0.0008913506,0.02786761,0.000492415,0.00021018856,0.010860794],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964108,0.0001383833,0.0016514328,0.0009059788,0.00034992633,0.0005434741],"domain_scores_gemma":[0.9957992,0.00074339425,0.0016589444,0.0008209367,0.0006915444,0.00028600646],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00048383637,0.000887373,0.0043223435,0.00016052894,0.00021551832,0.000058824244,0.00023843975,0.00029514928,0.00032224527],"category_scores_gemma":[0.00037573156,0.0006012859,0.00063522154,0.00041965337,0.000045158195,0.00019583695,0.000052544787,0.00034722374,0.000012712227],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006679964,0.00016524791,0.000003986607,0.81157994,0.0025240614,0.000020787485,0.00016905708,0.000013576859,4.4085482e-7,0.000009849701,0.020680299,0.16476592],"study_design_scores_gemma":[0.0017163866,0.00015954045,2.6455274e-7,0.341141,0.05257552,0.00010231919,0.000021247377,0.00006857872,0.0000011303994,0.0000012456991,0.6038538,0.00035896563],"about_ca_topic_score_codex":0.00057040487,"about_ca_topic_score_gemma":0.00022904444,"teacher_disagreement_score":0.5831735,"about_ca_system_score_codex":0.0012945834,"about_ca_system_score_gemma":0.002085456,"threshold_uncertainty_score":0.99964386},"labels":[],"label_agreement":null},{"id":"W2033412371","doi":"10.1016/j.lungcan.2004.11.003","title":"Surgical management of malignant pleural mesothelioma: a systematic review and evidence summary","year":2005,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; McMaster University; Cancer Care Ontario; Hamilton Health Sciences; University of Ottawa; Ottawa Hospital","funders":"","keywords":"Medicine; Mesothelioma; Extrapleural Pneumonectomy; Randomized controlled trial; Pneumonectomy; Pleural disease; Lung cancer; Clinical trial; Surgery; Pleurectomy; General surgery; Oncology; Internal medicine; Respiratory disease; Lung; Pathology; Peritoneal mesothelioma","score_opus":0.03974358463808642,"score_gpt":0.38401631942893144,"score_spread":0.344272734790845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2033412371","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000046822825,0.99670976,6.463174e-7,0.00012580266,0.000049575872,0.0026750786,0.000100400815,0.000016110276,0.00031796782],"genre_scores_gemma":[0.000020014399,0.99456173,0.000053399188,0.00016932291,0.00008566174,0.0007816728,0.000051238912,0.000029757419,0.004247222],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9983714,0.00009323091,0.0006838044,0.00031830184,0.00036890412,0.0001643595],"domain_scores_gemma":[0.99911207,0.00009730689,0.00032502235,0.00032279996,0.000017111528,0.00012567063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017036972,0.00028477015,0.0020682372,0.00006306957,0.000024028466,0.000006164898,0.00011123998,0.0000731502,0.00034996087],"category_scores_gemma":[0.000011284384,0.00017803362,0.00035192893,0.00015952358,0.00006593196,0.000054736705,0.0001023643,0.000099234334,0.000020061954],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015050197,0.000048326106,0.0000945282,0.969609,0.00065650075,0.00011181315,0.0000029988287,1.4456378e-7,2.6552346e-8,0.000044899363,0.001207464,0.028209204],"study_design_scores_gemma":[0.00014662516,0.000027657565,0.00014467583,0.87529844,0.029794946,0.00012677386,0.0000026270636,0.0000033930357,8.11487e-8,8.043274e-7,0.09429993,0.00015404914],"about_ca_topic_score_codex":0.000016490645,"about_ca_topic_score_gemma":0.0000011635932,"teacher_disagreement_score":0.094310604,"about_ca_system_score_codex":0.00023756025,"about_ca_system_score_gemma":0.00007374038,"threshold_uncertainty_score":0.7260001},"labels":[],"label_agreement":null},{"id":"W2034309045","doi":"10.1016/s0169-5002(03)00161-2","title":"Ongoing and future trials of biologic therapies in lung cancer","year":2003,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Radiation therapy; Chemotherapy; Oncology; Clinical trial; Cancer; Intensive care medicine; Targeted therapy; Internal medicine; Lung","score_opus":0.05967837281913717,"score_gpt":0.4635147829541828,"score_spread":0.4038364101350456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034309045","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00025730662,0.99508834,0.0000033127164,0.00028957936,0.00092312135,0.0020866576,0.00034635034,0.000021890708,0.000983422],"genre_scores_gemma":[0.00006664925,0.9961336,0.00014816926,0.00017676615,0.00074782316,0.0013157495,0.000087032975,0.00004924977,0.0012749147],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980665,0.00024126389,0.000857355,0.00041145436,0.0001560035,0.00026746182],"domain_scores_gemma":[0.99879915,0.00020189083,0.00059023383,0.0002603076,0.00006965641,0.00007877443],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038125122,0.00038208754,0.0027164218,0.00024173198,0.00004686977,0.000015739746,0.00007616207,0.00032214404,0.0007235485],"category_scores_gemma":[0.00003743191,0.00023261945,0.00035678336,0.0003908289,0.00006381038,0.000049127062,0.000021323962,0.0002749896,8.606506e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030846488,0.00006225829,0.0061176056,0.023816884,0.0022330356,0.000015668891,0.0005641655,0.0000015926429,0.0000031209443,0.00018559449,0.001828975,0.9651402],"study_design_scores_gemma":[0.0013237316,0.00005167404,0.0005096048,0.018827721,0.0061019324,0.000011437876,0.00006453917,0.0000041635353,0.0000026472228,0.0000108287795,0.97286516,0.00022653755],"about_ca_topic_score_codex":0.00091987086,"about_ca_topic_score_gemma":0.00052642985,"teacher_disagreement_score":0.9710362,"about_ca_system_score_codex":0.00063296786,"about_ca_system_score_gemma":0.0010789151,"threshold_uncertainty_score":0.94859457},"labels":[],"label_agreement":null},{"id":"W2036437506","doi":"10.1016/j.lungcan.2004.06.004","title":"Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage IIIA (T1-3, N2) unresectable non-small-cell lung cancer: final results of the Toronto phase II trial","year":2004,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; University Health Network; Toronto General Hospital; Princess Margaret Cancer Centre; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"","keywords":"Vindesine; Medicine; Cisplatin; Oncology; Mitomycin C; Chemotherapy; Internal medicine; Induction chemotherapy; Lung cancer; Stage (stratigraphy); Surgery; Vincristine","score_opus":0.01791368138287724,"score_gpt":0.3282780373517002,"score_spread":0.31036435596882295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2036437506","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98508453,0.006948498,0.00019042403,0.0025074964,0.0006583651,0.003601926,0.0003033788,0.000026915306,0.00067847746],"genre_scores_gemma":[0.9911172,0.0022572104,0.00060509593,0.00033279578,0.00077507825,0.0012119449,0.00002927823,0.000053028612,0.003618416],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99853015,0.000022026366,0.00036231807,0.000467929,0.00027130658,0.0003462456],"domain_scores_gemma":[0.9989698,0.000050463157,0.0003012949,0.00039066657,0.00017203872,0.000115747745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001584515,0.0002715548,0.00045328517,0.00003961018,0.00022045254,0.000022574359,0.00010155512,0.00012175192,0.00011704974],"category_scores_gemma":[0.000014576367,0.0001724333,0.0001132761,0.00018368899,0.00007108334,0.00013411143,0.00003178215,0.00014105151,1.2813877e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6827013,0.014142321,0.082645595,0.0071571907,0.0054681115,0.000054954522,0.022823155,0.005228897,0.062122583,0.000320687,0.07105949,0.04627574],"study_design_scores_gemma":[0.7112697,0.011004079,0.016878301,0.0029785612,0.0021671024,0.000013259923,0.00033522813,0.0012955618,0.24074255,0.000021531741,0.0127021605,0.00059200975],"about_ca_topic_score_codex":0.027229026,"about_ca_topic_score_gemma":0.021842001,"teacher_disagreement_score":0.17861997,"about_ca_system_score_codex":0.0014700365,"about_ca_system_score_gemma":0.0009428779,"threshold_uncertainty_score":0.99600685},"labels":[],"label_agreement":null},{"id":"W2037773581","doi":"10.1016/s0169-5002(03)00279-4","title":"Stimulation of the murine Uchl1 gene promoter by the B-Myb transcription factor","year":2003,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Regional Cancer Foundation","funders":"","keywords":"MYB; Transcription factor; Ectopic expression; Biology; Promoter; Transgene; Molecular biology; Gene expression; Gene; Genetics","score_opus":0.011591769996007207,"score_gpt":0.25886049443820053,"score_spread":0.24726872444219333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037773581","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949319,0.0027651696,0.00073545973,0.0002552787,0.00020320812,0.00034777162,0.00008097817,0.000004568755,0.0006756931],"genre_scores_gemma":[0.997921,0.00010221686,0.000058065867,0.00021604357,0.000084766434,0.00004894662,0.000020410276,0.000010614688,0.0015379742],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99950784,0.000067192006,0.00010116385,0.00012819972,0.000090782516,0.00010483691],"domain_scores_gemma":[0.99967754,0.000003570243,0.00005416522,0.00020817085,0.00003822564,0.0000183521],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006983015,0.000074864554,0.000056433175,0.0000055597193,0.00005832567,0.0000073356787,0.00010142909,0.00006427838,0.00015806175],"category_scores_gemma":[0.000013892694,0.00004343089,0.000058504214,0.00004795536,0.00003721385,0.0000022807797,0.000012260259,0.000054272194,0.0000010836133],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018022565,0.000017351646,0.00409378,0.000019287483,0.000023975463,4.4504187e-8,0.00011201545,0.00008338823,0.99322045,0.000038706832,0.0013317254,0.0010412787],"study_design_scores_gemma":[0.00026707622,0.000035812147,0.0039034225,0.00001022757,0.000016865099,0.0000018860987,0.000006553038,0.00010732707,0.96217376,0.000033778677,0.033380497,0.00006277796],"about_ca_topic_score_codex":0.000030987143,"about_ca_topic_score_gemma":0.0000207848,"teacher_disagreement_score":0.03204877,"about_ca_system_score_codex":0.000013554441,"about_ca_system_score_gemma":0.000040386243,"threshold_uncertainty_score":0.17710602},"labels":[],"label_agreement":null},{"id":"W2037994031","doi":"10.1016/s0169-5002(00)80748-5","title":"Diet, tea drinking and risk of lung cancer among non-smoking women in Canada","year":2000,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Tea Polyphenols and Effects","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Canada","funders":"","keywords":"Medicine; Lung cancer; Environmental health; Cancer; Oncology; Gerontology; Internal medicine","score_opus":0.003404514095020909,"score_gpt":0.24201310627956632,"score_spread":0.23860859218454541,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037994031","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99187773,0.005253938,0.0000019350505,0.00010888353,0.00022923893,0.0003167432,0.000018791126,0.000014438735,0.0021782801],"genre_scores_gemma":[0.9962106,0.0023824137,0.000012877276,0.00018328009,0.0001767615,0.00015015103,0.0000020531222,0.00002811335,0.000853766],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987884,0.000028364853,0.00022673908,0.00024574518,0.0002294972,0.0004812197],"domain_scores_gemma":[0.99949044,0.000051011717,0.00008846371,0.00018394172,0.000021459993,0.00016465485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015307759,0.000152556,0.00037295034,0.00005640362,0.000054143526,0.000008576657,0.00006411671,0.000050591694,0.0008154358],"category_scores_gemma":[0.000013833089,0.00013446047,0.00002953039,0.00019648974,0.00004060667,0.0000708683,0.000026591262,0.00025467583,2.3242282e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014152426,0.000011779845,0.96887046,0.0002561745,0.0001488592,0.00003603254,0.0023101468,0.00062269915,0.00019357899,0.0000012512903,0.00081485935,0.026592627],"study_design_scores_gemma":[0.001266047,0.00004247931,0.9882107,0.0010021769,0.00013446237,0.000002155928,0.00014744417,0.0074846046,0.00056647765,0.0000039486185,0.00098558,0.00015392095],"about_ca_topic_score_codex":0.97057354,"about_ca_topic_score_gemma":0.9493607,"teacher_disagreement_score":0.026438706,"about_ca_system_score_codex":0.0015860482,"about_ca_system_score_gemma":0.0007108466,"threshold_uncertainty_score":0.892845},"labels":[],"label_agreement":null},{"id":"W2040566551","doi":"10.1016/s0169-5002(00)80040-9","title":"Clinical dose-response relationships in non-small cell lung cancer: Implications for resistance mechanisms and resistance modulation","year":2000,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Medicine; Resistance (ecology); Lung cancer; Modulation (music); Oncology; Internal medicine; Biology","score_opus":0.023279597182410006,"score_gpt":0.32883180567986825,"score_spread":0.30555220849745823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040566551","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94162816,0.014406095,0.038315367,0.002348283,0.00034006176,0.001556628,0.00041966187,0.00002902959,0.0009566947],"genre_scores_gemma":[0.97158855,0.005995629,0.008220422,0.00058579136,0.00025431768,0.0012034329,0.00007410306,0.00005421821,0.012023553],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99846524,0.0001264611,0.0004134305,0.0005948896,0.00008478966,0.00031520356],"domain_scores_gemma":[0.99914867,0.00008736211,0.00013699177,0.00041953914,0.0001012615,0.00010620621],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060435664,0.00019163408,0.00022067866,0.000052802392,0.00020158193,0.000034124445,0.00016690495,0.00024593843,0.000041686715],"category_scores_gemma":[0.000027270355,0.00021064155,0.000094034986,0.00016080018,0.000046091296,0.000010554849,0.000029677129,0.00016514004,7.9476916e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011582177,0.00032779947,0.051686026,0.000593028,0.0002765204,0.0000030555336,0.00063877157,0.0035196585,0.8810945,0.01040144,0.009567718,0.03030929],"study_design_scores_gemma":[0.011443194,0.00040600818,0.6213819,0.0006712549,0.00048167325,0.0000033296972,0.0001403702,0.0141932415,0.04939969,0.02076972,0.27912277,0.0019868517],"about_ca_topic_score_codex":0.00007134943,"about_ca_topic_score_gemma":0.0048819575,"teacher_disagreement_score":0.83169484,"about_ca_system_score_codex":0.00013540439,"about_ca_system_score_gemma":0.00023534475,"threshold_uncertainty_score":0.8589713},"labels":[],"label_agreement":null},{"id":"W2044028214","doi":"10.1016/s0169-5002(00)80329-3","title":"Outcome results of long term follow up, for population based cohort of patients with stage IIIA NSCLC treated with aggressive combined modality treatment approach in a prospective study","year":2000,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Medicine; Stage (stratigraphy); Outcome (game theory); Prospective cohort study; Cohort; Term (time); Internal medicine; Physical therapy; Oncology","score_opus":0.01912592164815841,"score_gpt":0.33551937115371,"score_spread":0.3163934495055516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2044028214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98872405,0.00019941818,0.000030469871,0.000023018305,0.000012262908,0.010074579,0.0007326922,0.000021350299,0.00018213586],"genre_scores_gemma":[0.9955857,0.000007974914,0.00016885692,0.000007946874,0.000011809304,0.0024787125,0.0007343496,0.00003105831,0.0009736399],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982275,0.0000749027,0.00043838227,0.00045854904,0.00051857805,0.00028211199],"domain_scores_gemma":[0.99890476,0.000049943625,0.00030402545,0.00036902569,0.00026187123,0.000110385394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000120039855,0.00024725072,0.0006801447,0.0001272972,0.00004739276,0.0000072511925,0.000058154343,0.000050661245,0.000042883155],"category_scores_gemma":[0.000015998483,0.00015080166,0.00007718622,0.00033031547,0.0000531,0.000077183686,0.0000073888978,0.00008048482,1.8167286e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0730238,0.004705241,0.9176855,0.00025207765,0.00083297025,0.000043747754,0.0006075366,0.0005521986,0.0000017046071,0.000001952281,0.000002565921,0.0022906803],"study_design_scores_gemma":[0.0756854,0.010932037,0.91127086,0.0002549583,0.00049582275,3.0004665e-7,0.0000424493,0.0006311589,0.0005707574,0.0000015500298,2.32526e-7,0.000114506685],"about_ca_topic_score_codex":0.010240478,"about_ca_topic_score_gemma":0.0035546664,"teacher_disagreement_score":0.007595867,"about_ca_system_score_codex":0.001190763,"about_ca_system_score_gemma":0.00024450678,"threshold_uncertainty_score":0.9963504},"labels":[],"label_agreement":null},{"id":"W2048035888","doi":"10.1016/j.lungcan.2008.09.008","title":"Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: A review of practice in British Columbia","year":2008,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Pemetrexed; Gemcitabine; Medicine; Oncology; Internal medicine; Cisplatin; Mesothelioma; Chemotherapy; Surgery; Pathology","score_opus":0.018305678976831656,"score_gpt":0.3451744749100672,"score_spread":0.32686879593323553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048035888","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022177104,0.99502623,0.000022107813,0.00057986606,0.000065412,0.0032894502,0.00068113976,0.000019305036,0.00009474241],"genre_scores_gemma":[0.00016070074,0.99429846,0.0005812086,0.0016355598,0.000058408776,0.0014472398,0.000940936,0.00006571828,0.00081176695],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99842715,0.000062227584,0.00060945447,0.00032898638,0.00038793287,0.00018426435],"domain_scores_gemma":[0.9985772,0.00048831216,0.00055419403,0.00021484896,0.00009256863,0.00007292665],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011764934,0.00022147679,0.0014280743,0.00005819556,0.000054297452,0.000014727103,0.000088134424,0.00010851093,0.00034133368],"category_scores_gemma":[0.0001923356,0.00022110424,0.00032301774,0.00025429606,0.00007479966,0.00007872715,0.0000121875355,0.00014112773,0.0000018215111],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031344802,0.0017174174,0.08658291,0.4709941,0.00084939896,0.00012695763,0.000035281817,0.000015644737,1.984698e-7,0.000005221807,0.02360697,0.41575244],"study_design_scores_gemma":[0.0041496335,0.00036096646,0.03145497,0.2996844,0.0019629686,0.00011071126,0.000004591763,0.000046494097,6.9737865e-7,0.0000039223173,0.6618998,0.0003208544],"about_ca_topic_score_codex":0.003211567,"about_ca_topic_score_gemma":0.0046501383,"teacher_disagreement_score":0.6382928,"about_ca_system_score_codex":0.00037150513,"about_ca_system_score_gemma":0.00050538307,"threshold_uncertainty_score":0.90163696},"labels":[],"label_agreement":null},{"id":"W2050229398","doi":"10.1016/j.lungcan.2012.09.010","title":"Re-evaluation of the prognostic value of visceral pleura invasion in Stage IB non-small cell lung cancer using the prospective multicenter ACOSOG Z0030 trial data set","year":2012,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Cancer Institute","keywords":"Medicine; Context (archaeology); Stage (stratigraphy); Lung cancer; Internal medicine; Prospective cohort study; Multivariate analysis; Proportional hazards model; T-stage; Cancer; Gastroenterology; Surgery","score_opus":0.08286221255533598,"score_gpt":0.39448108810022103,"score_spread":0.31161887554488504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050229398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856552,0.005447356,0.000024643992,0.00054394535,0.0012537066,0.006475892,0.00034045067,0.000009483328,0.00024934372],"genre_scores_gemma":[0.9977507,0.00036637153,0.0001258279,0.00018302751,0.0005253167,0.0008424229,0.000049857255,0.000038690083,0.00011780068],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976816,0.00027660976,0.00050053385,0.0004041068,0.0007619613,0.00037517134],"domain_scores_gemma":[0.99815196,0.00017177218,0.000411142,0.0009209451,0.00026872102,0.00007545796],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010538077,0.00023340121,0.00041643632,0.00006835796,0.000090502566,0.000017598239,0.00031328623,0.00009749339,0.00020566907],"category_scores_gemma":[0.00014537488,0.00013252604,0.00010976842,0.00033396832,0.000088638706,0.0002181446,0.00025367577,0.00025596566,6.443906e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023794172,0.0006624633,0.98500764,0.00061948533,0.0002939995,0.0000013802235,0.0051147235,0.0029462345,0.0017830239,0.000013011268,0.00078500086,0.00039363027],"study_design_scores_gemma":[0.044328146,0.00020285152,0.76644343,0.0026548835,0.003982385,0.0000011049518,0.0007981954,0.15578903,0.02542985,0.0000060543257,0.00013183472,0.00023223727],"about_ca_topic_score_codex":0.008344606,"about_ca_topic_score_gemma":0.00456279,"teacher_disagreement_score":0.21856421,"about_ca_system_score_codex":0.0015830966,"about_ca_system_score_gemma":0.0009121708,"threshold_uncertainty_score":0.9982589},"labels":[],"label_agreement":null},{"id":"W2050506643","doi":"10.1016/j.lungcan.2003.08.012","title":"Induction therapy for stage III lung cancer","year":2003,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital","funders":"","keywords":"Medicine; Stage (stratigraphy); Induction therapy; Lung cancer; Radiation therapy; Disease; Induction chemotherapy; Surgery; Chemotherapy; Pneumonectomy; Oncology; Internal medicine","score_opus":0.05736270721518764,"score_gpt":0.43144547449529397,"score_spread":0.3740827672801063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050506643","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000044762244,0.98822075,0.00004706513,0.00037094194,0.0033120308,0.006239463,0.0005614968,0.000089905916,0.001113576],"genre_scores_gemma":[0.000014435224,0.9592796,0.000115075316,0.0006949355,0.0018406196,0.018594848,0.00028389547,0.00019317308,0.018983409],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975461,0.00006851782,0.0006137228,0.00085274695,0.000358797,0.0005601556],"domain_scores_gemma":[0.99843127,0.000095658645,0.00046506507,0.00061932177,0.00017966334,0.00020902464],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00016391299,0.0006815327,0.0020800154,0.00018223061,0.00015172437,0.000047995993,0.0001438923,0.00045993397,0.0019528241],"category_scores_gemma":[0.0000095542655,0.0004823193,0.00084947847,0.00037079348,0.000048607355,0.000090335634,0.000023041153,0.0003965577,0.0000073631104],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009011264,0.00019974337,0.0005996871,0.028512603,0.0030899646,0.000012753682,0.000104075036,0.000005176813,6.090952e-7,0.00014707743,0.08326677,0.88397145],"study_design_scores_gemma":[0.0028369299,0.00014790791,0.00004985133,0.021094378,0.005402503,0.000010339934,0.000008946137,0.000018442386,0.00001913789,0.0000037512043,0.96995014,0.00045767185],"about_ca_topic_score_codex":0.0010666439,"about_ca_topic_score_gemma":0.00021508752,"teacher_disagreement_score":0.88668334,"about_ca_system_score_codex":0.003917699,"about_ca_system_score_gemma":0.0019307163,"threshold_uncertainty_score":0.99990606},"labels":[],"label_agreement":null},{"id":"W2052354574","doi":"10.1016/j.lungcan.2013.07.023","title":"Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): Patient outcomes and prognostic factors","year":2013,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":156,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"University of Chicago","keywords":"Medicine; Radiation therapy; Lung; Primary tumor; Oncology; Lung cancer; Internal medicine; Carcinoma; Metastasis; Radiology; Cancer","score_opus":0.010122525381446625,"score_gpt":0.2650764802135764,"score_spread":0.25495395483212974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052354574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98476124,0.011183179,0.00002783475,0.00062283577,0.00027701436,0.0025001168,0.00005965132,0.00003399261,0.0005341426],"genre_scores_gemma":[0.99679816,0.0009379263,0.0004560366,0.00016758038,0.000051661493,0.001196512,0.00003328346,0.00004474062,0.00031407218],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984806,0.00003178795,0.0003975656,0.000423444,0.000263437,0.00040316366],"domain_scores_gemma":[0.9989141,0.00018599746,0.00016080226,0.00033782344,0.00009117189,0.00031006333],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000024474222,0.00034994338,0.0007104528,0.000115094714,0.000065345375,0.00002602284,0.000056455883,0.000079872334,0.0003762],"category_scores_gemma":[0.000013356716,0.00022656316,0.00017695583,0.00012782692,0.00009703326,0.00006556838,0.000032619035,0.000074315525,0.000010021423],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003491531,0.0009793929,0.98448807,0.00063605385,0.0005283181,0.000039268405,0.0023914133,0.00001353074,0.00015800631,0.000008343282,0.00096077536,0.009761893],"study_design_scores_gemma":[0.0042989943,0.0017141402,0.9828424,0.0003240902,0.0015521992,0.000008462068,0.00025435822,0.0008654723,0.0076074367,0.000005962042,0.00029488117,0.00023161556],"about_ca_topic_score_codex":0.0051918277,"about_ca_topic_score_gemma":0.00011460529,"teacher_disagreement_score":0.012036954,"about_ca_system_score_codex":0.0009041491,"about_ca_system_score_gemma":0.00026892903,"threshold_uncertainty_score":0.92389774},"labels":[],"label_agreement":null},{"id":"W2053609037","doi":"10.1016/j.lungcan.2004.01.016","title":"Lung cancer susceptibility and polymorphisms of glutathione-S-transferase genes in Hong Kong","year":2004,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Glutathione Transferases and Polymorphisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":56,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"University of Hong Kong","keywords":"Medicine; Glutathione S-transferase; Lung cancer; Glutathione transferase; Gene; Glutathione; Cancer research; Oncology; Cancer; Transferase; Genetics; Internal medicine; Enzyme; Biology; Biochemistry","score_opus":0.006984964008787215,"score_gpt":0.2764814705197298,"score_spread":0.2694965065109426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053609037","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95093215,0.04622399,0.0012127279,0.0007292929,0.00027829863,0.00034332572,0.00019305847,0.00001408449,0.00007305829],"genre_scores_gemma":[0.99150485,0.0075888266,0.00018150143,0.0002760931,0.00018049104,0.00008452204,0.00003612901,0.000035760204,0.000111846624],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985463,0.00004803842,0.00035811673,0.0005044565,0.00016855048,0.00037451123],"domain_scores_gemma":[0.9994349,0.00001185211,0.00005702967,0.0003044843,0.00006414908,0.00012757187],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014675452,0.00024968517,0.00029356964,0.00007523858,0.0000707233,0.000016117257,0.00014934425,0.00019193132,0.000115105446],"category_scores_gemma":[0.000009237041,0.00024230615,0.00011434535,0.0001752455,0.00016130933,0.000013632088,0.000042091797,0.00014537192,5.5451255e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026777337,0.00010306304,0.21230188,0.00020324455,0.000094256684,0.000014797393,0.00047001446,0.0035667198,0.77974313,0.00023366888,0.000074004834,0.002927458],"study_design_scores_gemma":[0.005757104,0.0003049028,0.15532155,0.00046854274,0.00023122392,0.000026164984,0.0001527159,0.0006316991,0.83525074,0.00017180685,0.00078073074,0.00090281776],"about_ca_topic_score_codex":0.0056417244,"about_ca_topic_score_gemma":0.008930363,"teacher_disagreement_score":0.056980327,"about_ca_system_score_codex":0.000078005316,"about_ca_system_score_gemma":0.0002565804,"threshold_uncertainty_score":0.9880958},"labels":[],"label_agreement":null},{"id":"W2054847513","doi":"10.1016/j.lungcan.2005.04.008","title":"cN-II expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancer","year":2005,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Fondation de France; Ligue Contre le Cancer","keywords":"Gemcitabine; Medicine; Oncology; Chemotherapy; Internal medicine; Lung cancer; Immunohistochemistry; Univariate analysis; Cancer research; Nucleoside analogue; Nucleoside; Multivariate analysis; Biology","score_opus":0.011942105896832894,"score_gpt":0.3245001958730316,"score_spread":0.3125580899761987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054847513","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894077,0.0035515602,0.0001563557,0.0012855601,0.00093508157,0.0028615221,0.0001070551,0.00010181409,0.0015933607],"genre_scores_gemma":[0.98623824,0.0012577726,0.002358052,0.00039643134,0.0007867995,0.0018200203,0.000055673554,0.00011717294,0.0069698174],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99709696,0.00005936062,0.00049619743,0.0007208793,0.00061946,0.0010071498],"domain_scores_gemma":[0.99859786,0.00015658424,0.00018351451,0.00044749962,0.0002916263,0.00032293407],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015886124,0.00034284973,0.0005356151,0.00022824877,0.00015962924,0.000022676888,0.0002608904,0.000036501584,0.0002957315],"category_scores_gemma":[0.00021539758,0.0003053865,0.00011544831,0.0003634453,0.000050770574,0.0003845516,0.00020444776,0.0004463597,0.0000040773484],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021595357,0.00060596806,0.9237588,0.0016298711,0.000047837657,0.00006551352,0.0005593102,0.0038996255,0.03824175,0.0000036087638,0.011330823,0.017697329],"study_design_scores_gemma":[0.047836706,0.0017581001,0.57946724,0.005980884,0.00028513256,0.000011280519,0.00021626367,0.025136827,0.27629784,0.000024922103,0.06163995,0.0013448702],"about_ca_topic_score_codex":0.00023660678,"about_ca_topic_score_gemma":0.0014292905,"teacher_disagreement_score":0.3442916,"about_ca_system_score_codex":0.00080004684,"about_ca_system_score_gemma":0.0003154083,"threshold_uncertainty_score":0.9999398},"labels":[],"label_agreement":null},{"id":"W2054887777","doi":"10.1016/j.lungcan.2014.04.005","title":"Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer","year":2014,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Ferroptosis and cancer prognosis","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"National Cancer Institute","keywords":"Platinum; Medicine; Lung cancer; Chemotherapy; Immunohistochemistry; Oncology; Internal medicine; Cancer; Pathology; Biology","score_opus":0.008513368554682004,"score_gpt":0.2763658677077164,"score_spread":0.2678524991530344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054887777","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98736274,0.006644767,0.0007160654,0.00093919673,0.00040550422,0.00075449183,0.000023193064,0.00003551177,0.003118526],"genre_scores_gemma":[0.99507284,0.0017471241,0.00024061541,0.0011366624,0.00034040242,0.0004424378,0.000020207151,0.000036382513,0.00096330786],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987697,0.00003124591,0.0002844767,0.00038761747,0.00020295357,0.00032399784],"domain_scores_gemma":[0.99950266,0.000024683082,0.00008858881,0.0001852322,0.000057379355,0.00014148312],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011235422,0.00019691935,0.00033385167,0.000045455847,0.0000567248,0.000023930796,0.000060534523,0.00014543002,0.0007495122],"category_scores_gemma":[0.0000033249523,0.0001660318,0.000042878906,0.00012310856,0.00004242297,0.00010951786,0.000011317702,0.0002085384,0.0000025768825],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022280808,0.000085540276,0.80489707,0.0008443977,0.000030097879,0.000007441539,0.002680125,0.00017964217,0.16531037,0.000015704094,0.010862854,0.0148639735],"study_design_scores_gemma":[0.008854861,0.00028564734,0.4334597,0.0033004726,0.00047323064,0.0000048909646,0.00021693388,0.028101968,0.5015276,0.0000087186845,0.023074878,0.00069107173],"about_ca_topic_score_codex":0.0010851838,"about_ca_topic_score_gemma":0.00078710273,"teacher_disagreement_score":0.37143737,"about_ca_system_score_codex":0.00018267344,"about_ca_system_score_gemma":0.00010677087,"threshold_uncertainty_score":0.82066333},"labels":[],"label_agreement":null},{"id":"W2056180028","doi":"10.1016/j.lungcan.2011.10.020","title":"Histopathological and immunohistochemical features associated with clinical response to neoadjuvant gefitinib therapy in early stage non-small cell lung cancer","year":2011,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Gefitinib; Adenocarcinoma; Erlotinib; Immunohistochemistry; Lung cancer; Epidermal growth factor receptor; Pathology; Adenosquamous carcinoma; Stage (stratigraphy); Oncology; Cancer; Cancer research; Internal medicine; Biology","score_opus":0.027699810195255678,"score_gpt":0.3586723438470089,"score_spread":0.3309725336517532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2056180028","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98894805,0.007002144,0.000038834238,0.0007392961,0.00025537264,0.0012626541,0.00010525409,0.00006278851,0.001585596],"genre_scores_gemma":[0.9894175,0.0008737362,0.0007551266,0.001549698,0.00010327206,0.0007304753,0.000019959922,0.000049933104,0.0065002944],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99824995,0.00013937087,0.0003896732,0.0005691194,0.00022100765,0.000430858],"domain_scores_gemma":[0.9989868,0.00016095296,0.00014415562,0.00030868917,0.00013456927,0.0002648678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003468436,0.00027696704,0.0005288285,0.0001137515,0.0000863202,0.000020638638,0.000115325514,0.00022887635,0.00024855378],"category_scores_gemma":[0.000073239484,0.00019546243,0.00009099893,0.00024282168,0.00013413302,0.00006300427,0.00004618451,0.0004532007,0.0000025022348],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011420159,0.0006557799,0.9638451,0.000047390615,0.0002675484,0.00048365092,0.008951757,0.000012072939,0.0090899505,0.000013491701,0.0021778992,0.0030352469],"study_design_scores_gemma":[0.006928773,0.0011822515,0.9881346,0.00040772246,0.00028591527,0.0000091647635,0.00012313272,0.000052784115,0.0013542101,0.000003827394,0.001248032,0.00026959347],"about_ca_topic_score_codex":0.003313867,"about_ca_topic_score_gemma":0.0007088424,"teacher_disagreement_score":0.024289541,"about_ca_system_score_codex":0.00081798004,"about_ca_system_score_gemma":0.00054634025,"threshold_uncertainty_score":0.7970727},"labels":[],"label_agreement":null},{"id":"W2057149384","doi":"10.1016/s0169-5002(01)00377-4","title":"Angiogenesis inhibitors in the treatment of lung cancer","year":2001,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Lung cancer; Oncology; Carboplatin; Internal medicine; Angiogenesis; Angiogenesis inhibitor; Cancer; Chemotherapy; Cancer research; Cisplatin","score_opus":0.026606143450541214,"score_gpt":0.3623009195765483,"score_spread":0.33569477612600707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057149384","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011797098,0.99648464,0.000009933159,0.000049333372,0.0006024523,0.0009304424,0.0003002053,0.0000061788555,0.00043713636],"genre_scores_gemma":[0.00031927985,0.99436826,0.000015615646,0.00009998624,0.0016555375,0.0019903013,0.00016693682,0.00007460959,0.0013094613],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981855,0.0001453619,0.0005350742,0.0005500169,0.00020647308,0.00037755258],"domain_scores_gemma":[0.99892753,0.000030085364,0.000330305,0.0005969142,0.00006000456,0.000055143406],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012285421,0.00047010602,0.00094957714,0.000107974105,0.000056957317,0.000017641094,0.0003789365,0.00041153093,0.00016820987],"category_scores_gemma":[0.000005198086,0.0002957421,0.0009123135,0.00045066368,0.00007560298,0.000002875017,0.00004294942,0.00007120274,0.0000017478217],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025459498,0.00018163596,0.00469729,0.0030110942,0.00084798696,0.000011468224,0.00014121698,0.000043374654,0.00008024049,0.000009800646,0.016261734,0.9746887],"study_design_scores_gemma":[0.0002671203,0.0001001529,0.0000908097,0.0021754047,0.0011578151,0.000006694304,0.000016342448,0.0000076159654,0.0002976058,6.4992156e-7,0.9955463,0.0003334969],"about_ca_topic_score_codex":0.0013751087,"about_ca_topic_score_gemma":0.001207857,"teacher_disagreement_score":0.9792846,"about_ca_system_score_codex":0.00032119144,"about_ca_system_score_gemma":0.00052373693,"threshold_uncertainty_score":0.99994946},"labels":[],"label_agreement":null},{"id":"W2059479059","doi":"10.1016/s0169-5002(00)80204-4","title":"Phase I/II study of biweekly paclitaxel and cisplatin in nonsmall cell lung cancer (NSCLC). Final result with QOL data","year":2000,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Cisplatin; Paclitaxel; Oncology; Internal medicine; Lung cancer; non-small cell lung cancer (NSCLC); Chemotherapy; A549 cell","score_opus":0.03128569605859117,"score_gpt":0.39326052230896336,"score_spread":0.3619748262503722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059479059","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9846221,0.007552459,0.000014112005,0.0006993613,0.000087570486,0.0015627746,0.0006740545,0.000027430202,0.004760132],"genre_scores_gemma":[0.99122024,0.00085928565,0.00035281607,0.00021274811,0.00012694814,0.00034491174,0.00012723269,0.00003749632,0.0067183413],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983957,0.000042583335,0.00037985216,0.00056184176,0.0003109633,0.00030906545],"domain_scores_gemma":[0.9989401,0.00005089244,0.00012796493,0.0006586916,0.00008467874,0.00013764268],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00012049907,0.0002312506,0.00041748813,0.00012359326,0.00011338865,0.000017995451,0.00015032521,0.000064609034,0.00096930435],"category_scores_gemma":[0.000009270364,0.0001737469,0.000024706964,0.00036853694,0.00006901421,0.00019377994,0.00006577034,0.00019882381,0.0000014978759],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009852224,0.019866485,0.7685075,0.0012441275,0.0019288856,0.00053039874,0.030217389,0.0011627732,0.0018171121,0.00003207842,0.02529011,0.13955091],"study_design_scores_gemma":[0.35378832,0.033707686,0.48504284,0.007781614,0.016402006,0.00010559042,0.009279173,0.046646614,0.0022260821,0.000032308766,0.04250514,0.0024826233],"about_ca_topic_score_codex":0.012978423,"about_ca_topic_score_gemma":0.010169155,"teacher_disagreement_score":0.3439361,"about_ca_system_score_codex":0.00023670387,"about_ca_system_score_gemma":0.0005618117,"threshold_uncertainty_score":0.999944},"labels":[],"label_agreement":null},{"id":"W2059645245","doi":"10.1016/s0169-5002(02)00167-8","title":"Second line chemotherapy for NSCLC: establishing a gold standard","year":2002,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Docetaxel; Medicine; Vinorelbine; Oncology; Lung cancer; Internal medicine; Paclitaxel; Ifosfamide; Chemotherapy; Population; Surgery; Etoposide; Cisplatin","score_opus":0.03752359896036843,"score_gpt":0.41298845336235307,"score_spread":0.3754648544019846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059645245","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000025312236,0.98434675,0.00035940687,0.0004139588,0.00084318896,0.003389253,0.001796319,0.000101494,0.0087471],"genre_scores_gemma":[0.0000029821676,0.9380054,0.0011161625,0.0006783788,0.0015080977,0.0022621737,0.00048223688,0.0001644532,0.05578012],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982827,0.000022672199,0.00049311307,0.000537686,0.00025392915,0.0004099456],"domain_scores_gemma":[0.99878454,0.00013608174,0.00029290162,0.00044037995,0.00016686512,0.00017924415],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000102786216,0.00045845078,0.0016653937,0.00016254699,0.00008706515,0.00008789518,0.00013899866,0.00029241052,0.0027336648],"category_scores_gemma":[0.000031734395,0.00033946734,0.00061431294,0.00029998773,0.000034338955,0.000117672986,0.000020351028,0.00030749626,0.000012119625],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004405346,0.000054821692,0.000007487476,0.020034438,0.0014916898,0.0000119495835,0.00018032957,8.291126e-7,3.3705857e-7,0.00006020216,0.10436472,0.87374914],"study_design_scores_gemma":[0.0024012711,0.00018319987,0.0000017656889,0.017319761,0.0057915864,0.000023344668,0.0000095930445,0.000038344217,0.0000034663333,0.000013343676,0.97390336,0.0003109365],"about_ca_topic_score_codex":0.00005435461,"about_ca_topic_score_gemma":0.00009810832,"teacher_disagreement_score":0.8734382,"about_ca_system_score_codex":0.0014025804,"about_ca_system_score_gemma":0.0009671226,"threshold_uncertainty_score":0.9999057},"labels":[],"label_agreement":null},{"id":"W2059812828","doi":"10.1016/j.lungcan.2013.07.026","title":"Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature","year":2013,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":288,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Radiosurgery; SABR volatility model; Lung cancer; Radiation therapy; Oncology; Internal medicine; Stage (stratigraphy); Randomized controlled trial; Surgery","score_opus":0.020849039471685926,"score_gpt":0.35157146969722763,"score_spread":0.3307224302255417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059812828","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019044752,0.98437643,0.0000017312626,0.00031743897,0.00052507693,0.013558931,0.000721749,0.000021684933,0.0002864863],"genre_scores_gemma":[0.00008898193,0.9818812,0.000054608772,0.0012532165,0.00014800427,0.013121424,0.00008307115,0.00013953977,0.0032299703],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9962824,0.00042309347,0.0015141208,0.0007246802,0.00054970436,0.00050599815],"domain_scores_gemma":[0.9964707,0.00013950154,0.0013543551,0.0015548595,0.00028206987,0.0001985441],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036617415,0.0008035414,0.0048415177,0.00019286583,0.000049824157,0.000060834962,0.00052289985,0.00023511621,0.0005773502],"category_scores_gemma":[0.000030935913,0.00040898085,0.0009569654,0.0011524162,0.00004888738,0.000106509615,0.00010372648,0.00066012924,0.000014483439],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000038389985,0.0001794687,0.0008639556,0.97853196,0.0011492111,0.000034717435,0.0010967902,0.0000017218081,2.114229e-7,0.0000034747964,0.0052419202,0.012892711],"study_design_scores_gemma":[0.000643397,0.000068190624,0.0001000066,0.9601562,0.017784309,0.000017472166,0.000020537736,0.00004199471,0.000009422687,0.0000045004545,0.02081783,0.00033612995],"about_ca_topic_score_codex":0.0021699518,"about_ca_topic_score_gemma":0.00060627895,"teacher_disagreement_score":0.01837577,"about_ca_system_score_codex":0.0019052398,"about_ca_system_score_gemma":0.0012444762,"threshold_uncertainty_score":0.9998362},"labels":[],"label_agreement":null},{"id":"W2060209568","doi":"10.1016/s0169-5002(03)00308-8","title":"Targeting angiogenesis: a review of angiogenesis inhibitors in the treatment of lung cancer","year":2003,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":103,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Angiogenesis; Medicine; Endostatin; Angiostatin; Lung cancer; Vascular endothelial growth factor; Pharmacology; Matrix metalloproteinase inhibitor; Matrix metalloproteinase; Cancer research; Sulindac; Immunology; Internal medicine; VEGF receptors","score_opus":0.022801210206394484,"score_gpt":0.35417343992182143,"score_spread":0.33137222971542696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060209568","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00028730603,0.9968151,0.000013397654,0.00004457121,0.0004940465,0.001690773,0.00048200335,0.000005525175,0.00016726411],"genre_scores_gemma":[0.00008863973,0.99590766,0.000067604975,0.00025736992,0.0006653199,0.0023847113,0.00023840104,0.000097679665,0.0002926114],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969887,0.00039270052,0.0011711092,0.0006711308,0.00032963598,0.00044670064],"domain_scores_gemma":[0.99804884,0.000050541512,0.00092579017,0.0007359909,0.00017193142,0.00006693337],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004163364,0.0006188334,0.0017949662,0.00013999251,0.000057514004,0.000009884288,0.00046573998,0.00039763903,0.00017308995],"category_scores_gemma":[0.000024889598,0.00040656998,0.0015955764,0.0007093361,0.00009922209,0.0000049306564,0.00005162356,0.00007418207,9.1122257e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000043784956,0.0004985486,0.004945644,0.18038177,0.0030038333,0.000013312378,0.00022663295,0.00006716176,0.0007297793,0.0000216072,0.05159213,0.7584758],"study_design_scores_gemma":[0.0002517006,0.0001129143,0.000021919952,0.04160207,0.0027153334,0.000005418629,0.000018486637,0.0000041893763,0.0008222071,3.9616117e-7,0.95402974,0.0004155952],"about_ca_topic_score_codex":0.0005810717,"about_ca_topic_score_gemma":0.00013375988,"teacher_disagreement_score":0.9024376,"about_ca_system_score_codex":0.00028020542,"about_ca_system_score_gemma":0.0008491603,"threshold_uncertainty_score":0.9998386},"labels":[],"label_agreement":null},{"id":"W2060696690","doi":"10.1016/j.lungcan.2013.11.020","title":"Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer","year":2013,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Merck Sharp and Dohme","keywords":"Medicine; Erlotinib; Internal medicine; Neutropenia; Oncology; Lung cancer; Adverse effect; Surgery; Cancer; Epidermal growth factor receptor; Chemotherapy","score_opus":0.009580312840794003,"score_gpt":0.29764311509174984,"score_spread":0.2880628022509558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060696690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876316,0.0019296771,0.000042812306,0.00029463525,0.0013122166,0.008305837,0.000054279706,0.00004602,0.0003828831],"genre_scores_gemma":[0.9952396,0.000084775595,0.00012295715,0.00022967938,0.00029147314,0.003122915,0.000009540511,0.0000962286,0.0008027866],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99724704,0.00018983484,0.0007124066,0.0005867099,0.00071611285,0.0005478832],"domain_scores_gemma":[0.9980309,0.00020152151,0.00050788047,0.00072053855,0.00036090292,0.00017826323],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002262297,0.00043293575,0.0010677825,0.00014633904,0.00009520655,0.000024827374,0.00029705415,0.00010769865,0.00057089824],"category_scores_gemma":[0.000053139604,0.00026987723,0.00016413817,0.00045985938,0.00018318785,0.00021516421,0.000128974,0.0004563308,0.000004706781],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27739123,0.004462022,0.6978638,0.0005351587,0.0008956105,0.000017955967,0.007144295,0.0013355599,0.0018449744,0.0000050929784,0.0003264945,0.008177772],"study_design_scores_gemma":[0.8903041,0.0009852032,0.09665453,0.0009962561,0.0011059281,7.2337247e-7,0.001571974,0.00090176857,0.0068712416,0.000006985354,0.00013727175,0.00046401576],"about_ca_topic_score_codex":0.005714357,"about_ca_topic_score_gemma":0.0018638256,"teacher_disagreement_score":0.6129129,"about_ca_system_score_codex":0.0007136589,"about_ca_system_score_gemma":0.00034427518,"threshold_uncertainty_score":0.9999753},"labels":[],"label_agreement":null},{"id":"W2062547449","doi":"10.1016/j.lungcan.2013.11.010","title":"KRAS mutations in non-small-cell lung cancer and colorectal cancer: Implications for EGFR-targeted therapies","year":2013,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Genetics","funders":"","keywords":"KRAS; Colorectal cancer; Medicine; Lung cancer; Carcinogenesis; Oncology; Internal medicine; Cancer research; Genotype; Cancer; Biology; Genetics; Gene","score_opus":0.010244901197998242,"score_gpt":0.32954041298713815,"score_spread":0.3192955117891399,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062547449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9478176,0.03118894,0.000460788,0.014251266,0.00040164945,0.0041480823,0.00058811076,0.000080841484,0.0010627025],"genre_scores_gemma":[0.96805453,0.004583617,0.0012506687,0.00093461,0.0002616719,0.021862091,0.00016195717,0.000063430845,0.002827426],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987026,0.000017734712,0.0003128578,0.0004341679,0.000110026915,0.0004226444],"domain_scores_gemma":[0.9990919,0.00011722203,0.00012859597,0.00020530734,0.00028290387,0.00017403258],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000050540813,0.00024777884,0.0003458577,0.0001596424,0.00023211379,0.000058060017,0.000090165,0.00011375175,0.00049760845],"category_scores_gemma":[0.0000109332805,0.00021239088,0.000088224515,0.00035283214,0.00008273892,0.00018597364,0.00002056396,0.00014839065,0.000003910828],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010348202,0.00029044325,0.9239288,0.0005711662,0.00090295053,0.000002502221,0.0075431797,0.000574183,0.024446027,0.00044722186,0.015788805,0.025401222],"study_design_scores_gemma":[0.0058182683,0.00013171135,0.97662765,0.0003573157,0.0012652291,0.000005023513,0.0006232204,0.0070600603,0.0034393098,0.00045093516,0.0038245225,0.00039678416],"about_ca_topic_score_codex":0.015609285,"about_ca_topic_score_gemma":0.009901478,"teacher_disagreement_score":0.0526988,"about_ca_system_score_codex":0.0007586382,"about_ca_system_score_gemma":0.00075925706,"threshold_uncertainty_score":0.9909459},"labels":[],"label_agreement":null},{"id":"W2063481154","doi":"10.1016/j.lungcan.2003.08.026","title":"Impaired diffusion capacity predicts for decreased treatment tolerance and survival in limited stage small cell lung cancer patients treated with concurrent chemoradiation","year":2004,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Western University","funders":"","keywords":"Medicine; DLCO; Internal medicine; Pulmonary function testing; Pulmonary toxicity; Toxicity; Diffusing capacity; Etoposide; Vincristine; Cumulative incidence; Gastroenterology; Urology; Surgery; Cyclophosphamide; Lung; Chemotherapy; Cohort","score_opus":0.02322103713015736,"score_gpt":0.3031683424275841,"score_spread":0.27994730529742673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063481154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901687,0.0044615446,0.000100383884,0.0004199227,0.00019769323,0.0038765983,0.00059994,0.000079494916,0.000095758216],"genre_scores_gemma":[0.9939985,0.0025035394,0.00011105339,0.00010792605,0.00015845508,0.0023967535,0.00016552774,0.00005189579,0.00050631206],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99808925,0.000050816994,0.00031468703,0.00057889766,0.00039836374,0.00056797446],"domain_scores_gemma":[0.9989441,0.000088574525,0.00016177821,0.00022685355,0.00029101418,0.00028770397],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00010024744,0.00035853143,0.00058395346,0.00014301753,0.0001368942,0.000029645798,0.00006997569,0.00010195198,0.000026900027],"category_scores_gemma":[0.0000491834,0.00026468435,0.00007110232,0.000327402,0.000108316555,0.00011292992,0.00003295617,0.00015198709,3.2666708e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021436696,0.00080272736,0.98885477,0.0010733808,0.00022452876,0.000013127215,0.0019418696,0.00064234476,0.0017034862,0.0000063984603,0.0001451833,0.0024485409],"study_design_scores_gemma":[0.047790643,0.0016745694,0.9211279,0.001298783,0.0004888544,9.0887096e-7,0.0000964521,0.012325028,0.014292238,0.0000023435914,0.0005244931,0.00037779126],"about_ca_topic_score_codex":0.01472032,"about_ca_topic_score_gemma":0.012408506,"teacher_disagreement_score":0.06772685,"about_ca_system_score_codex":0.0036743297,"about_ca_system_score_gemma":0.00058652495,"threshold_uncertainty_score":0.9999805},"labels":[],"label_agreement":null},{"id":"W2068132555","doi":"10.1016/j.lungcan.2009.09.007","title":"The role of βIII tubulin in predicting chemoresistance in non-small cell lung cancer","year":2009,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saint John Regional Hospital; Dalhousie University","funders":"","keywords":"Medicine; Taxane; Lung cancer; Oncology; Regimen; Internal medicine; Cancer; Disease; Chemotherapy; Bioinformatics; Breast cancer; Biology","score_opus":0.010544525231161473,"score_gpt":0.34552796477521425,"score_spread":0.3349834395440528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068132555","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00083719974,0.9879409,0.0000040353902,0.00016220972,0.00036421753,0.0024990092,0.00013997644,0.000025998424,0.008026466],"genre_scores_gemma":[0.0029298803,0.99167347,0.00009850422,0.00009018617,0.0003792209,0.0019013701,0.00007075959,0.00007980719,0.0027767958],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997563,0.00007061363,0.00095364754,0.0005492194,0.00031815088,0.0005453728],"domain_scores_gemma":[0.99853855,0.00018260327,0.00054436346,0.0005214933,0.00010209837,0.00011088384],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023065899,0.00046098966,0.0015284612,0.0002125138,0.00008769826,0.000025369998,0.00027491702,0.00028251088,0.00006902819],"category_scores_gemma":[0.000028954433,0.000315805,0.00031232825,0.00072542793,0.00006071476,0.000059213475,0.00005015644,0.00063370744,0.0000023751272],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000092068374,0.00025542456,0.039110757,0.022443857,0.0005503648,0.00006215897,0.0014464658,0.000097789445,0.00001604165,0.000040270705,0.0017437264,0.9341411],"study_design_scores_gemma":[0.0030044946,0.000085420805,0.0058564814,0.079063214,0.0048677754,0.000008629903,0.00026948904,0.0012261198,0.00010858573,0.000027097718,0.90489864,0.0005840363],"about_ca_topic_score_codex":0.004385485,"about_ca_topic_score_gemma":0.0073970533,"teacher_disagreement_score":0.93355703,"about_ca_system_score_codex":0.0021188408,"about_ca_system_score_gemma":0.0019830638,"threshold_uncertainty_score":0.9999294},"labels":[],"label_agreement":null},{"id":"W2068437736","doi":"10.1016/j.lungcan.2012.07.004","title":"An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastases","year":2012,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Allos Therapeutics; European Society for Medical Oncology; Chugai Pharmaceutical; Daiichi-Sankyo; GlaxoSmithKline; Daiichi Sankyo Europe; Eli Lilly and Company","keywords":"Medicine; Lung cancer; Oncology; Internal medicine; Bevacizumab; Incidence (geometry); Angiogenesis; Brain metastasis; Metastasis; Vascular endothelial growth factor; Cancer; Clinical trial; Lung; Chemotherapy; Pathology; VEGF receptors","score_opus":0.042605661423771216,"score_gpt":0.3554587908685443,"score_spread":0.3128531294447731,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068437736","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012202404,0.98163277,0.000032328346,0.00017873367,0.00016693874,0.0053224955,0.00041745728,0.0000133527,0.0000334992],"genre_scores_gemma":[0.018041557,0.97910994,0.0005402769,0.0007999583,0.000115937866,0.0011375289,0.00010070681,0.0001073528,0.000046750934],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9966151,0.00048124406,0.0009630001,0.0006156691,0.00082170666,0.00050328235],"domain_scores_gemma":[0.9964742,0.00041554225,0.0015160824,0.001012689,0.0004002704,0.0001812066],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00083327625,0.0006915328,0.0028355354,0.00020000243,0.0000606022,0.000014434837,0.00044289164,0.00014488708,0.00033838788],"category_scores_gemma":[0.00004698954,0.0003348039,0.00042667674,0.0011268201,0.00016995231,0.00021060849,0.000056439316,0.00044468953,6.611922e-7],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025158332,0.0011455676,0.31828597,0.3847232,0.001441438,0.000023116647,0.00023934126,0.000057709578,0.000013450207,0.00000966845,0.00047930595,0.29332966],"study_design_scores_gemma":[0.0032210692,0.0010992446,0.016088353,0.9305583,0.013773807,0.000007351748,0.000022599375,0.000034977253,0.00023804345,3.695601e-7,0.03435044,0.0006054215],"about_ca_topic_score_codex":0.0026089638,"about_ca_topic_score_gemma":0.0005576879,"teacher_disagreement_score":0.54583514,"about_ca_system_score_codex":0.0005358442,"about_ca_system_score_gemma":0.0020301428,"threshold_uncertainty_score":0.9999104},"labels":[],"label_agreement":null},{"id":"W2068558121","doi":"10.1016/j.lungcan.2006.10.006","title":"Safety and feasibility of cardiopulmonary exercise testing in patients with advanced cancer","year":2006,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer survivorship and care","field":"Medicine","cited_by":123,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary","funders":"Canadian Institutes of Health Research; Canada Research Chairs","keywords":"Medicine; Intensive care medicine; Internal medicine","score_opus":0.009922891560607522,"score_gpt":0.27498225672799337,"score_spread":0.2650593651673858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068558121","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882059,0.008811518,0.00001059121,0.000076688884,0.00016796718,0.00060671463,0.00009323924,0.000024644429,0.0020027189],"genre_scores_gemma":[0.999189,0.00022462608,0.00012915889,0.000053655684,0.00006934677,0.00007886433,0.000018574961,0.000021362215,0.0002153872],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990004,0.000018454308,0.00024014784,0.00029136884,0.00024358241,0.0002060832],"domain_scores_gemma":[0.99942213,0.000030302452,0.00008896673,0.00021757658,0.00018023505,0.00006079615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007901806,0.00013748356,0.00038009588,0.000056415956,0.000030641375,0.0000040201485,0.000039539707,0.00005388175,0.000039949264],"category_scores_gemma":[0.000012785414,0.00011246216,0.000034703608,0.0003231159,0.00006863353,0.0000775347,0.000026780479,0.00012402894,1.4357306e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017265201,0.00006753539,0.96427387,0.00038395642,0.00001532456,0.000005530389,0.00016141875,0.00042373245,0.000098200486,0.00000471527,0.000040256033,0.032798965],"study_design_scores_gemma":[0.0026112406,0.00009747564,0.9952461,0.0011097982,0.0001046453,7.6700195e-7,0.000057046356,0.00012660619,0.00019666846,0.0000115096545,0.00030624715,0.00013186544],"about_ca_topic_score_codex":0.019161979,"about_ca_topic_score_gemma":0.011230631,"teacher_disagreement_score":0.0326671,"about_ca_system_score_codex":0.0003118698,"about_ca_system_score_gemma":0.00015048271,"threshold_uncertainty_score":0.9873695},"labels":[],"label_agreement":null},{"id":"W2069169809","doi":"10.1016/s0169-5002(00)80490-0","title":"Outpatient management of malignant pleural effusions using an indwelling cuffed silastic catheter","year":2000,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Pleural and Pulmonary Diseases","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Silastic; Malignant pleural effusion; Catheter; Indwelling catheter; Surgery; Pleural effusion; Intensive care medicine","score_opus":0.02770053051704053,"score_gpt":0.31117535780643574,"score_spread":0.2834748272893952,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069169809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971239,0.0013273048,0.000040506533,0.00010232976,0.0001489916,0.00031526646,0.000051536925,0.000030154562,0.0008599939],"genre_scores_gemma":[0.997124,0.00034458374,0.00031659112,0.00023343762,0.000108616005,0.000025332622,0.000033065106,0.00001753113,0.0017968398],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99914193,0.00002465792,0.00020985468,0.00020021317,0.00020850376,0.00021485993],"domain_scores_gemma":[0.99956924,0.0000128291085,0.00004830613,0.00019425568,0.000031420885,0.0001439292],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0000332744,0.00012303249,0.00019253645,0.000046229143,0.00006681558,0.000006588982,0.00006688536,0.000034362012,0.0016101694],"category_scores_gemma":[0.0000015104978,0.00009304895,0.00008520302,0.00011691889,0.000034114957,0.00006655621,0.000022635364,0.00006934958,0.000009572445],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065531856,0.007929945,0.6054254,0.007200092,0.0018640684,0.001907932,0.007225911,0.074062645,0.054497972,0.00033948245,0.0024757604,0.23051757],"study_design_scores_gemma":[0.005940677,0.0017728141,0.6732112,0.0076708645,0.0044334605,0.00011103527,0.0007904995,0.28350192,0.010098849,0.00018150931,0.010990778,0.0012963734],"about_ca_topic_score_codex":0.00033371188,"about_ca_topic_score_gemma":0.000013761803,"teacher_disagreement_score":0.2292212,"about_ca_system_score_codex":0.00007667991,"about_ca_system_score_gemma":0.000035517212,"threshold_uncertainty_score":0.9993025},"labels":[],"label_agreement":null},{"id":"W2069954767","doi":"10.1016/j.lungcan.2007.06.013","title":"Lung cancer after exposure to disease modifying anti-rheumatic drugs","year":2007,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Medicine; Lung cancer; Internal medicine; Rheumatoid arthritis; Cohort; Cancer; Oncology; Cohort study; Logistic regression; Population; Relative risk; Confidence interval; Environmental health","score_opus":0.009153614697970517,"score_gpt":0.32510730099877794,"score_spread":0.31595368630080745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069954767","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8889995,0.10539272,0.0007545511,0.0027572103,0.0004540347,0.00080930715,0.000052536816,0.00010414678,0.000675958],"genre_scores_gemma":[0.98167557,0.013807909,0.00022678735,0.0016038965,0.0003298794,0.0005341178,0.000009711869,0.00006007734,0.0017520799],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997856,0.000033796503,0.0003278849,0.00038752833,0.00063003897,0.00076470646],"domain_scores_gemma":[0.99850464,0.000060015842,0.000053264976,0.00040442188,0.00015527257,0.0008223937],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002899994,0.0002314692,0.00035986424,0.00019789994,0.00013830936,0.00006469061,0.00013517706,0.00006486398,0.002015404],"category_scores_gemma":[0.00006591486,0.00019727019,0.00012769246,0.0003248889,0.00007215531,0.00017448788,0.000070624534,0.00024970222,0.000041815427],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023049773,0.00019439026,0.8755567,0.0014983373,0.00053594605,0.00042469206,0.0075919377,0.00026516113,0.0037199382,0.00014750617,0.014171783,0.0935886],"study_design_scores_gemma":[0.0063286778,0.0002009282,0.94173694,0.008656365,0.000117586285,0.000018874522,0.0006975713,0.00381519,0.002964422,0.00010769193,0.034421638,0.0009341455],"about_ca_topic_score_codex":0.0008180043,"about_ca_topic_score_gemma":0.00040256765,"teacher_disagreement_score":0.092676,"about_ca_system_score_codex":0.00033493468,"about_ca_system_score_gemma":0.00031195255,"threshold_uncertainty_score":0.9988969},"labels":[],"label_agreement":null},{"id":"W2069960588","doi":"10.1016/s0169-5002(02)00503-2","title":"Small stage I cancers of the lung: genuineness and curability","year":2003,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Lung cancer; Stage (stratigraphy); Asymptomatic; Lymph node; Case fatality rate; Cancer; Lung; Mediastinal lymph node; Surgery; Epidemiology; Radiology; Internal medicine; Metastasis","score_opus":0.019882833956268466,"score_gpt":0.3052485709424172,"score_spread":0.28536573698614875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069960588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97683924,0.017735647,0.00001839461,0.0012281263,0.00048565224,0.0006564649,0.000057141802,0.000017009115,0.0029623313],"genre_scores_gemma":[0.99628174,0.0013933176,0.00009075128,0.00043523926,0.000057171703,0.00018432613,0.0000019694382,0.000016943233,0.0015385136],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99915165,0.000045980356,0.00018056051,0.0002588616,0.00016966122,0.00019331081],"domain_scores_gemma":[0.999299,0.000047704965,0.00009013766,0.00039091308,0.000081058824,0.00009117153],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011214516,0.0001337528,0.00025407868,0.00002115143,0.00006068441,0.0000079577685,0.0000613071,0.000052148178,0.00032626343],"category_scores_gemma":[0.000037217742,0.00008316705,0.00008603764,0.00015619508,0.000109937726,0.000029862847,0.000025238794,0.00009739027,4.969788e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005486555,0.00007683528,0.9937331,0.0006208939,0.00020159956,0.0000036231095,0.00040439973,0.00010767679,0.00025737888,0.0009327038,0.0023252447,0.001281646],"study_design_scores_gemma":[0.003919321,0.00013971947,0.9130707,0.0007324837,0.0009463492,0.000010753011,0.00018196371,0.0004526082,0.030923866,0.000097261945,0.049264055,0.0002609261],"about_ca_topic_score_codex":0.0023714378,"about_ca_topic_score_gemma":0.0009908273,"teacher_disagreement_score":0.080662444,"about_ca_system_score_codex":0.000780755,"about_ca_system_score_gemma":0.00045958304,"threshold_uncertainty_score":0.35849205},"labels":[],"label_agreement":null},{"id":"W2071340558","doi":"10.1016/j.lungcan.2014.09.013","title":"A population-based study of the resource utilization and costs of managing resectable non-small cell lung cancer","year":2014,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Queen's University","funders":"Canadian Institutes of Health Research; Canada Research Chairs; Ontario Ministry of Health and Long-Term Care","keywords":"Medicine; Cohort; Lung cancer; Population; Chemotherapy; Retrospective cohort study; Cohort study; Emergency medicine; Cancer; Surgery; Internal medicine","score_opus":0.014337200830847788,"score_gpt":0.3034205436464504,"score_spread":0.2890833428156026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071340558","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929755,0.0038319402,0.00007975664,0.0005191085,0.0001513323,0.0011863088,0.000015056301,0.000013857916,0.0012271696],"genre_scores_gemma":[0.9988506,0.0001726606,0.00004237008,0.00022705791,0.00007849118,0.0002497847,0.000009027445,0.000024624002,0.00034537472],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99899936,0.00007085409,0.00025066052,0.00025371954,0.00026465746,0.00016077198],"domain_scores_gemma":[0.9991821,0.000092242735,0.00020328371,0.00035941185,0.000107822736,0.000055140365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000147158,0.00012837988,0.00028958172,0.00007040475,0.00008252619,0.000009861086,0.00007776389,0.000044334032,0.00005583437],"category_scores_gemma":[0.000017646822,0.000089746536,0.00004876271,0.0002555299,0.000021021731,0.000030671647,0.00004036434,0.00008017445,1.2097601e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000119285185,0.00026931384,0.9910313,0.0006553859,0.00010573595,7.5766314e-7,0.00078402244,0.0034331942,0.00016541389,0.000028042403,0.00081085676,0.0025966875],"study_design_scores_gemma":[0.004334246,0.00023404202,0.94996685,0.0017151195,0.0008437487,3.1137654e-7,0.00025817152,0.037485555,0.0046246164,0.000005556378,0.0004180253,0.00011374734],"about_ca_topic_score_codex":0.016249634,"about_ca_topic_score_gemma":0.0060271057,"teacher_disagreement_score":0.041064445,"about_ca_system_score_codex":0.00041907764,"about_ca_system_score_gemma":0.00011011792,"threshold_uncertainty_score":0.99030125},"labels":[],"label_agreement":null},{"id":"W2073260977","doi":"10.1016/j.lungcan.2015.11.018","title":"Overexpression of KIF23 predicts clinical outcome in primary lung cancer patients","year":2015,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":176,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto General Hospital; University Health Network","funders":"","keywords":"Lung cancer; Adenocarcinoma; Oncology; Medicine; Lung; Oncogene; Internal medicine; Cancer; Pathology; Cell cycle","score_opus":0.01760095957507451,"score_gpt":0.34243629148413984,"score_spread":0.32483533190906533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073260977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948237,0.0030725924,0.00007730455,0.000050297942,0.0006611052,0.00027951717,0.00012142795,0.000006686377,0.00090736203],"genre_scores_gemma":[0.9970934,0.0009917435,0.00014124943,0.0005374541,0.00028180575,0.0000675018,0.00013634235,0.000023579632,0.00072695257],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988293,0.000060088343,0.0004329698,0.00030137764,0.00016544957,0.00021083716],"domain_scores_gemma":[0.99934226,0.000009731704,0.00016322378,0.00026034765,0.00011815069,0.00010627883],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017097151,0.00013016385,0.00023320879,0.000032239455,0.000015002454,0.000005811815,0.00017170286,0.00021448315,0.000023829643],"category_scores_gemma":[0.000060967002,0.000116118616,0.00008298138,0.00006737073,0.00004681095,0.000006493948,0.00016450025,0.00012696465,8.582121e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017133901,0.00014175569,0.9489345,0.00010212918,0.00004217291,7.255844e-7,0.000049754704,0.00017697227,0.033088688,0.0000035083856,0.016120939,0.0011675254],"study_design_scores_gemma":[0.0054643927,0.0002830841,0.94225127,0.0004859459,0.000093503084,8.125274e-7,0.000020379352,0.001738787,0.031010952,0.000013133436,0.018201452,0.00043630967],"about_ca_topic_score_codex":0.00031106765,"about_ca_topic_score_gemma":0.00017808282,"teacher_disagreement_score":0.0066832425,"about_ca_system_score_codex":0.00010405068,"about_ca_system_score_gemma":0.00024776824,"threshold_uncertainty_score":0.47351798},"labels":[],"label_agreement":null},{"id":"W2073397984","doi":"10.1016/s0169-5002(00)80192-0","title":"Integrated analysis for two randomized phase III studies comparing Taxotere at 75 mg/m2 and 100 mg/m2 to control regimens in non-small cell lung cancer (NSCLC) patients previously treated with a platinum-based chemotherapy","year":2000,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Oncology; non-small cell lung cancer (NSCLC); Lung cancer; Randomized controlled trial","score_opus":0.013373242699183347,"score_gpt":0.33694084528434476,"score_spread":0.32356760258516143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073397984","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9833923,0.0057599237,0.0015234195,0.0005028049,0.00006741722,0.00806235,0.00027373945,0.00007363541,0.00034443027],"genre_scores_gemma":[0.9878162,0.00057624903,0.0007561769,0.001227109,0.00007628227,0.0059320065,0.00029903732,0.00007384941,0.0032430645],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99772084,0.000102546706,0.00064335327,0.00071993744,0.00025817615,0.0005551251],"domain_scores_gemma":[0.9985107,0.00025003657,0.00028800825,0.0003437036,0.00035934988,0.00024818158],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019141872,0.00049628486,0.0018884242,0.0003435194,0.0001948812,0.000044837485,0.0000936004,0.000089761474,0.00030070732],"category_scores_gemma":[0.000019960087,0.00035179098,0.0002458377,0.00082616054,0.000107605745,0.000089982386,0.000014385129,0.0001526354,0.0000013370711],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2277668,0.001095183,0.71665573,0.0005608055,0.015598631,0.000033953464,0.010087946,0.01680343,0.00072811864,0.0000017893228,0.0018313065,0.008836332],"study_design_scores_gemma":[0.8322114,0.0007357791,0.01928915,0.0017223591,0.01685592,0.0000013776908,0.00024661818,0.12643215,0.0014367277,0.0000015097747,0.00048597995,0.0005810449],"about_ca_topic_score_codex":0.009506693,"about_ca_topic_score_gemma":0.015403579,"teacher_disagreement_score":0.69736654,"about_ca_system_score_codex":0.0016073677,"about_ca_system_score_gemma":0.00030309267,"threshold_uncertainty_score":0.9998934},"labels":[],"label_agreement":null},{"id":"W2075202876","doi":"10.1016/j.lungcan.2014.12.014","title":"Maintenance chemotherapy in advanced NSCLC: A population-based assessment of eligibility","year":2015,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Eli Lilly and Company","keywords":"Medicine; Maintenance therapy; Chemotherapy; Internal medicine; Population; Performance status; Oncology; Cancer","score_opus":0.01605880244225595,"score_gpt":0.4216548494356635,"score_spread":0.40559604699340757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075202876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890113,0.0009541929,0.0010442829,0.0023140823,0.000235925,0.0008419147,0.000033712742,0.000036145113,0.005528444],"genre_scores_gemma":[0.9946937,0.00003758113,0.0038468572,0.0006627271,0.000040010993,0.00020779537,0.000042670446,0.000015723033,0.00045292487],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99914473,0.000020351128,0.00024193227,0.00021336507,0.00021929396,0.00016033101],"domain_scores_gemma":[0.9993839,0.000026904598,0.000098048265,0.00024926654,0.00015085374,0.00009098733],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011622935,0.00010269109,0.00025389247,0.00006851102,0.000015355063,0.0000043637438,0.00004319959,0.00004184763,0.000094176576],"category_scores_gemma":[0.00002920836,0.00008314808,0.000054670927,0.00023147096,0.000022509257,0.00006071877,0.000006145999,0.000075078635,7.669996e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023033388,0.00023035458,0.9879604,0.00009706123,0.00005911499,0.000004487148,0.00021719915,0.002769923,0.0002957289,0.00023591987,0.00054263417,0.0073568528],"study_design_scores_gemma":[0.0074057784,0.00013015055,0.98169154,0.00032987248,0.00008078518,8.7881693e-7,0.00007042308,0.008518908,0.0004347696,0.00017056092,0.0010708792,0.00009543818],"about_ca_topic_score_codex":0.0023504149,"about_ca_topic_score_gemma":0.0005983834,"teacher_disagreement_score":0.0072614145,"about_ca_system_score_codex":0.0010977439,"about_ca_system_score_gemma":0.0007920616,"threshold_uncertainty_score":0.355314},"labels":[],"label_agreement":null},{"id":"W2075402438","doi":"10.1016/j.lungcan.2010.08.002","title":"Effects of Aerobic Training on Oxidative Status in Postsurgical Non-Small Cell Lung Cancer Patients: A Pilot Study","year":2010,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Antioxidant Activity and Oxidative Stress","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Cancer Institute","keywords":"Medicine; Lung cancer; Oncology; Internal medicine; Aerobic exercise; Physical therapy","score_opus":0.013697876784615565,"score_gpt":0.29989237289991466,"score_spread":0.2861944961152991,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075402438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953868,0.00026530417,0.00004096871,0.00009284313,0.00058312155,0.0020453252,0.00004916219,0.000028811482,0.0015077083],"genre_scores_gemma":[0.99871564,0.00013986489,0.00007750514,0.00020240048,0.00015678926,0.00034003396,0.000014822438,0.00004071065,0.00031223486],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982142,0.00012193339,0.00033553556,0.00046567805,0.00036536812,0.00049727905],"domain_scores_gemma":[0.9988522,0.00036863238,0.00021608899,0.00022436843,0.00016647957,0.00017224283],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015923839,0.00028611277,0.0006151626,0.00020333285,0.000063858424,0.000012786364,0.000121748446,0.0001187855,0.00022365434],"category_scores_gemma":[0.00009902732,0.00024046289,0.000075234144,0.00036580476,0.00010444287,0.00012847873,0.000057004057,0.00094851496,0.0000029841526],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002167202,0.005047329,0.8447232,0.0007145707,0.00020953277,0.00006925463,0.010247531,0.00004348787,0.1339768,0.000037419155,0.00022389808,0.0025397367],"study_design_scores_gemma":[0.00910705,0.0027475697,0.9220596,0.00089364004,0.0002523542,5.506742e-7,0.0005985144,0.00033325778,0.06363947,0.000002110479,0.000104527746,0.000261383],"about_ca_topic_score_codex":0.0029973807,"about_ca_topic_score_gemma":0.004205487,"teacher_disagreement_score":0.07733635,"about_ca_system_score_codex":0.00022653793,"about_ca_system_score_gemma":0.00030012472,"threshold_uncertainty_score":0.9805792},"labels":[],"label_agreement":null},{"id":"W2080373479","doi":"10.1016/j.lungcan.2013.02.008","title":"The addition of amifostine to carboplatin and paclitaxel based chemoradiation in locally advanced non-small cell lung cancer: Long-term follow-up of Radiation Therapy Oncology Group (RTOG) randomized trial 9801","year":2013,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Effects of Radiation Exposure","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency","funders":"National Cancer Institute","keywords":"Medicine; Carboplatin; Amifostine; Internal medicine; Chemoradiotherapy; Oncology; Hazard ratio; Regimen; Paclitaxel; Radiation therapy; Lung cancer; Urology; Chemotherapy; Cisplatin; Confidence interval","score_opus":0.0061225479966184075,"score_gpt":0.2849646875992788,"score_spread":0.27884213960266035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080373479","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9813854,0.0066395323,0.0009883537,0.0015788687,0.00075095345,0.008402159,0.000051106537,0.00002608004,0.00017753824],"genre_scores_gemma":[0.99270296,0.0023943107,0.0004288113,0.0004690072,0.0003163861,0.0033879818,0.00013300547,0.000039970586,0.00012759239],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99788827,0.00033242384,0.00081248156,0.00034165292,0.00033038622,0.0002948077],"domain_scores_gemma":[0.9972146,0.0013631079,0.0007055305,0.00030147648,0.00027912893,0.00013612334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008276079,0.0002441448,0.00090877304,0.00021778891,0.000060226645,0.00001763947,0.00011593402,0.0002028051,0.00017587702],"category_scores_gemma":[0.0004399751,0.00018709246,0.00015004864,0.00037437366,0.0000981499,0.00015442402,0.000018216131,0.0002121782,0.0000010925085],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.53086835,0.0004077579,0.08122406,0.0009281299,0.0003280475,0.000005331632,0.002178224,0.0035825584,0.08520159,0.000031086067,0.0024746885,0.29277018],"study_design_scores_gemma":[0.7861951,0.0013802168,0.14675008,0.00046296022,0.00026426816,8.7301703e-7,0.00005425343,0.044084683,0.02045661,0.000014320256,0.00009665984,0.00023995897],"about_ca_topic_score_codex":0.0017993432,"about_ca_topic_score_gemma":0.0014829355,"teacher_disagreement_score":0.2925302,"about_ca_system_score_codex":0.0004535319,"about_ca_system_score_gemma":0.0004899766,"threshold_uncertainty_score":0.76294094},"labels":[],"label_agreement":null},{"id":"W2080555188","doi":"10.1016/j.lungcan.2015.02.018","title":"Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion","year":2015,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Taiwan University Hospital; Ministry of Health, British Columbia; Ministry of Science and Technology, Taiwan; Ministry of Health and Welfare","keywords":"Medicine; Malignant pleural effusion; Pleural effusion; Adenocarcinoma; Metastatic adenocarcinoma; Lung; Oncology; Internal medicine; Pathology; Radiology; Cancer","score_opus":0.033619703688109695,"score_gpt":0.3827414251283273,"score_spread":0.34912172144021764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080555188","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951411,0.002180662,0.000059811977,0.0006332231,0.000108483626,0.0012840655,0.00007737697,0.000015763724,0.0004995055],"genre_scores_gemma":[0.99808335,0.000090739486,0.0010500225,0.0001548297,0.00003235317,0.00024836542,0.000097326665,0.000018945248,0.00022406882],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99898046,0.00004797121,0.00033552025,0.00025363953,0.00021114126,0.00017123781],"domain_scores_gemma":[0.9992703,0.0000488992,0.00012377856,0.00020697583,0.00019284434,0.0001571974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001237002,0.00011570645,0.00028066634,0.000084163425,0.000030414893,0.00000802046,0.000044281085,0.00003413761,0.000030832794],"category_scores_gemma":[0.00005478476,0.00007990422,0.000030642077,0.00020760504,0.00008045919,0.00008174185,0.000031169988,0.00008633136,0.0000012216217],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025768988,0.0002780942,0.99499923,0.00013508325,0.00019619004,0.000008106224,0.00059263146,0.000009809544,0.000015524867,0.000058091806,0.0010791773,0.002370379],"study_design_scores_gemma":[0.006432017,0.00041114463,0.99119,0.00039697118,0.0008479476,0.0000039618135,0.00009574588,0.000319317,0.000016820279,0.000042057294,0.00015953467,0.00008448771],"about_ca_topic_score_codex":0.000461641,"about_ca_topic_score_gemma":0.00023609937,"teacher_disagreement_score":0.006174327,"about_ca_system_score_codex":0.00015373333,"about_ca_system_score_gemma":0.0002662148,"threshold_uncertainty_score":0.32583994},"labels":[],"label_agreement":null},{"id":"W2083528984","doi":"10.1016/s0169-5002(00)80809-0","title":"An evaluation of screening for lung cancer in Niigata prefecture, Japan. A population-based case control study","year":2000,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Aging","funders":"","keywords":"Medicine; Lung cancer; Oncology; Internal medicine","score_opus":0.028015871405128834,"score_gpt":0.4197786026991805,"score_spread":0.39176273129405165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083528984","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98950744,0.0029880893,0.00082739233,0.0002448083,0.00014107549,0.0054772887,0.0006294631,0.000035649133,0.00014880048],"genre_scores_gemma":[0.99560463,0.000012121578,0.00036565046,0.00025626476,0.00017941449,0.003276389,0.00012585109,0.00003546932,0.00014419333],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985553,0.000123546,0.00035198338,0.00034903435,0.00039271993,0.00022740674],"domain_scores_gemma":[0.999085,0.0000887812,0.000123729,0.0003111561,0.0002958368,0.0000954824],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004015575,0.00016993507,0.00034034398,0.00013699474,0.00010065751,0.000016737213,0.0000549683,0.00006911278,0.001634544],"category_scores_gemma":[0.000035953133,0.00014532136,0.00007690818,0.00025435825,0.000016598935,0.00014157259,0.0000030718727,0.0000933947,2.5225782e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006455598,0.00042811257,0.7401504,0.00013732462,0.00044902097,0.00001635756,0.0013118421,0.16751443,0.00009303035,0.000005334327,0.000099181336,0.08914941],"study_design_scores_gemma":[0.014485839,0.00028579019,0.5208445,0.00026090603,0.0035010346,0.000006660529,0.00019603508,0.4601581,0.000092801376,0.0000090763115,0.00003081209,0.00012841503],"about_ca_topic_score_codex":0.019676637,"about_ca_topic_score_gemma":0.018648801,"teacher_disagreement_score":0.2926437,"about_ca_system_score_codex":0.00069825543,"about_ca_system_score_gemma":0.00054123695,"threshold_uncertainty_score":0.99927807},"labels":[],"label_agreement":null},{"id":"W2083744249","doi":"10.1016/j.lungcan.2005.08.005","title":"A willingness-to-pay study of oral epidermal growth factor tyrosine kinase inhibitors in advanced non-small cell lung cancer","year":2005,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Willingness to pay; Internal medicine; Oncology; non-small cell lung cancer (NSCLC); Marital status; Population; Environmental health","score_opus":0.011568644818447691,"score_gpt":0.33183083068366953,"score_spread":0.3202621858652218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083744249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905214,0.004028313,0.000119725024,0.0014208092,0.00065501966,0.0025296984,0.00013142526,0.000054190583,0.0005394632],"genre_scores_gemma":[0.99475324,0.00026352672,0.0008755545,0.00061561365,0.0003856901,0.001059548,0.000021864103,0.00007249594,0.0019524663],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99794865,0.00004156942,0.0005881702,0.00055573694,0.0003528347,0.00051306305],"domain_scores_gemma":[0.99890256,0.000046788187,0.00019901012,0.00034428018,0.0002447287,0.00026265328],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00008367711,0.00034623075,0.0006350183,0.00023368851,0.00008349454,0.000018052295,0.0001344549,0.00009784762,0.0003788615],"category_scores_gemma":[0.000024899042,0.00026609216,0.00010762409,0.0006648385,0.000035161753,0.00020352042,0.00006003832,0.00025869915,0.000005659143],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037713334,0.0015193503,0.9623059,0.00040692362,0.000251368,0.000052614523,0.008785146,0.005221891,0.006288513,0.00000610944,0.0012264216,0.013558637],"study_design_scores_gemma":[0.017835874,0.00091371435,0.9376315,0.0012581946,0.0012428347,0.000003672344,0.0011843056,0.0029837736,0.033006504,0.000003553158,0.003303189,0.0006329194],"about_ca_topic_score_codex":0.009435058,"about_ca_topic_score_gemma":0.009730399,"teacher_disagreement_score":0.02671799,"about_ca_system_score_codex":0.0010648033,"about_ca_system_score_gemma":0.000549723,"threshold_uncertainty_score":0.99997914},"labels":[],"label_agreement":null},{"id":"W2084340355","doi":"10.1016/j.lungcan.2013.06.008","title":"An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib","year":2013,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Queen's University","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research","keywords":"Erlotinib; Medicine; Rash; Internal medicine; Adverse effect; Bioavailability; Gastroenterology; Tyrosine-kinase inhibitor; Diarrhea; Erlotinib Hydrochloride; Drug; Pharmacology; Oncology; Cancer; Epidermal growth factor receptor","score_opus":0.017004457116695577,"score_gpt":0.36295304428943587,"score_spread":0.3459485871727403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084340355","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99127996,0.0030545508,0.00011092071,0.0033699141,0.0003683397,0.0010983914,0.000012734354,0.000009719449,0.0006954683],"genre_scores_gemma":[0.9991116,0.000071706985,0.00015483545,0.00012167205,0.00013206198,0.0002458673,0.000021055757,0.000008910955,0.00013231763],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99916506,0.00010200099,0.00020483216,0.00011741316,0.00033172127,0.00007896583],"domain_scores_gemma":[0.9991542,0.00004081062,0.00020628532,0.00022637051,0.00033472842,0.000037571142],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024636177,0.00006929369,0.00012957038,0.000046409037,0.00007645247,0.000015501582,0.00004991168,0.00003320876,0.00025148256],"category_scores_gemma":[0.00007080205,0.000035762965,0.000036735604,0.0001665121,0.00012469919,0.00019050401,0.000015139972,0.00007137809,7.212586e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00083460106,0.0007353945,0.22109978,0.00065711583,0.00081618206,5.4106494e-7,0.015126889,0.0011182942,0.43146342,0.00071793067,0.00812965,0.3193002],"study_design_scores_gemma":[0.01155206,0.00022317217,0.7124754,0.0011073835,0.0035261633,0.000018062756,0.0015256407,0.070019454,0.19874233,0.0004006567,0.00028546428,0.00012418763],"about_ca_topic_score_codex":0.0011095951,"about_ca_topic_score_gemma":0.00008293373,"teacher_disagreement_score":0.49137565,"about_ca_system_score_codex":0.00015964496,"about_ca_system_score_gemma":0.00022013125,"threshold_uncertainty_score":0.2753558},"labels":[],"label_agreement":null},{"id":"W2085286841","doi":"10.1016/j.lungcan.2013.10.007","title":"A population-based review of the feasibility of platinum-based combination chemotherapy after tyrosine kinase inhibition in EGFR mutation positive non-small cell lung cancer patients with advanced disease","year":2013,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Lung cancer; Tyrosine kinase; Chemotherapy; Oncology; Disease; Mutation; Internal medicine; Tyrosine-kinase inhibitor; Population; Cancer research; Cancer; Gene; Genetics; Receptor","score_opus":0.010582962090107244,"score_gpt":0.33281845815150135,"score_spread":0.3222354960613941,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085286841","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07786177,0.90825534,0.000092662856,0.00027202565,0.00017444702,0.011846354,0.0014264514,0.000018417351,0.00005252791],"genre_scores_gemma":[0.2905539,0.6966635,0.00035492232,0.0008503522,0.00005309623,0.006929775,0.0043631573,0.00012240339,0.00010891685],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99760073,0.00017946091,0.0009342601,0.0005276638,0.0005171914,0.00024068731],"domain_scores_gemma":[0.9972263,0.00011517975,0.0012962098,0.0005116062,0.00073271943,0.00011801439],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00011664752,0.0004712598,0.0013095092,0.00019849512,0.00005652727,0.000011696284,0.00008463306,0.00014674576,0.00023522346],"category_scores_gemma":[0.000043185268,0.00030626642,0.00035902485,0.00078772614,0.00007102947,0.00014064235,0.000016917409,0.00023463836,6.848005e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00114152,0.0030047921,0.4642983,0.41854483,0.0004644678,0.000013381352,0.00029171625,0.0007950587,0.000012610874,0.000012012728,0.00023473742,0.11118655],"study_design_scores_gemma":[0.012633046,0.00038654995,0.48991156,0.48679426,0.007838693,4.5139913e-7,0.000008033453,0.0010556348,0.00020625316,0.000008443771,0.0005958512,0.0005612018],"about_ca_topic_score_codex":0.0014044751,"about_ca_topic_score_gemma":0.00034893755,"teacher_disagreement_score":0.21269213,"about_ca_system_score_codex":0.0022820435,"about_ca_system_score_gemma":0.0018496398,"threshold_uncertainty_score":0.99993896},"labels":[],"label_agreement":null},{"id":"W2085851845","doi":"10.1016/j.lungcan.2003.10.009","title":"Phase II study of alternating chemotherapy regimens for advanced non-small cell lung cancer","year":2003,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; University of Ottawa","funders":"","keywords":"Vinorelbine; Medicine; Gemcitabine; Cisplatin; Regimen; Etoposide; Lung cancer; Paclitaxel; Chemotherapy; Internal medicine; Oncology; Pharmacology; Cancer; Drug resistance; Biology","score_opus":0.01439211725772029,"score_gpt":0.38193406914075567,"score_spread":0.3675419518830354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085851845","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9861541,0.005083195,0.00086344586,0.00030994098,0.00061727583,0.0032887566,0.0001020625,0.00004318618,0.0035380593],"genre_scores_gemma":[0.985721,0.0004451169,0.0021524306,0.00047155452,0.00020490012,0.002025023,0.000020420299,0.000071434064,0.00888815],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99867684,0.00002040123,0.00034723151,0.0004017461,0.00021159959,0.00034221477],"domain_scores_gemma":[0.99901617,0.0000473042,0.0002507279,0.00033823538,0.00022635896,0.00012120348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009119937,0.00023251482,0.00042295133,0.000085521926,0.0001794663,0.000010691118,0.00008850191,0.00005733453,0.00025651237],"category_scores_gemma":[0.000014982425,0.00019874376,0.00011535734,0.00020653941,0.000023138104,0.00007772391,0.0000152019,0.00010720574,5.0446414e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057064937,0.04278496,0.3952089,0.0057948767,0.012045552,0.00011656921,0.118692234,0.011366238,0.22800782,0.00060866313,0.042325635,0.13734205],"study_design_scores_gemma":[0.39317545,0.022480031,0.00753335,0.003147516,0.01237112,0.000019652993,0.012057901,0.020407878,0.45208162,0.00011797732,0.074472114,0.0021353867],"about_ca_topic_score_codex":0.0009888127,"about_ca_topic_score_gemma":0.0003842668,"teacher_disagreement_score":0.38767555,"about_ca_system_score_codex":0.00046538527,"about_ca_system_score_gemma":0.00043003488,"threshold_uncertainty_score":0.81045353},"labels":[],"label_agreement":null},{"id":"W2085996111","doi":"10.1016/j.lungcan.2013.06.015","title":"Cross-validation analysis of the prognostic significance of mucin expression in patients with resected non-small cell lung cancer treated with adjuvant chemotherapy: Results from IALT, JBR.10 and ANITA","year":2013,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Glycosylation and Glycoproteins Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; Sanofi","keywords":"Medicine; Oncology; Mucin; Adjuvant chemotherapy; Lung cancer; Adjuvant; Internal medicine; Chemotherapy; Expression (computer science); Cancer; Pathology; Breast cancer","score_opus":0.005833187482472542,"score_gpt":0.26013805620361263,"score_spread":0.2543048687211401,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085996111","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99787915,0.0003894285,0.00007847558,0.00004605194,0.000013965703,0.0011568732,0.0003310352,0.0000038310086,0.00010120762],"genre_scores_gemma":[0.9984906,0.0001031323,0.00015207939,0.00002150043,0.000020618572,0.00022681612,0.00029435253,0.000018559489,0.00067234004],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988335,0.000089888665,0.00027077287,0.0003729396,0.00025175628,0.00018113694],"domain_scores_gemma":[0.9988699,0.000029774032,0.0002560255,0.00035838858,0.00043588973,0.000050034436],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000086764136,0.00014112175,0.00022398072,0.00009215995,0.000045499513,0.000023746856,0.00014812089,0.000101332225,0.00015974691],"category_scores_gemma":[0.000042508636,0.00008779384,0.000036684873,0.00055809086,0.00009824977,0.0000128832435,0.00004664175,0.00008876831,1.974432e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013353035,0.000078004814,0.73352724,0.000047085963,0.00013878586,2.021977e-7,0.0001808052,0.0018604343,0.2622509,6.023022e-8,0.0001416323,0.00043956],"study_design_scores_gemma":[0.0022077044,0.00011662651,0.6209273,0.00011412556,0.00007505538,1.4945789e-8,0.000013012808,0.002292985,0.3741388,3.3637042e-7,0.000034520333,0.00007957111],"about_ca_topic_score_codex":0.008169028,"about_ca_topic_score_gemma":0.0029900274,"teacher_disagreement_score":0.11259996,"about_ca_system_score_codex":0.000043283875,"about_ca_system_score_gemma":0.00014321865,"threshold_uncertainty_score":0.9984357},"labels":[],"label_agreement":null},{"id":"W2086962483","doi":"10.1016/s0169-5002(00)80188-9","title":"Phase II trial of alternating 4 chemotherapy regimens in non-small cell lung cancer","year":2000,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Medicine; Chemotherapy; Lung cancer; Oncology; Internal medicine","score_opus":0.01205030497229059,"score_gpt":0.36270405458209004,"score_spread":0.35065374960979945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086962483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97906524,0.0039128116,0.000027737318,0.0010932275,0.00043126073,0.0014104445,0.00006427056,0.000031354873,0.0139636705],"genre_scores_gemma":[0.9760094,0.0025340093,0.00040750852,0.0007365404,0.0006164176,0.0006048957,0.000025659574,0.00004826807,0.019017255],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99876636,0.000019821347,0.00037161406,0.00031615832,0.00021717344,0.00030887613],"domain_scores_gemma":[0.99939,0.000027452732,0.00014402767,0.00027143958,0.00006516105,0.00010189589],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000084586296,0.00019001351,0.0003881847,0.000100734964,0.00007294473,0.000009880762,0.00009205528,0.000080541875,0.0025563443],"category_scores_gemma":[0.00000435883,0.00016405291,0.00011260009,0.00025246321,0.00003443356,0.00007322533,0.000013393798,0.00015512935,0.0000027222407],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07841952,0.020225007,0.14673822,0.0027091692,0.0037852493,0.00032053448,0.04996464,0.005932286,0.048318285,0.000116446805,0.044055834,0.5994148],"study_design_scores_gemma":[0.85939485,0.0048325625,0.009562896,0.0030800127,0.002467958,0.000011112419,0.0003571347,0.02147016,0.060293034,0.000039035516,0.03754179,0.0009494302],"about_ca_topic_score_codex":0.0054635517,"about_ca_topic_score_gemma":0.0005345896,"teacher_disagreement_score":0.78097534,"about_ca_system_score_codex":0.0005386741,"about_ca_system_score_gemma":0.0004190527,"threshold_uncertainty_score":0.99835545},"labels":[],"label_agreement":null},{"id":"W2090077894","doi":"10.1016/s0169-5002(00)80641-8","title":"Hepatocyte growth factor and its isoforms are predominantly expressed by epithelial cells in normal lung and primary non-small cell lung cancer","year":2000,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Liver physiology and pathology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Hepatocyte growth factor; Medicine; Lung; Hepatocyte; Lung cancer; Gene isoform; Primary (astronomy); Cancer research; Growth factor; Cell growth; Internal medicine; Oncology; In vitro; Biology; Gene; Biochemistry; Receptor","score_opus":0.006075988665649558,"score_gpt":0.23714168083962772,"score_spread":0.23106569217397815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090077894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9832885,0.013708281,0.000011168185,0.00020299522,0.00030248892,0.000898852,0.00065960095,0.000032548807,0.00089555373],"genre_scores_gemma":[0.98362124,0.010807977,0.00005395827,0.001087229,0.00030078026,0.00025176443,0.000038130976,0.00004135288,0.0037975416],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984247,0.00006779038,0.00030031666,0.0005428852,0.00013018274,0.00053412246],"domain_scores_gemma":[0.9993741,0.000073488445,0.00012028822,0.00019290227,0.000056132947,0.00018307606],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00008549217,0.00030861236,0.00056952477,0.00008182718,0.000106108804,0.000014358878,0.000115453695,0.00029791024,0.00065448205],"category_scores_gemma":[0.0000049594096,0.0002553379,0.000057059697,0.00011687638,0.000111014415,0.00020333243,0.00007209002,0.00040885858,0.000006218326],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017816903,0.00014576595,0.49380845,0.0018682245,0.00010230596,0.00012862701,0.003302664,0.000024928035,0.49279493,0.0000031510224,0.0048006275,0.0012386431],"study_design_scores_gemma":[0.008101394,0.0002453838,0.7008342,0.00064250524,0.00034419217,0.000025489397,0.0000622796,0.0051115826,0.28260326,0.000014036251,0.0014098247,0.00060581596],"about_ca_topic_score_codex":0.0008792393,"about_ca_topic_score_gemma":0.00017868455,"teacher_disagreement_score":0.21019167,"about_ca_system_score_codex":0.00016007162,"about_ca_system_score_gemma":0.00018242378,"threshold_uncertainty_score":0.99998987},"labels":[],"label_agreement":null},{"id":"W2092041185","doi":"10.1016/s0169-5002(01)00289-6","title":"Commentary on “Carboplatin–etoposide association in small cell lung cancer patients older than 70 years: a phase II trial”","year":2002,"lang":"en","type":"letter","venue":"Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Carboplatin; Etoposide; Lung cancer; Oncology; Internal medicine; Clinical trial; Chemotherapy; Cisplatin","score_opus":0.020139594596299222,"score_gpt":0.34367419092856416,"score_spread":0.32353459633226495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2092041185","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.44447806,0.012397373,0.0000022689806,0.52418566,0.0045798062,0.00878329,0.0015491177,0.00018245913,0.0038419503],"genre_scores_gemma":[0.069129,0.008418793,0.000056220477,0.8459935,0.01930974,0.007380856,0.0018919056,0.0004921445,0.04732785],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9947759,0.00032768038,0.00086825894,0.0010876781,0.0016087948,0.0013316697],"domain_scores_gemma":[0.99774635,0.00038831274,0.0006879361,0.0006952584,0.00029129468,0.00019082992],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00036688455,0.00075339293,0.0013465111,0.0005645815,0.00019182054,0.00007079991,0.0003714853,0.0009093035,0.0013339798],"category_scores_gemma":[0.00014112587,0.0007142926,0.00036745804,0.00054068,0.000072449875,0.00013244775,0.00026437576,0.003373634,0.000021606425],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026634915,0.0010879134,0.08840163,0.0011938119,0.00090834475,0.00026410812,0.0019222354,0.00001613118,0.000021594558,2.616717e-7,0.90208,0.0014404473],"study_design_scores_gemma":[0.1981027,0.0036274479,0.016754882,0.0077676363,0.0024590397,0.0000012496386,0.000060883816,0.0009435375,0.00049637933,0.000009917718,0.76812077,0.0016555465],"about_ca_topic_score_codex":0.009719005,"about_ca_topic_score_gemma":0.0022802593,"teacher_disagreement_score":0.37534907,"about_ca_system_score_codex":0.0115334885,"about_ca_system_score_gemma":0.00045856595,"threshold_uncertainty_score":0.99957895},"labels":[],"label_agreement":null},{"id":"W2092373171","doi":"10.1016/s0169-5002(02)00025-9","title":"Regulation of E-cadherin/catenin complex patterns by epidermal growth factor receptor modulation in human lung cancer cells","year":2002,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Wnt/β-catenin signaling in development and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada; Biotechnology Research Institute; Jewish General Hospital","funders":"National Cancer Institute; National Research Council Canada","keywords":"Epidermal growth factor; Epidermal growth factor receptor; Cadherin; Catenin; Heparin-binding EGF-like growth factor; Cancer research; Cell culture; Biology; A549 cell; ErbB; Cell biology; Receptor; Cell; Signal transduction; Wnt signaling pathway; Biochemistry","score_opus":0.018491766832027388,"score_gpt":0.2745728072245829,"score_spread":0.25608104039255547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2092373171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957604,0.0021750699,0.00073496497,0.00022403442,0.00034509454,0.00030035307,0.00018822108,0.000017349212,0.00025452315],"genre_scores_gemma":[0.99556303,0.00081560324,0.00016529666,0.00014499294,0.00026931462,0.00014386381,0.0003182516,0.000039886418,0.002539766],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99862534,0.000061776715,0.00040090733,0.00040123856,0.00021120421,0.00029953933],"domain_scores_gemma":[0.9994202,0.00000874518,0.00021509573,0.00017806457,0.00011693945,0.000060956067],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000082190134,0.00021211627,0.0002304777,0.00006288606,0.000066414344,0.000017378332,0.0001797631,0.00018280589,0.002977437],"category_scores_gemma":[0.000006722756,0.00022027604,0.00007454915,0.0001407069,0.000049928498,0.000016211045,0.00005420359,0.000102225225,0.0000026915372],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027991762,0.00003428071,0.14059906,0.00009462081,0.000057772246,2.591887e-7,0.00020591203,0.0008873446,0.8247331,0.0000068610284,0.032425065,0.00092774775],"study_design_scores_gemma":[0.00083474227,0.000037403945,0.11538662,0.00011480715,0.000023517054,3.5073575e-7,0.000014029769,0.006088406,0.87410957,0.000008452374,0.0030371463,0.0003449315],"about_ca_topic_score_codex":0.0008598373,"about_ca_topic_score_gemma":0.00022385667,"teacher_disagreement_score":0.049376503,"about_ca_system_score_codex":0.00015721504,"about_ca_system_score_gemma":0.000035135698,"threshold_uncertainty_score":0.997934},"labels":[],"label_agreement":null},{"id":"W2093235552","doi":"10.1016/j.lungcan.2015.03.002","title":"The frequency and impact of FGFR1 amplification on clinical outcomes in Korean patients with small cell lung cancer","year":2015,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Fibroblast Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Ministry of Health, British Columbia; Yonsei University","keywords":"Medicine; Carboplatin; Internal medicine; Hazard ratio; Etoposide; Oncology; Fibroblast growth factor receptor 1; Chemotherapy; Lung cancer; Cisplatin; Cancer; Confidence interval; Fibroblast growth factor; Receptor","score_opus":0.028932526743423267,"score_gpt":0.36817816782713864,"score_spread":0.33924564108371535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2093235552","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998201,0.0008882209,0.000022674682,0.00008441791,0.00007948018,0.0003381545,0.00006481609,0.0000032104185,0.00031800233],"genre_scores_gemma":[0.9993006,0.0002768389,0.000070696115,0.00003277809,0.000050009636,0.000061104656,0.000028247925,0.00001784871,0.0001618833],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990917,0.0000846855,0.00020698439,0.00024370417,0.00016407038,0.00020888308],"domain_scores_gemma":[0.99932575,0.000045402052,0.000104409504,0.00027790273,0.0001485143,0.00009801779],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020153017,0.00011298293,0.00013861868,0.000028966557,0.000030160401,0.00001615651,0.00014745675,0.0000892815,0.0000070533456],"category_scores_gemma":[0.000078599245,0.000066459696,0.000047983045,0.00007572964,0.000098607445,0.000004297071,0.00005063109,0.0001304591,5.42953e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027645248,0.00006671309,0.994513,0.000021530828,0.0000635311,2.69281e-7,0.000060096125,0.0000819403,0.0032776874,0.000009075682,0.00065998296,0.00096972875],"study_design_scores_gemma":[0.0011935977,0.0005228447,0.9943515,0.0000365113,0.00001387046,8.55877e-8,0.000014006867,0.00007614917,0.003541035,0.000010382836,0.00014272526,0.000097293734],"about_ca_topic_score_codex":0.0020384137,"about_ca_topic_score_gemma":0.0018723691,"teacher_disagreement_score":0.0010995697,"about_ca_system_score_codex":0.00010200803,"about_ca_system_score_gemma":0.0002837003,"threshold_uncertainty_score":0.30814853},"labels":[],"label_agreement":null},{"id":"W2094897257","doi":"10.1016/j.lungcan.2007.09.027","title":"Current state and future directions of pleural mesothelioma imaging","year":2007,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute","keywords":"Mesothelioma; Medicine; Context (archaeology); Medical physics; Modalities; Radiology; Presentation (obstetrics); Pathology","score_opus":0.00611489564978099,"score_gpt":0.3067610939387378,"score_spread":0.3006461982889568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094897257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95451903,0.0436312,0.00004309052,0.0005410046,0.00030517124,0.00009756277,0.00006125411,0.0000133426065,0.0007883627],"genre_scores_gemma":[0.99594855,0.0031382684,0.00007453752,0.00013500119,0.00033506996,0.000007068769,0.000011948675,0.0000073811293,0.00034217464],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996354,0.000003593904,0.000086277476,0.000083765524,0.00010431524,0.00008664608],"domain_scores_gemma":[0.9998309,0.000010939773,0.000027564452,0.000051140592,0.000012345927,0.00006709914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000029975352,0.00005045307,0.00007052119,0.000039818922,0.000029368655,0.0000024458186,0.000012722164,0.00000666356,0.00019864958],"category_scores_gemma":[0.0000020456523,0.000040196384,0.000026985803,0.00006198908,0.00004079653,0.00003670086,0.000011741949,0.00003994919,0.0000021856881],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000118265525,0.000049343256,0.7982451,0.000088348635,0.00002350347,0.0000036055653,0.00013146308,0.000002636519,0.0013618364,0.000026327827,0.0008804072,0.19906917],"study_design_scores_gemma":[0.00029995255,0.000012247306,0.9473558,0.000064260086,0.00006430348,0.0000053754766,0.00003155565,0.00012029247,0.0009164529,0.000028583443,0.051058777,0.000042412037],"about_ca_topic_score_codex":0.000059531314,"about_ca_topic_score_gemma":0.00002573945,"teacher_disagreement_score":0.19902676,"about_ca_system_score_codex":0.00005226602,"about_ca_system_score_gemma":0.000016889726,"threshold_uncertainty_score":0.21750736},"labels":[],"label_agreement":null},{"id":"W2097042869","doi":"10.1016/j.lungcan.2004.02.002","title":"Response to ‘is “no treatment” better than radiotherapy and chemotherapy? by L. Debevec’","year":2004,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"","keywords":"Medicine; Radiation therapy; Chemotherapy; Lung cancer; Oncology; Surgery; Internal medicine; Carcinoma","score_opus":0.006875953594191144,"score_gpt":0.3305384188192248,"score_spread":0.32366246522503367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097042869","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9269582,0.0059909336,0.00027778622,0.064658575,0.00019457255,0.0008410077,0.00011486627,0.000070375645,0.00089364924],"genre_scores_gemma":[0.8547398,0.004190402,0.0059567117,0.07648018,0.00061981316,0.00094867096,0.000055116187,0.00014538724,0.05686395],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.999155,0.000018653482,0.00012730656,0.00031567574,0.00013931777,0.00024404666],"domain_scores_gemma":[0.9994576,0.000025425485,0.000032851738,0.00023783329,0.000046444005,0.0001998662],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000040346185,0.00019161077,0.00023557611,0.00006455068,0.000087817876,0.00002764378,0.000039103998,0.00006444036,0.0005642673],"category_scores_gemma":[0.0000050420026,0.00014161093,0.00006461994,0.00013211988,0.000035005116,0.000063519925,0.000006262179,0.00004816079,0.000023718605],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014310237,0.0013103975,0.26871005,0.00014902596,0.005314992,0.00014548321,0.029870547,0.00005662302,0.17735265,0.00008236198,0.32586294,0.17683469],"study_design_scores_gemma":[0.016993692,0.0016907878,0.06922648,0.00021943699,0.00046654546,0.00003234368,0.00006807224,0.000036581172,0.023382412,0.000054436412,0.8874748,0.00035444478],"about_ca_topic_score_codex":0.0012017696,"about_ca_topic_score_gemma":0.000079523095,"teacher_disagreement_score":0.56161183,"about_ca_system_score_codex":0.0010899199,"about_ca_system_score_gemma":0.00021358386,"threshold_uncertainty_score":0.6178331},"labels":[],"label_agreement":null},{"id":"W2097463411","doi":"10.1016/j.lungcan.2012.05.111","title":"A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma","year":2012,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"National Cancer Institute","keywords":"Medicine; Pemetrexed; Bevacizumab; Clinical endpoint; Internal medicine; Mesothelioma; Neutropenia; Progression-free survival; Oncology; Vascular endothelial growth factor; Gastroenterology; Cisplatin; Phases of clinical research; Survival rate; Chemotherapy; Surgery; Pathology; Clinical trial; VEGF receptors","score_opus":0.006440750221946768,"score_gpt":0.2942190817725004,"score_spread":0.2877783315505536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097463411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981574,0.000977316,0.0000019712147,0.000023326531,0.000046565285,0.0006510865,0.00005809525,0.00000685099,0.00007739901],"genre_scores_gemma":[0.99953943,0.000021304639,0.00012830977,0.00007649129,0.000024997431,0.000075325894,0.000023262268,0.000013224164,0.00009763565],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99931586,0.000014194108,0.0001523561,0.00013650945,0.0002296473,0.00015146424],"domain_scores_gemma":[0.9997006,0.000013522641,0.00006250976,0.00010936346,0.000019817959,0.00009416766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000030203071,0.00009893138,0.00016903349,0.000067537665,0.000030379977,0.0000018314034,0.000023672226,0.000017675637,0.0001858635],"category_scores_gemma":[0.0000063256334,0.00006886201,0.000016181484,0.000096217824,0.000029018885,0.00011435676,0.000035067,0.00004096655,0.0000011531822],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005123747,0.005282344,0.98088986,0.000079931764,0.00006950043,0.0000027137517,0.00081288925,0.000011475897,0.00032542524,0.0000026133437,0.000033808396,0.007365669],"study_design_scores_gemma":[0.018825905,0.0025874237,0.9774271,0.00015894225,0.00016774927,4.877878e-7,0.00031770932,0.00009086507,0.0002619507,4.631908e-7,0.00007965448,0.000081748665],"about_ca_topic_score_codex":0.00010008219,"about_ca_topic_score_gemma":0.000042119806,"teacher_disagreement_score":0.013702158,"about_ca_system_score_codex":0.00007789791,"about_ca_system_score_gemma":0.000011180282,"threshold_uncertainty_score":0.28081113},"labels":[],"label_agreement":null},{"id":"W2103524216","doi":"10.1016/j.lungcan.2013.05.014","title":"The role of epigenetics in malignant pleural mesothelioma","year":2013,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":49,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Fonds Spéciaux de Recherche; Belgian Federal Science Policy Office; Stichting Tegen Kanker; European Commission; Direction Générale des Infrastructures, des Transports et de la Mer; Gouvernement Wallon; Fonds De La Recherche Scientifique - FNRS; Institut National Du Cancer; Institut national de la recherche scientifique; Cement Association of Canada","keywords":"Medicine; Mesothelioma; Epigenetics; Oncology; Internal medicine; Cancer research; Pathology; Genetics; Biology","score_opus":0.01629315142229983,"score_gpt":0.3366757089558819,"score_spread":0.3203825575335821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103524216","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011718781,0.99739647,0.000023390448,0.000010675754,0.00023638028,0.00052685925,0.000041158084,0.0000026957155,0.00059048977],"genre_scores_gemma":[0.0009208758,0.99758536,0.00008129374,0.0000071349664,0.00023074125,0.00025526568,0.0000653194,0.000045071207,0.0008089255],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987274,0.00012641287,0.00047903045,0.00028369643,0.00013427829,0.000249208],"domain_scores_gemma":[0.9991072,0.000037380512,0.00029904925,0.00044350576,0.00006892531,0.00004394929],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018572411,0.00022872032,0.00046314296,0.00005434245,0.000043145603,0.000021556572,0.00031685017,0.00028076215,0.00002361266],"category_scores_gemma":[0.000032073876,0.00014929732,0.00021262818,0.00013630022,0.00006372745,0.0000011575271,0.000112452,0.00011706812,0.000004282973],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000004156523,0.000014111925,0.0004021583,0.0007999715,0.00009860035,5.23375e-7,0.00001746299,0.000026941816,0.0034892259,0.00007354482,0.00014539862,0.9949279],"study_design_scores_gemma":[0.000081104365,0.0000374664,0.000043873275,0.0008195239,0.00011010154,7.4072716e-7,0.000009348021,0.000044420405,0.0089083,0.00009808508,0.989662,0.00018504681],"about_ca_topic_score_codex":0.00015806899,"about_ca_topic_score_gemma":0.0002759113,"teacher_disagreement_score":0.9947429,"about_ca_system_score_codex":0.0000375474,"about_ca_system_score_gemma":0.00022943692,"threshold_uncertainty_score":0.60881686},"labels":[],"label_agreement":null},{"id":"W2104258423","doi":"10.1016/j.lungcan.2012.10.007","title":"Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer","year":2012,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"European Society for Medical Oncology","keywords":"Medicine; Oncology; Lung cancer; Internal medicine; Cancer; Overall survival; Progression-free survival","score_opus":0.055567186221244326,"score_gpt":0.4467526399012807,"score_spread":0.3911854536800364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2104258423","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014787668,0.9750661,0.000041283427,0.000088626715,0.0016087659,0.0062917504,0.00093808427,0.00003149384,0.001146189],"genre_scores_gemma":[0.006177458,0.9879559,0.00042965144,0.00006157907,0.00032578618,0.0035142426,0.0005528565,0.00015328333,0.0008292233],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954943,0.00045868466,0.0018909752,0.0008002466,0.0006160614,0.000739709],"domain_scores_gemma":[0.9972773,0.00031462286,0.0012168738,0.0007246021,0.00015180634,0.00031477615],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009837737,0.00076389866,0.004390813,0.00049623934,0.00005210018,0.000025451794,0.00028505732,0.00044314182,0.00046711654],"category_scores_gemma":[0.00013566163,0.00058378954,0.00050473434,0.00065266946,0.00007279629,0.00015473817,0.00017245642,0.00055778713,0.0000014415725],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011133556,0.0020683233,0.021554431,0.057911098,0.0029483652,0.0002846614,0.0012512954,0.00007083147,0.00026346318,0.000059335696,0.00083197915,0.91164285],"study_design_scores_gemma":[0.1973803,0.0009717964,0.009540208,0.21718617,0.054503627,0.000030467894,0.00032326978,0.00083941745,0.00092373847,0.00006182448,0.5142243,0.004014894],"about_ca_topic_score_codex":0.0028632767,"about_ca_topic_score_gemma":0.0014887626,"teacher_disagreement_score":0.90762794,"about_ca_system_score_codex":0.0013320977,"about_ca_system_score_gemma":0.0019525781,"threshold_uncertainty_score":0.9996613},"labels":[],"label_agreement":null},{"id":"W2104507554","doi":"10.1016/s0169-5002(99)00122-1","title":"RARβ2 specificity in mediating RA inhibition of growth of lung cancer-derived cells","year":2000,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Retinoids in leukemia and cellular processes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame","funders":"Medical Research Council","keywords":"Retinoic acid; Retinoid; Transfection; Cancer research; Cell culture; Gene isoform; In vivo; In vitro; Receptor; Retinoic acid receptor beta; Retinoic acid receptor; Tretinoin; Growth inhibition; Cell growth; Medicine; Retinoid X receptor gamma; Lung cancer; Epidermoid carcinoma; Biology; Internal medicine; Cancer; Biochemistry; Gene","score_opus":0.005271635240152299,"score_gpt":0.2538674442420975,"score_spread":0.2485958090019452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2104507554","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991253,0.0060674036,0.00013476465,0.00004861531,0.00014252894,0.00016154602,0.000048621794,0.000005740757,0.002137779],"genre_scores_gemma":[0.99358374,0.0055247876,0.0001625243,0.00006301089,0.00024385806,0.000044979337,0.000041229883,0.000017892306,0.00031799814],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99904716,0.000046444307,0.0003163485,0.00025511943,0.00014672866,0.00018822067],"domain_scores_gemma":[0.99954355,0.000012964279,0.00015269873,0.00016167058,0.000092720526,0.000036417998],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011530701,0.00012488828,0.00020251196,0.00003685096,0.000024742192,0.000005095894,0.0001179069,0.00013902584,0.0004004518],"category_scores_gemma":[0.000019452646,0.00012419351,0.00006511426,0.00015712238,0.00008330211,0.0000066611137,0.000031904496,0.00009672614,5.7473403e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009137975,0.000034582517,0.026374195,0.00037686332,0.000028334684,0.0000019949243,0.00020176399,0.0005782169,0.970301,0.000013511426,0.00051912904,0.0014790456],"study_design_scores_gemma":[0.0005763283,0.000035313853,0.0025198923,0.00014856836,0.000024481245,6.1838983e-7,0.000034550096,0.00042859366,0.9957668,0.000022632816,0.00030771922,0.0001345084],"about_ca_topic_score_codex":0.00061946874,"about_ca_topic_score_gemma":0.00012376308,"teacher_disagreement_score":0.02546581,"about_ca_system_score_codex":0.00006088125,"about_ca_system_score_gemma":0.0001790403,"threshold_uncertainty_score":0.5064464},"labels":[],"label_agreement":null},{"id":"W2104963800","doi":"10.1016/s0169-5002(00)00116-1","title":"Co-expression of epidermal growth factor receptor and transforming growth factor-α is independent of ras mutations in lung adenocarcinoma","year":2000,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Autocrine signalling; Epidermal growth factor receptor; TGF alpha; Cancer research; Epidermal growth factor; Adenocarcinoma; Transforming growth factor; Signal transduction; Medicine; Biology; Receptor; Internal medicine; Cancer; Cell biology","score_opus":0.013661247539169781,"score_gpt":0.3215154356152042,"score_spread":0.3078541880760344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2104963800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99273354,0.003836663,0.00009649895,0.00054370175,0.00009022484,0.00074719614,0.00052443997,0.00002107713,0.0014066898],"genre_scores_gemma":[0.9977569,0.0010151161,0.000251698,0.00013342801,0.000058051148,0.000101952115,0.00006533025,0.000028105569,0.00058940676],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986851,0.00003756031,0.00044679732,0.00028741956,0.00030184473,0.00024126878],"domain_scores_gemma":[0.99941677,0.00007496043,0.00012280283,0.0001477975,0.00011018641,0.00012750778],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00004635032,0.00018652914,0.00040424478,0.00017800106,0.00006387787,0.000008439626,0.00006482637,0.000115252325,0.0026162372],"category_scores_gemma":[0.00001566184,0.00015620976,0.00009172868,0.00021601285,0.000082048886,0.00021997545,0.000007704024,0.00015872823,0.0000022919646],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028159152,0.00020528726,0.9451855,0.00079852197,0.00022357721,0.000011564914,0.014140037,0.000016495123,0.033011053,0.000066976565,0.0005581494,0.0055012773],"study_design_scores_gemma":[0.0045250407,0.0001657599,0.7503831,0.0008129383,0.0003437298,0.000009931118,0.00044142015,0.00019041085,0.24262828,0.000046997695,0.00024956113,0.00020283484],"about_ca_topic_score_codex":0.0019931926,"about_ca_topic_score_gemma":0.000106371306,"teacher_disagreement_score":0.20961723,"about_ca_system_score_codex":0.00026650282,"about_ca_system_score_gemma":0.00024615272,"threshold_uncertainty_score":0.9982955},"labels":[],"label_agreement":null},{"id":"W2105518844","doi":"10.1016/j.lungcan.2010.05.022","title":"A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients","year":2010,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Research Resources; National Cancer Institute; Bayer Canada; Eli Lilly and Company","keywords":"Medicine; Sorafenib; Carboplatin; Pemetrexed; Internal medicine; Etoposide; Oncology; Refractory (planetary science); Lung cancer; Cisplatin; Urology; Chemotherapy; Hepatocellular carcinoma","score_opus":0.01762870376819342,"score_gpt":0.3877932423721357,"score_spread":0.3701645386039423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105518844","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99484247,0.00021900132,0.000005265761,0.0003632604,0.0006019026,0.0023128358,0.000073072195,0.000045897767,0.0015362991],"genre_scores_gemma":[0.9979302,0.00007040761,0.00034048338,0.00015804278,0.00026221442,0.0005345667,0.000028328179,0.00005264842,0.00062310556],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997753,0.0000515457,0.00052505283,0.00040045203,0.0007913173,0.00047858027],"domain_scores_gemma":[0.9985439,0.00017846462,0.0002727447,0.00046710935,0.00034832998,0.00018945982],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024231087,0.00026176256,0.00074290746,0.00026534733,0.000058934304,0.000012596998,0.00015820852,0.00008992929,0.00037213688],"category_scores_gemma":[0.00053784496,0.0001758243,0.00008164778,0.00055978494,0.00022583695,0.00013014398,0.0000827443,0.0006426192,0.0000030240578],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7576725,0.008504229,0.15795746,0.001978034,0.0010921311,0.00044903927,0.0040079933,0.000039353545,0.052375164,0.00011672175,0.004104169,0.011703213],"study_design_scores_gemma":[0.86559093,0.026782263,0.060313985,0.002056078,0.0006023924,0.000011681988,0.00031383644,0.00086357363,0.04107364,0.000053391726,0.0016403152,0.00069792446],"about_ca_topic_score_codex":0.001454586,"about_ca_topic_score_gemma":0.0063590263,"teacher_disagreement_score":0.10791843,"about_ca_system_score_codex":0.00045648223,"about_ca_system_score_gemma":0.0012705597,"threshold_uncertainty_score":0.7169907},"labels":[],"label_agreement":null},{"id":"W2106925270","doi":"10.1016/j.lungcan.2010.08.001","title":"Analysis of Wait Times and Costs During the Peri-Diagnostic Period for Non-Small Cell Lung Cancer","year":2010,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba; BC Cancer Agency","funders":"","keywords":"Medicine; Quartile; Lung cancer; Health care; Emergency medicine; Cancer registry; Population; Cohort; Demographics; Cancer; Confidence interval; Internal medicine; Demography","score_opus":0.005472328541034408,"score_gpt":0.2805572885981869,"score_spread":0.2750849600571525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106925270","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9847626,0.010894088,0.000016258098,0.0017818088,0.00042377107,0.0012410989,0.0002477079,0.000023325478,0.00060932455],"genre_scores_gemma":[0.99307996,0.0028377986,0.00013183583,0.0002788011,0.0003208935,0.0017097893,0.000024348295,0.00003824881,0.0015783319],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99880445,0.000015171787,0.00026555962,0.00039393845,0.00019769004,0.00032320165],"domain_scores_gemma":[0.9988289,0.000308726,0.00015029131,0.00040712286,0.00016582897,0.0001391543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010780862,0.00022389663,0.00051623787,0.00013008158,0.00016832529,0.000035823497,0.00011342785,0.000096855954,0.000753053],"category_scores_gemma":[0.000046049543,0.00014866708,0.00023655844,0.00033193428,0.0000990703,0.00005003378,0.000050817776,0.00017916616,0.0000011797069],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012224741,0.0001334364,0.9874836,0.00076079526,0.0024297356,0.0000100679135,0.001434335,0.00014782234,0.0038097466,0.000041883126,0.0018407918,0.0017855277],"study_design_scores_gemma":[0.002980403,0.000111271154,0.95412296,0.00043064202,0.0133986855,0.000004973705,0.00018524288,0.012234653,0.013797582,0.000002154855,0.002483738,0.0002477215],"about_ca_topic_score_codex":0.0023013186,"about_ca_topic_score_gemma":0.0061848834,"teacher_disagreement_score":0.03336068,"about_ca_system_score_codex":0.0003540116,"about_ca_system_score_gemma":0.00023270857,"threshold_uncertainty_score":0.8245402},"labels":[],"label_agreement":null},{"id":"W2111088515","doi":"10.1016/j.lungcan.2004.02.009","title":"15 years single center experience with surgical resection of the superior vena cava for non-small cell lung cancer","year":2004,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Lung cancer; Surgical resection; Single Center; Vena cava; Superior vena cava; Resection; Center (category theory); Surgery; Radiology; Oncology","score_opus":0.01292059429815852,"score_gpt":0.2944366569894449,"score_spread":0.2815160626912864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111088515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992926,0.0034185816,0.000043392956,0.0010383358,0.0006563107,0.0011765272,0.00007330764,0.00002056336,0.0006470071],"genre_scores_gemma":[0.99675375,0.00048330965,0.00017128745,0.00023806721,0.00033342975,0.0011265293,0.00000825061,0.0000385263,0.00084687705],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99889624,0.000013959687,0.00020019471,0.00032836836,0.00025854094,0.00030271173],"domain_scores_gemma":[0.9993421,0.000029752895,0.00009715196,0.00031592994,0.00011903579,0.000096070835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000046851972,0.00016427597,0.0002723793,0.000037404505,0.00008102702,0.000016711045,0.00010291183,0.00007342921,0.00013662451],"category_scores_gemma":[0.0000049897403,0.00010416078,0.00013399597,0.00019083949,0.00009152988,0.000060879727,0.000032146636,0.00011068297,9.477799e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014335554,0.0008423501,0.9795581,0.0009173787,0.00031118974,0.000054547494,0.0062225545,0.0010913352,0.005692541,0.00004264801,0.002755605,0.0010781718],"study_design_scores_gemma":[0.043540105,0.003229094,0.34758723,0.009021521,0.0020625843,0.00012898588,0.00113069,0.0007640971,0.53904754,0.000019713389,0.0525094,0.00095904723],"about_ca_topic_score_codex":0.0029888176,"about_ca_topic_score_gemma":0.0027137473,"teacher_disagreement_score":0.6319709,"about_ca_system_score_codex":0.001106112,"about_ca_system_score_gemma":0.00036995797,"threshold_uncertainty_score":0.4518218},"labels":[],"label_agreement":null},{"id":"W2113086549","doi":"10.1016/j.lungcan.2007.03.024","title":"General practitioner assessment of stage and performance status in lung cancer patients at a population level: Implications for prognosis and radiotherapy needs analyses","year":2007,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"University of British Columbia","keywords":"Medicine; Radiation therapy; Stage (stratigraphy); Lung cancer; Population; Oncology; Intensive care medicine; Internal medicine; Environmental health","score_opus":0.09381405147741641,"score_gpt":0.4650619677710754,"score_spread":0.371247916293659,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113086549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923989,0.0044921893,0.0015039563,0.00037599768,0.00006957137,0.00087021093,0.00018432023,0.000011812386,0.000093012066],"genre_scores_gemma":[0.9923914,0.0025253578,0.0040559326,0.00030435366,0.00008663916,0.00030900753,0.00009485548,0.000015606312,0.00021682616],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99905795,0.000014248375,0.00029437157,0.00019969071,0.00018043748,0.00025330146],"domain_scores_gemma":[0.9994107,0.00004075214,0.00018495932,0.00010021194,0.0001716947,0.00009171995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017260683,0.000113959024,0.00023001934,0.0001740509,0.00009024224,0.000013704322,0.000028395152,0.00005830604,0.000039831473],"category_scores_gemma":[0.000014292369,0.00010128995,0.00003232005,0.0002960645,0.000034268665,0.00022484272,0.000018121811,0.00007396884,1.6954793e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002716859,0.00004432313,0.9839226,0.00026318867,0.0000835928,2.5642225e-7,0.00031687133,0.0004811724,0.0026622259,0.00007769205,0.00027169057,0.011604707],"study_design_scores_gemma":[0.0016248396,0.00015800125,0.98343223,0.00019455556,0.00013166724,0.0000011382136,0.000054793363,0.013193496,0.00060108944,0.000003198175,0.0004978965,0.000107102234],"about_ca_topic_score_codex":0.0052278065,"about_ca_topic_score_gemma":0.0029860386,"teacher_disagreement_score":0.012712323,"about_ca_system_score_codex":0.000814542,"about_ca_system_score_gemma":0.00012107421,"threshold_uncertainty_score":0.7902914},"labels":[],"label_agreement":null},{"id":"W2114472079","doi":"10.1016/j.lungcan.2009.08.020","title":"Skeletal morbidity in lung cancer patients with bone metastases: Demonstrating the need for early diagnosis and treatment with bisphosphonates","year":2009,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Bone health and treatments","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; McGill University Health Centre; Royal Victoria Regional Health Centre","funders":"","keywords":"Medicine; Zoledronic acid; Lung cancer; Internal medicine; Placebo; Quality of life (healthcare); Oncology; Incidence (geometry); Cancer; Pathology","score_opus":0.026639713843766392,"score_gpt":0.35221910547645463,"score_spread":0.32557939163268823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114472079","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03750899,0.9542723,0.000004217305,0.00028517997,0.00010352071,0.0069835056,0.00077713677,0.00003052217,0.000034676243],"genre_scores_gemma":[0.009804603,0.9776577,0.0003717774,0.0002255206,0.00007779198,0.011272107,0.0002777645,0.00008251503,0.0002302417],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979384,0.00007779605,0.00051258504,0.00059466023,0.00030272646,0.00057386275],"domain_scores_gemma":[0.9986941,0.0002599869,0.0004098678,0.0002982332,0.00010311551,0.00023469809],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00010507248,0.0006259144,0.0017133498,0.00012092979,0.00018339022,0.0000422743,0.000069824295,0.0001698493,0.000033916585],"category_scores_gemma":[0.000013050427,0.00030160736,0.00018123261,0.00038952762,0.000091000475,0.00009631061,0.000016824506,0.00027841164,5.882469e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025017417,0.00037526636,0.25442016,0.0053931535,0.0010662529,0.000036787933,0.0001346447,0.0000016697256,1.3228688e-8,0.0000045208258,0.00023282679,0.73808455],"study_design_scores_gemma":[0.031090034,0.008593326,0.16727011,0.09573074,0.04361991,0.000063890795,0.00008357193,0.0002713269,0.000015033486,0.0000072421235,0.65140843,0.0018464081],"about_ca_topic_score_codex":0.018895196,"about_ca_topic_score_gemma":0.012426402,"teacher_disagreement_score":0.7362381,"about_ca_system_score_codex":0.0010511834,"about_ca_system_score_gemma":0.0011145191,"threshold_uncertainty_score":0.9999436},"labels":[],"label_agreement":null},{"id":"W2116664839","doi":"10.1016/j.lungcan.2006.02.006","title":"Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer","year":2006,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Humber River Regional Hospital; Ottawa Regional Cancer Foundation; Mount Sinai Hospital; Toronto East General Hospital; University of Toronto; Northeast Cancer Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Mucositis; Vincristine; Internal medicine; Cyclophosphamide; Gastroenterology; Chemotherapy; Oncology; Surgery","score_opus":0.009898937503427602,"score_gpt":0.31056079973476003,"score_spread":0.3006618622313324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116664839","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902698,0.005892615,0.000006972434,0.0001553747,0.00006781155,0.0030011393,0.0001612582,0.000030010682,0.00041502184],"genre_scores_gemma":[0.9972947,0.00034484133,0.00007816165,0.000029597099,0.00005695436,0.00052956573,0.00008083131,0.000050574286,0.0015347664],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99806386,0.00008219657,0.00050542085,0.00043081213,0.0005361625,0.00038156335],"domain_scores_gemma":[0.9987376,0.00007425647,0.0003156864,0.00029608206,0.00047194652,0.00010447507],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010723135,0.00032833396,0.0007514094,0.00022625504,0.000115134535,0.000009166695,0.000079238715,0.00006412052,0.00013726555],"category_scores_gemma":[0.000013574069,0.00022681757,0.000036248428,0.0005219169,0.0001424619,0.00009137648,0.000060737482,0.00019335443,2.1549863e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008600943,0.014204766,0.9660872,0.0010009862,0.00054871413,0.000057864814,0.004181387,0.0004110042,0.0026164027,0.0000065630193,0.0001862934,0.0020978695],"study_design_scores_gemma":[0.09032704,0.04076136,0.83852535,0.0008219284,0.0009800983,0.0000024176366,0.0006696013,0.0007793014,0.026629914,0.000006485438,0.00018103224,0.00031548121],"about_ca_topic_score_codex":0.048942294,"about_ca_topic_score_gemma":0.040766057,"teacher_disagreement_score":0.12756187,"about_ca_system_score_codex":0.0008936807,"about_ca_system_score_gemma":0.00035299192,"threshold_uncertainty_score":0.97673744},"labels":[],"label_agreement":null},{"id":"W2116720928","doi":"10.1016/j.lungcan.2013.07.025","title":"Genetic alterations defining NSCLC subtypes and their therapeutic implications","year":2013,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":375,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control; BC Cancer Agency","funders":"Congressionally Directed Medical Research Programs; National Cancer Institute; Canadian Institutes of Health Research; Canary Foundation; U.S. Department of Defense","keywords":"Lung cancer; Medicine; Disease; Cancer; Adenocarcinoma; Oncology; Bioinformatics; Cancer research; Internal medicine; Biology","score_opus":0.037756950148784545,"score_gpt":0.39314686098660384,"score_spread":0.3553899108378193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116720928","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000037808757,0.9948393,0.0004592128,0.00054143835,0.00019885764,0.001643605,0.00020872527,0.00006576196,0.0020053082],"genre_scores_gemma":[0.0003383415,0.9936609,0.00068847457,0.0003466969,0.00023245109,0.0031862976,0.0002228842,0.00007157964,0.0012523357],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99895674,0.000032818203,0.00032265994,0.00038147173,0.00007555393,0.00023075454],"domain_scores_gemma":[0.9991341,0.00009010689,0.00015949055,0.0003980347,0.000088778674,0.00012944294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000026926302,0.00032179005,0.00074841233,0.00012380214,0.00019204628,0.000069755675,0.00007815085,0.00014506072,0.00019660738],"category_scores_gemma":[0.0000071491204,0.0002077387,0.00018814385,0.0002136631,0.000055136024,0.000059176433,0.00002922625,0.00019115083,0.000047207774],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000001181537,0.000035356057,0.00029621107,0.002134889,0.0010067263,0.0000012149113,0.00024398127,0.0000023566724,0.0000024127735,0.0010406686,0.0011032971,0.9941317],"study_design_scores_gemma":[0.00039884352,0.000044742927,0.001127463,0.0044342694,0.005339234,0.00008411378,0.000024176188,0.000020375574,0.0000011983196,0.00018493338,0.9880963,0.0002443616],"about_ca_topic_score_codex":0.00022586626,"about_ca_topic_score_gemma":0.00007755151,"teacher_disagreement_score":0.99388736,"about_ca_system_score_codex":0.0002912852,"about_ca_system_score_gemma":0.00070260715,"threshold_uncertainty_score":0.8471339},"labels":[],"label_agreement":null},{"id":"W2119768199","doi":"10.1016/j.lungcan.2014.09.017","title":"Comparison of survival and hospitalization rates between Medicare patients with advanced NSCLC treated with bevacizumab–carboplatin–paclitaxel and carboplatin–paclitaxel: A retrospective cohort study","year":2014,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"National Cancer Institute; National Institute on Aging","keywords":"Medicine; Carboplatin; Hazard ratio; Bevacizumab; Internal medicine; Proportional hazards model; Cohort; Retrospective cohort study; Paclitaxel; Oncology; Lung cancer; Surgery; Cancer; Chemotherapy; Confidence interval","score_opus":0.00681406673692153,"score_gpt":0.33009641403799533,"score_spread":0.3232823473010738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119768199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945705,0.0008200238,0.00021638791,0.00010288673,0.000070407295,0.0025393742,0.00017319382,0.00006571667,0.0014415114],"genre_scores_gemma":[0.99885446,0.00004071487,0.00026665936,0.000019352105,0.000070205264,0.00028074975,0.00030605835,0.000055984252,0.000105795254],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980671,0.00009347336,0.00039195782,0.0005646507,0.00061474915,0.00026810495],"domain_scores_gemma":[0.9985188,0.00012318845,0.00033707067,0.00030702667,0.0005176331,0.00019623416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013474979,0.000326331,0.00092230755,0.00011437432,0.00015312336,0.000027059572,0.000053158426,0.00009020807,0.00002444495],"category_scores_gemma":[0.00007187738,0.0002248563,0.00003098044,0.0003551524,0.00018908353,0.00016448823,0.000032421114,0.00015813929,2.6070245e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005561986,0.00030291683,0.9909443,0.00012885615,0.0012568167,0.0000024423011,0.0032910246,0.000029183626,0.000019308214,0.00004499669,0.000034802146,0.003389137],"study_design_scores_gemma":[0.010956707,0.0040525384,0.97960216,0.00043661724,0.0025270872,8.6996624e-7,0.0015433951,0.0004351281,0.00015743404,0.000010971504,0.000024979137,0.00025209523],"about_ca_topic_score_codex":0.0015152557,"about_ca_topic_score_gemma":0.0009398412,"teacher_disagreement_score":0.01134214,"about_ca_system_score_codex":0.00031350812,"about_ca_system_score_gemma":0.000121328645,"threshold_uncertainty_score":0.91693735},"labels":[],"label_agreement":null},{"id":"W2120616064","doi":"10.1016/j.lungcan.2003.07.004","title":"Population-based outcomes for small cell lung cancer: impact of standard management policies in British Columbia","year":2003,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Stage (stratigraphy); Radiation therapy; Population; Lung cancer; Chemotherapy; Cancer; Disease; Internal medicine; Surgery","score_opus":0.015905256602102007,"score_gpt":0.3731261203917312,"score_spread":0.3572208637896292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120616064","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9866957,0.007868933,0.00014779356,0.00042949631,0.00024185398,0.002524126,0.0007062903,0.00004281341,0.0013430042],"genre_scores_gemma":[0.9920158,0.001191547,0.0007666839,0.00025916335,0.00006365268,0.0012444468,0.000030394405,0.000049222166,0.0043790843],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982382,0.000047639347,0.00039747768,0.00033201926,0.00042476482,0.00055989006],"domain_scores_gemma":[0.9991168,0.000113935406,0.00013878282,0.0002823314,0.0002233485,0.00012484683],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025564418,0.00016476691,0.0006293509,0.00013652525,0.00010172975,0.000064867425,0.000115193274,0.00006593017,0.0004570521],"category_scores_gemma":[0.000087685235,0.00019797367,0.00023646375,0.00036879454,0.000059418115,0.000057905214,0.000034521407,0.00013746317,2.894474e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001340296,0.000082936065,0.9754281,0.002108409,0.00040412846,0.0000132545065,0.00016543262,0.001509334,0.000045505727,0.000018154324,0.0187234,0.0013673072],"study_design_scores_gemma":[0.005265533,0.00017413293,0.99079245,0.0008328528,0.00026989254,8.039172e-7,0.00011725685,0.0006664418,0.00018026932,0.000043471948,0.0014538853,0.00020299763],"about_ca_topic_score_codex":0.3234169,"about_ca_topic_score_gemma":0.34695795,"teacher_disagreement_score":0.023541076,"about_ca_system_score_codex":0.002699871,"about_ca_system_score_gemma":0.0006592931,"threshold_uncertainty_score":0.8073132},"labels":[],"label_agreement":null},{"id":"W2122221221","doi":"10.1016/j.lungcan.2014.06.008","title":"Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma","year":2014,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pemetrexed; Medicine; Cisplatin; Mesothelioma; Internal medicine; Oncology; Chemotherapy; Clinical endpoint; Progression-free survival; Phases of clinical research; Performance status; Population; Randomized controlled trial; Gastroenterology; Urology; Pathology","score_opus":0.008115870399044054,"score_gpt":0.2984022568962651,"score_spread":0.29028638649722105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122221221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974009,0.00013581723,0.00009159705,0.00011940812,0.00008256779,0.0016951198,0.00006323027,0.000018992268,0.00039237406],"genre_scores_gemma":[0.99776334,0.000022620387,0.0007113769,0.00020142445,0.00007835515,0.00026958782,0.0000862863,0.00002864514,0.00083837396],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9986959,0.000069496375,0.00032736323,0.00025190052,0.00045906944,0.00019623336],"domain_scores_gemma":[0.9993728,0.00009304494,0.00019295426,0.0001909527,0.00004295934,0.00010732263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013110935,0.00018611072,0.0006575422,0.00010276596,0.000041497515,0.000004616778,0.000057871468,0.00003713567,0.0004279431],"category_scores_gemma":[0.00005777345,0.000098725126,0.00006994704,0.00018812438,0.00013577088,0.000094035786,0.000023258539,0.000071925955,0.0000020272703],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7858962,0.001125346,0.20916799,0.00009319322,0.00011742664,0.000003595222,0.000109336506,0.000134221,0.00012253218,0.000017115519,0.00006535023,0.0031477339],"study_design_scores_gemma":[0.92995054,0.0058113416,0.060593393,0.00052833656,0.00042550618,0.0000011837176,0.000021773347,0.0016486554,0.00064927683,0.0000072786224,0.00018992985,0.00017280834],"about_ca_topic_score_codex":0.00016973085,"about_ca_topic_score_gemma":0.00011619759,"teacher_disagreement_score":0.14857459,"about_ca_system_score_codex":0.00009564612,"about_ca_system_score_gemma":0.00008449587,"threshold_uncertainty_score":0.4685677},"labels":[],"label_agreement":null},{"id":"W2122397603","doi":"10.1007/978-1-60761-524-8_10","title":"Epidermal Growth Factor Receptor Inhibitors in the Treatment of Non-small Cell Lung Cancer","year":2010,"lang":"en","type":"book-chapter","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Erlotinib; Gefitinib; Cetuximab; Medicine; Epidermal growth factor receptor; Docetaxel; Lung cancer; Oncology; Bevacizumab; Erlotinib Hydrochloride; Internal medicine; Chemotherapy; Clinical trial; EGFR inhibitors; Monoclonal antibody; Tyrosine kinase; Pharmacology; Cancer research; Cancer; Immunology; Receptor; Antibody","score_opus":0.014440951987985687,"score_gpt":0.30870348784135115,"score_spread":0.2942625358533655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122397603","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.26835072,0.13056256,0.0000678889,0.008197107,0.010359427,0.015479058,0.0058047012,0.00019599502,0.5609825],"genre_scores_gemma":[0.25884986,0.04850296,0.000849482,0.0016007337,0.005381537,0.0037506903,0.00078127166,0.000468521,0.67981493],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979428,0.000024946245,0.0006071378,0.0005831835,0.0004163131,0.00042560836],"domain_scores_gemma":[0.99852276,0.00012775512,0.00041978963,0.00056465,0.00020286987,0.00016218724],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00006232126,0.0006053624,0.00088205794,0.00023418093,0.00010066168,0.000023267325,0.00018698623,0.00049175014,0.0024818494],"category_scores_gemma":[0.0000063383304,0.0003904519,0.00040444068,0.00009753129,0.00012842916,0.000065568616,0.00002478071,0.0005033016,0.000016652815],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025301727,0.0062889676,0.54108727,0.012832098,0.01559454,0.0010339186,0.107400864,0.00018254336,0.024610158,0.005048384,0.13579094,0.14760013],"study_design_scores_gemma":[0.016420297,0.001971197,0.029480556,0.0056537003,0.01150438,0.000025317291,0.00035637213,0.00019318085,0.03047373,0.00022416351,0.90173054,0.0019665519],"about_ca_topic_score_codex":0.0055820243,"about_ca_topic_score_gemma":0.0035808678,"teacher_disagreement_score":0.7659396,"about_ca_system_score_codex":0.0015111322,"about_ca_system_score_gemma":0.0011067977,"threshold_uncertainty_score":0.99985474},"labels":[],"label_agreement":null},{"id":"W2126013413","doi":"10.1016/j.lungcan.2004.03.007","title":"Docetaxel and Gemcitabine administered on days 1 and 8 for metastatic non-small cell lung carcinoma (NSCLC): a phase II multicenter trial","year":2004,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal; Hôpital Charles-Le Moyne; McGill University; Royal Victoria Hospital","funders":"","keywords":"Docetaxel; Medicine; Gemcitabine; Internal medicine; Regimen; Toxicity; Oncology; Phases of clinical research; Chemotherapy; Progressive disease; Performance status; Gastroenterology; Surgery","score_opus":0.02758055674964294,"score_gpt":0.3685417805657494,"score_spread":0.34096122381610644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2126013413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885514,0.003710206,0.0008084058,0.001550566,0.00045513702,0.0036210713,0.0003451742,0.000032214943,0.0009258287],"genre_scores_gemma":[0.9927494,0.00014137127,0.002599891,0.00090816646,0.00029193584,0.0010543307,0.00009488411,0.00004501531,0.0021150236],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.998833,0.00001480251,0.00027521458,0.00042221483,0.00014342472,0.0003113211],"domain_scores_gemma":[0.9992956,0.000067572786,0.00010989099,0.00022329827,0.00007823647,0.00022542017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007386928,0.0002447227,0.00038798866,0.00009698355,0.00019418569,0.000037634094,0.000045513,0.000053660446,0.00005760077],"category_scores_gemma":[0.000023167302,0.00019175843,0.00009172176,0.000084106876,0.000053888823,0.00008403713,0.00003255457,0.00010264633,0.0000014735418],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.53871065,0.043681357,0.059369355,0.022502916,0.014460224,0.0016497936,0.10284748,0.0006210275,0.053899366,0.00311916,0.03762536,0.121513315],"study_design_scores_gemma":[0.94480914,0.013835861,0.0071196505,0.0010208314,0.008997319,0.00004123597,0.00063912274,0.0052952818,0.008717283,0.000102836115,0.008715867,0.0007055739],"about_ca_topic_score_codex":0.00029062064,"about_ca_topic_score_gemma":0.00013211265,"teacher_disagreement_score":0.40609848,"about_ca_system_score_codex":0.00026512516,"about_ca_system_score_gemma":0.00030307315,"threshold_uncertainty_score":0.7819682},"labels":[],"label_agreement":null},{"id":"W2126270742","doi":"10.1016/j.lungcan.2009.11.018","title":"Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology","year":2009,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Pemetrexed; Medicine; Erlotinib; Gefitinib; Oncology; Cetuximab; Bevacizumab; Internal medicine; Lung cancer; Adenocarcinoma; Clinical trial; Chemotherapy; Cancer; Epidermal growth factor receptor; Cisplatin; Colorectal cancer","score_opus":0.04081135753217011,"score_gpt":0.44960652796712375,"score_spread":0.4087951704349536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2126270742","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01063804,0.9820114,0.000002224985,0.0011213901,0.00079976325,0.0022235813,0.0010234391,0.000010464285,0.0021697166],"genre_scores_gemma":[0.006168726,0.9900777,0.00049162126,0.00003426832,0.00024008079,0.00051932305,0.0003745883,0.000037975926,0.002055721],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974024,0.00016278058,0.0013884166,0.00039680436,0.00041430173,0.00023526335],"domain_scores_gemma":[0.99643075,0.00019898402,0.0023932073,0.00044991,0.00046434908,0.000062802676],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023548641,0.00033420126,0.001801007,0.00021364428,0.00003311336,0.0000040733153,0.00023086976,0.00028043386,0.00006389949],"category_scores_gemma":[0.00008977702,0.00022510764,0.00035480165,0.00044061377,0.000046150693,0.00007543611,0.00003612487,0.00014777773,2.0840062e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040416574,0.0013919699,0.0036413795,0.005659519,0.0013059766,0.0000065020604,0.004334113,0.00076737895,0.00008415378,0.0000042393535,0.0003381485,0.98206246],"study_design_scores_gemma":[0.007236693,0.0015518675,0.00298668,0.052082423,0.006808992,0.000004630886,0.00044537566,0.000503578,0.0047394596,0.000008087071,0.92325836,0.00037384548],"about_ca_topic_score_codex":0.0058399634,"about_ca_topic_score_gemma":0.0059090606,"teacher_disagreement_score":0.9816886,"about_ca_system_score_codex":0.004538605,"about_ca_system_score_gemma":0.0014303855,"threshold_uncertainty_score":0.9992828},"labels":[],"label_agreement":null},{"id":"W2127759166","doi":"10.1016/j.lungcan.2005.03.037","title":"Differential expression of survivin-2B and survivin-ΔEx3 is inversely associated with disease relapse and patient survival in non-small-cell lung cancer (NSCLC)","year":2005,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"National Cancer Institute","keywords":"Survivin; Lung cancer; Medicine; Apoptosis; Cancer research; Inhibitor of apoptosis; Cell; Programmed cell death; Cancer; Oncology; Internal medicine; Biology; Genetics","score_opus":0.005188085557054171,"score_gpt":0.22435495131988595,"score_spread":0.2191668657628318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127759166","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99455833,0.0042973123,0.0002729728,0.00009968377,0.00019553867,0.00034534992,0.000114785056,0.000006639309,0.00010937351],"genre_scores_gemma":[0.99662536,0.002413805,0.000057749512,0.00008293321,0.00009109884,0.000055807555,0.00007188156,0.000029187124,0.00057218637],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99889547,0.000075741664,0.00021784655,0.00039703175,0.00018243764,0.00023146585],"domain_scores_gemma":[0.99942833,0.000017063056,0.00015705527,0.00018716381,0.00007980445,0.00013055837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008152544,0.00019719376,0.00021808343,0.00004981407,0.000060280563,0.000018148314,0.00006492859,0.00014836734,0.00007721269],"category_scores_gemma":[0.000009029319,0.00016273692,0.00004208767,0.000083958395,0.00005347493,0.000010696806,0.00010403581,0.00009082718,1.02588714e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000617745,0.00022782164,0.4663044,0.00022308042,0.00009874474,0.0000030859085,0.0010545008,0.0007051491,0.5259064,0.00001048705,0.0008238177,0.004024819],"study_design_scores_gemma":[0.005929644,0.0002991686,0.56810886,0.001005111,0.0003271847,0.0000011193501,0.00023663849,0.021217374,0.40073287,0.000016130081,0.0012634959,0.0008623784],"about_ca_topic_score_codex":0.00081594306,"about_ca_topic_score_gemma":0.0044397577,"teacher_disagreement_score":0.1251735,"about_ca_system_score_codex":0.00005636647,"about_ca_system_score_gemma":0.00010410005,"threshold_uncertainty_score":0.6636219},"labels":[],"label_agreement":null},{"id":"W2132037522","doi":"10.1016/j.lungcan.2004.11.029","title":"Sequential therapy with Vinorelbine followed by Gemcitabine in patients with metastatic non small cell lung cancer (NSCLC), performance status (PS) 2, or elderly with comorbidities—a multicenter phase II trial","year":2005,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal; Jewish General Hospital; Centre Hospitalier de l’Université de Montréal; Hôpital Charles-Le Moyne; McGill University; Royal Victoria Hospital","funders":"GlaxoSmithKline","keywords":"Vinorelbine; Gemcitabine; Medicine; Internal medicine; Lung cancer; Performance status; Population; Chemotherapy; Progressive disease; Oncology; Phases of clinical research; Antimetabolite; Gastroenterology; Surgery","score_opus":0.011925274054068338,"score_gpt":0.3126804444621362,"score_spread":0.3007551704080679,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132037522","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99062026,0.0022854835,0.0002709088,0.00042663678,0.00031386895,0.0049984646,0.0005402888,0.00007162586,0.00047247557],"genre_scores_gemma":[0.98925275,0.0009282757,0.0013747032,0.00070817274,0.00027398046,0.002159004,0.00059894565,0.00013402732,0.004570127],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973253,0.000054947963,0.00049674994,0.0006526001,0.0006402393,0.00083014654],"domain_scores_gemma":[0.9986459,0.00004255884,0.00031874285,0.00041560733,0.00028106038,0.0002961568],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00008342087,0.00056856475,0.00071510504,0.00018876027,0.00022921126,0.000057801095,0.00013989143,0.00008222607,0.0010664902],"category_scores_gemma":[0.0000038465746,0.00033174676,0.00007747527,0.0004605467,0.00011697313,0.00041715382,0.0000274259,0.00033991528,0.0000028843872],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5602076,0.01014423,0.3861542,0.00063130783,0.0029482043,0.000104948005,0.0053406004,0.001797813,0.0005319462,0.0000027136514,0.0077657886,0.02437061],"study_design_scores_gemma":[0.9117421,0.03695508,0.022479821,0.0015933241,0.0034093107,0.000006209549,0.0002559691,0.006046393,0.0036831426,1.9077481e-7,0.012838585,0.0009898982],"about_ca_topic_score_codex":0.003455975,"about_ca_topic_score_gemma":0.005843234,"teacher_disagreement_score":0.3636744,"about_ca_system_score_codex":0.0012563884,"about_ca_system_score_gemma":0.0014834645,"threshold_uncertainty_score":0.99991345},"labels":[],"label_agreement":null},{"id":"W2132247116","doi":"10.1016/j.lungcan.2003.09.002","title":"Practice guideline for the role of combination chemotherapy in the initial management of limited-stage small-cell lung cancer","year":2003,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"Cancer Care Ontario","keywords":"Medicine; Regimen; Etoposide; Guideline; Vincristine; Oncology; Randomized controlled trial; Chemotherapy; Internal medicine; Anthracycline; Chemotherapy regimen; Intensive care medicine; Cyclophosphamide; Cancer; Breast cancer; Pathology","score_opus":0.06482960285760901,"score_gpt":0.47039443093817324,"score_spread":0.4055648280805642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132247116","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000011253516,0.98059386,0.00023064771,0.0024601256,0.00032582373,0.0076644756,0.00021457604,0.000013268001,0.00848596],"genre_scores_gemma":[0.00007697751,0.9908258,0.00059252325,0.0011244789,0.0002646843,0.0050506224,0.00006664394,0.00007927988,0.0019190401],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99712276,0.0002755153,0.0010450769,0.00040713564,0.0007391865,0.00041034477],"domain_scores_gemma":[0.9968151,0.00092845055,0.00092805753,0.00069959194,0.00058446534,0.000044353754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015660485,0.0003807916,0.0012420089,0.00018184881,0.00009000231,0.000020701757,0.0005022328,0.00016549499,0.00015912179],"category_scores_gemma":[0.00012636164,0.00021564844,0.00037118202,0.0007351843,0.00013287687,0.00007317506,0.000097611955,0.00050644804,6.721541e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005045619,0.0006243104,0.00020082078,0.10260086,0.004114448,0.00001889369,0.0014687452,0.000056391644,0.0000059219265,0.0014807925,0.039140992,0.84978324],"study_design_scores_gemma":[0.0023996506,0.00012786937,0.00002467641,0.010392733,0.004256169,0.0000033709541,0.000835814,0.00052034884,0.000049739814,0.000014754946,0.9811877,0.00018715675],"about_ca_topic_score_codex":0.0013327867,"about_ca_topic_score_gemma":0.00022634948,"teacher_disagreement_score":0.9420467,"about_ca_system_score_codex":0.000862483,"about_ca_system_score_gemma":0.0008107439,"threshold_uncertainty_score":0.87938887},"labels":[],"label_agreement":null},{"id":"W2136509120","doi":"10.1016/j.lungcan.2015.05.018","title":"Patient-derived tumor xenograft models established from samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration","year":2015,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Toronto General Hospital; University Health Network","funders":"Ministry of Health, British Columbia; Ontario Ministry of Health and Long-Term Care","keywords":"Medicine; Histopathology; Endobronchial ultrasound; Lung cancer; Pathology; Lymph; Cancer; Radiology; Internal medicine","score_opus":0.02311757728303318,"score_gpt":0.2882637951881348,"score_spread":0.2651462179051016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136509120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98842347,0.004766204,0.0034279579,0.00012208575,0.00035489877,0.000564928,0.001375849,0.000038460912,0.00092614105],"genre_scores_gemma":[0.9955095,0.00016158148,0.0005757395,0.00033716465,0.00049323845,0.00031610677,0.0024303184,0.000042464213,0.00013389479],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983475,0.000091095724,0.00025723214,0.000500258,0.00035364178,0.00045022188],"domain_scores_gemma":[0.99910575,0.000019155133,0.00009292265,0.00032789426,0.00014929505,0.0003050033],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007018608,0.0002475418,0.00021606969,0.00003849142,0.00010791542,0.00009751753,0.00018064851,0.00010987208,0.000108171],"category_scores_gemma":[0.00005876418,0.00023258883,0.00011015917,0.00010941714,0.00007810991,0.00003341974,0.000049894225,0.00010723968,0.000004392063],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010406448,0.00020603386,0.0070224176,0.000017201766,0.00034501424,0.0000065492777,0.00072912715,0.00164636,0.90503293,0.000020394291,0.08043165,0.0035016695],"study_design_scores_gemma":[0.010314437,0.0013050645,0.0013414824,0.00004318553,0.00018074477,0.000013326364,0.00038577928,0.0018424497,0.94711506,0.0008712336,0.035783216,0.0008040282],"about_ca_topic_score_codex":0.016730396,"about_ca_topic_score_gemma":0.0036910847,"teacher_disagreement_score":0.04464843,"about_ca_system_score_codex":0.00018632026,"about_ca_system_score_gemma":0.00045007162,"threshold_uncertainty_score":0.98981726},"labels":[],"label_agreement":null},{"id":"W2138158777","doi":"10.1016/s0169-5002(02)00384-7","title":"Patterns of allelic loss differ in lung adenocarcinomas of smokers and nonsmokers","year":2002,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer-related molecular mechanisms research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"National Institute of Environmental Health Sciences; National Heart, Lung, and Blood Institute; National Institutes of Health","keywords":"Loss of heterozygosity; Lung cancer; Carcinogenesis; Adenocarcinoma; Medicine; Pathogenesis; Lung; Allele; Pathology; Internal medicine; Gastroenterology; Oncology; Cancer; Biology; Genetics; Gene","score_opus":0.010056139901448954,"score_gpt":0.27317194805641315,"score_spread":0.2631158081549642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138158777","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98447603,0.013506621,0.0011204733,0.00019772969,0.00009048964,0.000262897,0.000057926645,0.000003892872,0.00028392975],"genre_scores_gemma":[0.9952714,0.003945754,0.000054660806,0.00009127095,0.000046812656,0.00004786688,0.00001605386,0.000027203372,0.00049896754],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99895585,0.00004931005,0.00022924237,0.0003061015,0.00019621514,0.00026327808],"domain_scores_gemma":[0.9994842,0.0000099120525,0.00007859512,0.0002937279,0.00006200878,0.00007157396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008463812,0.00013358491,0.0001986303,0.000097902885,0.000018230394,0.0000057862926,0.0001529727,0.00016033479,0.00020841043],"category_scores_gemma":[0.000021477783,0.0001359589,0.00006861564,0.00012139212,0.000068963345,0.000003630902,0.000120607714,0.00013354396,5.0397415e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018378106,0.00011414218,0.2536971,0.00056452415,0.00028512927,0.000026969223,0.00049656554,0.0005000743,0.73910487,0.00014060878,0.001850941,0.0030352946],"study_design_scores_gemma":[0.003350954,0.0003353319,0.10661615,0.00032911956,0.00009699713,0.000018221877,0.00015355017,0.0056279884,0.8805159,0.000028739962,0.0024566986,0.00047036592],"about_ca_topic_score_codex":0.0006596987,"about_ca_topic_score_gemma":0.00036250494,"teacher_disagreement_score":0.14708096,"about_ca_system_score_codex":0.00005433885,"about_ca_system_score_gemma":0.00004298087,"threshold_uncertainty_score":0.5544243},"labels":[],"label_agreement":null},{"id":"W2139248900","doi":"10.1016/j.lungcan.2013.07.017","title":"Diagnostic evaluation following a positive lung screening chest radiograph in the Prostate, Lung, Colorectal, Ovarian (PLCO) Cancer Screening Trial","year":2013,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brock University","funders":"National Cancer Institute","keywords":"Medicine; Chest radiograph; Lung cancer; Radiology; Biopsy; Cancer screening; Cancer; Lung; Lung cancer screening; Colorectal cancer; Radiography; Internal medicine","score_opus":0.018258253489458205,"score_gpt":0.3354660521680322,"score_spread":0.317207798678574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139248900","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95441604,0.022944843,0.00032939363,0.007254614,0.0011837764,0.012510461,0.00007205784,0.00009851922,0.0011903006],"genre_scores_gemma":[0.97448283,0.0012641788,0.00058948377,0.0013459814,0.0009475505,0.020971552,0.00017229596,0.000082350736,0.0001437939],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99631256,0.00037000037,0.00062368653,0.00078536157,0.0011108641,0.00079752516],"domain_scores_gemma":[0.99790585,0.00087511074,0.0002772536,0.00045043055,0.00028181428,0.00020952296],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009866272,0.00047280447,0.0006690397,0.00030878853,0.00034596483,0.00021934534,0.00023630251,0.00018864255,0.00072281336],"category_scores_gemma":[0.00030250734,0.00034313748,0.000396266,0.0011131071,0.00009014321,0.00046338083,0.00006240242,0.0004832631,0.0000067397755],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037265564,0.0005197844,0.937747,0.00023456923,0.0019004698,0.00013610737,0.0056950226,0.001241175,0.00020794231,0.000048339887,0.017266877,0.031276133],"study_design_scores_gemma":[0.05150264,0.0005404675,0.9131838,0.0032436894,0.0031953452,0.000015317519,0.00062843296,0.026393127,0.00032377493,0.000029294471,0.00045590286,0.00048821975],"about_ca_topic_score_codex":0.023518309,"about_ca_topic_score_gemma":0.0023092139,"teacher_disagreement_score":0.047776084,"about_ca_system_score_codex":0.0014989169,"about_ca_system_score_gemma":0.0005475603,"threshold_uncertainty_score":0.99990207},"labels":[],"label_agreement":null},{"id":"W2142559775","doi":"10.1016/j.lungcan.2011.10.009","title":"Prognostic significance of functional capacity and exercise behavior in patients with metastatic non-small cell lung cancer","year":2011,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer survivorship and care","field":"Medicine","cited_by":221,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia, Okanagan Campus; University of British Columbia","funders":"National Cancer Institute; National Institutes of Health","keywords":"Medicine; Internal medicine; Hazard ratio; Lung cancer; Proportional hazards model; Oncology; Prospective cohort study; Performance status; Cancer; Physical therapy; Confidence interval","score_opus":0.021640138703919252,"score_gpt":0.24715349456760763,"score_spread":0.22551335586368837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142559775","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947878,0.0025984691,0.00017595127,0.000017680377,0.000362646,0.0014880614,0.00013569252,0.000018368573,0.00041529073],"genre_scores_gemma":[0.99774975,0.00016169209,0.00026855787,0.00008231333,0.000043657168,0.0012958103,0.000019157265,0.000033903078,0.00034513843],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99878573,0.00002553601,0.00025990797,0.00034948802,0.00030298592,0.00027631925],"domain_scores_gemma":[0.99925035,0.000030202757,0.00014091891,0.00021007717,0.00023131029,0.00013712193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008143112,0.00020258351,0.00038804553,0.00011060565,0.00003432863,0.000007053461,0.000064339365,0.000058933,0.0004944726],"category_scores_gemma":[0.0000071504055,0.00016551654,0.00005003153,0.00026574847,0.000107749016,0.00009174041,0.000025110437,0.00019603499,8.083681e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00087880105,0.00034332252,0.9931175,0.0011021661,0.0000549991,0.000010127072,0.0025787896,0.00002347623,0.00026045722,0.0000042728593,0.00014057284,0.0014855228],"study_design_scores_gemma":[0.0025275904,0.00022066486,0.992489,0.00074248516,0.00096444436,8.9075655e-7,0.00018697223,0.00014761026,0.002478244,0.0000036049605,0.000037024907,0.00020148577],"about_ca_topic_score_codex":0.012591265,"about_ca_topic_score_gemma":0.010789707,"teacher_disagreement_score":0.0029619304,"about_ca_system_score_codex":0.00019929433,"about_ca_system_score_gemma":0.00029146025,"threshold_uncertainty_score":0.993984},"labels":[],"label_agreement":null},{"id":"W2146428449","doi":"10.1016/j.lungcan.2003.09.020","title":"Postoperative radiotherapy in stage II or IIIA completely resected non-small cell lung cancer: a systematic review and practice guideline","year":2003,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Hamilton Regional Laboratory Medicine Program; Cancer Care Ontario","funders":"Lake Champlain Sea Grant, University of Vermont; Cancer Care Ontario","keywords":"Medicine; Radiation therapy; Guideline; Lung cancer; Meta-analysis; Randomized controlled trial; Stage (stratigraphy); Surgery; Cancer; Clinical trial; Oncology; Internal medicine; Pathology","score_opus":0.04559062140614087,"score_gpt":0.4188323485450281,"score_spread":0.37324172713888726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146428449","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000010890179,0.9778642,0.000031528078,0.0024296488,0.00040179084,0.017768295,0.00052581244,0.000052928546,0.00091487425],"genre_scores_gemma":[0.0000033177032,0.97015244,0.0013955393,0.009195009,0.00018624788,0.010751914,0.00020132797,0.00019977143,0.007914446],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9945129,0.0009529275,0.0021720424,0.0011699173,0.000514472,0.0006777266],"domain_scores_gemma":[0.9959802,0.00077420945,0.0013802638,0.0010117261,0.0005340355,0.0003195481],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010094052,0.0010709113,0.0066420045,0.00028333458,0.00018353718,0.00007183309,0.00027079196,0.00035897974,0.0011286832],"category_scores_gemma":[0.00032151595,0.0006794931,0.0004219323,0.0010137032,0.00007267262,0.0001584774,0.00009999684,0.0007676387,0.000005404409],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001375821,0.00036984985,0.000090130336,0.94657576,0.0026037227,0.00038448334,0.0005461658,0.000004239244,0.0000014206257,0.000013391018,0.042738553,0.006534724],"study_design_scores_gemma":[0.0019852694,0.00033689226,0.0000038648104,0.46148998,0.018231686,0.00014268604,0.000032489024,0.00007656286,0.0000013426848,1.0629099e-7,0.5172522,0.00044690582],"about_ca_topic_score_codex":0.0039195074,"about_ca_topic_score_gemma":0.0021577529,"teacher_disagreement_score":0.48508576,"about_ca_system_score_codex":0.0049385037,"about_ca_system_score_gemma":0.003143159,"threshold_uncertainty_score":0.9997844},"labels":[],"label_agreement":null},{"id":"W2146508678","doi":"10.1016/j.lungcan.2004.04.002","title":"Validating the prognostic value of marker genes derived from a non-small cell lung cancer microarray study","year":2004,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Gene expression and cancer classification","field":"Biochemistry, Genetics and Molecular Biology","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University Health Network","funders":"","keywords":"Microarray; Medicine; Lung cancer; Microarray analysis techniques; Oncology; Univariate analysis; Gene; Internal medicine; Significance analysis of microarrays; Log-rank test; Multivariate analysis; Cancer research; Survival analysis; Pathology; Gene expression; Biology; Genetics","score_opus":0.010127123842548554,"score_gpt":0.27535194305599037,"score_spread":0.2652248192134418,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146508678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9834701,0.011305624,0.0034006524,0.00023110531,0.00043881094,0.0008286855,0.00005104612,0.000011364853,0.00026264082],"genre_scores_gemma":[0.9968985,0.00073158595,0.00065380684,0.00025742367,0.00035630455,0.00063156633,0.000038222843,0.000035494966,0.0003971067],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987787,0.00009280047,0.00027569523,0.00044914774,0.00016908054,0.00023456913],"domain_scores_gemma":[0.99911183,0.000018680645,0.00021828474,0.00046675024,0.0001239888,0.000060482023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013019759,0.00019231348,0.0001731017,0.000028231703,0.00012326115,0.000030621002,0.00031706566,0.00010365162,0.000084446794],"category_scores_gemma":[0.00001886925,0.00014379084,0.000090111884,0.0001337985,0.000052058087,0.0000046151576,0.00011003121,0.000104228486,0.0000013518511],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000056581877,0.00010750079,0.16402914,0.000047854963,0.000119722295,7.958672e-7,0.0007953678,0.0028553975,0.83045095,0.0000022732354,0.00064364745,0.000890759],"study_design_scores_gemma":[0.0012838537,0.00006962904,0.11869469,0.00012663391,0.00021292402,5.236236e-7,0.00087864173,0.00049400673,0.8765039,0.000010351262,0.001499331,0.00022554978],"about_ca_topic_score_codex":0.0020412933,"about_ca_topic_score_gemma":0.0005916933,"teacher_disagreement_score":0.0460529,"about_ca_system_score_codex":0.00007539575,"about_ca_system_score_gemma":0.00034482495,"threshold_uncertainty_score":0.586362},"labels":[],"label_agreement":null},{"id":"W2152671064","doi":"10.1016/j.lungcan.2010.03.012","title":"The function of IGF-IR in NNK-mediated lung tumorigenesis","year":2010,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Growth Hormone and Insulin-like Growth Factors","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Cancer Society Research Institute","keywords":"Carcinogenesis; Transgene; Genetically modified mouse; Cancer research; Lung cancer; Biology; Endocrinology; Medicine; Cancer; Pathology; Internal medicine; Gene; Biochemistry","score_opus":0.006085799970421772,"score_gpt":0.265390230194649,"score_spread":0.2593044302242273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152671064","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922568,0.0024378886,0.00002122279,0.00082156336,0.0015644514,0.00032488263,0.000010902265,0.000039349892,0.0025229135],"genre_scores_gemma":[0.99789554,0.0005143022,0.000025459709,0.0002962984,0.0003344362,0.00007320708,0.000016164135,0.000023902223,0.00082070485],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989408,0.000023917773,0.00032130178,0.00019070215,0.00025088154,0.00027237553],"domain_scores_gemma":[0.99926716,0.000114429524,0.00010675641,0.00029921441,0.00011781188,0.00009460687],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002092,0.00013071607,0.0002312052,0.00010283696,0.00007335197,0.000010066153,0.00010094899,0.00012022296,0.00023294635],"category_scores_gemma":[0.00013310893,0.00008772105,0.00007699409,0.00038931216,0.00008200907,0.00007952003,0.00002515335,0.00035385322,0.0000136660865],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048616255,0.00008681726,0.8549368,0.00013508668,0.000107849504,0.00001024779,0.00043153923,0.000006680075,0.1256211,0.00030011512,0.011985041,0.005892592],"study_design_scores_gemma":[0.0011707256,0.00009555442,0.9650881,0.00006654919,0.000127786,0.0000030618166,0.000099202014,0.0010287447,0.013982,0.00003762133,0.018177405,0.00012324176],"about_ca_topic_score_codex":0.0008182383,"about_ca_topic_score_gemma":0.00089703954,"teacher_disagreement_score":0.11163909,"about_ca_system_score_codex":0.000090794936,"about_ca_system_score_gemma":0.00021635511,"threshold_uncertainty_score":0.35771605},"labels":[],"label_agreement":null},{"id":"W2154916497","doi":"10.1016/s0169-5002(03)00144-2","title":"Angiogenesis inhibitors under study for the treatment of lung cancer","year":2003,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Angiogenesis; Endostatin; Vascular endothelial growth factor; Matrix metalloproteinase inhibitor; Thalidomide; Pharmacology; Matrix metalloproteinase; Lung cancer; Clinical trial; Cancer research; Internal medicine; Immunology; Oncology; Multiple myeloma; VEGF receptors","score_opus":0.039632083794956356,"score_gpt":0.3885463755680744,"score_spread":0.34891429177311806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154916497","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006380514,0.9939464,0.00017093979,0.000027886072,0.0014034066,0.0031546808,0.000595247,0.000008437304,0.00005498897],"genre_scores_gemma":[0.00037815655,0.98752505,0.000029821387,0.00008379831,0.001451319,0.006979257,0.000095296135,0.00012676168,0.0033305231],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99810696,0.000110397224,0.0005431902,0.000664518,0.00019207364,0.00038285257],"domain_scores_gemma":[0.9986016,0.00006746026,0.0004133088,0.00070013985,0.00014358661,0.00007391694],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013748452,0.0005437793,0.0010467296,0.00006510906,0.0001557867,0.000022349335,0.00030838724,0.00033382574,0.00012641872],"category_scores_gemma":[0.000005736818,0.00033293248,0.001244814,0.00022756225,0.00007793216,0.0000025687657,0.00004543898,0.000049832524,8.491831e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000097405085,0.00076862524,0.0041453117,0.0056890817,0.010120922,0.0000021173103,0.00018621612,0.00031349674,0.00013193574,0.000030877505,0.03843978,0.9400742],"study_design_scores_gemma":[0.000564685,0.00033393694,0.000051551124,0.0007388777,0.005705037,0.0000017029937,0.000055587447,0.000012682496,0.00041183576,8.1627246e-7,0.99172765,0.0003956249],"about_ca_topic_score_codex":0.00050075655,"about_ca_topic_score_gemma":0.0006170507,"teacher_disagreement_score":0.9532879,"about_ca_system_score_codex":0.00033961204,"about_ca_system_score_gemma":0.0007218322,"threshold_uncertainty_score":0.99991226},"labels":[],"label_agreement":null},{"id":"W2155240409","doi":"10.1016/j.lungcan.2005.07.003","title":"Interleukin 1 receptor antagonist gene polymorphism and risk of lung cancer: A possible interaction with polymorphisms in the interleukin 1 beta gene","year":2005,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Inflammasome and immune disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":68,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Norges Forskningsråd; Cancer Research Society; Kreftforeningen; Cancer Research Institute","keywords":"Lung cancer; Interleukin 1 receptor antagonist; Medicine; Odds ratio; Carcinogenesis; Allele; Immunology; Internal medicine; Receptor antagonist; Oncology; Cancer research; Cancer; Gene; Genetics; Receptor; Biology; Antagonist","score_opus":0.0045534807937737155,"score_gpt":0.25280510815699875,"score_spread":0.24825162736322504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155240409","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9795723,0.018337095,0.00012726587,0.00094646076,0.0002387473,0.0003229711,0.00012147685,0.0000086946775,0.00032498888],"genre_scores_gemma":[0.9923257,0.005649786,0.00025683464,0.00039914675,0.00030940468,0.00016176829,0.00009613156,0.0000345417,0.0007666373],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987502,0.000102398,0.00032755057,0.00037090734,0.00014510281,0.0003038075],"domain_scores_gemma":[0.9992867,0.000014372391,0.00023422233,0.00035855637,0.00006383777,0.000042324064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018477555,0.00023387295,0.00023121084,0.000096288175,0.00009601146,0.000041599124,0.00026521634,0.00012374375,0.00016931647],"category_scores_gemma":[0.000009169258,0.00017347718,0.0000800475,0.0001712614,0.00014145167,0.000025826188,0.000087436696,0.0002193874,0.0000015054242],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011684878,0.00011302321,0.19037713,0.000057198253,0.00046086128,0.0000039394067,0.0023112367,0.00026359473,0.7855401,0.00002197919,0.004702349,0.014980124],"study_design_scores_gemma":[0.0020301868,0.00032306835,0.031567693,0.00019110533,0.00018343398,0.000033960114,0.00045456408,0.0007853046,0.93933326,0.00000357825,0.024690764,0.00040307734],"about_ca_topic_score_codex":0.0028700635,"about_ca_topic_score_gemma":0.0064111855,"teacher_disagreement_score":0.15880944,"about_ca_system_score_codex":0.00010262848,"about_ca_system_score_gemma":0.00013651585,"threshold_uncertainty_score":0.70741946},"labels":[],"label_agreement":null},{"id":"W2158708198","doi":"10.1016/j.lungcan.2011.05.010","title":"Time and dose-related changes in radiological lung density after concurrent chemoradiotherapy for lung cancer","year":2011,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Hounsfield scale; Chemoradiotherapy; Lung cancer; Nuclear medicine; Radiological weapon; Radiation therapy; Radiology; Lung; Radiation treatment planning; Pneumonitis; Asymptomatic; Surgery; Computed tomography; Internal medicine","score_opus":0.01981456385210116,"score_gpt":0.31745330301067526,"score_spread":0.2976387391585741,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158708198","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.934006,0.061104022,0.000018677922,0.0021252607,0.0005869279,0.001750217,0.000097871394,0.00006744751,0.00024359184],"genre_scores_gemma":[0.9834144,0.0112246955,0.00019799358,0.0013080128,0.00033661575,0.0026355837,0.000029808627,0.00004656745,0.0008063264],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985591,0.000037810452,0.0002602511,0.0005425255,0.00015456781,0.00044570756],"domain_scores_gemma":[0.99935746,0.000059116966,0.00009937568,0.00022280957,0.000077658166,0.00018360098],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00013762893,0.00029062864,0.00063318264,0.00008731079,0.000056042343,0.000014285444,0.00006987447,0.00019157006,0.0019123008],"category_scores_gemma":[0.0000112873895,0.0002181436,0.00010602474,0.00014900137,0.00013101891,0.00006354627,0.000032217944,0.00017741947,0.0000023087441],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012954801,0.00035184828,0.970038,0.00058961153,0.0008424512,0.000100697325,0.003442427,0.000011068176,0.0007395598,0.000074123105,0.009390303,0.013124461],"study_design_scores_gemma":[0.013962393,0.00055419526,0.9551267,0.0015639291,0.0012756278,0.000038017944,0.000038001,0.01781085,0.0054393806,0.00003058452,0.003521506,0.0006388149],"about_ca_topic_score_codex":0.0009986224,"about_ca_topic_score_gemma":0.0009869756,"teacher_disagreement_score":0.049879324,"about_ca_system_score_codex":0.0010350512,"about_ca_system_score_gemma":0.00013301826,"threshold_uncertainty_score":0.9990001},"labels":[],"label_agreement":null},{"id":"W2159023504","doi":"10.1016/j.lungcan.2014.03.008","title":"A genetic sequence variant (GSV) at susceptibility loci of 5p15.33 (TERT-CLPTM1L) is associated with survival outcome in locally advanced and metastatic non-small-cell lung cancer (NSCLC)","year":2014,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Public Health Ontario; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Oncology; Lung cancer; Hazard ratio; Internal medicine; Proportional hazards model; Stage (stratigraphy); Cancer; Biology; Confidence interval","score_opus":0.01713595473144952,"score_gpt":0.3254411212676625,"score_spread":0.308305166536213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159023504","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921268,0.0028684796,0.0015188843,0.00054843276,0.00022672274,0.0015453555,0.0003057859,0.00004205138,0.0008174541],"genre_scores_gemma":[0.9948381,0.00043874438,0.0016310812,0.0006783463,0.000051434105,0.00041760036,0.000046667257,0.00006456256,0.0018334405],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99756354,0.00013162316,0.0006296796,0.00070105575,0.0004354135,0.00053868146],"domain_scores_gemma":[0.9984598,0.000184588,0.00034923537,0.00049354474,0.00028171713,0.00023111177],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029517178,0.000384058,0.00086958834,0.000121652,0.00010018983,0.000021765813,0.00013681313,0.000109570115,0.00031749957],"category_scores_gemma":[0.00006351859,0.0002985261,0.00010016194,0.00042995243,0.00017631565,0.00011149283,0.000073424104,0.0002257199,0.0000024438916],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004806644,0.00029435343,0.9856133,0.0009779572,0.0007075947,0.00008354115,0.0023903623,0.0015092168,0.0053412174,0.000017180717,0.00016586421,0.0024187607],"study_design_scores_gemma":[0.015626164,0.00066680106,0.9486163,0.0015711667,0.002988525,0.000020390053,0.00024754708,0.02696884,0.0024065713,0.000040435647,0.0002324545,0.0006147725],"about_ca_topic_score_codex":0.0068910345,"about_ca_topic_score_gemma":0.018828603,"teacher_disagreement_score":0.036996957,"about_ca_system_score_codex":0.001475377,"about_ca_system_score_gemma":0.0007196969,"threshold_uncertainty_score":0.9999467},"labels":[],"label_agreement":null},{"id":"W2163703503","doi":"10.1016/j.lungcan.2014.08.012","title":"Chemotherapy for locally advanced and metastatic pulmonary carcinoid tumors","year":2014,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Canadian Lung Association; American Society of Clinical Oncology; Uniting Against Lung Cancer; American Cancer Society","keywords":"Medicine; Carcinoid tumors; Etoposide; Octreotide; Internal medicine; Regimen; Chemotherapy; Gastroenterology; Progressive disease; Chemotherapy regimen; Neuroendocrine tumors; Surgery; Oncology; Somatostatin","score_opus":0.01264226874378579,"score_gpt":0.3416283456782169,"score_spread":0.32898607693443116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163703503","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97408366,0.008118734,0.0030082369,0.00922789,0.00024529686,0.0025785957,0.00003837054,0.00015738588,0.0025418238],"genre_scores_gemma":[0.9886518,0.00056949654,0.004191451,0.0021607662,0.00018423692,0.00053925015,0.00001016948,0.000060301536,0.003632516],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988311,0.000030162164,0.00017145027,0.0003363954,0.00023649466,0.0003944297],"domain_scores_gemma":[0.99927634,0.00013723134,0.00005433514,0.00023434943,0.00009916107,0.00019858267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000093077164,0.00015639034,0.00031410478,0.000074204225,0.000063430685,0.000014413369,0.00008131618,0.0000055340192,0.00008581979],"category_scores_gemma":[0.00012709454,0.00012849807,0.00005835524,0.000120105884,0.00009537337,0.000102923186,0.00002792923,0.00013424759,0.0000027611188],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007781499,0.0005005219,0.11157392,0.0070040156,0.00046439152,0.0012700362,0.00036165657,0.0005132913,0.21372569,0.0021835738,0.011666558,0.6429548],"study_design_scores_gemma":[0.036669306,0.0059008696,0.12418014,0.0022450055,0.00074680964,0.0033494493,0.0005631869,0.10632108,0.25073662,0.0061588185,0.46116963,0.0019590675],"about_ca_topic_score_codex":0.00005020188,"about_ca_topic_score_gemma":0.000031108222,"teacher_disagreement_score":0.6409958,"about_ca_system_score_codex":0.000068571644,"about_ca_system_score_gemma":0.00010097576,"threshold_uncertainty_score":0.5239999},"labels":[],"label_agreement":null},{"id":"W2166913932","doi":"10.1016/j.lungcan.2011.05.026","title":"Feasibility and preliminary efficacy of progressive resistance exercise training in lung cancer survivors","year":2011,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer survivorship and care","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canada Research Chairs","keywords":"Medicine; Physical therapy; Lung cancer; Quality of life (healthcare); Physical strength; Internal medicine","score_opus":0.03817123558172534,"score_gpt":0.32995214051964655,"score_spread":0.2917809049379212,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166913932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90043616,0.09499267,0.000012064327,0.00016417704,0.00049714086,0.001131966,0.00005579716,0.000045797253,0.0026642366],"genre_scores_gemma":[0.99615026,0.002187998,0.00014924945,0.00008955554,0.000120822566,0.00046167572,0.0000071786817,0.000038166858,0.00079506956],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983676,0.000064784464,0.00039020515,0.0005062109,0.00029240616,0.00037875609],"domain_scores_gemma":[0.9990381,0.00007360303,0.00017956663,0.00039314607,0.00015234758,0.00016321578],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026718344,0.00022546558,0.00054925383,0.00011983338,0.000047944533,0.000008281131,0.00012037751,0.0001343725,0.000417278],"category_scores_gemma":[0.00005177705,0.00020629165,0.00009375785,0.0003930037,0.00019878006,0.000119531134,0.00005874947,0.0002623328,3.3955823e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004368737,0.00016200289,0.915472,0.0022670312,0.00008919579,0.00007572405,0.054896235,0.0000072426237,0.00014506589,0.00008640159,0.00032964876,0.02210072],"study_design_scores_gemma":[0.0030142795,0.00013444573,0.9850639,0.0051110233,0.00040230624,0.0000053798008,0.0026571262,0.00026995645,0.0023927265,0.00007420834,0.0005290558,0.00034558805],"about_ca_topic_score_codex":0.011068815,"about_ca_topic_score_gemma":0.05053819,"teacher_disagreement_score":0.09571413,"about_ca_system_score_codex":0.00031550584,"about_ca_system_score_gemma":0.0004406231,"threshold_uncertainty_score":0.99551654},"labels":[],"label_agreement":null},{"id":"W2168227366","doi":"10.1016/j.lungcan.2005.02.008","title":"A randomised phase II study of the efficacy and safety of intravenous topotecan in combination with either cisplatin or etoposide in patients with untreated extensive disease small-cell lung cancer","year":2005,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Humber River Regional Hospital","funders":"","keywords":"Medicine; Topotecan; Neutropenia; Etoposide; Internal medicine; Gastroenterology; Regimen; Surgery; Febrile neutropenia; Lung cancer; Chemotherapy","score_opus":0.00883246383519371,"score_gpt":0.30646718245021914,"score_spread":0.29763471861502544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168227366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918319,0.0013172983,0.00000892686,0.000637658,0.000030611438,0.006023855,0.00005176653,0.000011398305,0.00008658453],"genre_scores_gemma":[0.99880135,0.00020978371,0.000034742643,0.000098634584,0.000026407977,0.00048530614,0.00000741182,0.000032571945,0.0003037787],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983307,0.00014721738,0.00041225797,0.00033905153,0.00048053215,0.00029024205],"domain_scores_gemma":[0.9988547,0.00015040523,0.00023762762,0.00030946307,0.00033925087,0.00010853837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016462924,0.0002199168,0.00057466805,0.00015927498,0.000082743485,0.000006747396,0.000104034145,0.000041475698,0.00007024531],"category_scores_gemma":[0.00009231702,0.00012173667,0.000027691334,0.00057715777,0.0001587413,0.00006767282,0.000080937185,0.00023633319,6.378069e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15100962,0.0051193708,0.81784505,0.0005247026,0.0004294692,0.00002968492,0.014287461,0.0018043193,0.00023680563,0.0000031019722,0.00006253251,0.008647897],"study_design_scores_gemma":[0.23450367,0.0029345164,0.7573652,0.0015217727,0.0005353705,5.1517566e-7,0.0004701052,0.0018782844,0.00062913244,0.000001005074,0.000013975731,0.0001463943],"about_ca_topic_score_codex":0.0042402856,"about_ca_topic_score_gemma":0.019166445,"teacher_disagreement_score":0.08349405,"about_ca_system_score_codex":0.00060593366,"about_ca_system_score_gemma":0.00052763266,"threshold_uncertainty_score":0.9987312},"labels":[],"label_agreement":null},{"id":"W2169810666","doi":"10.1016/j.lungcan.2013.04.018","title":"A genome-wide association study for malignant mesothelioma risk","year":2013,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Canada Research Chairs; Ontario Institute for Cancer Research; University of Toronto; Women's College Hospital","funders":"National Medical Research Council; National Health and Medical Research Council; Cancer Australia; Ontario Institute for Cancer Research","keywords":"Asbestos; Mesothelioma; Single-nucleotide polymorphism; Genotyping; Medicine; Genome-wide association study; Genetic association; Genetics; Case-control study; Genotype; Oncology; Pathology; Gene; Biology","score_opus":0.007849009480797028,"score_gpt":0.2772130378574949,"score_spread":0.2693640283766979,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169810666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960597,0.0007505105,0.000064459,0.00092665805,0.00011688509,0.001405865,0.00011279798,0.000031582713,0.00053151825],"genre_scores_gemma":[0.991129,0.00008552251,0.00013004639,0.00078059005,0.00021891165,0.0010087091,0.000039507173,0.000017094972,0.006590608],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993242,0.00002425455,0.00012729384,0.00016087352,0.00020855162,0.00015479785],"domain_scores_gemma":[0.99957913,0.00010942084,0.00008343369,0.00010695355,0.000040276722,0.00008077628],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00008798751,0.000081325496,0.00012699774,0.000031582964,0.00008211755,0.000014205937,0.00003478804,0.00003146852,0.0012319599],"category_scores_gemma":[0.000088679284,0.00006329105,0.00006808126,0.00005566441,0.00000899268,0.00006310912,0.00001533326,0.0000490924,0.00009896847],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000079719954,0.00025345167,0.9912747,0.00003417697,0.00019472484,0.0000011172508,0.000145428,0.000027226202,0.0005639988,0.0000039732313,0.0067811264,0.0006403142],"study_design_scores_gemma":[0.001135414,0.00017263877,0.99395007,0.000018485844,0.0003474935,1.8299977e-7,0.00013292705,0.00026058595,0.000108184904,0.000116427545,0.0036782182,0.00007939752],"about_ca_topic_score_codex":0.0005780249,"about_ca_topic_score_gemma":0.00004069374,"teacher_disagreement_score":0.0060590897,"about_ca_system_score_codex":0.00039882207,"about_ca_system_score_gemma":0.00003065878,"threshold_uncertainty_score":0.99968106},"labels":[],"label_agreement":null},{"id":"W2170603432","doi":"10.1016/j.lungcan.2010.07.015","title":"Inoperable early stage non-small cell lung cancer: Comorbidity, patterns of care and survival","year":2010,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Ontario Institute for Cancer Research","keywords":"Medicine; Comorbidity; Stage (stratigraphy); Internal medicine; Proportional hazards model; Lung cancer; Radiation therapy; Retrospective cohort study; Cancer; Performance status; Oncology; Surgery","score_opus":0.010356648751411126,"score_gpt":0.29477256964678145,"score_spread":0.2844159208953703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2170603432","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857017,0.008160924,0.000016206026,0.00039450554,0.0012793414,0.0007459407,0.00048138207,0.000034026754,0.00318597],"genre_scores_gemma":[0.9902813,0.0065371143,0.00013877131,0.00019823825,0.00038671566,0.0003124101,0.000033224416,0.00004812619,0.0020641321],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99871254,0.000022022412,0.000249051,0.00039997473,0.00027398625,0.00034243145],"domain_scores_gemma":[0.99901336,0.000049895534,0.0001220169,0.00041288455,0.0001933859,0.00020844195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000781331,0.00024023843,0.00048030124,0.00006627872,0.0000834349,0.00003209426,0.000113757895,0.00012853247,0.00079288555],"category_scores_gemma":[0.0000049464443,0.00019964608,0.00009762942,0.000104787236,0.00005300262,0.000076882876,0.00008811227,0.00032230234,0.000002342094],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000080152975,0.00012560333,0.9892414,0.0021629517,0.00018910696,0.000031220374,0.0020501753,0.000023072764,0.0029104538,0.000044380882,0.0011006731,0.0020408044],"study_design_scores_gemma":[0.0043107015,0.0003607066,0.9396756,0.000822292,0.00076602097,0.000002806378,0.00032317088,0.00029498446,0.04522729,0.0000017770243,0.007909126,0.0003054918],"about_ca_topic_score_codex":0.05117788,"about_ca_topic_score_gemma":0.029247863,"teacher_disagreement_score":0.04956577,"about_ca_system_score_codex":0.00029829587,"about_ca_system_score_gemma":0.00034923173,"threshold_uncertainty_score":0.98846585},"labels":[],"label_agreement":null},{"id":"W2258384277","doi":"10.1016/j.lungcan.2016.02.002","title":"Approach to the non-operative management of patients with stage II non-small cell lung cancer (NSCLC): A survey of Canadian medical and radiation oncologists","year":2016,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; BC Cancer Agency; University of Toronto; Princess Margaret Cancer Centre; University of Ottawa","funders":"","keywords":"Medicine; Stage (stratigraphy); Oncology; Lung cancer; Cancer; General surgery; Internal medicine","score_opus":0.012496099743748972,"score_gpt":0.2878871232613033,"score_spread":0.2753910235175543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2258384277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879981,0.0019574028,0.00023722183,0.002356025,0.0002104627,0.0024572306,0.0007115554,0.000007374008,0.0040645977],"genre_scores_gemma":[0.9943876,0.0026038277,0.0002280872,0.0005769531,0.00005930107,0.0008707558,0.000040199542,0.000024268933,0.0012089635],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99855906,0.000060264592,0.00026940164,0.00035519886,0.00045952175,0.0002965615],"domain_scores_gemma":[0.99887955,0.00006810724,0.00014552729,0.0002956088,0.00025798634,0.00035320845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028393563,0.00018852844,0.00036387346,0.00013980242,0.00009005937,0.000007835495,0.00013050594,0.000087854605,0.00022536035],"category_scores_gemma":[0.000015786502,0.00009442599,0.000035599664,0.00038094152,0.00009012167,0.000046887246,0.0000658647,0.00008787957,0.0000010628154],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003544784,0.00035164462,0.9740055,0.0005461555,0.0006146245,0.000009675102,0.0016341121,0.00010442945,0.000009255384,0.000028809529,0.0099802045,0.012361082],"study_design_scores_gemma":[0.0047190464,0.00043251403,0.98944783,0.00096274156,0.00033481503,3.0452787e-7,0.00008527336,0.0003539032,0.0005610777,1.8329457e-7,0.0029684328,0.00013387178],"about_ca_topic_score_codex":0.26922014,"about_ca_topic_score_gemma":0.34325278,"teacher_disagreement_score":0.07403265,"about_ca_system_score_codex":0.0009959963,"about_ca_system_score_gemma":0.0010859706,"threshold_uncertainty_score":0.7356462},"labels":[],"label_agreement":null},{"id":"W2260636514","doi":"10.1016/j.lungcan.2016.01.021","title":"Leisure-time physical activity and lung cancer risk: A systematic review and meta-analysis","year":2016,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Physical Activity and Health","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Alberta Health Services","funders":"Canadian Cancer Society Research Institute; Alberta Innovates - Health Solutions; World Health Organization; Alberta Cancer Foundation; Cancer Research Institute","keywords":"Medicine; Relative risk; Lung cancer; Meta-analysis; Confidence interval; Confounding; Internal medicine; Population; Lower risk; Cancer; Oncology; Demography; Environmental health","score_opus":0.07407870955170781,"score_gpt":0.44193483318317395,"score_spread":0.36785612363146614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2260636514","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006349228,0.9935427,0.000031868403,0.0009939026,0.000037084454,0.0041763755,0.0009683673,0.000052191495,0.00013402344],"genre_scores_gemma":[0.0002486414,0.99343157,0.000010166347,0.00024181334,0.00031863735,0.0026342715,0.0000150087935,0.00006317258,0.003036697],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9968864,0.0007361676,0.0005632302,0.00089253247,0.00046776395,0.00045390695],"domain_scores_gemma":[0.9970153,0.00070157973,0.0010431133,0.00074275816,0.000109323075,0.0003879367],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0005060227,0.0007040979,0.017343272,0.00015943898,0.00014578296,0.00003658955,0.0001441068,0.00023129894,0.00048804024],"category_scores_gemma":[0.00010998948,0.00036939533,0.002359048,0.0006752938,0.00012317854,0.00017284563,0.000117053154,0.0007473962,0.000020628726],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000007850721,0.00014143085,0.000009651784,0.8298796,0.15604149,0.000004930547,0.000028770502,7.9102605e-8,8.7416646e-7,0.00001834913,0.00062469824,0.013242266],"study_design_scores_gemma":[0.00015874606,0.00003734243,0.000021855438,0.11958904,0.86600333,0.000009422659,3.9916353e-7,0.00014566781,8.4614527e-7,0.0000072049024,0.013673451,0.00035270964],"about_ca_topic_score_codex":0.00094673474,"about_ca_topic_score_gemma":0.00012647414,"teacher_disagreement_score":0.71029055,"about_ca_system_score_codex":0.00048140908,"about_ca_system_score_gemma":0.0005204027,"threshold_uncertainty_score":0.9998758},"labels":[],"label_agreement":null},{"id":"W2266584353","doi":"10.1016/j.lungcan.2016.01.022","title":"Treatment and survival of second primary early-stage lung cancer, following treatment of head and neck cancer in the Netherlands","year":2016,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Cancer Care Ontario","funders":"","keywords":"Medicine; Radiation therapy; Internal medicine; Stage (stratigraphy); Lung cancer; Proportional hazards model; Oncology; Head and neck cancer; Cancer; Cancer registry","score_opus":0.020771305269990752,"score_gpt":0.3339487697123087,"score_spread":0.3131774644423179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2266584353","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91359925,0.0824614,0.0000023973373,0.0015281125,0.00028067792,0.0006043116,0.00023313863,0.000010524084,0.0012801571],"genre_scores_gemma":[0.95585126,0.040434558,0.00001945159,0.00010861629,0.00017859615,0.0004182819,0.0000025911231,0.000022978427,0.002963695],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99885315,0.000057199984,0.00030220154,0.00030422313,0.00018879974,0.00029443437],"domain_scores_gemma":[0.9993879,0.00015796622,0.00011040804,0.00022742157,0.000037857302,0.000078440884],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009790794,0.00023252456,0.0007282455,0.000066987464,0.000059028775,0.000007039513,0.000050898245,0.000068884605,0.00015982856],"category_scores_gemma":[0.0000056305985,0.00011776822,0.0001013061,0.00013707438,0.00010671758,0.0000702059,0.000023339015,0.000049694354,1.2431794e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046253667,0.00013206285,0.94344646,0.0003221916,0.00058399374,0.000020517116,0.0066090464,0.0000027582296,0.0053760875,0.00001778648,0.00018854982,0.042837996],"study_design_scores_gemma":[0.009837734,0.0011880542,0.9755391,0.0011031559,0.00045209334,0.000002929704,0.000255047,0.000047998237,0.003024423,0.0000049290766,0.008375309,0.00016923192],"about_ca_topic_score_codex":0.0137276845,"about_ca_topic_score_gemma":0.025539024,"teacher_disagreement_score":0.042668767,"about_ca_system_score_codex":0.00061949424,"about_ca_system_score_gemma":0.00028782984,"threshold_uncertainty_score":0.99284},"labels":[],"label_agreement":null},{"id":"W2273853937","doi":"10.1016/j.lungcan.2016.02.013","title":"ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models","year":2016,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Biotechnology Research Institute","funders":"","keywords":"Cetuximab; In vivo; Monoclonal antibody; A549 cell; Epidermal growth factor receptor; Chemistry; Cancer research; Apoptosis; Pharmacology; Receptor; Medicine; Biology; Antibody; Immunology; Biochemistry","score_opus":0.0188192176814274,"score_gpt":0.35069398863298906,"score_spread":0.33187477095156165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2273853937","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858063,0.0021374475,0.0028087208,0.0016461915,0.00044232534,0.0012893878,0.00036579813,0.000083263425,0.005420579],"genre_scores_gemma":[0.991749,0.0004423235,0.0004025897,0.00059746904,0.00041837397,0.0007034887,0.000031008058,0.000079746605,0.005576032],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9979622,0.00002652112,0.00035706363,0.00067949196,0.00033750702,0.0006372358],"domain_scores_gemma":[0.9989568,0.000050418083,0.00019150016,0.00041482234,0.00015037345,0.00023611348],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00011129805,0.0003697995,0.00055474014,0.0002136228,0.00015342132,0.00003373976,0.00014705818,0.00012814104,0.00045682862],"category_scores_gemma":[0.0000072575885,0.00026425192,0.0001580681,0.0003356902,0.00008251202,0.0003548334,0.00007926124,0.00025017315,0.000009579949],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002328236,0.0010585408,0.44502974,0.0005991514,0.0004528946,0.00013416115,0.0013212829,0.0014225787,0.54385227,0.00023303802,0.002830837,0.0028326858],"study_design_scores_gemma":[0.03270685,0.0004055232,0.7994503,0.005872838,0.0023738162,0.000042852003,0.00016453602,0.0290117,0.12509976,0.00025285833,0.002955091,0.0016639156],"about_ca_topic_score_codex":0.009842866,"about_ca_topic_score_gemma":0.0026407759,"teacher_disagreement_score":0.41875252,"about_ca_system_score_codex":0.0016253953,"about_ca_system_score_gemma":0.00080509245,"threshold_uncertainty_score":0.999981},"labels":[],"label_agreement":null},{"id":"W2325642881","doi":"10.1016/j.lungcan.2016.04.004","title":"EGFR mutation status on brain metastases from non-small cell lung cancer","year":2016,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":134,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Oncology; Internal medicine; Lung cancer; Incidence (geometry); Clinical endpoint; Brain metastasis; Cumulative incidence; Epidermal growth factor receptor; Multivariate analysis; Population; Cancer; Metastasis; Cohort; Clinical trial","score_opus":0.011819419277273258,"score_gpt":0.3313313429954913,"score_spread":0.319511923718218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2325642881","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94824785,0.012525218,0.0036752252,0.018293342,0.0019660247,0.0019503535,0.0033365595,0.00020842737,0.009796978],"genre_scores_gemma":[0.9684246,0.0014668398,0.0010922286,0.0047544907,0.00081663294,0.001059842,0.00027778736,0.00009084172,0.02201673],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.998412,0.000046424484,0.00027232638,0.00049939315,0.00030900844,0.00046083768],"domain_scores_gemma":[0.99880505,0.00029166517,0.0001506145,0.0003614755,0.00013854158,0.0002526441],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00006217025,0.0002715071,0.00033602453,0.00011631555,0.000117441596,0.000031017513,0.00008119498,0.00008962547,0.0026519906],"category_scores_gemma":[0.00004214821,0.00015931591,0.0001257808,0.00018822061,0.00004754058,0.0001436618,0.000024436291,0.00011713539,0.000056212408],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014163445,0.0009947759,0.33420098,0.0006727481,0.004027733,0.00037405858,0.0066274153,0.0012469548,0.049218312,0.00039442355,0.38163635,0.2191899],"study_design_scores_gemma":[0.045951452,0.0013902191,0.38146245,0.0058880975,0.012188421,0.00001472735,0.0010505702,0.0043641794,0.17919326,0.0004512571,0.36593196,0.002113392],"about_ca_topic_score_codex":0.010234592,"about_ca_topic_score_gemma":0.0020117774,"teacher_disagreement_score":0.21707651,"about_ca_system_score_codex":0.0013533668,"about_ca_system_score_gemma":0.0007136854,"threshold_uncertainty_score":0.9982597},"labels":[],"label_agreement":null},{"id":"W2337624919","doi":"10.1016/j.lungcan.2016.04.007","title":"Palliative systemic therapy for advanced non-small cell lung cancer: Investigating disparities between patients who are treated versus those who are not","year":2016,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Lung cancer; Systemic therapy; Intensive care medicine; Cancer; Palliative care; Oncology; Internal medicine; Nursing","score_opus":0.14783931423759905,"score_gpt":0.4464103802403956,"score_spread":0.29857106600279654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2337624919","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.017024525,0.9702069,0.000076660566,0.0000841511,0.0010642112,0.004944916,0.0062552183,0.00009199956,0.00025137383],"genre_scores_gemma":[0.0016281432,0.98988974,0.0002099324,0.00016630409,0.001313693,0.004080243,0.0006276953,0.000239494,0.0018447806],"study_design_codex":"observational","study_design_gemma":"systematic_review","domain_scores_codex":[0.9962585,0.00020162393,0.0012278488,0.0009844312,0.0005274714,0.0008001129],"domain_scores_gemma":[0.99450713,0.0012969484,0.0023523818,0.00062461506,0.000896228,0.0003227022],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001710019,0.0010581103,0.004615507,0.00023633309,0.00017969271,0.000038162274,0.0004158535,0.0005888228,0.00003844261],"category_scores_gemma":[0.0002688367,0.0007475879,0.0007898306,0.0004131706,0.00016430732,0.0001555105,0.00009275255,0.0005092443,0.0000042106776],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005592597,0.00007854393,0.4832643,0.13342437,0.0028466105,0.000008175565,0.002136733,0.000009171371,0.000010717059,0.000008461851,0.0048585334,0.37279513],"study_design_scores_gemma":[0.009474418,0.00039087687,0.0042469227,0.70160764,0.003977906,1.9815742e-7,0.0003443031,0.00004885953,0.00064747466,0.0000034460816,0.2781706,0.001087382],"about_ca_topic_score_codex":0.00076230924,"about_ca_topic_score_gemma":0.00021021461,"teacher_disagreement_score":0.56818324,"about_ca_system_score_codex":0.001804607,"about_ca_system_score_gemma":0.000879923,"threshold_uncertainty_score":0.99949753},"labels":[],"label_agreement":null},{"id":"W2345787467","doi":"10.1016/j.lungcan.2016.04.020","title":"Erratum to “The function of IGF-IR in NNK-mediated lung tumorigenesis” [Lung Cancer 71 (1) (2011) 11–18]","year":2016,"lang":"en","type":"erratum","venue":"Lung Cancer","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"","keywords":"Lung cancer; Carcinogenesis; Magnification; Lung; Medicine; Cancer research; Cancer; Pathology; Epidermal growth factor receptor; Internal medicine; Physics","score_opus":0.007828705652879176,"score_gpt":0.2700077450826435,"score_spread":0.26217903942976434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2345787467","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.035099644,0.66228545,0.0008938249,0.0027786414,0.27983052,0.0032403744,0.003396398,0.00010483744,0.012370296],"genre_scores_gemma":[0.042679258,0.16753094,0.00007402739,0.004095539,0.06872789,0.0039287847,0.00225167,0.00056442857,0.71014744],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99624634,0.00017296679,0.000809217,0.0012268781,0.00057733955,0.0009672637],"domain_scores_gemma":[0.9974926,0.000030749474,0.0005624428,0.0012119361,0.00043268534,0.00026957635],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00039087192,0.0007410094,0.0009186038,0.00027811248,0.00014387826,0.000044389366,0.00078642747,0.0010243228,0.0010916243],"category_scores_gemma":[0.000099773875,0.00057188846,0.000369026,0.00040750368,0.00015019982,0.000016647591,0.00030198472,0.00062059966,0.000022074762],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003640114,0.00004865911,0.002555732,0.000447691,0.00036838648,0.000002958387,0.0001314303,0.00015878974,0.039013058,0.000011406657,0.953958,0.0029399307],"study_design_scores_gemma":[0.0010969773,0.00008153663,0.0093528535,0.0006542821,0.0004763985,0.0000034338443,0.0000367601,0.0001431759,0.004356113,0.000008898283,0.98301584,0.000773764],"about_ca_topic_score_codex":0.0048945723,"about_ca_topic_score_gemma":0.026809024,"teacher_disagreement_score":0.69777715,"about_ca_system_score_codex":0.0004668604,"about_ca_system_score_gemma":0.0022847676,"threshold_uncertainty_score":0.9998215},"labels":[],"label_agreement":null},{"id":"W2470680043","doi":"10.1016/j.lungcan.2016.06.018","title":"Quality of life, symptom status and physical performance in patients with advanced non-small cell lung cancer undergoing chemotherapy: an exploratory analysis of secondary data","year":2016,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer survivorship and care","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish Rehabilitation Hospital; University of Ottawa; Jewish General Hospital; Hôpital du Sacré-Cœur de Montréal; McGill University Health Centre","funders":"Jewish General Hospital","keywords":"Medicine; Quality of life (healthcare); Chemotherapy; Oncology; Lung cancer; Performance status; Cancer; Internal medicine; Physical therapy; Intensive care medicine","score_opus":0.013960056677810416,"score_gpt":0.295440526174325,"score_spread":0.28148046949651456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2470680043","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99642426,0.0022163223,0.000105404426,0.00004957022,0.00010646053,0.00035002464,0.0005673207,0.000015478372,0.00016513644],"genre_scores_gemma":[0.9977,0.0017606968,0.00006010179,0.00017748169,0.00006427414,0.0000594106,0.000093472874,0.00003372487,0.000050877374],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99844736,0.00006235011,0.0003665291,0.00048796853,0.00033981635,0.0002959995],"domain_scores_gemma":[0.9985102,0.00009994721,0.00029409304,0.00073668954,0.00018978873,0.00016930877],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016964988,0.00020227185,0.00071215467,0.000182597,0.00002777678,0.0000063917087,0.00016517045,0.00006274963,0.00012646329],"category_scores_gemma":[0.000012372396,0.00014337774,0.000056784247,0.00058313675,0.000104148814,0.00040635766,0.0000807266,0.00013557571,1.2440147e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013616821,0.00023567659,0.974557,0.0011105381,0.0005509024,3.6587505e-7,0.004158259,0.00013478001,0.0010780684,0.0000033335252,0.00002146719,0.016787957],"study_design_scores_gemma":[0.005628208,0.00026772002,0.9884144,0.0006132008,0.0005519147,2.1839188e-8,0.0006327798,0.0018427068,0.0017495041,0.0000012663564,0.00007956352,0.00021872397],"about_ca_topic_score_codex":0.0017467657,"about_ca_topic_score_gemma":0.026250053,"teacher_disagreement_score":0.024503289,"about_ca_system_score_codex":0.00023907683,"about_ca_system_score_gemma":0.0007835709,"threshold_uncertainty_score":0.9915183},"labels":[],"label_agreement":null},{"id":"W2471534305","doi":"10.1016/j.lungcan.2016.06.026","title":"Severe agranulocytosis in a patient with metastatic non-small-cell lung cancer treated with nivolumab","year":2016,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"AstraZeneca; Pfizer","keywords":"Medicine; Nivolumab; Adverse effect; Lung cancer; Immune system; Cancer; Combination therapy; Toxicity; Oncology; Internal medicine; Immunology; Immunotherapy","score_opus":0.008072019970002274,"score_gpt":0.251468389813785,"score_spread":0.2433963698437827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2471534305","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98945755,0.0061878446,0.00019454173,0.0010896438,0.00010906157,0.001289484,0.000100064055,0.000059357768,0.0015124672],"genre_scores_gemma":[0.99224514,0.0017092878,0.00032948374,0.0008547332,0.000066683046,0.00093273364,0.0000109839975,0.000073242794,0.0037776958],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99832076,0.000045002264,0.0003116193,0.0004829512,0.00034211494,0.0004975835],"domain_scores_gemma":[0.99914557,0.000048892776,0.00016688023,0.00037335366,0.00012648919,0.00013883774],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00007893961,0.00033133104,0.00048796352,0.00016313334,0.00006487434,0.000020664687,0.00010503398,0.00007418498,0.0009775478],"category_scores_gemma":[0.000003181098,0.00017741697,0.000089528636,0.0005670972,0.000101880505,0.00011632326,0.00001999904,0.00014757678,0.000004127954],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02929897,0.000595778,0.82668597,0.0012569292,0.0021944852,0.0006801486,0.0034105051,0.00015557151,0.039306607,0.000003938219,0.008355578,0.08805555],"study_design_scores_gemma":[0.20103538,0.009466388,0.4558422,0.03749129,0.008074891,0.0008018486,0.0024458175,0.004193751,0.24397938,0.000010693583,0.031764608,0.0048937667],"about_ca_topic_score_codex":0.012944956,"about_ca_topic_score_gemma":0.012397001,"teacher_disagreement_score":0.37084374,"about_ca_system_score_codex":0.0011449987,"about_ca_system_score_gemma":0.0006136883,"threshold_uncertainty_score":0.9999357},"labels":[],"label_agreement":null},{"id":"W2479045143","doi":"10.1016/j.lungcan.2016.07.016","title":"Chemoradiotherapy versus radiotherapy alone in elderly patients with stage III non-small cell lung cancer: A systematic review and meta-analysis","year":2016,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"George & Fay Yee Centre for Healthcare Innovation; Manitoba Health; Winnipeg Regional Health Authority; University of Manitoba; McMaster University; CancerCare Manitoba","funders":"","keywords":"Medicine; Chemoradiotherapy; Internal medicine; Radiation therapy; Lung cancer; Randomized controlled trial; Meta-analysis; Oncology; Stage (stratigraphy); Blinding; Hazard ratio; Clinical trial; MEDLINE; Subgroup analysis; Confidence interval","score_opus":0.027030630380851833,"score_gpt":0.3465600761323956,"score_spread":0.31952944575154374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2479045143","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000073079165,0.9857463,0.000040919927,0.0004090754,0.00017322504,0.012697628,0.0006967644,0.00004303146,0.00011994996],"genre_scores_gemma":[0.000052110372,0.9796198,0.00017476773,0.0007548951,0.00011708111,0.015497472,0.00013907897,0.0001984269,0.003446396],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9957384,0.00026335067,0.001410186,0.0012861481,0.00064451783,0.00065741193],"domain_scores_gemma":[0.9965179,0.00029111063,0.0013443037,0.0013231646,0.00020616199,0.00031733813],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003533848,0.0012114295,0.014441436,0.0004703424,0.00007703662,0.00006480723,0.00030405796,0.00030500814,0.0015481203],"category_scores_gemma":[0.0000097632255,0.00063682377,0.0019173409,0.0012292817,0.000073519026,0.000111173824,0.0000366644,0.00037828035,0.0000044401],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013921579,0.00026017695,0.0013129417,0.74348956,0.24838588,0.00004209522,0.00013491491,0.000002724577,4.906824e-8,0.0000016790501,0.00090123323,0.0053295307],"study_design_scores_gemma":[0.0079127615,0.00034205825,0.00004621922,0.16601004,0.78750193,0.0000024143565,0.0000039716,0.000012953096,0.0000012922492,8.220776e-8,0.03749193,0.00067432283],"about_ca_topic_score_codex":0.0018563109,"about_ca_topic_score_gemma":0.0015539802,"teacher_disagreement_score":0.57747954,"about_ca_system_score_codex":0.0035394626,"about_ca_system_score_gemma":0.00087209424,"threshold_uncertainty_score":0.9996083},"labels":[],"label_agreement":null},{"id":"W2520203377","doi":"10.1016/j.lungcan.2016.09.009","title":"High-MET status in non-small cell lung tumors correlates with receptor phosphorylation but not with the serum level of soluble form","year":2016,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Liver physiology and pathology","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Institut National Du Cancer; Centre National de la Recherche Scientifique; Association pour la Recherche sur le Cancer","keywords":"Medicine; Receptor tyrosine kinase; Phosphorylation; Carcinogenesis; Cancer research; Biomarker; Lung cancer; Receptor; Proteases; Immunohistochemistry; Tumor progression; Kinase; Cancer; Pathology; Internal medicine; Biology; Cell biology; Enzyme","score_opus":0.01484584182013317,"score_gpt":0.24558744532706114,"score_spread":0.23074160350692796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2520203377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974188,0.00027775098,0.000373959,0.0007418898,0.00024582495,0.0004623552,0.0000877216,0.000015950529,0.00037573205],"genre_scores_gemma":[0.99356216,0.00013334939,0.00048932986,0.00034046965,0.0000773531,0.00008103076,0.000016664044,0.000022477096,0.0052771918],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999153,0.000036748483,0.00016611912,0.00022418826,0.000113601454,0.000306338],"domain_scores_gemma":[0.9993404,0.00013391605,0.00015208828,0.00022457557,0.000096490614,0.000052532385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012381346,0.00014141249,0.00028068008,0.00005019897,0.000049909188,0.0000026283667,0.00007970102,0.000104665916,0.00026563293],"category_scores_gemma":[0.0000075049,0.00006664103,0.000027498027,0.00013649385,0.00015548487,0.00007953868,0.000027725857,0.00019192966,0.000009924001],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00278393,0.00007935343,0.9055721,0.00019507635,0.00010634265,0.000017479624,0.0025470532,0.00018745237,0.085097775,0.00018389312,0.0020893237,0.0011402271],"study_design_scores_gemma":[0.0046042455,0.00079061976,0.83849794,0.00053981785,0.00016552302,0.000008298797,0.00030274442,0.00020766343,0.15445341,0.00003538103,0.00022433189,0.00017002168],"about_ca_topic_score_codex":0.0014674509,"about_ca_topic_score_gemma":0.0013108415,"teacher_disagreement_score":0.06935564,"about_ca_system_score_codex":0.00012939348,"about_ca_system_score_gemma":0.00024822116,"threshold_uncertainty_score":0.29084942},"labels":[],"label_agreement":null},{"id":"W2526187706","doi":"10.1016/j.lungcan.2016.09.013","title":"Biennial lung cancer screening in Canada with smoking cessation—outcomes and cost-effectiveness","year":2016,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa; Canadian Partnership Against Cancer; Public Health Ontario; University of Toronto; Statistics Canada; Cancer Care Ontario; McMaster University","funders":"Economic and Social Research Council; Medical Research Council; Health Canada","keywords":"Medicine; Smoking cessation; Lung cancer screening; Lung cancer; Oncology; Environmental health; Pathology","score_opus":0.015248205644547421,"score_gpt":0.3161021554672888,"score_spread":0.3008539498227414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2526187706","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98975587,0.0045715417,0.0002545707,0.0036824732,0.00034492006,0.0010104295,0.00008458137,0.000026104253,0.00026949236],"genre_scores_gemma":[0.9966969,0.0009328425,0.000060713424,0.00055179064,0.00012919048,0.0014070496,0.000005714632,0.0000332313,0.00018258936],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987116,0.000043583575,0.00018369431,0.00038853247,0.00032100806,0.0003515988],"domain_scores_gemma":[0.99927926,0.00022356953,0.00008803109,0.000183965,0.000082004364,0.00014313984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010459178,0.00021029421,0.0003814675,0.000082941166,0.0000770298,0.000019068957,0.000053519132,0.000047195354,0.0002513361],"category_scores_gemma":[0.00001566963,0.00012214087,0.000030911673,0.00020128433,0.000043635468,0.00013813416,0.00003048146,0.00010036814,1.9630932e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024495093,0.00002643198,0.9681128,0.00019878104,0.00037173677,0.00006710341,0.000114996845,0.00018196806,0.000057053992,0.000040223596,0.00055172807,0.030032223],"study_design_scores_gemma":[0.0067130607,0.000042152344,0.987057,0.0028325494,0.00030695234,0.000006494817,0.000038930757,0.00034912128,0.0010547764,0.0000034000952,0.0013995392,0.00019604494],"about_ca_topic_score_codex":0.87265176,"about_ca_topic_score_gemma":0.93544036,"teacher_disagreement_score":0.06278863,"about_ca_system_score_codex":0.0034111638,"about_ca_system_score_gemma":0.0014097906,"threshold_uncertainty_score":0.89200747},"labels":[],"label_agreement":null},{"id":"W2544627141","doi":"10.1016/j.lungcan.2016.10.011","title":"Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial","year":2016,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Boehringer Ingelheim (Canada)","funders":"","keywords":"Pemetrexed; Medicine; Nintedanib; Internal medicine; Lung cancer; Hazard ratio; Placebo; Clinical endpoint; Oncology; Bevacizumab; Gastroenterology; Chemotherapy; Surgery; Randomized controlled trial; Confidence interval; Lung; Idiopathic pulmonary fibrosis; Pathology","score_opus":0.02024304551739279,"score_gpt":0.34881623179503624,"score_spread":0.3285731862776434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2544627141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9683908,0.0045611425,0.001155256,0.0006685322,0.0038338283,0.017350316,0.0003219633,0.00020810119,0.003510011],"genre_scores_gemma":[0.96745664,0.0013466033,0.00067294284,0.0002536439,0.00070325227,0.009671536,0.0002835212,0.00022988356,0.019381968],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99514693,0.0002023445,0.0012283842,0.0012932541,0.0009987602,0.0011303277],"domain_scores_gemma":[0.99639565,0.0007477094,0.00083947816,0.0008968005,0.00058322493,0.00053713296],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00043506426,0.0008850746,0.0020497579,0.00063663354,0.00023786406,0.00006972992,0.00033645358,0.00033695923,0.0019561488],"category_scores_gemma":[0.00018621141,0.0005321265,0.0003985378,0.0010814356,0.00021347616,0.0005106374,0.00009992493,0.00054235704,0.000017219118],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9787383,0.0012673303,0.005004304,0.000347928,0.0021613047,0.00010342097,0.0020361084,0.0003321663,0.00021465051,0.000014268265,0.0035923566,0.006187828],"study_design_scores_gemma":[0.9845324,0.0022914584,0.0005540967,0.0019507712,0.0049039153,0.000001971387,0.00026829855,0.0021731737,0.0007990851,0.0000015529333,0.001730748,0.00079249835],"about_ca_topic_score_codex":0.004556204,"about_ca_topic_score_gemma":0.0058196187,"teacher_disagreement_score":0.015871957,"about_ca_system_score_codex":0.006582998,"about_ca_system_score_gemma":0.0035166962,"threshold_uncertainty_score":0.999713},"labels":[],"label_agreement":null},{"id":"W2562390400","doi":"10.1016/j.lungcan.2016.12.019","title":"An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC)","year":2016,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Nausea; Neutropenia; Internal medicine; Vomiting; Constipation; Phases of clinical research; Adverse effect; Lung cancer; Polo-like kinase; Gastroenterology; Oncology; Cancer; Surgery; Clinical trial; Chemotherapy; Cell cycle","score_opus":0.02410631831682526,"score_gpt":0.36205355458020266,"score_spread":0.3379472362633774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2562390400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893896,0.0025502183,0.000005301273,0.0013897775,0.0007106164,0.0051079206,0.00020858773,0.000049939554,0.000588064],"genre_scores_gemma":[0.9940921,0.00036049308,0.000055835677,0.0004685615,0.00022531711,0.0013033256,0.000008231636,0.00009630265,0.0033898312],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966075,0.00024272889,0.0005636485,0.0008149015,0.001002184,0.00076906243],"domain_scores_gemma":[0.9976834,0.000092486196,0.00031925915,0.0011580498,0.0004899862,0.0002568207],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036534911,0.00040953018,0.00073238794,0.00021567065,0.00028613387,0.00003637078,0.0007865151,0.00011400777,0.00027830852],"category_scores_gemma":[0.00006658796,0.00021417945,0.000046349956,0.0008735682,0.00025757783,0.0003343282,0.0006918794,0.00042241017,0.0000023376074],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005439741,0.008734931,0.95361423,0.00037783766,0.000442497,0.000027216476,0.004604442,0.000019909845,0.009478211,0.000007728713,0.012049122,0.005204123],"study_design_scores_gemma":[0.21119843,0.026263468,0.7331953,0.005587197,0.0012552302,0.0000015274566,0.0014352814,0.0002745415,0.0140724005,0.000011726491,0.0056139296,0.0010909701],"about_ca_topic_score_codex":0.011173712,"about_ca_topic_score_gemma":0.01550998,"teacher_disagreement_score":0.22041894,"about_ca_system_score_codex":0.001424909,"about_ca_system_score_gemma":0.0009668237,"threshold_uncertainty_score":0.995411},"labels":[],"label_agreement":null},{"id":"W2565864153","doi":"10.1016/j.lungcan.2016.12.004","title":"A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group","year":2016,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Clinical Oncology Group; McMaster University; Juravinski Cancer Centre; Northeast Cancer Centre; Princess Margaret Cancer Centre; Ottawa Hospital","funders":"","keywords":"Medicine; Mesothelioma; Internal medicine; Oncology; Pathology","score_opus":0.03524471519742882,"score_gpt":0.4049771911149531,"score_spread":0.3697324759175243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2565864153","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99563074,0.00058108586,0.0000045193624,0.0014873608,0.00029814115,0.0008866879,0.000052175474,0.000015922178,0.001043364],"genre_scores_gemma":[0.9959008,0.0002686426,0.00006119568,0.00044543113,0.00025278406,0.00022857937,0.000023724953,0.000012513445,0.0028062933],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99885464,0.000089212845,0.000453031,0.00022074253,0.00019276819,0.0001896029],"domain_scores_gemma":[0.999316,0.00021926982,0.00015107941,0.00019880924,0.000017332864,0.00009751057],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00019755356,0.00011267989,0.00034628774,0.00003761999,0.00003843002,0.0000017394061,0.00008240582,0.00007911758,0.0010257717],"category_scores_gemma":[0.000074619034,0.000056707115,0.00014230693,0.00008433103,0.00017425776,0.00006191811,0.000049029593,0.000113198395,0.000007745087],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1703169,0.0068614827,0.67677087,0.000047731242,0.00021065403,0.000050946473,0.00044120982,0.0000053119115,0.0042413957,0.000087858614,0.0017745856,0.13919106],"study_design_scores_gemma":[0.3098048,0.014046713,0.6279475,0.0004425678,0.00048586476,0.000009573094,0.000046439472,0.00005925378,0.00079223013,0.00009487954,0.046074625,0.00019557873],"about_ca_topic_score_codex":0.0038658017,"about_ca_topic_score_gemma":0.018255908,"teacher_disagreement_score":0.13948789,"about_ca_system_score_codex":0.00049329054,"about_ca_system_score_gemma":0.00022727663,"threshold_uncertainty_score":0.9998874},"labels":[],"label_agreement":null},{"id":"W2566738039","doi":"10.1016/j.lungcan.2016.12.014","title":"Oligometastatic non-small cell lung cancer: Where do we go next?","year":2016,"lang":"de","type":"editorial","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Lung cancer; Oncology; Internal medicine; Disease; Cancer","score_opus":0.008859829446741413,"score_gpt":0.3254124924975059,"score_spread":0.3165526630507645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2566738039","genre_codex":"review","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006117128,0.51151204,0.00026985104,0.0035550757,0.47048712,0.00298711,0.0047857505,0.00014604034,0.005645331],"genre_scores_gemma":[0.0017610764,0.41748288,0.00031150857,0.00026462376,0.46952084,0.0037196146,0.0005077688,0.0004724796,0.10595921],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99212617,0.00021099088,0.0015124595,0.002230088,0.0017767028,0.0021436012],"domain_scores_gemma":[0.9939834,0.0008529044,0.001293384,0.0017233719,0.001044872,0.0011020831],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.00032377196,0.0018513419,0.0024115664,0.00054838735,0.00058232126,0.00045645318,0.000890738,0.001418633,0.010219685],"category_scores_gemma":[0.00008247982,0.0014350632,0.00083745207,0.000822653,0.00028060857,0.0004961793,0.0002680171,0.0016748107,0.001054103],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00046228917,0.00039996704,0.0075830603,0.009622802,0.0074628247,0.00028936312,0.0036290581,0.00012564124,0.00024884625,0.000029839099,0.9415153,0.02863097],"study_design_scores_gemma":[0.011111848,0.00034719778,0.00022905452,0.019542662,0.026144274,0.0000034122968,0.00032175583,0.00042315276,0.00026796391,0.00004015473,0.9400237,0.0015447923],"about_ca_topic_score_codex":0.006822259,"about_ca_topic_score_gemma":0.0021533414,"teacher_disagreement_score":0.10031388,"about_ca_system_score_codex":0.007634582,"about_ca_system_score_gemma":0.009913978,"threshold_uncertainty_score":0.99987775},"labels":[],"label_agreement":null},{"id":"W2609723037","doi":"10.1016/j.lungcan.2017.04.016","title":"Uncommon EGFR mutations in advanced non-small cell lung cancer","year":2017,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":151,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Exon; Epidermal growth factor receptor; Point mutation; Lung cancer; Medicine; Cancer research; Mutation; Tyrosine kinase; Gefitinib; Gene; Genetics; Biology; Cancer; Oncology; Internal medicine; Receptor","score_opus":0.040083472598513976,"score_gpt":0.4348004016307965,"score_spread":0.3947169290322825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2609723037","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021206836,0.973859,0.000037412883,0.00028005906,0.0017607623,0.0038268566,0.0005942669,0.00007860945,0.019350974],"genre_scores_gemma":[0.0004060653,0.96718097,0.00039286798,0.0001842868,0.000628839,0.006762262,0.0006497035,0.0001803052,0.023614718],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972989,0.00006721431,0.0008049636,0.00085167727,0.00032320892,0.00065404706],"domain_scores_gemma":[0.9976869,0.00011865831,0.00071518205,0.0010391742,0.000169802,0.00027024577],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00011479076,0.0007156984,0.002163444,0.00039613937,0.000267305,0.00008232752,0.00037252915,0.0004101035,0.0005570449],"category_scores_gemma":[0.000028886883,0.0005823736,0.0005646922,0.00042245572,0.00007975487,0.00017993752,0.00009365442,0.00073256856,0.000037252932],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029773393,0.0002484394,0.00604914,0.035462182,0.0011143825,0.00019218051,0.00075384084,0.00018529904,0.0000022976958,0.000027826984,0.006268657,0.94966596],"study_design_scores_gemma":[0.0024942553,0.000057602945,0.00086877024,0.04244018,0.009350734,0.000013675683,0.00004551241,0.00019107803,0.000006591406,0.000008592909,0.9439292,0.00059382746],"about_ca_topic_score_codex":0.0045008026,"about_ca_topic_score_gemma":0.0058072386,"teacher_disagreement_score":0.9490722,"about_ca_system_score_codex":0.0034549441,"about_ca_system_score_gemma":0.004058841,"threshold_uncertainty_score":0.99966276},"labels":[],"label_agreement":null},{"id":"W2611025812","doi":"10.1016/j.lungcan.2017.04.021","title":"Surgery Versus Chemotherapy and Radiotherapy For Early and Locally Advanced Small Cell Lung Cancer: A Propensity-Matched Analysis of Survival","year":2017,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":130,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"","keywords":"Medicine; Propensity score matching; Radiation therapy; Chemotherapy; Lung cancer; Oncology; Surgery; Internal medicine","score_opus":0.03873701686102035,"score_gpt":0.3714446377825013,"score_spread":0.332707620921481,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2611025812","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96201754,0.032614615,0.00045746553,0.0025623848,0.0003986331,0.0015546381,0.0001206262,0.00003519883,0.00023892774],"genre_scores_gemma":[0.9559302,0.040611364,0.00088532915,0.00023904913,0.00027536557,0.0005899028,0.000012272084,0.00006948604,0.0013870568],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982465,0.000045462395,0.0003278307,0.0005507239,0.00035344344,0.00047607833],"domain_scores_gemma":[0.9981231,0.00037423027,0.0003314937,0.0005977793,0.00037590598,0.00019745603],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004310796,0.00027555795,0.0013288521,0.00022069993,0.00028557362,0.000078240155,0.00017170473,0.00010262874,0.00006267977],"category_scores_gemma":[0.00012161362,0.00022943068,0.00021723504,0.00024972856,0.000341837,0.0001511647,0.00008375029,0.00016756136,9.8804826e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009662268,0.00008443223,0.9354464,0.0018228621,0.007933772,0.000012123701,0.0016793777,0.00006405559,0.011800385,0.00001683448,0.0010815035,0.030396022],"study_design_scores_gemma":[0.014954527,0.00045488143,0.9589415,0.0006043954,0.0039441753,0.0000010965924,0.00012728885,0.009382363,0.007465178,0.000007514525,0.003623781,0.00049325405],"about_ca_topic_score_codex":0.0043239985,"about_ca_topic_score_gemma":0.0035647927,"teacher_disagreement_score":0.029902767,"about_ca_system_score_codex":0.0003431333,"about_ca_system_score_gemma":0.0004543796,"threshold_uncertainty_score":0.93559116},"labels":[],"label_agreement":null},{"id":"W2612399534","doi":"10.1016/j.lungcan.2017.05.010","title":"Evaluation of the VeriStrat ® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study","year":2017,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Afatinib; Erlotinib; Medicine; Internal medicine; Lung cancer; Oncology; Clinical endpoint; Population; Gastroenterology; Adenocarcinoma; Randomized controlled trial; Cancer; Epidermal growth factor receptor","score_opus":0.01816073625509867,"score_gpt":0.3500462134743749,"score_spread":0.33188547721927625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2612399534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887367,0.00029945903,0.0000015419068,0.00023656039,0.00008437251,0.0094346665,0.00019865,0.000007709033,0.0010003694],"genre_scores_gemma":[0.99794537,0.0000019058024,0.000020824411,0.00004828848,0.000031868047,0.0012769278,0.000021635098,0.000030474952,0.0006226797],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99799174,0.00020062807,0.0004130229,0.00031368763,0.00084413897,0.00023675681],"domain_scores_gemma":[0.9979091,0.000070186215,0.0006004771,0.00095049076,0.00043096635,0.00003876948],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003949301,0.00023255147,0.00035840395,0.000056917037,0.00021341945,0.000023960527,0.0003138923,0.000051542753,0.00013330978],"category_scores_gemma":[0.00010396028,0.00009647708,0.000051933403,0.00035079115,0.000131807,0.00014962353,0.000042697593,0.00021474891,1.8379964e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019330312,0.0026148097,0.9876743,0.00017641862,0.000107324486,0.0000072132934,0.005012426,0.0005075082,0.00035000057,0.0000018284364,0.000058830647,0.0015562845],"study_design_scores_gemma":[0.048888233,0.0019870051,0.93838876,0.00047333725,0.0013814787,0.0000013353407,0.0013704589,0.0017948403,0.005581689,0.0000016291181,0.000010194003,0.00012104666],"about_ca_topic_score_codex":0.001973308,"about_ca_topic_score_gemma":0.01466972,"teacher_disagreement_score":0.049285572,"about_ca_system_score_codex":0.00046558422,"about_ca_system_score_gemma":0.0009583559,"threshold_uncertainty_score":0.81860477},"labels":[],"label_agreement":null},{"id":"W2613700593","doi":"10.1016/j.lungcan.2017.05.004","title":"Trends, practice patterns and underuse of surgery in the treatment of early stage small cell lung cancer","year":2017,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Contraindication; Stage (stratigraphy); Lung cancer; Cancer; Logistic regression; Pneumonectomy; Medicaid; Surgical oncology; Surgery; General surgery; Internal medicine; Health care; Pathology","score_opus":0.07380272844780107,"score_gpt":0.41596516259941896,"score_spread":0.3421624341516179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2613700593","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97068995,0.021995535,0.0000063789325,0.0042130803,0.00018353302,0.0005106532,0.00018829205,0.0000088146835,0.0022037586],"genre_scores_gemma":[0.95326483,0.0432652,0.0000299421,0.00014003422,0.00015247532,0.00029006228,0.0000041711432,0.000022207094,0.0028310583],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986566,0.000100041085,0.00028497743,0.00027030316,0.00037356597,0.00031454442],"domain_scores_gemma":[0.9983077,0.0005140793,0.0003403065,0.00063137285,0.0001337243,0.0000727934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030721087,0.00017313226,0.0004799285,0.00014084202,0.000109939465,0.000033637476,0.00015470531,0.000056020905,0.00011318856],"category_scores_gemma":[0.0000979033,0.00011102534,0.000099609955,0.000114429124,0.00016766813,0.00014904953,0.00005647919,0.00013996015,2.9398493e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004992398,0.00030902008,0.97941947,0.0009328022,0.00036634845,0.00007246294,0.006730468,0.000008883682,0.00025638036,0.000017553126,0.0013534933,0.010033873],"study_design_scores_gemma":[0.0020913926,0.00027469662,0.98616314,0.0005621169,0.00047389412,0.0000023862522,0.0008474548,0.00010852984,0.002586817,0.0000023570226,0.006764764,0.00012242633],"about_ca_topic_score_codex":0.0899809,"about_ca_topic_score_gemma":0.017450009,"teacher_disagreement_score":0.07253089,"about_ca_system_score_codex":0.0004086155,"about_ca_system_score_gemma":0.0003481058,"threshold_uncertainty_score":0.9737514},"labels":[],"label_agreement":null},{"id":"W2655216406","doi":"10.1016/j.lungcan.2017.06.014","title":"Prognostic and predictive effects of TP53 co-mutation in patients with EGFR -mutated non-small cell lung cancer (NSCLC)","year":2017,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":246,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal; Institut universitaire de cardiologie et de pneumologie de Québec; Princess Margaret Cancer Centre; Queen's University; University Health Network","funders":"","keywords":"Medicine; Lung cancer; T790M; Internal medicine; Missense mutation; Oncology; Epidermal growth factor receptor; Sanger sequencing; Mutation; Cancer; Gefitinib; Gene; Biology","score_opus":0.004125159358973921,"score_gpt":0.2923107701616074,"score_spread":0.2881856108026335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2655216406","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931352,0.0019422019,0.00018373542,0.00014881328,0.00024969046,0.0027071515,0.00014072953,0.000022664364,0.0014698029],"genre_scores_gemma":[0.9981935,0.00018387884,0.00015546253,0.00008295144,0.00006481873,0.0008190715,0.000104466926,0.000038358256,0.00035751663],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99891675,0.000024424246,0.00021797663,0.0003396672,0.00023969881,0.00026147356],"domain_scores_gemma":[0.99902594,0.00007221336,0.0002808459,0.00027739414,0.0002249838,0.00011863216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000043601154,0.00020583466,0.0003413852,0.00010771769,0.0001435348,0.00003216537,0.000078475015,0.00008225939,0.000028766377],"category_scores_gemma":[0.00003866337,0.00015797002,0.000034572593,0.00010605933,0.00010841814,0.00018636641,0.00002659791,0.00013776522,9.2610605e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00058079796,0.00028256152,0.991522,0.0012815914,0.00038565454,0.000035111127,0.0024164286,0.00021264104,0.00024738736,0.0000040299583,0.00027713203,0.0027546221],"study_design_scores_gemma":[0.010959287,0.0006027328,0.97880137,0.0021232218,0.0015360874,0.0000010692262,0.00005454873,0.002428324,0.0033022426,0.0000057472166,0.000025283698,0.00016011104],"about_ca_topic_score_codex":0.0021608907,"about_ca_topic_score_gemma":0.0005446101,"teacher_disagreement_score":0.012720698,"about_ca_system_score_codex":0.00042755075,"about_ca_system_score_gemma":0.00042246588,"threshold_uncertainty_score":0.64418304},"labels":[],"label_agreement":null},{"id":"W2735375447","doi":"10.1016/j.lungcan.2017.07.012","title":"Lack of response to nivolumab in a patient with EGFR -mutant non-small cell lung cancer adenocarcinoma sub-type transformed to small cell lung cancer","year":2017,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Niilo Helanderin Säätiö; Institute of Cancer Research","keywords":"Nivolumab; Medicine; Lung cancer; Adenocarcinoma; Oncology; Cancer research; Mutant; Cell; Internal medicine; Cancer; Immunotherapy; Gene; Biology","score_opus":0.017948375462460104,"score_gpt":0.3245573099012019,"score_spread":0.3066089344387418,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2735375447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97982424,0.008527286,0.00016788697,0.0036219163,0.000852942,0.004343375,0.00044883805,0.000050325598,0.0021631862],"genre_scores_gemma":[0.99040556,0.0009063665,0.0005977517,0.001318835,0.00021861916,0.0022080475,0.000024736259,0.00014382567,0.0041762665],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996834,0.00008069353,0.00068092055,0.00092226715,0.00054056104,0.000941571],"domain_scores_gemma":[0.99740255,0.00008458775,0.0003659935,0.0010590496,0.00049042644,0.00059739145],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000205515,0.00055996433,0.00090079836,0.00036263897,0.00028141902,0.00007583466,0.00040715197,0.00020012674,0.00036464827],"category_scores_gemma":[0.000034563578,0.00046273007,0.00016415959,0.00054578006,0.00009437976,0.00017573549,0.00009932717,0.00035959884,0.0000097511975],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018608345,0.0007567865,0.8635374,0.0023751373,0.0007886019,0.0005783956,0.030676756,0.004773674,0.06664368,0.000008012214,0.0065742745,0.004678956],"study_design_scores_gemma":[0.021165976,0.0030774872,0.76407075,0.006347331,0.0037231029,0.000027268283,0.0013530527,0.0032382598,0.18877774,0.000004568934,0.006744184,0.0014702999],"about_ca_topic_score_codex":0.03686217,"about_ca_topic_score_gemma":0.05584424,"teacher_disagreement_score":0.12213406,"about_ca_system_score_codex":0.0030108837,"about_ca_system_score_gemma":0.0032697725,"threshold_uncertainty_score":0.99978244},"labels":[],"label_agreement":null},{"id":"W2738954122","doi":"10.1016/j.lungcan.2017.07.017","title":"Tobacco use and motivation to stop smoking among long-term smokers who are ineligible for lung cancer screening","year":2017,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Alexandra Hospital; Alberta Health Services; University of Alberta; University of Saskatchewan; Foothills Medical Centre; BC Cancer Agency; Brock University; University of Calgary","funders":"Alberta Cancer Foundation; Arnie Charbonneau Cancer Institute, University of Calgary","keywords":"Medicine; Lung cancer; Term (time); Tobacco use; Environmental health; Cancer; Oncology; Internal medicine","score_opus":0.04444944837980226,"score_gpt":0.36314412029608634,"score_spread":0.3186946719162841,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2738954122","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889144,0.0040053916,0.0009508728,0.0035898262,0.00057120447,0.001688543,0.00011559348,0.0000618783,0.0001023454],"genre_scores_gemma":[0.9934149,0.0016373709,0.00037920696,0.0011131787,0.0006611566,0.0015060956,0.000030046804,0.000066683424,0.0011913937],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99846804,0.000014299525,0.00025776305,0.00057104777,0.0002480713,0.0004407495],"domain_scores_gemma":[0.9985638,0.00009818173,0.00028185913,0.0005650396,0.0002338352,0.00025726075],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000119847085,0.00027825826,0.0004637545,0.00012299897,0.0005053925,0.00031426668,0.00013857381,0.00011964007,0.00007724064],"category_scores_gemma":[0.00014140578,0.00024296992,0.00010785163,0.000097017306,0.00006982803,0.0005589479,0.00010926501,0.00014137472,3.7829602e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021878247,0.000041470565,0.97875404,0.0004012611,0.00049895974,0.000018978331,0.00046061652,0.00034585295,0.00009728525,0.000029479512,0.0076718763,0.011461367],"study_design_scores_gemma":[0.0030082213,0.00007449711,0.98791456,0.0048964648,0.0007228805,0.0000018945029,0.00004438546,0.0011471267,0.0014190308,0.0000032880318,0.0004975819,0.0002700881],"about_ca_topic_score_codex":0.007364921,"about_ca_topic_score_gemma":0.003705886,"teacher_disagreement_score":0.011191279,"about_ca_system_score_codex":0.00070805935,"about_ca_system_score_gemma":0.00011199775,"threshold_uncertainty_score":0.9992451},"labels":[],"label_agreement":null},{"id":"W2740458257","doi":"10.1016/j.lungcan.2017.07.033","title":"Prospective analysis of patient reported symptoms and quality of life in patients with incurable lung cancer treated in a rapid access clinic","year":2017,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Quality of life (healthcare); Palliative care; Radiation therapy; Lung cancer; Physical therapy; Performance status; Cancer; Internal medicine","score_opus":0.029245556888266605,"score_gpt":0.38288724949363295,"score_spread":0.3536416926053664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2740458257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99677277,0.00091760687,0.0000055621986,0.000112329035,0.000048189533,0.0014110446,0.00009313648,0.00000922131,0.00063013396],"genre_scores_gemma":[0.99925274,0.00016950133,0.00002902046,0.00009765035,0.0000065234644,0.0002632873,0.000035843965,0.0000150309415,0.00013040639],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979708,0.000099739016,0.0008707747,0.0003990894,0.00046168084,0.0001978911],"domain_scores_gemma":[0.99766546,0.000055663437,0.0012600746,0.0006348498,0.00027228528,0.00011166179],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038033305,0.00016254892,0.0009373392,0.00038838128,0.000035489425,0.000020036407,0.0001269678,0.00004826503,0.000384885],"category_scores_gemma":[0.00037787072,0.00012750614,0.000079174606,0.0006235,0.0001251201,0.00021457461,0.00009751746,0.000113725124,7.472659e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029656885,0.00061611424,0.9903908,0.0007563497,0.0028596274,0.000007991122,0.0006148867,0.00014420769,0.000007114968,0.000008800944,0.00006794105,0.0015605014],"study_design_scores_gemma":[0.007519923,0.00015242396,0.9865726,0.00055886665,0.002701527,1.9214804e-8,0.00007684696,0.00222132,0.00006007896,0.000004350345,0.0000042831443,0.00012775078],"about_ca_topic_score_codex":0.024693796,"about_ca_topic_score_gemma":0.0073058354,"teacher_disagreement_score":0.01738796,"about_ca_system_score_codex":0.00023110094,"about_ca_system_score_gemma":0.00019622208,"threshold_uncertainty_score":0.98180085},"labels":[],"label_agreement":null},{"id":"W2744441485","doi":"10.1016/j.lungcan.2017.07.038","title":"Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer","year":2017,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Eli Lilly and Company","keywords":"Medicine; Ramucirumab; Internal medicine; Docetaxel; Refractory (planetary science); Population; Placebo; Lung cancer; Clinical endpoint; Surgery; Randomized controlled trial; Oncology; Cancer; Pathology","score_opus":0.02050992220569165,"score_gpt":0.37174037695729134,"score_spread":0.3512304547515997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2744441485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9815339,0.0018012426,0.00014581128,0.000150627,0.00021483653,0.012464286,0.0035779814,0.00001978319,0.000091521586],"genre_scores_gemma":[0.9821231,0.00032765325,0.00041957016,0.000074120166,0.00008260897,0.0062112384,0.00022218384,0.00007717976,0.010462393],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99793255,0.00007287477,0.00067778834,0.00058050593,0.0003896697,0.00034662636],"domain_scores_gemma":[0.9966918,0.000327425,0.0015253999,0.00084974593,0.0003713855,0.00023422622],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009708165,0.00044729255,0.0017417499,0.00014999985,0.00016295549,0.000028450113,0.00017179232,0.00007210808,0.0006119526],"category_scores_gemma":[0.000079242396,0.00022718041,0.00015809028,0.00010865149,0.00014076947,0.00018931254,0.000034599343,0.000099999044,2.9985682e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.49213836,0.0086084595,0.4871347,0.0005513274,0.0042592767,0.00011889787,0.005361603,0.00015907765,0.000024690733,9.1188133e-7,0.00013640027,0.001506305],"study_design_scores_gemma":[0.83621013,0.0050864466,0.14656511,0.0015054699,0.0081120385,2.742602e-7,0.0007168817,0.00086565776,0.00050427846,0.0000017693541,0.00012343233,0.00030854432],"about_ca_topic_score_codex":0.0107741095,"about_ca_topic_score_gemma":0.023496168,"teacher_disagreement_score":0.34407175,"about_ca_system_score_codex":0.0007995626,"about_ca_system_score_gemma":0.0015888587,"threshold_uncertainty_score":0.99581325},"labels":[],"label_agreement":null},{"id":"W2747540574","doi":"10.1016/j.lungcan.2017.08.007","title":"Phenotypes of lung cancer and statistical interactions between tobacco smoking and occupational exposure to asbestos and crystalline silica from a large case-only study: The CaProMat study","year":2017,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Cancer Research Society","funders":"Agence Nationale de Sécurité Sanitaire de l’Alimentation, de l’Environnement et du Travail","keywords":"Asbestos; Medicine; Lung cancer; Logistic regression; Occupational exposure; Tobacco smoke; Cancer; Environmental health; Pathology; Internal medicine; Oncology","score_opus":0.024921894114561433,"score_gpt":0.37046707656793265,"score_spread":0.34554518245337124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2747540574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99494773,0.0013994693,0.00007788822,0.0004986074,0.000079296195,0.0009503019,0.0020019985,0.000011168317,0.000033563283],"genre_scores_gemma":[0.99912065,0.000047300116,0.000108564906,0.00013043343,0.0002614014,0.00016845683,0.00004641315,0.00001547458,0.000101315716],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99904823,0.00003772838,0.00021779661,0.0003019779,0.00025494312,0.00013933505],"domain_scores_gemma":[0.99928933,0.00018373069,0.00010597452,0.00023543369,0.00004137547,0.0001441408],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009539946,0.00014312542,0.00025239625,0.00003384627,0.00038674596,0.00005587417,0.000060608992,0.000028968516,0.00022202005],"category_scores_gemma":[0.00006109015,0.00010254381,0.000019123172,0.00003211243,0.00010021334,0.00012458516,0.0001558678,0.0001156221,3.6332057e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033150724,0.00031599865,0.9928334,0.000043936303,0.00042525257,0.000052286112,0.0016985048,0.000011483996,0.000118495205,0.000021872358,0.00030282536,0.0038444607],"study_design_scores_gemma":[0.0014758902,0.00027457855,0.99520975,0.00010330418,0.0010806145,0.000014176941,0.0012345328,0.00029219853,0.000009738992,0.00001553407,0.000180446,0.000109242435],"about_ca_topic_score_codex":0.008976297,"about_ca_topic_score_gemma":0.009421073,"teacher_disagreement_score":0.0041729333,"about_ca_system_score_codex":0.00007565371,"about_ca_system_score_gemma":0.00006916679,"threshold_uncertainty_score":0.997623},"labels":[],"label_agreement":null},{"id":"W2748332094","doi":"10.1016/j.lungcan.2017.08.012","title":"Adherence to surveillance guidelines in resected NSCLC: Physician compliance and impact on outcomes","year":2017,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"BC Cancer Foundation","keywords":"Medicine; Guideline; Stage (stratigraphy); Retrospective cohort study; Cancer; Lung cancer; Internal medicine; Surgery","score_opus":0.09635859508647926,"score_gpt":0.3858657086977959,"score_spread":0.28950711361131665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2748332094","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9631644,0.0034807785,0.00018230703,0.004214503,0.0009155777,0.00042478903,0.0005143928,0.000034075325,0.027069196],"genre_scores_gemma":[0.9944921,0.00062993116,0.00017821041,0.0023235946,0.00026621745,0.000086774104,0.000003167871,0.000033423254,0.0019865637],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99830997,0.0000098461205,0.0005827521,0.0005760372,0.000044560216,0.00047680532],"domain_scores_gemma":[0.9985242,0.000056151246,0.00045116176,0.0007343568,0.00007532033,0.00015880127],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003479674,0.00026270357,0.00069726625,0.0001539821,0.00021089401,0.00021779691,0.00048804012,0.00009600297,0.00014633543],"category_scores_gemma":[0.0004112797,0.00025877476,0.000100031706,0.00011180514,0.00008947881,0.0004025525,0.00011196047,0.00018133603,0.00014694601],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011210817,0.000023909128,0.96413,0.000025019925,0.000038916227,0.0000036363906,0.00012717675,0.00043018968,0.000023239723,0.0051231645,0.0060859467,0.023876702],"study_design_scores_gemma":[0.00065919146,0.000112592636,0.9870584,0.00017869424,0.0000019800466,3.673971e-7,0.000007112315,0.001945383,0.000035306624,0.0023831832,0.0072632427,0.00035452197],"about_ca_topic_score_codex":0.0124971,"about_ca_topic_score_gemma":0.0047079823,"teacher_disagreement_score":0.031327736,"about_ca_system_score_codex":0.00033035554,"about_ca_system_score_gemma":0.00005868451,"threshold_uncertainty_score":0.99998647},"labels":[],"label_agreement":null},{"id":"W2752034854","doi":"10.1016/j.lungcan.2017.09.002","title":"Nanoparticle targeted folate receptor 1-enhanced photodynamic therapy for lung cancer","year":2017,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Photodynamic Therapy Research Studies","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network; Toronto General Hospital","funders":"","keywords":"Medicine; Lung cancer; Folate receptor; In vivo; Lymph node; Cancer; Cancer research; Photodynamic therapy; Pathology; Lung; Cancer cell; Internal medicine; Biology; Chemistry","score_opus":0.017785663424110452,"score_gpt":0.37541122422792067,"score_spread":0.3576255608038102,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2752034854","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9733622,0.018296925,0.00019472587,0.0033381348,0.0012034754,0.0027269647,0.00026393757,0.00015338973,0.00046025933],"genre_scores_gemma":[0.9746613,0.012702044,0.00025806294,0.0007177779,0.00051273487,0.0036067346,0.000024701574,0.000096438875,0.007420198],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997727,0.000041976604,0.00031638757,0.0005802005,0.00040427034,0.0009301646],"domain_scores_gemma":[0.99822015,0.000089091176,0.0002419412,0.0008697727,0.0003304249,0.00024863816],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00030173536,0.00032145414,0.0005691263,0.000083584375,0.000784318,0.00010273515,0.00041015077,0.00012340832,0.0011314817],"category_scores_gemma":[0.00016115872,0.00026047826,0.00022070999,0.00012412215,0.0002282621,0.00025085587,0.00009996294,0.0002644521,0.000007715362],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025816995,0.00010940911,0.006548649,0.00022170469,0.0009558286,0.0000051134753,0.0007237142,0.000029498962,0.9643239,0.000030435798,0.009124987,0.015345073],"study_design_scores_gemma":[0.012755566,0.0006184904,0.037853424,0.0007135629,0.00024107305,0.000002551538,0.00009374354,0.038149823,0.89419174,0.000118129516,0.014612452,0.00064945355],"about_ca_topic_score_codex":0.0014788798,"about_ca_topic_score_gemma":0.0008799274,"teacher_disagreement_score":0.07013216,"about_ca_system_score_codex":0.00073797005,"about_ca_system_score_gemma":0.0004404387,"threshold_uncertainty_score":0.99998474},"labels":[],"label_agreement":null},{"id":"W2754952150","doi":"10.1016/j.lungcan.2017.08.022","title":"An international epidemiological analysis of young patients with non-small cell lung cancer (AduJov-CLICaP)","year":2017,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame","funders":"","keywords":"Medicine; Epidemiology; Internal medicine; Adenocarcinoma; Population; Lung cancer; Metastasis; Stage (stratigraphy); Oncology; Bone metastasis; Cancer; Environmental health","score_opus":0.015829704587617663,"score_gpt":0.37095163349537746,"score_spread":0.3551219289077598,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2754952150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878033,0.0005115575,0.0006179765,0.00060896616,0.00051738846,0.000564909,0.0004095717,0.00002851325,0.00893782],"genre_scores_gemma":[0.99612904,0.0003751565,0.0009344915,0.0003664004,0.00021820607,0.0002948091,0.00029354575,0.000024564319,0.0013637724],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99862623,0.000029691235,0.00032671302,0.0004416055,0.00030276534,0.00027297426],"domain_scores_gemma":[0.998308,0.000041228253,0.00042490105,0.0006713176,0.00037555574,0.00017902152],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001051428,0.00020846746,0.00055347866,0.00016435918,0.00019360679,0.000040751165,0.00029842526,0.00009973555,0.00090793404],"category_scores_gemma":[0.000036213474,0.00013963901,0.0001789005,0.00017307802,0.00011145341,0.00022091264,0.00004949491,0.00014337801,0.0000019024903],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019525859,0.0003396378,0.9916198,0.00006059812,0.003546284,0.000008040922,0.00047841287,0.0011034341,0.000155694,0.0000454254,0.00073145167,0.0017159303],"study_design_scores_gemma":[0.0025321608,0.00014904763,0.9771278,0.00014090988,0.0070855985,3.4014005e-7,0.000035438537,0.012000327,0.0002495494,0.0000039867377,0.0005248248,0.00015002604],"about_ca_topic_score_codex":0.006185226,"about_ca_topic_score_gemma":0.0020870417,"teacher_disagreement_score":0.014492042,"about_ca_system_score_codex":0.0004167064,"about_ca_system_score_gemma":0.00022351359,"threshold_uncertainty_score":0.9941241},"labels":[],"label_agreement":null},{"id":"W2765592067","doi":"10.1016/j.lungcan.2017.10.011","title":"GCC2-ALK as a targetable fusion in lung adenocarcinoma and its enduring clinical responses to ALK inhibitors","year":2017,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario","funders":"","keywords":"Medicine; Crizotinib; Adenocarcinoma; Internal medicine; Lung; Oncology; Lung cancer; Cancer","score_opus":0.030852924415628154,"score_gpt":0.42492225879756107,"score_spread":0.3940693343819329,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765592067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97545576,0.011567009,0.000005592535,0.004203369,0.00078951486,0.000802334,0.000024342395,0.000036599726,0.0071154563],"genre_scores_gemma":[0.988536,0.00080512324,0.00020644147,0.0007213849,0.0004971443,0.0002054782,0.0000072771672,0.00003052167,0.0089906175],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986262,0.000048878348,0.00033108026,0.00044261728,0.00021918913,0.00033203867],"domain_scores_gemma":[0.9990614,0.00007891972,0.00011952769,0.00039128956,0.00007647182,0.00027239916],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002465971,0.00016888094,0.00033360475,0.00013784604,0.00029800925,0.0000706608,0.000108405686,0.00011191363,0.00019345926],"category_scores_gemma":[0.0003152804,0.00014340604,0.000067869354,0.00009855599,0.000046553265,0.00021880808,0.00013898437,0.00020200337,0.000020312003],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000710664,0.00010855782,0.98585,0.0001446143,0.00013441042,0.000201253,0.001269585,0.000014197451,0.0015309822,0.00012437675,0.003561413,0.006349973],"study_design_scores_gemma":[0.0034018215,0.00022097093,0.977771,0.00077704166,0.0003081444,0.000023341487,0.00012732203,0.00056387164,0.0025882781,0.000027540893,0.013996624,0.00019407186],"about_ca_topic_score_codex":0.0021584055,"about_ca_topic_score_gemma":0.00070244644,"teacher_disagreement_score":0.013080229,"about_ca_system_score_codex":0.00031963977,"about_ca_system_score_gemma":0.0003777091,"threshold_uncertainty_score":0.58479285},"labels":[],"label_agreement":null},{"id":"W2789558317","doi":"10.1016/j.lungcan.2018.03.005","title":"Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy","year":2018,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Viral gastroenteritis research and epidemiology","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Abbotsford Veterinary Clinic; University of the Fraser Valley; Lakeridge Health; Juravinski Cancer Centre; Cancer Care Ontario; BC Cancer Agency; Hôpital Notre-Dame; Queen's University; Ottawa Hospital; Princess Margaret Cancer Centre; Hamilton Health Sciences; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Pemetrexed; Hazard ratio; Docetaxel; Chemotherapy; Oncology; Lung cancer; Progression-free survival; Taxane; KRAS; Randomized controlled trial; Cancer; Confidence interval; Gastroenterology; Breast cancer; Colorectal cancer","score_opus":0.02215609923453452,"score_gpt":0.35197683959996273,"score_spread":0.3298207403654282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789558317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98263466,0.0052387877,0.00026355532,0.0006398537,0.00054408365,0.009860219,0.0006007128,0.000033703494,0.00018442438],"genre_scores_gemma":[0.98314315,0.009882783,0.0011658651,0.00066753937,0.00041886058,0.0038688914,0.00012688548,0.000101717174,0.0006243215],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.994239,0.0016412891,0.0015365286,0.00073203543,0.0005806313,0.0012705196],"domain_scores_gemma":[0.997139,0.00038374588,0.0007952887,0.0004903978,0.0005923186,0.0005992852],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0028226268,0.00049837615,0.0033430858,0.00051812374,0.00011716644,0.00003282542,0.0002654687,0.00017114625,0.0020354437],"category_scores_gemma":[0.0011748796,0.00031701944,0.00033659954,0.0007110509,0.00032530498,0.00019395292,0.000043505697,0.00046308973,0.0000015375163],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.77311933,0.00020110757,0.20714124,0.00034540784,0.0010082781,0.000043823733,0.00084671227,0.00007409478,0.00057015737,0.0000011561183,0.0015926589,0.015056032],"study_design_scores_gemma":[0.9627976,0.005823416,0.024337407,0.0026623271,0.0008778646,0.0000021551482,0.00009379818,0.0012730968,0.0010525583,0.000008658864,0.00067618134,0.000394958],"about_ca_topic_score_codex":0.2788227,"about_ca_topic_score_gemma":0.630109,"teacher_disagreement_score":0.3512863,"about_ca_system_score_codex":0.0018791221,"about_ca_system_score_gemma":0.0025101886,"threshold_uncertainty_score":0.9999282},"labels":[],"label_agreement":null},{"id":"W2789688210","doi":"10.1016/j.lungcan.2018.03.009","title":"Malignant cells from pleural fluids in malignant mesothelioma patients reveal novel mutations","year":2018,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency","funders":"","keywords":"CDKN2A; Mesothelioma; BAP1; Medicine; Pleural effusion; Pathology; Exome sequencing; Mutation; Somatic cell; Cancer research; Malignant pleural effusion; Pleural disease; Cancer; Gene; Biology; Lung; Respiratory disease; Internal medicine; Genetics","score_opus":0.01181235053123601,"score_gpt":0.280764804200338,"score_spread":0.268952453669102,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789688210","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970628,0.000376929,0.000042405634,0.00031652013,0.00041413293,0.00031230593,0.00071666634,0.000025577849,0.0007326807],"genre_scores_gemma":[0.9960249,0.00003221336,0.00065353303,0.0010283085,0.0003649979,0.00007367218,0.00031742512,0.000023717013,0.001481208],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989695,0.000015419635,0.000233634,0.00027432368,0.00028449195,0.00022266404],"domain_scores_gemma":[0.99958795,0.00002712045,0.00005137286,0.0001696352,0.00003811066,0.00012577896],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000031538748,0.00013540796,0.00016882169,0.000072617884,0.000059891263,0.000010604847,0.00006848946,0.000052666608,0.0013305721],"category_scores_gemma":[0.000011237181,0.0001106842,0.000060658196,0.00014362077,0.00009873696,0.00008518195,0.00003952419,0.000062183,0.00012496689],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030898929,0.00042597388,0.90785843,0.000033203945,0.000058255842,0.000014273277,0.0003976501,0.000024148123,0.084791616,0.000034909073,0.0049808724,0.0010717013],"study_design_scores_gemma":[0.0018750611,0.00013215655,0.9768727,0.00024166486,0.00011203004,0.0000010783682,0.000050246646,0.0009341391,0.017878423,0.00005569032,0.0016978444,0.00014899686],"about_ca_topic_score_codex":0.0014086738,"about_ca_topic_score_gemma":0.00021816773,"teacher_disagreement_score":0.06901426,"about_ca_system_score_codex":0.00025174758,"about_ca_system_score_gemma":0.0000671559,"threshold_uncertainty_score":0.99958235},"labels":[],"label_agreement":null},{"id":"W2789788927","doi":"10.1016/j.lungcan.2018.03.010","title":"Associations of objectively assessed physical activity and sedentary time with health-related quality of life among lung cancer survivors: A quantile regression approach","year":2018,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer survivorship and care","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Athabasca University","funders":"National Medical Research Council; Alberta Innovates - Health Solutions; National Health and Medical Research Council; Canada Research Chairs; Athabasca University","keywords":"Medicine; Percentile; Lung cancer; Quality of life (healthcare); Physical therapy; Quantile regression; Internal medicine","score_opus":0.02950641604610083,"score_gpt":0.3615634614051252,"score_spread":0.33205704535902436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789788927","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953144,0.0016136827,0.00018769166,0.0004065081,0.00020494711,0.00067888544,0.00042937652,0.000053368454,0.0011111208],"genre_scores_gemma":[0.99898577,0.0000831379,0.00005398365,0.00010210372,0.00022849423,0.00010286956,0.00005191568,0.000035246416,0.00035650606],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99804294,0.00029609553,0.00038183352,0.0004237247,0.00056152605,0.00029386248],"domain_scores_gemma":[0.99816924,0.00017849465,0.0007333544,0.00030550075,0.00041969965,0.00019369673],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044299872,0.00022312022,0.0009415148,0.00009439887,0.00012644813,0.00001160743,0.000085879416,0.00013565448,0.0001265364],"category_scores_gemma":[0.00006667561,0.00017402667,0.000115629045,0.0005497208,0.00030145887,0.00018930007,0.00005296231,0.00028757914,3.6505446e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012228488,0.00055896916,0.9794558,0.0010519959,0.0007302075,9.551816e-7,0.008620483,0.000025590505,0.0059434148,0.00005010623,0.0009871679,0.0013524364],"study_design_scores_gemma":[0.001661094,0.00025371593,0.9839165,0.00077022787,0.00025940445,9.3920903e-7,0.00062121154,0.0089066895,0.003387591,0.000007488369,0.000013651885,0.00020145366],"about_ca_topic_score_codex":0.25030044,"about_ca_topic_score_gemma":0.06253114,"teacher_disagreement_score":0.1877693,"about_ca_system_score_codex":0.00043670184,"about_ca_system_score_gemma":0.00089353096,"threshold_uncertainty_score":0.95457524},"labels":[],"label_agreement":null},{"id":"W2793051369","doi":"10.1016/j.lungcan.2018.02.011","title":"Severe adverse events impact overall survival and costs in elderly patients with advanced non-small cell lung cancer on second-line therapy","year":2018,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Lung cancer; Adverse effect; Oncology; Internal medicine; Overall survival; Intensive care medicine; Lung","score_opus":0.007534355708445017,"score_gpt":0.3166972310667556,"score_spread":0.3091628753583106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793051369","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99234694,0.0017089354,0.0000241596,0.00017057007,0.0005119825,0.0016815605,0.00027165498,0.00003482497,0.0032493414],"genre_scores_gemma":[0.9956705,0.0007671514,0.0001594713,0.00067477254,0.00023429652,0.0003255563,0.000107409265,0.000066992514,0.0019938431],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99847215,0.00003586998,0.00024700921,0.00049797434,0.00029868112,0.00044829384],"domain_scores_gemma":[0.9990759,0.000043419495,0.00014856944,0.00030127622,0.00021569271,0.00021516747],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000056500518,0.00034446566,0.000401401,0.00012480027,0.00010376398,0.0000119919805,0.0000810538,0.000101505546,0.00096042006],"category_scores_gemma":[0.0000051432985,0.00024214172,0.00007136214,0.00021766365,0.000051022434,0.00018725515,0.00002290503,0.00020852327,0.000005499916],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028643422,0.00045634568,0.9767081,0.00011250969,0.00044746805,0.000016430462,0.001355855,0.00037991107,0.00024352873,0.0000046495825,0.0006480895,0.016762735],"study_design_scores_gemma":[0.024046347,0.002349382,0.969908,0.00081015925,0.00023964398,0.000001816187,0.00008958799,0.00075120793,0.0005736983,0.0000053560066,0.0008654909,0.00035929854],"about_ca_topic_score_codex":0.0022639032,"about_ca_topic_score_gemma":0.0061252583,"teacher_disagreement_score":0.021182004,"about_ca_system_score_codex":0.0012527658,"about_ca_system_score_gemma":0.00046294628,"threshold_uncertainty_score":0.99995285},"labels":[],"label_agreement":null},{"id":"W2794945244","doi":"10.1016/j.lungcan.2018.03.025","title":"Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting","year":2018,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Eli Lilly and Company","keywords":"Medicine; Oncology; Docetaxel; Internal medicine; Bevacizumab; Ramucirumab; Lung cancer; Nintedanib; Refractory (planetary science); Chemotherapy; Lung; Idiopathic pulmonary fibrosis","score_opus":0.018027658250240105,"score_gpt":0.3736487933526319,"score_spread":0.3556211351023918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794945244","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005497033,0.9825032,0.000038851504,0.00010584909,0.0007888542,0.0088733,0.0017420511,0.000037442325,0.00041345737],"genre_scores_gemma":[0.00071989145,0.9825436,0.0005388483,0.0007381599,0.0009886442,0.008498965,0.0007707047,0.0001954842,0.005005716],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975472,0.000093622875,0.0006339252,0.0007778582,0.00033246801,0.0006149172],"domain_scores_gemma":[0.99753314,0.00029911104,0.001075383,0.0006353323,0.00033683653,0.0001201919],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014987917,0.00066838285,0.0013631938,0.00020398473,0.00019881863,0.000045145694,0.00031339453,0.00027363258,0.0006444003],"category_scores_gemma":[0.000023757431,0.0003382952,0.0004202219,0.00051863043,0.00007297489,0.00012269345,0.0000343807,0.00039530065,0.0000043483774],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010556072,0.0007565594,0.0073289964,0.03196022,0.0032142873,0.000080667225,0.0028601633,0.000017235769,0.0000029235548,0.0000020016653,0.014290103,0.93843126],"study_design_scores_gemma":[0.008081618,0.0009968415,0.0010350966,0.03415545,0.0050245635,0.000008878369,0.00009311466,0.0000577164,0.00001541933,0.0000015610477,0.94994485,0.0005849144],"about_ca_topic_score_codex":0.00017178046,"about_ca_topic_score_gemma":0.0014296834,"teacher_disagreement_score":0.9378463,"about_ca_system_score_codex":0.0010873041,"about_ca_system_score_gemma":0.0025582968,"threshold_uncertainty_score":0.9999069},"labels":[],"label_agreement":null},{"id":"W2800404669","doi":"10.1016/j.lungcan.2018.04.018","title":"The eighth TNM classification for lung cancer—What is next?","year":2018,"lang":"en","type":"editorial","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Oncology; Internal medicine","score_opus":0.020716744633585277,"score_gpt":0.37177032357607254,"score_spread":0.35105357894248723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2800404669","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020409714,0.18123522,0.000052499807,0.013172117,0.80079573,0.0028610702,0.0008659859,0.00009999054,0.0007132703],"genre_scores_gemma":[0.0005209613,0.23273456,0.00008276127,0.00091438554,0.73990124,0.009609936,0.0006896846,0.0001668414,0.015379657],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99663645,0.000048523685,0.00056173373,0.0010266068,0.0010131776,0.00071352976],"domain_scores_gemma":[0.99633133,0.0008248193,0.0005310371,0.0011017801,0.0009766703,0.0002343726],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029624053,0.00058521115,0.000768575,0.0000894875,0.00055535545,0.0005008394,0.00038430654,0.0008099206,0.00059075665],"category_scores_gemma":[0.000110463814,0.0003799282,0.00042807125,0.00022589063,0.00018357625,0.00032436664,0.00006974151,0.0005323853,0.0000189611],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048691386,0.00009420606,0.001092936,0.0011529244,0.0015651681,0.000004022979,0.00038039513,0.000001574398,0.0000145683225,0.00008446829,0.97039926,0.024723561],"study_design_scores_gemma":[0.0025750017,0.00023996607,0.0004122793,0.0035058912,0.003352262,8.8507795e-7,0.00009320768,0.0014931286,0.00033248588,0.000039188104,0.9875472,0.0004084792],"about_ca_topic_score_codex":0.0015848551,"about_ca_topic_score_gemma":0.0017089238,"teacher_disagreement_score":0.060894523,"about_ca_system_score_codex":0.0046156454,"about_ca_system_score_gemma":0.0025017974,"threshold_uncertainty_score":0.9998653},"labels":[],"label_agreement":null},{"id":"W2801122736","doi":"10.1016/j.lungcan.2018.04.010","title":"Building the case for comprehensive hospital-based tobacco addiction services: Applying the Ottawa Model to the City of Manchester","year":2018,"lang":"en","type":"letter","venue":"Lung Cancer","topic":"Smoking Behavior and Cessation","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Pfizer","keywords":"Medicine; Abstinence; Smoking cessation; Scopus; Intervention (counseling); Intensive care; Family medicine; Addiction; MEDLINE; Psychiatry","score_opus":0.03987965582644165,"score_gpt":0.33592257070484494,"score_spread":0.2960429148784033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2801122736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6289954,0.0005753103,0.010911235,0.34917775,0.0022435482,0.0073767407,0.00052454363,0.000101485464,0.00009393967],"genre_scores_gemma":[0.61379695,0.000012892707,0.00045955082,0.37503573,0.0050743213,0.005159104,0.00016856432,0.0000850877,0.00020779276],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998539,0.00006352925,0.00032142687,0.00036913087,0.0004061701,0.00030076507],"domain_scores_gemma":[0.99813277,0.00026503557,0.0003201245,0.0007943222,0.0004537143,0.000034038316],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002586245,0.00027614355,0.00031762946,0.00006556796,0.00036479637,0.00005821001,0.0003119816,0.0003250943,0.000048669015],"category_scores_gemma":[0.000014045241,0.00013898427,0.00021164388,0.00019240429,0.000099045246,0.000056195593,0.000058238737,0.0006826402,9.557797e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013706902,0.000036673802,0.010017823,0.0008754489,0.0003524137,0.00005558599,0.0027752789,0.0022979183,0.00016831225,0.000018234263,0.9768455,0.006419728],"study_design_scores_gemma":[0.0018635646,0.00027383317,0.0160389,0.0024946602,0.0045088446,0.0000972739,0.00091229193,0.0607298,0.0014684128,0.00005313456,0.91094327,0.0006160109],"about_ca_topic_score_codex":0.0009857995,"about_ca_topic_score_gemma":0.00019868475,"teacher_disagreement_score":0.06590224,"about_ca_system_score_codex":0.0002849603,"about_ca_system_score_gemma":0.0001288941,"threshold_uncertainty_score":0.5667614},"labels":[],"label_agreement":null},{"id":"W2808151162","doi":"10.1016/j.lungcan.2018.06.011","title":"The role of endobronchial ultrasound-guided transbronchial needle aspiration in stereotactic body radiation therapy for non-small cell lung cancer","year":2018,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; Toronto General Hospital; University of Toronto","funders":"","keywords":"Medicine; Radiology; Lung cancer; Biopsy; Malignancy; Retrospective cohort study; Positron emission tomography; Lymph node; Nuclear medicine; Surgery; Oncology; Internal medicine","score_opus":0.010758052397543252,"score_gpt":0.302814488675023,"score_spread":0.29205643627747974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808151162","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97869426,0.014620557,0.000092269765,0.00086032046,0.0011009426,0.002900099,0.000080565966,0.000026310563,0.0016246573],"genre_scores_gemma":[0.9917564,0.003904131,0.000079704936,0.00034127373,0.0014786904,0.0020777972,0.000033096116,0.00004525783,0.0002836844],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985346,0.000050051232,0.00043652102,0.00034589402,0.00025068215,0.00038226083],"domain_scores_gemma":[0.9989894,0.00021689726,0.00022668867,0.00030184686,0.00017866971,0.00008650656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019949018,0.00022735003,0.00034017762,0.000079542995,0.00016515044,0.00003779074,0.00012099725,0.000110951136,0.00014590671],"category_scores_gemma":[0.000018691895,0.00016271442,0.00015763575,0.00019979436,0.00007569384,0.000118533,0.00000855905,0.00012663552,0.0000015760781],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017736069,0.00046196446,0.93894625,0.00032000925,0.0004785096,0.0000013954638,0.004198469,0.000103825994,0.027279843,0.00017220859,0.0041917413,0.022072174],"study_design_scores_gemma":[0.020154035,0.0019057845,0.6070346,0.0005384553,0.00087599683,0.0000057186608,0.00019019288,0.009100156,0.34226078,0.00013145097,0.017377714,0.0004250983],"about_ca_topic_score_codex":0.0047541857,"about_ca_topic_score_gemma":0.004428692,"teacher_disagreement_score":0.33191162,"about_ca_system_score_codex":0.0009056421,"about_ca_system_score_gemma":0.0005805555,"threshold_uncertainty_score":0.71869385},"labels":[],"label_agreement":null},{"id":"W2808971718","doi":"10.1016/j.lungcan.2018.06.023","title":"The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer","year":2018,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; KRAS; Lung cancer; Internal medicine; Oncology; Univariate analysis; Adenocarcinoma; Stage (stratigraphy); Somatic cell; Mutation; Cancer; Multivariate analysis; Gene; Genetics; Biology; Colorectal cancer","score_opus":0.008431921663189132,"score_gpt":0.3190394140510542,"score_spread":0.31060749238786506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808971718","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98017263,0.014885978,0.00002349784,0.00079679623,0.0005276052,0.0023731622,0.00006683143,0.00006092505,0.0010925514],"genre_scores_gemma":[0.99641645,0.00069575955,0.0001218346,0.00006464336,0.00014391827,0.0012882348,0.000025731331,0.000044146665,0.0011993117],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986199,0.00008828675,0.00038720854,0.00032094948,0.0002135975,0.00037004534],"domain_scores_gemma":[0.99869317,0.00053840125,0.00019191974,0.0002693438,0.00019365968,0.00011349093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014522362,0.0002195083,0.00035898224,0.00012379372,0.00023876883,0.00003081026,0.00009548523,0.00010102024,0.00012839661],"category_scores_gemma":[0.000110560555,0.00014623077,0.000064806234,0.00050014944,0.00018137475,0.00008106345,0.000037976206,0.00017047592,0.0000029983548],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024174564,0.00021539214,0.96772325,0.0011098975,0.00069574383,0.000014151392,0.005558541,0.00029615668,0.018537907,0.000009930826,0.0009610831,0.004636181],"study_design_scores_gemma":[0.018207485,0.0014949229,0.81849194,0.0043286155,0.0054121236,0.000014953446,0.0004524187,0.08669588,0.06344803,0.000050793653,0.00087348354,0.00052935723],"about_ca_topic_score_codex":0.0072044716,"about_ca_topic_score_gemma":0.011822085,"teacher_disagreement_score":0.14923133,"about_ca_system_score_codex":0.0006237705,"about_ca_system_score_gemma":0.00052057503,"threshold_uncertainty_score":0.99940664},"labels":[],"label_agreement":null},{"id":"W2810920486","doi":"10.1016/j.lungcan.2018.06.029","title":"Comparison of 7th and 8th editions of the UICC/AJCC TNM staging for non-small cell lung cancer in a non-metastatic North American cohort undergoing primary radiation treatment","year":2018,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Medicine; Cohort; Proportional hazards model; Oncology; Internal medicine; Hazard ratio; AJCC staging system; Lung cancer; Stage (stratigraphy); Cancer; Primary tumor; Metastasis; Staging system; Confidence interval","score_opus":0.012809949895531265,"score_gpt":0.3324448465430033,"score_spread":0.3196348966474721,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2810920486","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929646,0.002550528,0.0005654182,0.0006331655,0.00034101296,0.002265213,0.0003397066,0.000011314887,0.00032901764],"genre_scores_gemma":[0.994832,0.0025256993,0.0007511364,0.00020712594,0.0002300528,0.0012401841,0.00005421632,0.00003263651,0.00012698912],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99871,0.000034483888,0.00042318783,0.00033109344,0.00022049401,0.00028079006],"domain_scores_gemma":[0.99887437,0.0002121378,0.0004077794,0.00028504396,0.00013483934,0.00008580892],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000088037195,0.00021079891,0.0006214719,0.00011745896,0.00010292917,0.000011685537,0.000072134215,0.000035132725,0.00002775744],"category_scores_gemma":[0.000010964964,0.00015086608,0.00010820621,0.00036990907,0.00016571057,0.00006377361,0.000031906202,0.00010135921,2.41708e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014127843,0.00045918263,0.9835494,0.0010364746,0.00046694628,0.0000012414342,0.0026134087,0.00065935473,0.0004366141,0.0000056669583,0.0013362711,0.009294134],"study_design_scores_gemma":[0.0037925534,0.00068745046,0.9725374,0.0009392457,0.0015255007,6.824352e-7,0.00030896324,0.0107467575,0.009138597,0.000003466356,0.0001776129,0.00014178439],"about_ca_topic_score_codex":0.0074695637,"about_ca_topic_score_gemma":0.02188411,"teacher_disagreement_score":0.014414546,"about_ca_system_score_codex":0.0015986004,"about_ca_system_score_gemma":0.00065968506,"threshold_uncertainty_score":0.9991398},"labels":[],"label_agreement":null},{"id":"W2885572675","doi":"10.1016/j.lungcan.2018.08.005","title":"Multisite stereotactic body radiotherapy for metastatic non-small-cell lung cancer: Delaying the need to start or change systemic therapy?","year":2018,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; William Osler Health System; University of Calgary; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Systemic therapy; Multivariate analysis; Oncology; Internal medicine; Lung cancer; Radiation therapy; Radiosurgery; Univariate analysis; Cancer; Incidence (geometry)","score_opus":0.04174369330707757,"score_gpt":0.3573469884208799,"score_spread":0.31560329511380236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2885572675","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91463226,0.06166015,0.0018096074,0.007786946,0.0021492678,0.011459894,0.0002484953,0.0001188607,0.00013452601],"genre_scores_gemma":[0.9557582,0.011922526,0.0012439822,0.010668332,0.0023927414,0.015539958,0.000021470109,0.00016531003,0.0022874794],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99777913,0.000079038924,0.00043705327,0.00063683174,0.0003559682,0.00071199157],"domain_scores_gemma":[0.99822444,0.0002732206,0.00023319009,0.0006972543,0.00030356584,0.00026833836],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002774265,0.00044353356,0.0006913555,0.00014081525,0.00032802043,0.00009649612,0.0002521038,0.000084182255,0.00054655387],"category_scores_gemma":[0.000014352889,0.000259904,0.00021796006,0.00040822092,0.000059109414,0.00014191786,0.000040345712,0.00016430224,0.00001279341],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011693966,0.0013171268,0.74897546,0.006176881,0.011641119,0.00016432273,0.044583343,0.00018791537,0.01823912,0.00005585294,0.08625846,0.07070646],"study_design_scores_gemma":[0.13442501,0.018354816,0.1881162,0.02549924,0.02118137,0.0004484517,0.005794566,0.15280424,0.091307916,0.000023699047,0.3563851,0.0056593963],"about_ca_topic_score_codex":0.006965104,"about_ca_topic_score_gemma":0.003086257,"teacher_disagreement_score":0.56085926,"about_ca_system_score_codex":0.0017594482,"about_ca_system_score_gemma":0.0003456467,"threshold_uncertainty_score":0.99998534},"labels":[],"label_agreement":null},{"id":"W2885834865","doi":"10.1016/j.lungcan.2018.07.041","title":"Highlights of the 14th international mesothelioma interest group meeting: Pathologic separation of benign from malignant mesothelial proliferations and histologic/molecular analysis of malignant mesothelioma subtypes","year":2018,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"National Cancer Institute; Japan Society for the Promotion of Science; World Health Organization","keywords":"Mesothelioma; Medicine; Pathology; BAP1; CDKN2A; Biopsy; Immunohistochemistry; Mesothelial Cell; Cancer; Internal medicine","score_opus":0.013346659137844462,"score_gpt":0.2951272475276357,"score_spread":0.28178058838979125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2885834865","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955433,0.0015894476,0.0003061403,0.00089562073,0.00021253759,0.00030554656,0.00062065356,0.000012564118,0.00051419844],"genre_scores_gemma":[0.99859595,0.00020943941,0.00057640194,0.0001894449,0.00010301725,0.000039208215,0.00012617561,0.000012136527,0.00014824171],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9987021,0.000090313224,0.00045938967,0.00028564723,0.00034567446,0.000116884265],"domain_scores_gemma":[0.99909925,0.000059291822,0.00038352236,0.0002686417,0.0001358364,0.000053441403],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000116732,0.00015066627,0.00037890783,0.00020230899,0.000058358688,0.000007719405,0.00015851288,0.000081540165,0.00038595634],"category_scores_gemma":[0.00004920683,0.000095323456,0.00018970472,0.00033084652,0.00036305725,0.00006561507,0.00008490717,0.000048184753,0.000001224926],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006096626,0.0002962486,0.44647655,0.00006698139,0.0013851108,0.000009045222,0.00054305815,0.00012260904,0.54485124,0.0050914404,0.00025244794,0.00029561692],"study_design_scores_gemma":[0.00072661956,0.000284015,0.73362386,0.0002716413,0.0025019944,0.0000053818144,0.00008092545,0.002994514,0.25838682,0.00044512548,0.0005440424,0.00013508022],"about_ca_topic_score_codex":0.000478932,"about_ca_topic_score_gemma":0.0003647539,"teacher_disagreement_score":0.2871473,"about_ca_system_score_codex":0.000082159655,"about_ca_system_score_gemma":0.000055807188,"threshold_uncertainty_score":0.42259514},"labels":[],"label_agreement":null},{"id":"W2888952267","doi":"10.1016/j.lungcan.2018.08.024","title":"Economic analysis of osimertinib in previously untreated EGFR-mutant advanced non-small cell lung cancer in Canada","year":2018,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Alberta Cancer Foundation; University of Calgary; University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"Innovative Research Group Project of the National Natural Science Foundation of China","keywords":"Osimertinib; Medicine; Lung cancer; Afatinib; Cost effectiveness; Oncology; Quality-adjusted life year; Confidence interval; Internal medicine; Adenocarcinoma; Cancer; Epidermal growth factor receptor; Erlotinib","score_opus":0.005681807896931517,"score_gpt":0.30050355462623246,"score_spread":0.29482174672930095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888952267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99027383,0.004973591,0.000018680374,0.00036837533,0.0003915182,0.0009791986,0.000305411,0.00001534773,0.002674035],"genre_scores_gemma":[0.9970434,0.0010112727,0.00009758571,0.0003381971,0.00009225059,0.00041985777,0.000063817875,0.00003564181,0.0008979819],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99828273,0.000032125903,0.00058746163,0.0004671299,0.00016205433,0.0004685011],"domain_scores_gemma":[0.9990737,0.000052101735,0.0002418245,0.0003716207,0.0001102729,0.00015050864],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00007592326,0.00024545373,0.0007332078,0.0003817679,0.00004017174,0.00000866332,0.00012511604,0.00007246119,0.0013918781],"category_scores_gemma":[0.0000083267005,0.00021906575,0.00011112153,0.00096134207,0.000047161717,0.0000813552,0.000030024212,0.00013805469,0.0000025814136],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024637714,0.00008915685,0.9697231,0.00018535058,0.001436014,0.0000367191,0.0016768248,0.020856367,0.0017240831,0.0000059557274,0.00051633315,0.003503692],"study_design_scores_gemma":[0.0069147493,0.0001559653,0.8770173,0.000824737,0.006317189,0.0000015032942,0.0004535562,0.0912798,0.015633881,0.0000032493144,0.0009914933,0.00040657286],"about_ca_topic_score_codex":0.9534879,"about_ca_topic_score_gemma":0.99411106,"teacher_disagreement_score":0.092705816,"about_ca_system_score_codex":0.0064379876,"about_ca_system_score_gemma":0.005111837,"threshold_uncertainty_score":0.99952096},"labels":[],"label_agreement":null},{"id":"W2898895536","doi":"10.1016/j.lungcan.2018.10.020","title":"Ultrasonographic characteristics of lymph nodes as predictors of malignancy during endobronchial ultrasound (EBUS): A systematic review","year":2018,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McMaster University; Impact","funders":"","keywords":"Medicine; Endobronchial ultrasound; Malignancy; Radiology; Lymph; Ultrasound; Bronchoscopy; Pathology","score_opus":0.013493070367048821,"score_gpt":0.32200076768064045,"score_spread":0.3085076973135916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898895536","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0021553063,0.99054044,0.0000013552136,0.000015251623,0.0008822254,0.0049871523,0.00097079726,0.000052555184,0.00039492382],"genre_scores_gemma":[0.0026902412,0.9933,0.000036344103,0.00006226947,0.0006237211,0.0025598106,0.00024022863,0.00012669405,0.00036069026],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99573267,0.00020948735,0.0022542435,0.0006601927,0.0006917614,0.00045165082],"domain_scores_gemma":[0.9955327,0.00036999158,0.002430067,0.001123128,0.00032946552,0.0002146846],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031242167,0.0007593991,0.0064062867,0.00027080227,0.00006426907,0.000016986301,0.00033136172,0.00031782838,0.00037798192],"category_scores_gemma":[0.00032456833,0.00052853685,0.0014721731,0.00062212755,0.0002136398,0.00006885026,0.000056341923,0.00022674639,0.00001674772],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027286422,0.00025014294,0.009826714,0.9836515,0.0042647845,0.000027180822,0.00008854468,2.8549415e-8,0.0000034944012,0.000028490733,0.00032586086,0.001505928],"study_design_scores_gemma":[0.0007834656,0.0001490924,0.0019971211,0.94364697,0.046344314,0.00022265615,0.000006558788,2.5253726e-7,0.000060883078,0.0000019018341,0.006423963,0.00036281435],"about_ca_topic_score_codex":0.00025109854,"about_ca_topic_score_gemma":0.000011079007,"teacher_disagreement_score":0.042079527,"about_ca_system_score_codex":0.0008481663,"about_ca_system_score_gemma":0.0010373503,"threshold_uncertainty_score":0.99971664},"labels":[],"label_agreement":null},{"id":"W2899436946","doi":"10.1016/j.lungcan.2018.10.028","title":"Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo)","year":2018,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Boehringer Ingelheim","keywords":"Medicine; Afatinib; Tolerability; Adverse effect; Internal medicine; Incidence (geometry); Medical record; Observational study; Oncology; Surgery; Epidermal growth factor receptor; Cancer; Gefitinib","score_opus":0.008844275390835923,"score_gpt":0.37523411298275683,"score_spread":0.3663898375919209,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899436946","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99301815,0.00006236674,0.00006731748,0.000052571955,0.00008624323,0.0022928924,0.0012733646,0.000022696415,0.0031244105],"genre_scores_gemma":[0.9990681,0.000019652744,0.00018509467,0.000023906869,0.00005157669,0.00016808299,0.00042620327,0.000017461769,0.00003993775],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987802,0.00009995216,0.00029317534,0.00040637763,0.0002537702,0.00016652117],"domain_scores_gemma":[0.9989839,0.00015948691,0.00020340522,0.00026108653,0.00030709346,0.000084988824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009017377,0.00018134843,0.00032383858,0.00009352794,0.00006949076,0.000010259951,0.000040959454,0.0000390572,0.000018362742],"category_scores_gemma":[0.000039037,0.00012957239,0.0000364548,0.00043815226,0.000072651135,0.0001230575,0.000013848232,0.00007256298,0.0000015373715],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033036325,0.0011212722,0.9429465,0.000024146097,0.0006015926,0.000007096549,0.0033424282,0.00071347546,0.00004779363,0.000045519715,0.000018088915,0.01809575],"study_design_scores_gemma":[0.026152615,0.0034417987,0.96869457,0.00062280236,0.00037221302,2.586779e-7,0.00014026262,0.0002998455,0.00012788776,0.000027278162,0.000002974268,0.00011747547],"about_ca_topic_score_codex":0.024115253,"about_ca_topic_score_gemma":0.00612697,"teacher_disagreement_score":0.025748078,"about_ca_system_score_codex":0.0014418811,"about_ca_system_score_gemma":0.0002532165,"threshold_uncertainty_score":0.98238325},"labels":[],"label_agreement":null},{"id":"W2900911329","doi":"10.1016/j.lungcan.2018.11.016","title":"Outcome of EGFR-mutated adenocarcinoma NSCLC patients with changed phenotype to squamous cell carcinoma after tyrosine kinase inhibitors: A pooled analysis with an additional case","year":2018,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada)","funders":"Fondazione Internazionale di Ricerca in Medicina Onlus","keywords":"Medicine; Osimertinib; Gefitinib; Lung cancer; Oncology; Adenocarcinoma; Internal medicine; Cancer research; Histology; Cancer; Epidermal growth factor receptor","score_opus":0.016816815831995433,"score_gpt":0.3249436643751616,"score_spread":0.30812684854316613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900911329","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.064304836,0.90633327,0.00006835423,0.00005988972,0.00023746281,0.004493591,0.024190607,0.00008518895,0.00022683396],"genre_scores_gemma":[0.9449653,0.022401277,0.0018323147,0.0005226339,0.0011491509,0.0057672677,0.021709675,0.0003908672,0.0012615264],"study_design_codex":"observational","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99686587,0.00011815925,0.0008316664,0.0009841019,0.0006761432,0.00052405015],"domain_scores_gemma":[0.99701595,0.000081245824,0.0006141883,0.0008685826,0.0008857998,0.00053423503],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00007323344,0.00078929926,0.0021918425,0.00086707366,0.00012868627,0.0000405776,0.00015104402,0.00025081538,0.0034022068],"category_scores_gemma":[0.000019807556,0.0005126771,0.00043910422,0.0020562138,0.0001315679,0.00014633629,0.00005996418,0.00028566914,0.000028331826],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014544795,0.010050841,0.67755574,0.081611075,0.04257308,0.016745169,0.007025,0.0001250942,0.0000029099706,0.000015985323,0.023827387,0.1259229],"study_design_scores_gemma":[0.028871248,0.017469862,0.1591412,0.02842512,0.5743391,0.0005941806,0.00038869953,0.00018471417,0.00004601779,0.0000028568347,0.18589668,0.0046403417],"about_ca_topic_score_codex":0.0020698863,"about_ca_topic_score_gemma":0.0030939488,"teacher_disagreement_score":0.88393193,"about_ca_system_score_codex":0.0012233551,"about_ca_system_score_gemma":0.00095200905,"threshold_uncertainty_score":0.9997325},"labels":[],"label_agreement":null},{"id":"W2901525385","doi":"10.1016/j.lungcan.2018.11.024","title":"Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer","year":2018,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario","funders":"National Key Research and Development Program of China; National Natural Science Foundation of China","keywords":"Crizotinib; Medicine; Lung cancer; Anaplastic lymphoma kinase; Cancer research; Tyrosine kinase; ALK inhibitor; Internal medicine; Concomitant; Oncology; Cancer; Tyrosine-kinase inhibitor; Receptor","score_opus":0.008287191718323293,"score_gpt":0.3050793065326908,"score_spread":0.29679211481436746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901525385","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9397941,0.015146625,0.004356134,0.0071672993,0.0033049067,0.0050964216,0.0008346083,0.00017848122,0.02412141],"genre_scores_gemma":[0.9808839,0.00025812356,0.0031539567,0.0026833478,0.0007077355,0.0012288038,0.000044520937,0.00007879481,0.010960844],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980613,0.000037499118,0.0003963921,0.0006347316,0.00029568226,0.0005744044],"domain_scores_gemma":[0.99877447,0.000072135925,0.00013429817,0.00039007855,0.00031371682,0.00031530982],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000112221955,0.00032805873,0.00045383422,0.00019161416,0.00016845262,0.000036588146,0.00013092459,0.00013249443,0.00032052607],"category_scores_gemma":[0.000032038548,0.0002895059,0.00010066472,0.00057809177,0.00007762679,0.000115387535,0.000067017434,0.00020748441,0.000026990727],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004673711,0.0016571052,0.3911313,0.0017229728,0.0014536644,0.0008615384,0.032890797,0.0007326637,0.38293216,0.0013439141,0.17029203,0.010308122],"study_design_scores_gemma":[0.024834717,0.0011933696,0.16143984,0.008209374,0.0024782966,0.00001125349,0.0014548211,0.0062750573,0.74512243,0.0001817758,0.047026515,0.001772555],"about_ca_topic_score_codex":0.0062224325,"about_ca_topic_score_gemma":0.027810723,"teacher_disagreement_score":0.36219028,"about_ca_system_score_codex":0.0019160816,"about_ca_system_score_gemma":0.0006505924,"threshold_uncertainty_score":0.9999557},"labels":[],"label_agreement":null},{"id":"W2901988630","doi":"10.1016/j.lungcan.2018.11.032","title":"Molecular pathways and diagnosis in malignant mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group","year":2018,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Mesothelioma; Medicine; Peritoneal mesothelioma; Grading (engineering); Interest group; Oncology; Pathology; BAP1; Internal medicine","score_opus":0.051219217279755695,"score_gpt":0.33936100552375503,"score_spread":0.28814178824399933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901988630","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0026954005,0.99332595,0.0000028381726,0.0008885086,0.0006336642,0.00090812275,0.0006586446,0.0000051735847,0.00088168576],"genre_scores_gemma":[0.015510616,0.98316115,0.000028880651,0.00058769726,0.00012226657,0.00037834613,0.000063424304,0.00002616387,0.0001214694],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9983556,0.00010557308,0.0006163024,0.00030616682,0.0004939236,0.00012242426],"domain_scores_gemma":[0.9989057,0.00007162427,0.0005191665,0.00036731662,0.00008549492,0.00005066892],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017410242,0.00024229374,0.000705505,0.00010246979,0.000022039623,0.000010538045,0.000555819,0.00009294664,0.0007363423],"category_scores_gemma":[0.00012103527,0.00012752689,0.00039366516,0.00022745809,0.000266608,0.000047757214,0.0004040853,0.00016599316,0.0000029141313],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027324498,0.00172712,0.25404352,0.2770796,0.0037940748,0.00008207771,0.00038641877,0.0000021385667,0.00046700623,0.013715239,0.017905926,0.43052363],"study_design_scores_gemma":[0.0006941986,0.000072353214,0.024500938,0.49305552,0.0018319063,0.000058030913,0.000021426096,0.000055638044,0.000284052,0.00015575797,0.47898334,0.00028682468],"about_ca_topic_score_codex":0.00010856671,"about_ca_topic_score_gemma":0.00006610716,"teacher_disagreement_score":0.46107742,"about_ca_system_score_codex":0.00024136208,"about_ca_system_score_gemma":0.00021598097,"threshold_uncertainty_score":0.8062432},"labels":[],"label_agreement":null},{"id":"W2903232319","doi":"10.1016/j.lungcan.2018.11.034","title":"Progress of malignant mesothelioma research in basic science: A review of the 14th international conference of the international mesothelioma interest group (iMig2018)","year":2018,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Mesothelioma; Medicine; Interest group; Therapeutic modalities; Cancer research; Basic research; Basic science; Internal medicine; Pathology; Biology; Library science; Political science; Neuroscience; Computer science","score_opus":0.150914233341361,"score_gpt":0.46003951698894857,"score_spread":0.30912528364758757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2903232319","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0025270944,0.9903868,8.570467e-7,0.0013644708,0.0010258864,0.0015923757,0.00055881345,0.0000050415647,0.0025386931],"genre_scores_gemma":[0.02767229,0.9709993,0.00004688781,0.00012984869,0.00022170934,0.00028484067,0.00003820133,0.000026546235,0.00058035407],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9963636,0.00021483914,0.000930407,0.00043002292,0.0018119568,0.0002492123],"domain_scores_gemma":[0.9978552,0.00011359101,0.0007706486,0.00067514577,0.0005132317,0.00007221784],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012417433,0.00023680607,0.00082992855,0.0004038949,0.00005700379,0.000016397165,0.0017789163,0.0000981679,0.0012984651],"category_scores_gemma":[0.00022478559,0.00012148707,0.0004212452,0.0011959281,0.002310614,0.00010212959,0.00085476565,0.00032111825,0.000008268493],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006121501,0.0023718842,0.10027666,0.3474652,0.0016698025,0.000022693308,0.00053061236,0.0000013444683,0.0008581495,0.012943741,0.01876236,0.5144854],"study_design_scores_gemma":[0.00063027046,0.0001467561,0.02864597,0.6182951,0.0006864408,0.000043390886,0.0000471741,0.00009601481,0.0005442512,0.00016921997,0.35046586,0.0002295562],"about_ca_topic_score_codex":0.00013239295,"about_ca_topic_score_gemma":0.000043676617,"teacher_disagreement_score":0.5142559,"about_ca_system_score_codex":0.0006061014,"about_ca_system_score_gemma":0.001354878,"threshold_uncertainty_score":0.9996145},"labels":[],"label_agreement":null},{"id":"W2916205918","doi":"10.1016/j.lungcan.2019.02.024","title":"Palliative thoracic radiotherapy near the end of life in lung cancer: A population-based analysis","year":2019,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Positive Living North; University of Northern British Columbia; University of British Columbia","funders":"","keywords":"Medicine; Palliative care; Lung cancer; Quality of life (healthcare); Radiation therapy; Population; Performance status; Univariate analysis; Internal medicine; Cancer; Oncology; Surgery; Multivariate analysis; Nursing","score_opus":0.011899394943807547,"score_gpt":0.35208368562929454,"score_spread":0.340184290685487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2916205918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96335584,0.02996254,0.00007003858,0.00509824,0.0002182692,0.0010083125,0.00007991478,0.000020540654,0.00018627604],"genre_scores_gemma":[0.9956763,0.0017612668,0.00019744044,0.0014254499,0.00012226324,0.0004821505,0.000045288925,0.000026241556,0.0002636302],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998677,0.000076014214,0.00033681592,0.00032390188,0.00035031274,0.00023594058],"domain_scores_gemma":[0.9990222,0.00017231547,0.00021447113,0.00042096013,0.00008566964,0.00008438863],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00014638125,0.00018003337,0.00059135346,0.00014757586,0.00005964918,0.000025726957,0.000103132435,0.00007321285,0.0022691253],"category_scores_gemma":[0.000014095293,0.00011704791,0.00023704134,0.000961578,0.00005734548,0.000050788807,0.000011136357,0.00013930132,0.0000021996846],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030700897,0.00012220332,0.9631058,0.00029319536,0.002133595,0.0000028564396,0.00088661886,0.030530166,0.00004142112,0.00004557449,0.00045259527,0.0020789406],"study_design_scores_gemma":[0.0018660607,0.000065976834,0.90536624,0.00038225102,0.0014568096,8.669408e-8,0.000035955436,0.08977329,0.00024466237,0.000004499183,0.0006852298,0.000118907476],"about_ca_topic_score_codex":0.035845436,"about_ca_topic_score_gemma":0.010651859,"teacher_disagreement_score":0.059243128,"about_ca_system_score_codex":0.00128397,"about_ca_system_score_gemma":0.0006856492,"threshold_uncertainty_score":0.9986429},"labels":[],"label_agreement":null},{"id":"W2916233810","doi":"10.1016/j.lungcan.2019.02.015","title":"A study of ALK-positive pulmonary squamous-cell carcinoma: From diagnostic methodologies to clinical efficacy","year":2019,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Anaplastic lymphoma kinase; Medicine; Immunohistochemistry; Concordance; Lung cancer; Crizotinib; Fluorescence in situ hybridization; Internal medicine; Adenocarcinoma; Carcinoma; Oncology; Fish <Actinopterygii>; Pathology; Cancer; Biology; Gene","score_opus":0.04933984428612437,"score_gpt":0.4332631489433579,"score_spread":0.3839233046572335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2916233810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894491,0.0025983327,0.00009477926,0.00043330988,0.0008425413,0.0023629586,0.00012115251,0.000043081363,0.0040547554],"genre_scores_gemma":[0.9962238,0.000042875443,0.0013369302,0.0004579358,0.0002505509,0.00021530352,0.000040499042,0.00003062949,0.0014014811],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985033,0.00017799581,0.000401447,0.0004601325,0.00023755388,0.00021952609],"domain_scores_gemma":[0.99651134,0.0026450218,0.00012614578,0.00044166727,0.00013062551,0.00014521225],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015354344,0.00017704924,0.0005507686,0.000076014105,0.000039465423,0.000008811068,0.00011326002,0.000082769984,0.00027877517],"category_scores_gemma":[0.00031239618,0.00013735042,0.00012645105,0.00019987841,0.000035437337,0.000050188093,0.00008539675,0.00016895085,0.000049470473],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005925185,0.0016737077,0.98356146,0.00006281437,0.000343191,0.00013679407,0.0043091523,0.00024197072,0.0006405146,0.0000084695175,0.0015821654,0.006847253],"study_design_scores_gemma":[0.005532343,0.0018573082,0.98700815,0.00009878853,0.0016602605,0.0000026842954,0.002020673,0.00005280295,0.001243822,0.000019485175,0.00035534936,0.00014834429],"about_ca_topic_score_codex":0.004689018,"about_ca_topic_score_gemma":0.00016625956,"teacher_disagreement_score":0.006774706,"about_ca_system_score_codex":0.00019762742,"about_ca_system_score_gemma":0.0002274056,"threshold_uncertainty_score":0.70884234},"labels":[],"label_agreement":null},{"id":"W2917122354","doi":"10.1016/j.lungcan.2018.11.033","title":"Imaging in pleural mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group","year":2018,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"National Center for Research Resources; National Cancer Institute; Cancer Research UK; National Institutes of Health; University of Glasgow; Perelman School of Medicine, University of Pennsylvania; University of Pennsylvania","keywords":"Mesothelioma; Medicine; Magnetic resonance imaging; Interest group; Radiology; Medical physics; Pathology","score_opus":0.05369259205617618,"score_gpt":0.3733222517528264,"score_spread":0.31962965969665025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2917122354","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003508577,0.99254835,0.0000033951521,0.0014405992,0.0015019453,0.0008065295,0.0005738515,0.000007780251,0.0027667216],"genre_scores_gemma":[0.0073510823,0.9904105,0.000029086597,0.00076199527,0.00034502364,0.000150892,0.0001001577,0.00003049886,0.00082074286],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99813485,0.00010301563,0.00073544617,0.00029734592,0.0005840209,0.00014533676],"domain_scores_gemma":[0.99869937,0.0000635269,0.0006576855,0.00042397686,0.000110221816,0.000045193214],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00019311937,0.0002559071,0.0007165329,0.00012386052,0.000026895477,0.000011840771,0.0008626623,0.0000657609,0.0018069419],"category_scores_gemma":[0.00012501876,0.00013510542,0.0005642878,0.0002787851,0.0002954502,0.0000785901,0.00042190708,0.00022751275,0.000008397085],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034819255,0.0011637923,0.2640294,0.21739224,0.0022777815,0.000032948883,0.00032206782,0.0000022619363,0.00017970096,0.0041472423,0.057577856,0.4525265],"study_design_scores_gemma":[0.00053981156,0.000020844169,0.025361612,0.32452053,0.0010600343,0.0000577024,0.000019756872,0.00010920408,0.00003140295,0.000057306574,0.6480198,0.00020199528],"about_ca_topic_score_codex":0.00015185722,"about_ca_topic_score_gemma":0.000093902396,"teacher_disagreement_score":0.59044194,"about_ca_system_score_codex":0.00043629186,"about_ca_system_score_gemma":0.0003157224,"threshold_uncertainty_score":0.9991055},"labels":[],"label_agreement":null},{"id":"W2923788634","doi":"10.1016/j.lungcan.2019.03.019","title":"The presence and variant allele fraction of EGFR mutations in ctDNA and development of resistance","year":2019,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Princess Margaret Cancer Foundation","keywords":"T790M; Medicine; Osimertinib; KRAS; Lung cancer; Internal medicine; Oncology; Allele; Mutation; Gene; Cancer; Genetics; Biology","score_opus":0.008538635240453023,"score_gpt":0.3203514058084362,"score_spread":0.3118127705679832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2923788634","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99110943,0.0059157163,0.00024986657,0.00065855513,0.000060816903,0.0004258321,0.000008822214,0.0000044961816,0.0015664531],"genre_scores_gemma":[0.9965678,0.00050355226,0.0016102734,0.000024915871,0.0000093034705,0.00006371875,0.0000057150087,0.0000047857206,0.0012099767],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995714,0.000011117453,0.0001513326,0.000100511155,0.000095388736,0.00007025642],"domain_scores_gemma":[0.9996842,0.00007643008,0.00007264497,0.00009129967,0.000052664767,0.00002272528],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000680332,0.000045043103,0.00010713121,0.000029218289,0.000042587337,0.0000044996364,0.000019642272,0.000020824367,0.000027476615],"category_scores_gemma":[0.000016299711,0.000031021867,0.000007939467,0.000075766606,0.000040006802,0.000050028364,0.000011317191,0.000040484996,4.2012678e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070697116,0.00027402726,0.9001276,0.0014172111,0.000746882,0.000009850357,0.024759762,0.00023822917,0.012981814,0.0044840924,0.001603842,0.05264972],"study_design_scores_gemma":[0.001988069,0.00005028417,0.97651345,0.000440482,0.00012212092,0.0000033693943,0.0019284516,0.00060582056,0.0028837794,0.00022588135,0.015159465,0.00007880455],"about_ca_topic_score_codex":0.00031378402,"about_ca_topic_score_gemma":0.0011164113,"teacher_disagreement_score":0.07638588,"about_ca_system_score_codex":0.00008762631,"about_ca_system_score_gemma":0.00020328256,"threshold_uncertainty_score":0.1265035},"labels":[],"label_agreement":null},{"id":"W2925781938","doi":"10.1016/j.lungcan.2019.02.021","title":"Re-administration of osimertinib in osimertinib-acquired resistant non-small-cell lung cancer","year":2019,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"MSD K.K.; Chugai Pharmaceutical; Novartis Pharmaceuticals Canada; Kyowa Hakko Kirin; Eli Lilly Japan; Boehringer Ingelheim","keywords":"Osimertinib; Medicine; T790M; Lung cancer; Internal medicine; Oncology; Epidermal growth factor receptor; Cancer; Erlotinib; Gefitinib","score_opus":0.013287339905226491,"score_gpt":0.33521453676778146,"score_spread":0.32192719686255494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2925781938","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9714847,0.007641975,0.000052362026,0.001867445,0.0007124938,0.0018182148,0.00011190217,0.00004702782,0.01626387],"genre_scores_gemma":[0.9893658,0.00046735437,0.00032825588,0.0005398823,0.00015861972,0.0005399804,0.0000698486,0.00005242065,0.008477834],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982244,0.00003697637,0.00058509957,0.00045867258,0.00031421357,0.0003806433],"domain_scores_gemma":[0.9989253,0.000050337785,0.0002838991,0.00044913797,0.00015836643,0.000132946],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001273676,0.00024705034,0.0004908442,0.00015326474,0.000050359482,0.000018511764,0.000116111565,0.00013741002,0.0014833668],"category_scores_gemma":[0.000014954024,0.00021716724,0.00012635987,0.00041529784,0.00004607827,0.000122021855,0.00003072878,0.00013186017,0.000013485114],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032784333,0.0008472487,0.8418149,0.002636032,0.00078672596,0.000080248974,0.0057806135,0.0008834287,0.1309322,0.000119756354,0.009706986,0.0031334434],"study_design_scores_gemma":[0.026298799,0.0017870782,0.6551053,0.006323521,0.0041513606,0.000009092444,0.0026037656,0.019549126,0.2667192,0.000047467256,0.016025176,0.0013801593],"about_ca_topic_score_codex":0.0031824848,"about_ca_topic_score_gemma":0.002416157,"teacher_disagreement_score":0.18670963,"about_ca_system_score_codex":0.00061351777,"about_ca_system_score_gemma":0.0011533654,"threshold_uncertainty_score":0.9994294},"labels":[],"label_agreement":null},{"id":"W2932878974","doi":"10.1016/j.lungcan.2019.03.023","title":"The role of radiation treatment in pleural mesothelioma: Highlights of the 14th International Conference of the International mesothelioma interest group","year":2019,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Extrapleural Pneumonectomy; Mesothelioma; Radiation therapy; Interest group; Radiation treatment planning; Adjuvant; Medical physics; Pneumonectomy; Oncology; Surgery; Lung cancer; Pathology","score_opus":0.03697254372315475,"score_gpt":0.3332652654075072,"score_spread":0.2962927216843525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2932878974","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012583884,0.9801391,0.0000017790818,0.0008506307,0.0017707653,0.0013649093,0.0009427239,0.000006423586,0.0023398225],"genre_scores_gemma":[0.25290263,0.7452485,0.0000066347484,0.000031175598,0.00018307268,0.0001499662,0.00010732665,0.000021558428,0.0013491728],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984638,0.00009925406,0.00060481037,0.00021658726,0.0004960638,0.00011949409],"domain_scores_gemma":[0.9986664,0.00015571545,0.00070332555,0.00038454734,0.000059876147,0.000030155494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009286697,0.00022095311,0.0005603974,0.00010340546,0.000034543096,0.00001145356,0.00059518276,0.00009315057,0.0002576834],"category_scores_gemma":[0.000033330864,0.000096724405,0.0004487931,0.00017601202,0.00018515102,0.000057513458,0.00015877688,0.00012219309,0.0000039787624],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056823605,0.0009239194,0.117657855,0.0034898699,0.0025165656,0.0000027109897,0.00055207056,0.000046876066,0.00073064136,0.017596621,0.0007749563,0.8551397],"study_design_scores_gemma":[0.0015154871,0.00013605329,0.09663701,0.01114042,0.0014255205,0.000013630792,0.00010838866,0.0005194992,0.0017972712,0.00022116468,0.8862785,0.00020704116],"about_ca_topic_score_codex":0.0004760612,"about_ca_topic_score_gemma":0.00034827154,"teacher_disagreement_score":0.88550353,"about_ca_system_score_codex":0.00062727585,"about_ca_system_score_gemma":0.00031757553,"threshold_uncertainty_score":0.39443067},"labels":[],"label_agreement":null},{"id":"W2936115947","doi":"10.1016/j.lungcan.2019.04.014","title":"Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer","year":2019,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Boehringer Ingelheim","keywords":"Afatinib; Osimertinib; Medicine; Discontinuation; Internal medicine; Oncology; Lung cancer; Retrospective cohort study; Progression-free survival; Epidermal growth factor receptor; Chemotherapy; Cancer; Erlotinib","score_opus":0.007479056460664642,"score_gpt":0.29370941121208277,"score_spread":0.2862303547514181,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2936115947","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917832,0.0025682019,0.00016912047,0.00024126159,0.00040643694,0.0020892348,0.00009256521,0.000024785537,0.0026251862],"genre_scores_gemma":[0.99708736,0.00020132403,0.00054788345,0.000382921,0.00008013779,0.00039934984,0.00011470779,0.000052686835,0.0011336119],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99868995,0.000021917136,0.00032116318,0.000357081,0.00030895864,0.00030091952],"domain_scores_gemma":[0.9991933,0.00007050773,0.00020096233,0.0002405014,0.00021025755,0.000084447136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000064207285,0.00022659265,0.00040648432,0.00013777596,0.00006211215,0.000013969557,0.000075932076,0.000077238685,0.00028418988],"category_scores_gemma":[0.0000057869943,0.00017361053,0.000100364756,0.00036405664,0.000022935728,0.00015791599,0.000016690126,0.00015232724,0.0000035229755],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003921593,0.00020092004,0.98447704,0.00029991163,0.0005300558,0.000018322906,0.0055581513,0.005979452,0.0005719525,0.000008063538,0.00009993591,0.0018640066],"study_design_scores_gemma":[0.022221658,0.0007683925,0.9578106,0.002828597,0.0008067353,0.0000010451029,0.00046360018,0.0045627505,0.009996241,0.000008754381,0.00014756108,0.00038405595],"about_ca_topic_score_codex":0.0055357227,"about_ca_topic_score_gemma":0.0014515996,"teacher_disagreement_score":0.02666646,"about_ca_system_score_codex":0.001152131,"about_ca_system_score_gemma":0.00067743164,"threshold_uncertainty_score":0.8368394},"labels":[],"label_agreement":null},{"id":"W2937704370","doi":"10.1016/j.lungcan.2019.04.006","title":"First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials","year":2019,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Boehringer Ingelheim","keywords":"Afatinib; Medicine; Term (time); Oncology; Internal medicine; Gefitinib; Cancer; Astronomy","score_opus":0.03130357438398415,"score_gpt":0.4238187698056362,"score_spread":0.39251519542165203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2937704370","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865708,0.007272365,0.0005200356,0.002087789,0.00021637611,0.0023699855,0.00019872292,0.000014285069,0.00074967725],"genre_scores_gemma":[0.99607474,0.0008201147,0.0002649596,0.00045708244,0.00007954302,0.00048364795,0.00013376668,0.000017352706,0.0016688049],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988598,0.00006816713,0.0004202929,0.00026651713,0.00019399481,0.00019123494],"domain_scores_gemma":[0.9986984,0.0006378219,0.00021241815,0.00031278774,0.000090558475,0.00004799844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047616728,0.00013726256,0.0006442468,0.0002470009,0.000047936315,0.0000143522275,0.00007668053,0.000061630024,0.0002680413],"category_scores_gemma":[0.00013545706,0.00008697412,0.00020154206,0.0005898029,0.000037301576,0.0000784144,0.000013800334,0.000075144206,7.775542e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028182643,0.00022778417,0.9633772,0.0007583712,0.005072991,0.000011670383,0.004794656,0.0036067644,0.001173692,0.00034304618,0.0009011936,0.016914405],"study_design_scores_gemma":[0.016837578,0.00045213258,0.9553209,0.0006704951,0.0152600845,0.0000032341743,0.00063136156,0.007828711,0.00073924643,0.000051857005,0.0019660636,0.00023832839],"about_ca_topic_score_codex":0.00024823233,"about_ca_topic_score_gemma":0.0014388663,"teacher_disagreement_score":0.016676076,"about_ca_system_score_codex":0.00017708544,"about_ca_system_score_gemma":0.00015417919,"threshold_uncertainty_score":0.35467017},"labels":[],"label_agreement":null},{"id":"W2937841409","doi":"10.1016/j.lungcan.2019.04.009","title":"The metastatic site does not influence PD-L1 expression in advanced non-small cell lung carcinoma","year":2019,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; McGill University Health Centre","funders":"","keywords":"Medicine; Immunohistochemistry; Biopsy; Pathology; Pembrolizumab; Metastasis; Serous fluid; Lung cancer; Oncology; Lung; Carcinoma; Serous membrane; Internal medicine; Radiology; Cancer; Immunotherapy","score_opus":0.006195992376352095,"score_gpt":0.270509923954496,"score_spread":0.2643139315781439,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2937841409","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98849475,0.008076528,0.000033272907,0.0006373103,0.0006622319,0.0010596568,0.000023431148,0.000029082687,0.0009837376],"genre_scores_gemma":[0.9901581,0.001235772,0.00026792218,0.0012667316,0.000075870325,0.00021467899,0.000007642695,0.000033837186,0.0067394613],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99856746,0.000052774172,0.00033930628,0.00036424695,0.00027389283,0.00040232207],"domain_scores_gemma":[0.99903995,0.00015078105,0.00014876576,0.000511577,0.00007182585,0.00007712193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023718775,0.0002109441,0.00030339515,0.00007788539,0.000095300624,0.000035006473,0.00018517533,0.00006565488,0.00023411974],"category_scores_gemma":[0.000016193242,0.0001206307,0.00011187526,0.00025090436,0.00006069101,0.0001439626,0.000057195506,0.0002547535,0.000021193408],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023974609,0.000038823753,0.3619139,0.00035496536,0.00004193524,0.000018843237,0.001321965,0.00020297614,0.62915903,0.0000025267764,0.0005061532,0.0040414035],"study_design_scores_gemma":[0.006340711,0.0001544331,0.6156345,0.0010305583,0.0001147478,0.000005866817,0.0005070562,0.0024581666,0.362544,0.0000078586045,0.010870663,0.00033143046],"about_ca_topic_score_codex":0.0009837783,"about_ca_topic_score_gemma":0.0006536229,"teacher_disagreement_score":0.26661506,"about_ca_system_score_codex":0.00032531552,"about_ca_system_score_gemma":0.00022535949,"threshold_uncertainty_score":0.4919177},"labels":[],"label_agreement":null},{"id":"W2943711511","doi":"10.1016/j.lungcan.2019.04.027","title":"Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219","year":2019,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Abbotsford Veterinary Clinic; Juravinski Cancer Centre; Lakeridge Health; BC Cancer Agency; Princess Margaret Cancer Centre; Ottawa Hospital; Hôpital Notre-Dame; Hamilton Health Sciences; University of Toronto","funders":"AstraZeneca","keywords":"Medicine; Pemetrexed; Selumetinib; Chemotherapy; Internal medicine; Hazard ratio; Tolerability; Carboplatin; Oncology; Lung cancer; Surgery; Adverse effect; Gastroenterology; KRAS; Cancer; Cisplatin; Confidence interval; Colorectal cancer","score_opus":0.016899006242002086,"score_gpt":0.3665936275924145,"score_spread":0.3496946213504124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943711511","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9667688,0.003600554,0.000486848,0.0006242168,0.0014055797,0.025324488,0.0015867947,0.000059105347,0.0001436278],"genre_scores_gemma":[0.9815077,0.0011064145,0.0032713031,0.001272556,0.00019536894,0.009638309,0.0002657203,0.00018512546,0.0025574889],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9957635,0.00032483213,0.0013520707,0.0010502898,0.00053173123,0.0009775839],"domain_scores_gemma":[0.9964609,0.0012464536,0.0007962549,0.0005018186,0.00045956098,0.0005349869],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012237754,0.00072166475,0.0025788087,0.00058193173,0.00031745786,0.00009113301,0.00020790454,0.00016654974,0.0011429106],"category_scores_gemma":[0.00044473395,0.00051004224,0.00029212135,0.000747404,0.000078657526,0.00024592478,0.00004127877,0.00033387347,0.0000017054653],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5156343,0.0039896443,0.32418525,0.0029421854,0.003963154,0.00007006091,0.014037302,0.0015443115,0.0008027546,0.0000028749887,0.0031089222,0.12971923],"study_design_scores_gemma":[0.9478691,0.006537994,0.009054765,0.0021647946,0.005447234,0.0000011822268,0.0010916934,0.021152852,0.0013108832,0.0000033320632,0.0044483948,0.00091773324],"about_ca_topic_score_codex":0.093407124,"about_ca_topic_score_gemma":0.4388573,"teacher_disagreement_score":0.43223482,"about_ca_system_score_codex":0.0028308723,"about_ca_system_score_gemma":0.0037006442,"threshold_uncertainty_score":0.99977016},"labels":[],"label_agreement":null},{"id":"W2946397648","doi":"10.1016/j.lungcan.2019.05.005","title":"Pembrolizumab for advanced nonsmall cell lung cancer: Efficacy and safety in everyday clinical practice","year":2019,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria","funders":"BC Cancer Foundation","keywords":"Medicine; Pembrolizumab; Clinical Practice; Oncology; Lung cancer; Internal medicine; Intensive care medicine; Cancer; Family medicine; Immunotherapy","score_opus":0.012976930031351913,"score_gpt":0.3767882010690081,"score_spread":0.3638112710376562,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946397648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9312025,0.052170657,0.00014808027,0.005021975,0.0021163996,0.0033589108,0.00008764969,0.00006406461,0.0058298195],"genre_scores_gemma":[0.954983,0.02902815,0.0017890934,0.0052811224,0.00060154125,0.00048235577,0.00003002979,0.000084320964,0.0077203624],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980994,0.00007956887,0.0005926818,0.0005653325,0.00023298101,0.00043005365],"domain_scores_gemma":[0.9984113,0.0007098041,0.00023660986,0.0003700231,0.00013719684,0.00013504716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005547534,0.0002333591,0.000539505,0.000085185784,0.00006305052,0.00002262536,0.00011653542,0.00019179049,0.00041514295],"category_scores_gemma":[0.00012242315,0.00020475451,0.00015098818,0.000231214,0.0000728618,0.00021462631,0.00004316518,0.00034491866,0.0000051963834],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17782503,0.0010998168,0.49557084,0.0032192322,0.0011890548,0.00005322132,0.002002338,0.0004064187,0.021521434,0.00015013418,0.025581358,0.2713811],"study_design_scores_gemma":[0.06941635,0.0010271922,0.26722378,0.0015601914,0.0007315897,0.000032328357,0.0002593621,0.004933034,0.0014601079,0.000006213755,0.6526971,0.00065272884],"about_ca_topic_score_codex":0.0007896633,"about_ca_topic_score_gemma":0.00036733356,"teacher_disagreement_score":0.6271157,"about_ca_system_score_codex":0.0005327202,"about_ca_system_score_gemma":0.0006351893,"threshold_uncertainty_score":0.8349647},"labels":[],"label_agreement":null},{"id":"W2946988148","doi":"10.1016/j.lungcan.2019.05.027","title":"Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer","year":2019,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Juravinski Cancer Centre; McMaster University; Vancouver Hospital and Health Sciences Centre; University of Toronto; Princess Margaret Cancer Centre; BC Cancer Agency","funders":"Merck Canada; AstraZeneca Canada","keywords":"Durvalumab; Medicine; Oncology; Lung cancer; Pneumonitis; Internal medicine; Chemoradiotherapy; Context (archaeology); Clinical trial; Adverse effect; Cancer; Nivolumab; Immunotherapy; Lung","score_opus":0.019804051459983922,"score_gpt":0.3242405323665668,"score_spread":0.3044364809065829,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2946988148","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0037232072,0.98890567,0.0000080272,0.00013497671,0.0017459224,0.0032211416,0.00016428927,0.000046542646,0.002050208],"genre_scores_gemma":[0.0004875466,0.9726162,0.0000359702,0.00016205684,0.0007264881,0.0009556658,0.00017288029,0.00015212227,0.024691066],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970784,0.00007805041,0.0010513798,0.00080406875,0.00033487557,0.0006532174],"domain_scores_gemma":[0.998409,0.00008638139,0.00066743384,0.0006101114,0.000081520484,0.00014558288],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004605832,0.0006607216,0.0022143235,0.0003868545,0.000075268275,0.00006578476,0.00021326283,0.00057059625,0.0010282967],"category_scores_gemma":[0.000012947314,0.000557395,0.00050767587,0.0007367854,0.00007146882,0.000139702,0.0000979864,0.000774708,0.000009592742],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010452826,0.00019957431,0.006251302,0.20552127,0.0014063299,0.00006647737,0.0011338252,0.000026709135,0.0016091614,0.00000422905,0.008115609,0.77462023],"study_design_scores_gemma":[0.0056577157,0.00009173268,0.00070771924,0.04159258,0.0018869067,0.000011321618,0.000065156135,0.0004949918,0.00085004023,4.1116462e-7,0.9478544,0.0007870218],"about_ca_topic_score_codex":0.012917148,"about_ca_topic_score_gemma":0.0013284115,"teacher_disagreement_score":0.9397388,"about_ca_system_score_codex":0.0022430979,"about_ca_system_score_gemma":0.0019885164,"threshold_uncertainty_score":0.9998849},"labels":[],"label_agreement":null},{"id":"W2949244813","doi":"10.1016/j.lungcan.2019.06.012","title":"Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non–small-cell lung cancer: The global, multicenter EXPRESS study","year":2019,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":160,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Merck Sharp and Dohme; Merck","keywords":"Medicine; Lung cancer; Oncology; Expression (computer science); Cancer; Ligand (biochemistry); Pathology; Cancer research; Internal medicine; Receptor","score_opus":0.017161885430112406,"score_gpt":0.34280352524772334,"score_spread":0.32564163981761096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949244813","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98157924,0.010217617,0.000086344684,0.0002379158,0.000546466,0.00671574,0.00006967162,0.000042819924,0.0005042052],"genre_scores_gemma":[0.9879411,0.0048328065,0.0007228102,0.00030894284,0.00007165456,0.0016195677,0.0000058700075,0.000044410044,0.0044528325],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99762404,0.00013697933,0.0006468132,0.00057771086,0.00050672586,0.0005077289],"domain_scores_gemma":[0.9985328,0.00012779924,0.0003523718,0.0007165302,0.00015959846,0.00011093258],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003657109,0.00033502607,0.00059661065,0.00009495734,0.00006360479,0.000031200365,0.00037192486,0.000064921755,0.0004489173],"category_scores_gemma":[0.000018781937,0.00020203198,0.00013748404,0.0006040578,0.00008183804,0.0001493855,0.00011125368,0.0002481384,0.0000021916899],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013066967,0.0010396197,0.92083377,0.0033558912,0.00034377322,0.0000346671,0.0027650644,0.00039135834,0.048876807,0.0000014103874,0.00044798676,0.008842669],"study_design_scores_gemma":[0.045541517,0.0018519586,0.8164268,0.012729729,0.0017661825,0.000007790393,0.0033317674,0.00887241,0.1052665,0.0000046918753,0.0033218013,0.00087886455],"about_ca_topic_score_codex":0.0058483826,"about_ca_topic_score_gemma":0.007023771,"teacher_disagreement_score":0.104407,"about_ca_system_score_codex":0.00067184505,"about_ca_system_score_gemma":0.00054428505,"threshold_uncertainty_score":0.88410443},"labels":[],"label_agreement":null},{"id":"W2950153856","doi":"10.1016/j.lungcan.2019.06.003","title":"Factors associated with early mortality in non-small cell lung cancer patients following systemic anti-cancer therapy: A 10 year population-based study","year":2019,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; University of Calgary","funders":"","keywords":"Medicine; Lung cancer; Internal medicine; Logistic regression; Population; Regimen; Cancer; Multivariate analysis; Mortality rate","score_opus":0.01801350174991846,"score_gpt":0.3217315413157189,"score_spread":0.30371803956580046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950153856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935681,0.0011161988,0.0000065914596,0.000031218522,0.0006779012,0.0040189456,0.00021314679,0.00007864338,0.000289218],"genre_scores_gemma":[0.9965429,0.000031456417,0.000006140803,0.00012953032,0.00006961022,0.0010085797,0.00022298354,0.00008833595,0.0019005089],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979147,0.000085619,0.00041575017,0.0005782833,0.00055594055,0.00044973902],"domain_scores_gemma":[0.99895126,0.000063634805,0.00028783432,0.000368964,0.00019713787,0.00013116414],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000119701996,0.00036441852,0.0006622542,0.00017095168,0.00010291752,0.000048945873,0.0001228767,0.00012953758,0.000501312],"category_scores_gemma":[0.000010862369,0.00026717386,0.00015288102,0.000524034,0.00001172661,0.00016735005,0.000019275043,0.00021898784,0.000004583252],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000109898596,0.0008283152,0.9929177,0.0001755136,0.0012482578,0.00000726657,0.00235556,0.0019860726,0.00021428584,5.0087596e-7,0.000076959135,0.00007966398],"study_design_scores_gemma":[0.01177147,0.00030281793,0.9840308,0.0011247274,0.0009876671,2.3524212e-8,0.00033606598,0.00088522135,0.0002369235,3.5319184e-7,0.000010435481,0.00031352276],"about_ca_topic_score_codex":0.026414393,"about_ca_topic_score_gemma":0.0064037265,"teacher_disagreement_score":0.020010665,"about_ca_system_score_codex":0.0020635305,"about_ca_system_score_gemma":0.0006138018,"threshold_uncertainty_score":0.99997807},"labels":[],"label_agreement":null},{"id":"W2962768820","doi":"10.1016/j.lungcan.2019.07.021","title":"The rate of occurrence, healthcare resource use and costs of adverse events among metastatic non-small cell lung cancer patients treated with first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors","year":2019,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"AstraZeneca","keywords":"Medicine; Erlotinib; Afatinib; Adverse effect; Internal medicine; Gefitinib; Lung cancer; Population; Epidermal growth factor receptor; Rate ratio; Cancer; Oncology; Confidence interval","score_opus":0.011533414860820022,"score_gpt":0.2730662465461996,"score_spread":0.26153283168537955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2962768820","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99394447,0.0024817977,0.000006798449,0.00022108656,0.00019686848,0.0018205424,0.001290911,0.000012068118,0.000025469904],"genre_scores_gemma":[0.9978523,0.00084955414,0.00007790743,0.00011589664,0.00004096756,0.00021348304,0.00026431188,0.000027196576,0.000558336],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987626,0.00009227438,0.0003724737,0.0003352257,0.00019146857,0.00024596593],"domain_scores_gemma":[0.99872553,0.00015757508,0.0003860745,0.00020446851,0.00036774867,0.00015860463],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008003813,0.00023022543,0.00037479613,0.00009037938,0.00013712185,0.000011267665,0.00004872407,0.000058315414,0.0000643676],"category_scores_gemma":[0.000027370725,0.00014894317,0.000047245463,0.00022478389,0.000095927164,0.00021854532,0.00002974137,0.00011772705,4.3452414e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037847273,0.00011188799,0.99422204,0.00086446333,0.00029374464,0.0000019023659,0.0012045391,0.000075607306,0.0012168624,0.000005127367,0.0012056547,0.00041970744],"study_design_scores_gemma":[0.0068509886,0.0006264142,0.9708676,0.0015870434,0.0008576281,9.941838e-7,0.00021471719,0.0013411039,0.017114127,5.494438e-7,0.00031382847,0.00022501635],"about_ca_topic_score_codex":0.005536805,"about_ca_topic_score_gemma":0.005807912,"teacher_disagreement_score":0.023354443,"about_ca_system_score_codex":0.00031267552,"about_ca_system_score_gemma":0.0002618861,"threshold_uncertainty_score":0.837003},"labels":[],"label_agreement":null},{"id":"W2965354595","doi":"10.1016/j.lungcan.2019.07.033","title":"PD-L1 testing on the EBUS-FNA cytology specimens of non-small cell lung cancer","year":2019,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"Law Foundation of British Columbia","keywords":"Medicine; Cytology; Concordance; Lung cancer; Histology; Lung; Lymph; Pathology; Radiology; Internal medicine","score_opus":0.017871589380297107,"score_gpt":0.2916921288345026,"score_spread":0.2738205394542055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965354595","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94959307,0.0070161712,0.000021170064,0.0023299376,0.0012332966,0.0009402897,0.00003691466,0.00003780424,0.038791336],"genre_scores_gemma":[0.98852324,0.0007623775,0.00015936492,0.0030932452,0.0004905005,0.00013216806,0.000004879518,0.000048223417,0.006786001],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9986229,0.00004376077,0.00033273068,0.00035279867,0.00024805745,0.00039976113],"domain_scores_gemma":[0.9988072,0.00026326257,0.00022837431,0.0005039582,0.00013098122,0.000066245324],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00021599805,0.00022476932,0.0004034117,0.00008120438,0.000072597635,0.000011951494,0.0002005157,0.0001260217,0.002647819],"category_scores_gemma":[0.00002149269,0.0001512887,0.00014703693,0.00033636822,0.0001023873,0.00003464003,0.000045019347,0.00030394786,0.000025176983],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002389773,0.00015622875,0.46270773,0.00087365456,0.0005926698,0.000020811709,0.0012307062,0.000262993,0.49710327,0.000076159995,0.023714224,0.010871777],"study_design_scores_gemma":[0.008097918,0.00088784186,0.7848752,0.0026270968,0.00065703114,0.000027762571,0.00048811632,0.008085609,0.16286694,0.000020205227,0.030673243,0.0006930291],"about_ca_topic_score_codex":0.002918254,"about_ca_topic_score_gemma":0.0004534066,"teacher_disagreement_score":0.33423632,"about_ca_system_score_codex":0.0003823603,"about_ca_system_score_gemma":0.00035917468,"threshold_uncertainty_score":0.9982639},"labels":[],"label_agreement":null},{"id":"W2969365775","doi":"10.1016/j.lungcan.2019.08.016","title":"Erratum to “The metastatic site does not influence PD-L1 expression in advanced non-small cell lung carcinoma” [Lung Cancer 132 (June) (2019) 36–38]","year":2019,"lang":"en","type":"erratum","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; McGill University Health Centre","funders":"","keywords":"Nivolumab; Atezolizumab; Medicine; Pembrolizumab; ROS1; Lung cancer; Durvalumab; Oncology; Internal medicine; Cancer; Cancer research; Immunotherapy; Adenocarcinoma","score_opus":0.009040041164799914,"score_gpt":0.28580558810533935,"score_spread":0.27676554694053945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2969365775","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.56981695,0.26469052,0.0003899371,0.010369714,0.123902865,0.015217996,0.002959787,0.0003606541,0.01229158],"genre_scores_gemma":[0.1724444,0.024821006,0.0006086675,0.011441724,0.0034232459,0.004011648,0.00070303073,0.00057633244,0.78196996],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9935698,0.00023519839,0.0014085659,0.0018994184,0.0012625371,0.0016244646],"domain_scores_gemma":[0.9958832,0.00020296333,0.0009357625,0.0021036707,0.00045269268,0.0004216907],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00061456306,0.0013706888,0.0019488046,0.0006641929,0.00028461093,0.00016168537,0.0010888834,0.00079759915,0.0011266195],"category_scores_gemma":[0.00007597003,0.00092555885,0.0005885359,0.0012076611,0.00016090025,0.00037432805,0.00038896775,0.0025373544,0.000060967915],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048857844,0.00013802196,0.023672692,0.0045097424,0.00046834498,0.00013239235,0.0041248165,0.0010338785,0.06958783,9.660287e-7,0.8896171,0.0018284462],"study_design_scores_gemma":[0.010205181,0.0003845211,0.11011778,0.020468738,0.002064639,0.00002552209,0.0006552895,0.004815893,0.029099636,0.000005481121,0.8193402,0.0028170669],"about_ca_topic_score_codex":0.012573814,"about_ca_topic_score_gemma":0.0130610885,"teacher_disagreement_score":0.76967835,"about_ca_system_score_codex":0.0026961353,"about_ca_system_score_gemma":0.0030325104,"threshold_uncertainty_score":0.9999044},"labels":[],"label_agreement":null},{"id":"W2981392910","doi":"10.1016/j.lungcan.2019.10.019","title":"Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model","year":2019,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency; Mount Sinai Hospital; McMaster University; Alberta Cancer Foundation; William Osler Health System; AstraZeneca (Canada)","funders":"AstraZeneca Canada","keywords":"Medicine; Lung cancer; Health care; Delphi method; Oncology; Internal medicine; Statistics","score_opus":0.017134282541400463,"score_gpt":0.31103216051956356,"score_spread":0.2938978779781631,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981392910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99168336,0.0055911285,0.000076290045,0.000354625,0.00013964117,0.001198645,0.00025408802,0.00001379024,0.00068845093],"genre_scores_gemma":[0.9958878,0.0023039998,0.00040212867,0.00005791478,0.0000884639,0.0003847892,0.00011764327,0.000022929873,0.0007343117],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988678,0.000023904804,0.0003597099,0.00036552598,0.00015250813,0.00023055587],"domain_scores_gemma":[0.9992848,0.0000815061,0.0001881581,0.00029951404,0.00007171315,0.00007429874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010597672,0.00020571948,0.0003237447,0.00006242465,0.000041256757,0.000014875063,0.000058088408,0.000080626225,0.00008230218],"category_scores_gemma":[0.000006327697,0.00012387948,0.000086035485,0.00015075521,0.000020034671,0.00008257206,0.000027993174,0.000081792336,0.0000035033468],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051284855,0.00020853819,0.9661305,0.00009636466,0.00035982463,0.0000018135058,0.004151021,0.022716898,0.0026171263,0.000007524395,0.00093590055,0.002261661],"study_design_scores_gemma":[0.008293582,0.00019141157,0.8917508,0.0008846549,0.00039637033,6.781276e-7,0.00009529199,0.091013215,0.0070768413,0.000017509474,0.00010948963,0.00017011724],"about_ca_topic_score_codex":0.040088963,"about_ca_topic_score_gemma":0.0035805227,"teacher_disagreement_score":0.07437964,"about_ca_system_score_codex":0.0041904277,"about_ca_system_score_gemma":0.00090946496,"threshold_uncertainty_score":0.9996323},"labels":[],"label_agreement":null},{"id":"W2990345401","doi":"10.1183/13993003.congress-2019.pa3076","title":"Central tumor location and presence of occult lymph node metastasis in cT1N0M0 NSCLC","year":2019,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec; Université Laval","funders":"","keywords":"Medicine; Occult; Hilum (anatomy); Radiology; Lymph node; Lung cancer; Mediastinal lymph node; Metastasis; Lung; Incidence (geometry); Lymph; Cancer; Oncology; Internal medicine; Pathology","score_opus":0.009000430885864961,"score_gpt":0.2942786289980203,"score_spread":0.2852781981121554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990345401","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904363,0.0068787695,0.000031748506,0.00085518096,0.0002154311,0.0005178703,0.00002735345,0.000013178979,0.0010241581],"genre_scores_gemma":[0.9983159,0.00075525104,0.0001746364,0.00030782417,0.00004915837,0.000106341024,0.000009458519,0.0000118519765,0.00026961064],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999205,0.000019016254,0.00017480887,0.00023129773,0.0001750935,0.00019478633],"domain_scores_gemma":[0.99955404,0.000040179562,0.0000697441,0.00019948895,0.00006456419,0.00007197105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000059146958,0.00010158046,0.00024904762,0.00005483031,0.0000119037895,0.0000072822418,0.000041025287,0.000029615181,0.00020760935],"category_scores_gemma":[0.000017824812,0.000080593614,0.00003620755,0.00017467003,0.000031587115,0.00007553991,0.000021993506,0.00004844642,0.000004590103],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013936163,0.00013405252,0.9939026,0.0006303559,0.000111398214,0.000009427237,0.00040702088,0.00033222567,0.0006791924,0.00015378786,0.00070503936,0.0027955056],"study_design_scores_gemma":[0.0028864583,0.0000623183,0.9831721,0.0010886062,0.00021788746,0.0000067760643,0.00008558744,0.0022065563,0.009623889,0.000010069941,0.00054047594,0.00009923098],"about_ca_topic_score_codex":0.0023764812,"about_ca_topic_score_gemma":0.00018330109,"teacher_disagreement_score":0.010730489,"about_ca_system_score_codex":0.0003621055,"about_ca_system_score_gemma":0.00018360825,"threshold_uncertainty_score":0.35925445},"labels":[],"label_agreement":null},{"id":"W2994716574","doi":"10.1016/j.lungcan.2019.12.005","title":"Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomas","year":2019,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Company; Allergan Foundation; Sanofi; AstraZeneca; Canadian Institutes of Health Research; Bristol-Myers Squibb","keywords":"Medicine; Oncology; Internal medicine; Cohort; Microsatellite instability; Clinical trial; Lung cancer; Targeted therapy; Cancer; Gene; Genetics","score_opus":0.027241171574302885,"score_gpt":0.3084478449207322,"score_spread":0.2812066733464293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2994716574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9703244,0.025930537,0.00003702014,0.0003749006,0.0004689805,0.0009367122,0.000014527916,0.00004599856,0.0018669543],"genre_scores_gemma":[0.9956915,0.0007580369,0.000072195304,0.00051312865,0.00013779024,0.0004239163,0.000083244675,0.000026269801,0.0022939402],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99906677,0.000018889385,0.00022953379,0.00026880487,0.00017449427,0.00024151223],"domain_scores_gemma":[0.99954766,0.000042417778,0.00007599019,0.00018897468,0.00006992378,0.00007505607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004784544,0.00015995147,0.00022950652,0.00013844768,0.000071701026,0.0000606828,0.00004138695,0.00007706621,0.00034965406],"category_scores_gemma":[0.000009378258,0.00012920005,0.000044765864,0.00021378607,0.000024677627,0.00030633764,0.000020955216,0.00011997328,0.000009201175],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000046573816,0.00006804452,0.93942726,0.00044514937,0.00012020613,0.000025053894,0.007942177,0.0005154961,0.047708757,0.000087420165,0.0010841414,0.0025297257],"study_design_scores_gemma":[0.012973481,0.00049713196,0.77851,0.0006531006,0.0017971405,0.00003257341,0.0047542127,0.07082287,0.12495109,0.0001330341,0.0038543437,0.0010210521],"about_ca_topic_score_codex":0.00280063,"about_ca_topic_score_gemma":0.0014800869,"teacher_disagreement_score":0.16091728,"about_ca_system_score_codex":0.0007862253,"about_ca_system_score_gemma":0.00025767097,"threshold_uncertainty_score":0.5268625},"labels":[],"label_agreement":null},{"id":"W2995735677","doi":"10.1016/j.lungcan.2019.12.007","title":"Survival disparities following surgery among patients with different histological types of non-small cell lung cancer","year":2019,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Dalhousie University","funders":"","keywords":"Medicine; Lung cancer; Internal medicine; Oncology; Adenocarcinoma; Proportional hazards model; Pneumonectomy; Stage (stratigraphy); Carcinoma; Lymph node; Survival analysis; Cohort; Cancer; Surgery","score_opus":0.009230554469763548,"score_gpt":0.25354110793386525,"score_spread":0.24431055346410172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2995735677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891047,0.006828552,0.000019139232,0.00021810288,0.0015940685,0.00086744706,0.00006253616,0.000038042257,0.0012674077],"genre_scores_gemma":[0.9969591,0.0006756098,0.00003115201,0.00014719406,0.00012455104,0.00038496457,0.00005637822,0.00004604359,0.0015749981],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983679,0.00003624003,0.00031869602,0.00042316073,0.00042385844,0.00043015036],"domain_scores_gemma":[0.99901944,0.00018758563,0.00019385567,0.00032746335,0.000116528696,0.00015510397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007343189,0.0002897136,0.0008201997,0.00008114364,0.000053021125,0.0000163757,0.000089559704,0.00010992973,0.0005363718],"category_scores_gemma":[0.0000095224505,0.00018741682,0.000251402,0.00013494013,0.00006165799,0.00007832207,0.000050470087,0.00016056809,0.0000029555536],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002746319,0.00043406727,0.9944744,0.0009994602,0.00068703777,0.000016575088,0.0001791073,0.00009417837,0.000040325434,0.000013084672,0.0023446032,0.00044253533],"study_design_scores_gemma":[0.0024334153,0.00016346591,0.9930152,0.001391603,0.0010790698,2.3444102e-7,0.000025632804,0.00028358452,0.0011556472,0.0000017131435,0.00021164681,0.00023874115],"about_ca_topic_score_codex":0.0037489955,"about_ca_topic_score_gemma":0.0014196147,"teacher_disagreement_score":0.007854404,"about_ca_system_score_codex":0.00082324503,"about_ca_system_score_gemma":0.00023919815,"threshold_uncertainty_score":0.76426363},"labels":[],"label_agreement":null},{"id":"W3006944857","doi":"10.1016/j.lungcan.2020.02.004","title":"RET isoform-specific interaction with scaffold protein Ezrin promotes cell migration and chemotaxis in lung adenocarcinoma","year":2020,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Neurofibromatosis and Schwannoma Cases","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Canadian Institutes of Health Research","keywords":"Ezrin; Medicine; Chemotaxis; Gene isoform; Cancer research; Scaffold protein; Lung; Adenocarcinoma; Scaffold; Cell; Cell migration; Cell biology; Internal medicine; Signal transduction; Receptor; Biology; Cancer; Biochemistry; Gene; Biomedical engineering; Cytoskeleton","score_opus":0.016727888700035574,"score_gpt":0.25387894200942385,"score_spread":0.23715105330938827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006944857","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910516,0.002758048,0.000033757682,0.004582615,0.00004676028,0.0009776333,0.000008778112,0.000053827895,0.00048697522],"genre_scores_gemma":[0.99859834,0.00011629955,0.00038429955,0.00029799243,0.00016621221,0.00014423637,0.000014203441,0.000029734492,0.00024870338],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990276,0.000027454853,0.00021764317,0.00035843483,0.0001812648,0.00018760035],"domain_scores_gemma":[0.9995827,0.000016605205,0.00009125425,0.00014515617,0.000044077206,0.00012017699],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000050175564,0.00015969103,0.00023735981,0.00006774484,0.00004283223,0.0000454116,0.000041558684,0.000059441656,0.00012719675],"category_scores_gemma":[0.000012647628,0.00012742088,0.000032483862,0.00023975306,0.00003132243,0.00020863782,0.000026573782,0.00018128348,0.0000042647443],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015343041,0.00010788082,0.6408818,0.0015427694,0.0000344382,0.00022415725,0.0021921454,0.000010469321,0.34681815,0.000049115326,0.004622756,0.001982034],"study_design_scores_gemma":[0.003689016,0.0014110991,0.39762357,0.0015301495,0.00010758549,0.00015212955,0.00054827123,0.012744606,0.5757622,0.000007024347,0.0059848526,0.0004394894],"about_ca_topic_score_codex":0.00023737046,"about_ca_topic_score_gemma":0.00014409739,"teacher_disagreement_score":0.2432582,"about_ca_system_score_codex":0.00010379328,"about_ca_system_score_gemma":0.00006130878,"threshold_uncertainty_score":0.51960725},"labels":[],"label_agreement":null},{"id":"W3007268864","doi":"10.1016/j.lungcan.2020.02.014","title":"Severe symptoms persist for Up to one year after diagnosis of stage I-III lung cancer: An analysis of province-wide patient reported outcomes","year":2020,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer survivorship and care","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Manitoba; Sunnybrook Health Science Centre; University of Toronto","funders":"Ontario Ministry of Health and Long-Term Care; Institute for Clinical Evaluative Sciences","keywords":"Medicine; Lung cancer; Stage (stratigraphy); Comorbidity; Disease; Cancer; Population; Cohort; Internal medicine; Retrospective cohort study; Pediatrics; Physical therapy","score_opus":0.018736776937923444,"score_gpt":0.30309725357507694,"score_spread":0.28436047663715347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007268864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99210167,0.00200931,0.00026156785,0.0023360248,0.0003721418,0.0012846822,0.0014152223,0.00004615094,0.00017321501],"genre_scores_gemma":[0.994503,0.00018577428,0.00009399623,0.002704098,0.00011689616,0.0012167547,0.000090971895,0.000043678803,0.0010448303],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980691,0.00003272923,0.0005950486,0.00050974725,0.00050055457,0.00029282045],"domain_scores_gemma":[0.9984145,0.00010003922,0.00032144957,0.00048212626,0.00037466243,0.0003072269],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000091389025,0.00022055523,0.00091339555,0.00018644752,0.0000358759,0.000012668899,0.00012831805,0.000094981915,0.0014011814],"category_scores_gemma":[0.00010481521,0.00020047437,0.00043727874,0.0007532406,0.000047534344,0.00009080045,0.00006400893,0.000109787,4.2734305e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015196643,0.000090236026,0.97683805,0.0008980334,0.003929671,0.000007875732,0.0101579875,0.0006678012,0.00012533288,0.0000117258205,0.002533273,0.003220347],"study_design_scores_gemma":[0.0030023714,0.0011235392,0.9433104,0.00081241265,0.01967616,3.5816103e-7,0.0043595927,0.0039820806,0.008554985,0.000001463089,0.014485163,0.00069149147],"about_ca_topic_score_codex":0.0145653915,"about_ca_topic_score_gemma":0.03201001,"teacher_disagreement_score":0.03352767,"about_ca_system_score_codex":0.0004439196,"about_ca_system_score_gemma":0.00038648283,"threshold_uncertainty_score":0.99951166},"labels":[],"label_agreement":null},{"id":"W3008374819","doi":"10.1016/j.lungcan.2020.02.016","title":"A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226","year":2020,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; Princess Margaret Cancer Centre; BC Cancer Agency; Cancer Care South East; McMaster University; Queen's University; Centre Hospitalier de l’Université de Montréal; University of Calgary; Juravinski Cancer Centre","funders":"Canadian Cancer Society Research Institute","keywords":"Medicine; Internal medicine; Carboplatin; Durvalumab; Tremelimumab; Chemotherapy; Gemcitabine; Pemetrexed; Pneumonitis; Lung cancer; Oxaliplatin; Gastroenterology; Oncology; Surgery; Cancer; Cisplatin; Pembrolizumab; Immunotherapy; Ipilimumab; Colorectal cancer; Lung","score_opus":0.05066850904979687,"score_gpt":0.39482714856463014,"score_spread":0.3441586395148333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008374819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989626,0.002729361,0.000008148533,0.0015950571,0.00015809764,0.0056330147,0.00010559801,0.00004217264,0.000102589365],"genre_scores_gemma":[0.99612767,0.0006396206,0.00008386815,0.0017084854,0.00022884575,0.0009491887,0.000011160428,0.00008133094,0.00016981852],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973355,0.00021533732,0.0008511196,0.00065054203,0.0004744673,0.00047304947],"domain_scores_gemma":[0.99871904,0.00008415563,0.00039491645,0.00033917092,0.00011665836,0.0003460557],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006010929,0.00039241047,0.001484672,0.00023866499,0.00009298524,0.000037473244,0.00016638525,0.00009280128,0.0006964994],"category_scores_gemma":[0.000055425087,0.0002741041,0.00007566296,0.0008245649,0.00009304477,0.00016028732,0.00002343902,0.00029333992,5.170745e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1758902,0.003936703,0.6536161,0.00032994678,0.0023102937,0.00025101865,0.060660042,0.000099835204,0.013011096,0.0000013029544,0.00072824355,0.08916522],"study_design_scores_gemma":[0.58003193,0.051344585,0.29879636,0.0020188072,0.0020120097,0.000038579758,0.05223447,0.0027698968,0.0050409557,0.0000025119803,0.0042871786,0.0014227495],"about_ca_topic_score_codex":0.1901607,"about_ca_topic_score_gemma":0.6798894,"teacher_disagreement_score":0.48972866,"about_ca_system_score_codex":0.0005731597,"about_ca_system_score_gemma":0.0013235452,"threshold_uncertainty_score":0.9999711},"labels":[],"label_agreement":null},{"id":"W3012479383","doi":"10.1016/j.lungcan.2020.03.014","title":"EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study","year":2020,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":105,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Lung cancer; Internal medicine; Oncology; Chemotherapy; Epidermal growth factor receptor; Brain metastasis; Metastasis; Medical record; Exon; Cancer; Gene","score_opus":0.014483637179825948,"score_gpt":0.34744462399859594,"score_spread":0.33296098681877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012479383","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924636,0.0016474338,0.00013859318,0.0016378253,0.0002841679,0.0028925247,0.0003620486,0.00007153875,0.0005022607],"genre_scores_gemma":[0.9953809,0.0004448974,0.00039422925,0.00089761935,0.00012761111,0.0018865627,0.00044390117,0.000054511867,0.0003697653],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982665,0.00006342721,0.0004919141,0.00062029826,0.00027227122,0.00028557816],"domain_scores_gemma":[0.99912405,0.00005505908,0.00018213637,0.0002462212,0.00015038867,0.0002421675],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00003689431,0.00033830942,0.00048095052,0.00015709092,0.00012081583,0.000036255868,0.00007266398,0.00006453888,0.00009134375],"category_scores_gemma":[0.000023211958,0.00025626167,0.000095534,0.0005168731,0.000026207306,0.00019102039,0.00004039646,0.00014099127,0.0000036586944],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022317586,0.0009046911,0.98606086,0.00009045121,0.0004016286,0.000041609885,0.0050957478,0.0028046397,0.001855621,0.0000024297635,0.000048639802,0.0024705261],"study_design_scores_gemma":[0.011212731,0.0004324331,0.97992766,0.00011175289,0.0010775703,2.2264021e-7,0.00029004287,0.004967694,0.001493357,0.000008272013,0.00021785937,0.00026040128],"about_ca_topic_score_codex":0.018049331,"about_ca_topic_score_gemma":0.05911162,"teacher_disagreement_score":0.041062288,"about_ca_system_score_codex":0.0013889669,"about_ca_system_score_gemma":0.00026098793,"threshold_uncertainty_score":0.999989},"labels":[],"label_agreement":null},{"id":"W3014650073","doi":"10.1016/j.lungcan.2020.03.021","title":"Correspondence Re: Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model","year":2020,"lang":"en","type":"letter","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Health Canada","keywords":"Medicine; Lung cancer; Oncology; Internal medicine","score_opus":0.025668098241412522,"score_gpt":0.33683787634941825,"score_spread":0.3111697781080057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3014650073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.71638155,0.03196811,0.0024967836,0.22841029,0.0012925718,0.007672481,0.009236659,0.00013388299,0.0024076875],"genre_scores_gemma":[0.9150326,0.0059488434,0.0017964717,0.04961908,0.002659721,0.0026778625,0.0060185688,0.0002224222,0.016024414],"study_design_codex":"not_applicable","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99792457,0.00007404061,0.00064891425,0.00068126275,0.0003112114,0.00036002064],"domain_scores_gemma":[0.99862444,0.00020659252,0.00049363996,0.0004220281,0.00015514625,0.00009816956],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00008512879,0.0004454492,0.0006020001,0.00013914262,0.00010956767,0.00003653086,0.00014359118,0.00031943954,0.0001130327],"category_scores_gemma":[0.00003251829,0.0002907933,0.00015577444,0.00032010663,0.00006162218,0.00011128731,0.000050298375,0.0005212066,0.000003689008],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015857242,0.00016845422,0.14726903,0.00055490836,0.001958047,0.0001221921,0.018429136,0.02110512,0.0013223349,0.0000015584003,0.8048347,0.0026487987],"study_design_scores_gemma":[0.043909416,0.0015919312,0.40756086,0.012657531,0.01461082,0.00001891906,0.00067265995,0.45732614,0.0049736407,0.00023699887,0.053613346,0.0028277359],"about_ca_topic_score_codex":0.037369635,"about_ca_topic_score_gemma":0.0019397101,"teacher_disagreement_score":0.75122136,"about_ca_system_score_codex":0.005548197,"about_ca_system_score_gemma":0.003623563,"threshold_uncertainty_score":0.9999544},"labels":[],"label_agreement":null},{"id":"W3017107411","doi":"10.1016/j.lungcan.2020.04.011","title":"Efficacy and safety of ALK inhibitors in ALK-rearranged non-small cell lung cancer: A systematic review and meta-analysis","year":2020,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Victoria Hospital","funders":"","keywords":"Medicine; Internal medicine; Meta-analysis; Hazard ratio; Oncology; Anaplastic lymphoma kinase; Cochrane Library; Lung cancer; ALK inhibitor; Randomized controlled trial; Subgroup analysis; Confidence interval","score_opus":0.032884582674672175,"score_gpt":0.37616885597003563,"score_spread":0.3432842732953635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3017107411","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000007846873,0.9884874,0.000015418782,0.0006652352,0.00007888154,0.009294534,0.00056166784,0.00002445439,0.00086455233],"genre_scores_gemma":[0.00024760887,0.993938,0.00011986439,0.00042722662,0.000073447976,0.003812482,0.00014678639,0.00007875532,0.0011557936],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9967038,0.0002696762,0.0015800638,0.0007848479,0.00034277697,0.00031885583],"domain_scores_gemma":[0.99776036,0.00025908902,0.0010109522,0.00057793624,0.00013141346,0.00026026162],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032980938,0.0006682434,0.010299036,0.00036161684,0.000062131294,0.000026533566,0.00014805145,0.00021943015,0.00025683304],"category_scores_gemma":[0.000059732076,0.00043458992,0.0013591545,0.0014499881,0.0000654629,0.000060506867,0.000084566855,0.00038570588,0.0000020302637],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016705304,0.000065316,0.00012058628,0.8598888,0.13291107,0.000033922617,0.00045571238,0.000005248698,4.885686e-7,0.0000035037983,0.00063229754,0.0058663497],"study_design_scores_gemma":[0.0010595876,0.000041022395,0.000025301539,0.12495365,0.82167125,0.000009109618,0.000019385043,0.000037138365,0.0000011630235,3.0027803e-7,0.051888473,0.0002936342],"about_ca_topic_score_codex":0.0019243642,"about_ca_topic_score_gemma":0.00080814806,"teacher_disagreement_score":0.73493516,"about_ca_system_score_codex":0.0006363451,"about_ca_system_score_gemma":0.0008404131,"threshold_uncertainty_score":0.9998106},"labels":[],"label_agreement":null},{"id":"W3019468486","doi":"10.1016/j.lungcan.2020.04.021","title":"Addition of ramucirumab enhances docetaxel efficacy in patients who had received anti-PD-1/PD-L1 treatment","year":2020,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada; MSD Life Science Foundation, Public Interest Incorporated Foundation; Ono Pharmaceutical; Nippon Kayaku; AstraZeneca; Astellas Pharma US; Taiho Pharmaceutical; Novartis; Chugai Pharmaceutical; Pfizer","keywords":"Medicine; Ramucirumab; Docetaxel; Internal medicine; Oncology; Chemotherapy","score_opus":0.01685621219898133,"score_gpt":0.3003720634411888,"score_spread":0.28351585124220746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3019468486","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99323654,0.0029098622,0.000012269313,0.0016204983,0.0002817802,0.00072599686,0.00013602272,0.0000337981,0.0010432121],"genre_scores_gemma":[0.995817,0.002513022,0.000056036235,0.0009028201,0.00017095738,0.00008306689,0.000116420015,0.000021563565,0.0003191134],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9988443,0.000041999792,0.00035272588,0.00030228516,0.00023883197,0.00021980338],"domain_scores_gemma":[0.9994617,0.000036621197,0.0001627045,0.00018319556,0.00007167828,0.00008409831],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000051020248,0.00017571863,0.0004274232,0.000070679365,0.000034693763,0.000009541451,0.00007487096,0.00008247255,0.0011899844],"category_scores_gemma":[0.000026850708,0.00014233288,0.00013598506,0.0003218225,0.00006691816,0.00008474516,0.000013608573,0.00009291615,0.0000072776184],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03173922,0.0032329971,0.40619227,0.0010334397,0.0018639553,0.00003985094,0.011299942,0.0001916682,0.08087416,0.000018325249,0.03836016,0.42515403],"study_design_scores_gemma":[0.017537681,0.001599563,0.87807643,0.00084344967,0.00018537836,8.053647e-7,0.00010950027,0.00039031293,0.07646223,0.0000029395521,0.024556816,0.00023487225],"about_ca_topic_score_codex":0.0006476516,"about_ca_topic_score_gemma":0.0001396413,"teacher_disagreement_score":0.4718842,"about_ca_system_score_codex":0.00038210538,"about_ca_system_score_gemma":0.00015681941,"threshold_uncertainty_score":0.9997231},"labels":[],"label_agreement":null},{"id":"W3020949563","doi":"10.1016/j.lungcan.2020.03.028","title":"High risk, same reward?","year":2020,"lang":"en","type":"letter","venue":"Lung Cancer","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre","funders":"","keywords":"Medicine; Lung cancer; Organ transplantation; Lung transplantation; Malignancy; Transplantation; Cancer; Solid organ; Single Center; Surgery; Stage (stratigraphy); Oncology; Internal medicine","score_opus":0.010168717155205134,"score_gpt":0.27272546762376226,"score_spread":0.26255675046855714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3020949563","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009232354,0.011279911,0.000036247402,0.976683,0.0025184045,0.0006148311,0.0005937302,0.00027135093,0.0070792767],"genre_scores_gemma":[0.0017830045,0.0053875316,0.00014487909,0.9556294,0.011455312,0.000193105,0.0006094686,0.00015830305,0.024638984],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978301,0.0000710854,0.0003226651,0.000630437,0.00058478385,0.00056095066],"domain_scores_gemma":[0.99895275,0.000046360987,0.00031925668,0.00043649663,0.0000994686,0.00014567815],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000056601108,0.00040825218,0.00082677836,0.00009229755,0.00010899303,0.00003689776,0.00019017226,0.0008010003,0.0026516158],"category_scores_gemma":[0.00007266462,0.00036618285,0.00034318757,0.00028480927,0.000073826566,0.000046340814,0.000053090505,0.0029422913,0.00015967699],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007429369,0.000010973298,0.0036353709,0.00038735074,0.00061758223,0.00048050497,0.00016755125,0.0000093806975,0.000007972221,0.0000041778676,0.9888413,0.005763562],"study_design_scores_gemma":[0.0022733558,0.0001334556,0.00067414716,0.00039900432,0.0014182964,0.000004157279,0.00002582083,0.00010566085,0.000027362314,0.00018900933,0.9943313,0.0004184468],"about_ca_topic_score_codex":0.008512897,"about_ca_topic_score_gemma":0.00022353567,"teacher_disagreement_score":0.021053601,"about_ca_system_score_codex":0.0008527449,"about_ca_system_score_gemma":0.00059553963,"threshold_uncertainty_score":0.999879},"labels":[],"label_agreement":null},{"id":"W3025802953","doi":"10.1016/j.lungcan.2020.03.022","title":"EGFR-mutated lung adenocarcinomas from patients who progressed on EGFR-inhibitors show high engraftment rates in xenograft models","year":2020,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Public Health Ontario; University of Toronto; University Health Network","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Terry Fox Foundation; Ontario Institute for Cancer Research; Canadian Cancer Society","keywords":"Medicine; Oncology; Cancer research; Lung; Internal medicine; EGFR inhibitors; Epidermal growth factor receptor; Cancer","score_opus":0.0160674318140488,"score_gpt":0.3089211713185431,"score_spread":0.2928537395044943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3025802953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9828613,0.0049116146,0.00006542499,0.007625521,0.0005431417,0.0024327626,0.00041272037,0.00017500734,0.0009725127],"genre_scores_gemma":[0.9942033,0.00021757852,0.00029781566,0.0027855444,0.000400681,0.00083048124,0.00079788215,0.000085373795,0.00038128937],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976916,0.00006845617,0.00046856093,0.00072753715,0.0005387898,0.00050505524],"domain_scores_gemma":[0.9989448,0.000063886466,0.00015978214,0.00031538503,0.00016003828,0.000356082],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000043511976,0.00040149878,0.0005583026,0.00014240277,0.00011219828,0.00006066813,0.00013651597,0.00014575754,0.0003247933],"category_scores_gemma":[0.000023738032,0.00030229992,0.00013505183,0.000498246,0.000056910507,0.00021905851,0.000054634314,0.00030409117,0.000021288],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019281302,0.0014731826,0.92866766,0.00042871555,0.0017522477,0.00028076262,0.011765603,0.0069130077,0.0007190946,0.00028427213,0.03419347,0.011593873],"study_design_scores_gemma":[0.047674995,0.0031366,0.7686769,0.0039093127,0.0037567422,0.0000025472248,0.00102084,0.12063887,0.038953833,0.0005512912,0.009753826,0.0019242633],"about_ca_topic_score_codex":0.0024504603,"about_ca_topic_score_gemma":0.00022903127,"teacher_disagreement_score":0.15999076,"about_ca_system_score_codex":0.0011963756,"about_ca_system_score_gemma":0.00031909428,"threshold_uncertainty_score":0.9999429},"labels":[],"label_agreement":null},{"id":"W3026323309","doi":"10.1016/j.lungcan.2020.05.013","title":"Predictors of participant nonadherence in lung cancer screening programs: a systematic review and meta-analysis","year":2020,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Canada Research Chairs; BC Cancer Agency; University of Toronto","funders":"Bristol-Myers Squibb Canada; Roche; AbbVie; Merck; Bayer; AstraZeneca; Novartis; Princess Margaret Cancer Foundation; Pfizer","keywords":"Medicine; CINAHL; Meta-analysis; MEDLINE; Lung cancer; Psychological intervention; Lung cancer screening; Relative risk; Cochrane Library; Internal medicine; Physical therapy; Confidence interval; Psychiatry","score_opus":0.13721857430288784,"score_gpt":0.4262249540346403,"score_spread":0.28900637973175247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3026323309","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000004432366,0.98926306,0.000013179675,0.00067186286,0.00006629233,0.009552651,0.00034287953,0.000038532868,0.00004712854],"genre_scores_gemma":[0.0002749803,0.97069913,0.00011736574,0.00038063858,0.000066909226,0.027955046,0.00008712059,0.00006809906,0.00035072907],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9958771,0.0003258064,0.0018635094,0.0008872852,0.0005915139,0.00045480952],"domain_scores_gemma":[0.9974149,0.00019351108,0.0012404937,0.00069611135,0.00015170641,0.00030331084],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004374768,0.00070739567,0.013531877,0.00025712734,0.00003589313,0.00003117999,0.00021624709,0.00019354984,0.00060954725],"category_scores_gemma":[0.000085789114,0.0004281269,0.0023097892,0.0018259622,0.000080258316,0.00007186384,0.00010663743,0.00037742822,0.000002493231],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000055140595,0.000080998936,0.0027109864,0.721167,0.27227873,0.000045978817,0.00012418468,0.0000038295193,9.857678e-9,0.0000058209753,0.0003539517,0.00322301],"study_design_scores_gemma":[0.00023258312,0.000058544792,0.0000378514,0.2796229,0.7072694,0.0000055440137,0.000009853448,0.00010323724,2.6247608e-7,2.2413246e-7,0.012425589,0.00023402474],"about_ca_topic_score_codex":0.002401894,"about_ca_topic_score_gemma":0.001195812,"teacher_disagreement_score":0.44154412,"about_ca_system_score_codex":0.00068337785,"about_ca_system_score_gemma":0.0007622132,"threshold_uncertainty_score":0.9998171},"labels":[],"label_agreement":null},{"id":"W3027882342","doi":"10.1016/j.lungcan.2020.05.018","title":"BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer","year":2020,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Public Health Ontario; Ontario Institute for Cancer Research; University of Toronto; University Health Network","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Canadian Cancer Society; Princess Margaret Cancer Foundation","keywords":"Alectinib; Crizotinib; Anaplastic lymphoma kinase; ALK inhibitor; Medicine; Cancer research; Lung cancer; Exome sequencing; Adenocarcinoma; Oncology; Mutation; Internal medicine; Cancer; Biology; Gene","score_opus":0.01857981633021402,"score_gpt":0.31091791521905204,"score_spread":0.29233809888883805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3027882342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98711914,0.0070694964,0.0001692817,0.0030842111,0.0004440353,0.00097234483,0.00019801292,0.000033050568,0.0009104464],"genre_scores_gemma":[0.99668854,0.0002580691,0.00018677804,0.0011161475,0.00035194703,0.00043417807,0.000072168405,0.000027819578,0.00086434855],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.998812,0.00006019586,0.00033814268,0.00036368993,0.0002481176,0.00017785485],"domain_scores_gemma":[0.99929726,0.000057692,0.00020899376,0.000191379,0.0001410884,0.000103596845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000069789334,0.00016313021,0.00024271011,0.0000711459,0.00011536937,0.000026566408,0.00006195886,0.00007943317,0.00020789598],"category_scores_gemma":[0.000087704386,0.00012896236,0.000054698106,0.00048825913,0.000058601407,0.00016291127,0.000021895798,0.0000947653,0.0000014683426],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029113465,0.0007684922,0.29410625,0.005489859,0.0015641099,0.00013508201,0.04510734,0.0036922977,0.55414623,0.006339655,0.034967553,0.05077181],"study_design_scores_gemma":[0.020025473,0.0007490523,0.62675744,0.0023857348,0.0024932066,0.000036008496,0.0016883371,0.032007053,0.29430595,0.00034924885,0.018245729,0.00095677556],"about_ca_topic_score_codex":0.0006659251,"about_ca_topic_score_gemma":0.007624599,"teacher_disagreement_score":0.33265117,"about_ca_system_score_codex":0.0005341046,"about_ca_system_score_gemma":0.00059056736,"threshold_uncertainty_score":0.5258933},"labels":[],"label_agreement":null},{"id":"W3034428807","doi":"10.1016/j.lungcan.2020.06.005","title":"ALK-rearranged lung adenocarcinoma transformation into high-grade large cell neuroendocrine carcinoma: Clinical and molecular description of two cases","year":2020,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Adenocarcinoma; Internal medicine; Neuroendocrine carcinoma; Oncology; Lung; Lung cancer; Mutation; Carcinoma; Small Cell Lung Carcinoma; Large cell; Transformation (genetics); Cancer research; Pathology; Small-cell carcinoma; Cancer; Gene; Genetics; Biology","score_opus":0.033944475025264716,"score_gpt":0.3577773740189569,"score_spread":0.32383289899369216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034428807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9824983,0.008117014,0.0006483797,0.0072077317,0.00019209544,0.0009936019,0.000058350044,0.000081434686,0.00020308861],"genre_scores_gemma":[0.9966287,0.00096963,0.0005369355,0.0013901629,0.00022390262,0.000083154235,0.00004420929,0.000054250453,0.00006902868],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977244,0.000204584,0.0006034105,0.0004903989,0.00050631433,0.00047088755],"domain_scores_gemma":[0.99890316,0.00010373741,0.00014252035,0.0002783151,0.00013947739,0.00043277044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009120467,0.0002484174,0.0005485472,0.00012516284,0.00007740329,0.000024923098,0.00013604302,0.000015081878,0.0000927274],"category_scores_gemma":[0.00016065077,0.0002307099,0.00014530844,0.0003372192,0.0001601477,0.00030430272,0.000079091216,0.0004733062,0.000004606954],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017668126,0.00041988376,0.83096147,0.0035491765,0.00012568512,0.007937683,0.00083098543,0.00007465249,0.14909562,0.00038476905,0.0035516059,0.0013016317],"study_design_scores_gemma":[0.05031623,0.004707523,0.33303595,0.0005187696,0.0018765532,0.0023808305,0.0009048223,0.036460567,0.55896574,0.00023985357,0.009486527,0.001106621],"about_ca_topic_score_codex":0.00090093125,"about_ca_topic_score_gemma":0.0001289387,"teacher_disagreement_score":0.49792555,"about_ca_system_score_codex":0.00007030607,"about_ca_system_score_gemma":0.00014090001,"threshold_uncertainty_score":0.9408077},"labels":[],"label_agreement":null},{"id":"W3036335108","doi":"10.1016/j.lungcan.2020.06.002","title":"Comprehensive assessment of PD-L1 immunohistochemistry on paired tissue and cytology specimens from non-small cell lung cancer","year":2020,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Ottawa; Princess Margaret Cancer Centre; BC Cancer Agency; Institut Universitaire de Cardiologie et de Pneumologie de Québec","funders":"Bristol-Myers Squibb Canada","keywords":"Concordance; Medicine; Cytology; Lung cancer; Biopsy; Immunohistochemistry; Pathology; Staining; PD-L1; Cancer; Internal medicine; Immunotherapy","score_opus":0.01781178098782026,"score_gpt":0.3258548896462878,"score_spread":0.3080431086584675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3036335108","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.967167,0.025169514,0.00014976501,0.0033307597,0.00048079513,0.00063742755,0.0002576719,0.000039057508,0.0027680048],"genre_scores_gemma":[0.9911143,0.0036709406,0.0006243505,0.0032532257,0.0004399158,0.00012489753,0.00006601245,0.000042055308,0.00066429964],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99866956,0.000033815475,0.00035432243,0.00045804316,0.0002164029,0.00026787058],"domain_scores_gemma":[0.9991562,0.00008416277,0.0002099982,0.0003023994,0.000105348656,0.00014192502],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00003831624,0.0002563669,0.00057079794,0.00003667792,0.00006083598,0.000011175845,0.00012267924,0.00013620323,0.0014828756],"category_scores_gemma":[0.000004666128,0.00023661631,0.00010350711,0.00014430987,0.00014253148,0.000028489949,0.000058573103,0.0002760575,0.000001926811],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020058174,0.00008601641,0.029135967,0.00077775674,0.0005871528,0.00004988695,0.0010783751,0.000052871153,0.95102435,0.0000045493225,0.013064878,0.0021323483],"study_design_scores_gemma":[0.012601213,0.0009136673,0.31622368,0.0013442033,0.001063817,0.000012811827,0.00069870375,0.0059042093,0.6191509,0.0000068721015,0.041354943,0.0007250101],"about_ca_topic_score_codex":0.0025503938,"about_ca_topic_score_gemma":0.00005356352,"teacher_disagreement_score":0.3318735,"about_ca_system_score_codex":0.00041857097,"about_ca_system_score_gemma":0.0003755939,"threshold_uncertainty_score":0.9994299},"labels":[],"label_agreement":null},{"id":"W3037298679","doi":"10.1016/j.lungcan.2020.06.028","title":"Acceptability and accuracy of patient-reported outcome measures (PROMs) for surveillance of breathlessness in routine lung cancer care: A mixed-method study","year":2020,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Public Health Ontario; York University; University of Toronto","funders":"Ontario Institute for Cancer Research; Cancer Care Ontario","keywords":"Medicine; Patient-reported outcome; Quality of life (healthcare); Lung cancer; Physical therapy; Receiver operating characteristic; Distress; Rating scale; Scale (ratio); Visual analogue scale; Multivariate analysis; Clinical psychology; Nursing; Internal medicine; Psychology","score_opus":0.03209781318424323,"score_gpt":0.3849937800934827,"score_spread":0.35289596690923947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037298679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.979862,0.014341196,0.00018721193,0.0011918679,0.00032411327,0.003660711,0.0003508604,0.000031746622,0.00005032005],"genre_scores_gemma":[0.99708515,0.00044601737,0.00045496837,0.00016391279,0.00009562431,0.0016820148,0.000022854798,0.000039800794,0.000009645247],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99755335,0.00013960179,0.0009334435,0.0006469538,0.00042360267,0.00030305993],"domain_scores_gemma":[0.99810195,0.00033390796,0.0005107683,0.0004204938,0.00047399133,0.0001589119],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003318496,0.00028864824,0.0011586228,0.00007529998,0.000041722164,0.000011819968,0.00011496215,0.000091311456,0.00009297711],"category_scores_gemma":[0.00038818826,0.0002302076,0.0001601424,0.00040548044,0.00006206969,0.00009099465,0.000089811154,0.00014490058,7.314406e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010739597,0.0005765514,0.9548258,0.0027687242,0.0006249543,0.000013256134,0.009124349,0.00023952794,0.00020764857,0.000007231866,0.00013609113,0.030401878],"study_design_scores_gemma":[0.0076678316,0.0005116457,0.9831391,0.00029359755,0.0007374476,0.0000017477709,0.001954814,0.0008501848,0.0044614593,0.0000039490014,0.00016870939,0.00020951072],"about_ca_topic_score_codex":0.011184279,"about_ca_topic_score_gemma":0.008099883,"teacher_disagreement_score":0.030192368,"about_ca_system_score_codex":0.0006009986,"about_ca_system_score_gemma":0.00037526613,"threshold_uncertainty_score":0.9954003},"labels":[],"label_agreement":null},{"id":"W3037872250","doi":"10.1016/j.lungcan.2020.06.031","title":"Radiological-pathological correlation of subsolid pulmonary nodules: A single centre retrospective evaluation of the 2011 IASLC adenocarcinoma classification system","year":2020,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Medicine; Pathological; Adenocarcinoma; Radiological weapon; Radiology; Retrospective cohort study; Correlation; Pathology; Internal medicine; Cancer","score_opus":0.054103775629033776,"score_gpt":0.3014180484604574,"score_spread":0.2473142728314236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037872250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98777497,0.005391946,0.000095891475,0.002633247,0.00031454966,0.0013007623,0.00006266513,0.00003949858,0.0023864435],"genre_scores_gemma":[0.9993135,0.00010442087,0.00006810135,0.000115428375,0.00018101247,0.00013325296,0.000035902507,0.000012908069,0.000035478108],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99841344,0.00020340522,0.00035967494,0.00034573136,0.00053796347,0.0001397822],"domain_scores_gemma":[0.99880505,0.000050350223,0.00036509451,0.00028481553,0.0004238869,0.00007077737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002264167,0.00013466559,0.00035657044,0.000027447066,0.000049621907,0.00000457631,0.00009308452,0.00012767826,0.00022940693],"category_scores_gemma":[0.00010872199,0.000083230996,0.0001490369,0.00021431202,0.00009796672,0.0000479352,0.000032283682,0.00012959703,0.0000062946397],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025305455,0.00028896861,0.98860216,0.00030501507,0.0001191305,0.000004608923,0.001075896,0.00035330153,0.0060360064,0.00078128977,0.0008900483,0.0012905339],"study_design_scores_gemma":[0.0011294564,0.0002794563,0.9541947,0.0003955904,0.0009828011,0.000011304764,0.0006724462,0.038298603,0.003917365,0.000023247168,0.00001887224,0.00007610477],"about_ca_topic_score_codex":0.00006786842,"about_ca_topic_score_gemma":0.000011712548,"teacher_disagreement_score":0.037945304,"about_ca_system_score_codex":0.0012468284,"about_ca_system_score_gemma":0.00011784003,"threshold_uncertainty_score":0.33940616},"labels":[],"label_agreement":null},{"id":"W3039432873","doi":"10.1016/j.lungcan.2020.06.032","title":"Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study","year":2020,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Agenzia Italiana del Farmaco, Ministero della Salute; Eli Lilly and Company; Associazione Italiana per la Ricerca sul Cancro; Ignyta; Merck Sharp and Dohme; EMD Serono; Genentech; Foundation Medicine; MacroGenics; Juno Therapeutics; Pfizer; Incyte; Kite Pharma; Spectrum Pharmaceuticals; Yuhan; Merck KGaA; Regeneron Pharmaceuticals; Sanofi; Memorial Sloan-Kettering Cancer Center; GlaxoSmithKline; Amgen; Celgene; AstraZeneca; Bristol-Myers Squibb","keywords":"Durvalumab; Medicine; Internal medicine; Tolerability; Oncology; Cohort; Clinical endpoint; Adverse effect; Cancer; Clinical trial; Nivolumab; Immunotherapy","score_opus":0.033566138407838154,"score_gpt":0.387555711866924,"score_spread":0.3539895734590858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3039432873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9796407,0.0011110501,0.00030991473,0.015549217,0.00027252905,0.002548205,0.00014457901,0.000047408565,0.00037639562],"genre_scores_gemma":[0.995663,0.00038087292,0.00020265557,0.0015051427,0.00024696204,0.00039261955,0.00007371939,0.000026721424,0.0015083031],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99899054,0.00003654865,0.0002579062,0.00031510825,0.00016617919,0.00023373366],"domain_scores_gemma":[0.99952286,0.00007886281,0.00006890373,0.00016969779,0.000058291855,0.00010138155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010532106,0.00016441493,0.0003172321,0.000028289862,0.00017056808,0.000019602388,0.000070948234,0.0000353928,0.00016512493],"category_scores_gemma":[0.000044254524,0.0000968263,0.000050223112,0.00015321832,0.000033309185,0.0000901847,0.000048905502,0.00012899766,0.0000020799475],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16800062,0.013963667,0.4067583,0.0027583162,0.0076552494,0.0011528645,0.077351905,0.0050578928,0.004841517,0.0025766871,0.030430336,0.27945262],"study_design_scores_gemma":[0.4014795,0.02742528,0.25344998,0.0013264917,0.007390874,0.000060894163,0.0057605924,0.05202652,0.0008261818,0.0002973502,0.24837634,0.0015799707],"about_ca_topic_score_codex":0.0004374394,"about_ca_topic_score_gemma":0.0016734747,"teacher_disagreement_score":0.27787265,"about_ca_system_score_codex":0.00014730768,"about_ca_system_score_gemma":0.00022377155,"threshold_uncertainty_score":0.39484617},"labels":[],"label_agreement":null},{"id":"W3043250176","doi":"10.1016/j.lungcan.2020.07.014","title":"Mechanisms of osimertinib resistance and emerging treatment options","year":2020,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":183,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Princess Margaret Cancer Foundation","keywords":"Osimertinib; Medicine; Acquired resistance; Cancer research; Epidermal growth factor receptor; Internal medicine; Receptor; Cancer","score_opus":0.03198790611506145,"score_gpt":0.4082846209134547,"score_spread":0.3762967147983932,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3043250176","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000017996069,0.9953352,0.00022450357,0.0005078306,0.0002176418,0.001254893,0.00034468033,0.000043432945,0.0020699967],"genre_scores_gemma":[0.00004399309,0.9916248,0.001415305,0.000064272994,0.000117938944,0.0008255472,0.00013005851,0.000055921544,0.005722219],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988546,0.000033586275,0.00040196883,0.00037663305,0.00015523052,0.00017801179],"domain_scores_gemma":[0.99923986,0.00004714012,0.00025860503,0.00025719934,0.000053045453,0.0001441301],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000028133718,0.00030377024,0.0012792777,0.000097382486,0.000073387586,0.000010935652,0.000052115014,0.000112885384,0.00019812176],"category_scores_gemma":[0.0000108101,0.00021705644,0.00028064242,0.00025669392,0.00003879811,0.00003429082,0.000024602912,0.00010756675,0.0000052655687],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029533134,0.00010415215,0.0000151191125,0.017201854,0.003039409,0.00004876733,0.0004215337,0.0000012985107,0.000008280057,0.00339503,0.0015679273,0.9741671],"study_design_scores_gemma":[0.0006934862,0.00011609337,0.000011707825,0.011549693,0.012462086,0.000011596377,0.00002816939,0.000012783827,0.000014462085,0.00006557743,0.97487193,0.00016238914],"about_ca_topic_score_codex":0.00011622116,"about_ca_topic_score_gemma":0.00006401341,"teacher_disagreement_score":0.9740047,"about_ca_system_score_codex":0.00057078956,"about_ca_system_score_gemma":0.00071034644,"threshold_uncertainty_score":0.88513047},"labels":[],"label_agreement":null},{"id":"W3045441518","doi":"10.1016/j.lungcan.2020.07.020","title":"Retrospective study of the incidence and outcomes from lung cancer in solid organ transplant recipients","year":2020,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Lung cancer; Cancer registry; Retrospective cohort study; Cancer; Oncology; Population; Neutropenia; Univariate analysis; Incidence (geometry); Chemotherapy; Surgery; Multivariate analysis","score_opus":0.011311917309429615,"score_gpt":0.3030001983973754,"score_spread":0.2916882810879458,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3045441518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99254644,0.0029661541,0.0000056416247,0.0030944853,0.00031433703,0.00070738,0.00015216156,0.000019534515,0.0001938751],"genre_scores_gemma":[0.99752367,0.0008511031,0.000004834475,0.0013488041,0.00006799031,0.00008305922,0.0000026588427,0.000020289528,0.000097605895],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99883515,0.00004806018,0.0002596631,0.00032053184,0.00033591932,0.00020067234],"domain_scores_gemma":[0.99953395,0.00002012543,0.00013035079,0.00016873403,0.000061374354,0.00008546542],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000635628,0.00014849406,0.00043018378,0.00003131281,0.000056032808,0.000009332542,0.00012131781,0.00007046472,0.00025765772],"category_scores_gemma":[0.000054027223,0.00010285484,0.000053100917,0.00035522284,0.000047510024,0.000067146444,0.00004449928,0.0002629563,3.946321e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002775086,0.000091059475,0.974265,0.000038386712,0.00023020468,0.000009332909,0.02302414,0.0000987779,0.0009209308,0.0000034013542,0.0004836611,0.0005576177],"study_design_scores_gemma":[0.004472303,0.00012668413,0.99165446,0.0003548847,0.00032173676,2.1461032e-7,0.0015332293,0.0010333864,0.0003562108,0.000016529473,0.000015554571,0.0001147969],"about_ca_topic_score_codex":0.014504845,"about_ca_topic_score_gemma":0.016341697,"teacher_disagreement_score":0.021490911,"about_ca_system_score_codex":0.00041796512,"about_ca_system_score_gemma":0.00018036459,"threshold_uncertainty_score":0.9920577},"labels":[],"label_agreement":null},{"id":"W3046772302","doi":"10.1016/j.lungcan.2020.07.013","title":"PD-L1 lineage-specific quantification in malignant pleural effusions of lung adenocarcinoma by flow cytometry","year":2020,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Queen's University; Cystic Fibrosis Canada; University of Toronto","funders":"University Health Network","keywords":"Medicine; Adenocarcinoma; Immunohistochemistry; Pathology; PD-L1; clone (Java method); Flow cytometry; Lung cancer; Carcinoma; Antibody; Antigen; Concordance; Cancer; Immunotherapy; Internal medicine; Immunology; Biology","score_opus":0.026740633659572962,"score_gpt":0.3051447161582569,"score_spread":0.2784040824986839,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3046772302","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9403391,0.051739626,0.0009325876,0.005223861,0.000491256,0.0006848368,0.00015945686,0.00005987,0.0003693998],"genre_scores_gemma":[0.9949316,0.0029492185,0.0002717639,0.0009818923,0.00024462762,0.000062372535,0.00010490508,0.00003252173,0.00042110722],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9986029,0.00004532069,0.0004620381,0.00035501123,0.0002846068,0.00025006858],"domain_scores_gemma":[0.99934334,0.000050383413,0.00013884861,0.00028166207,0.00007144326,0.00011431992],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014522205,0.0001657776,0.00034897286,0.00012940887,0.000045101802,0.000013881513,0.00013810492,0.00011033919,0.0007751015],"category_scores_gemma":[0.00002523218,0.0001450274,0.00013043998,0.00080078025,0.00007763043,0.00007075753,0.000031912372,0.00020626897,0.000008025456],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035722866,0.0001487382,0.25832367,0.0004573408,0.00016720379,0.000029912808,0.0019050583,0.000052931427,0.6588212,0.000026881567,0.06760689,0.008887895],"study_design_scores_gemma":[0.008103693,0.00040808078,0.6700263,0.0010763982,0.00022862774,0.000018894434,0.000574111,0.04154997,0.23382626,0.0000024141661,0.043637313,0.0005479478],"about_ca_topic_score_codex":0.00040403922,"about_ca_topic_score_gemma":0.00005358884,"teacher_disagreement_score":0.42499495,"about_ca_system_score_codex":0.00023140582,"about_ca_system_score_gemma":0.00013067208,"threshold_uncertainty_score":0.84868175},"labels":[],"label_agreement":null},{"id":"W3083196805","doi":"10.1016/j.lungcan.2020.09.002","title":"Whole exome sequencing reveals BAP1 somatic abnormalities in mesothelioma in situ","year":2020,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"","keywords":"BAP1; Mesothelioma; Peritoneal mesothelioma; Germline mutation; Exome sequencing; Cancer research; Copy number analysis; Somatic cell; Germline; Fluorescence in situ hybridization; Exome; Biology; Pathology; Copy-number variation; Mutation; Medicine; Genetics; Gene; Chromosome; Genome","score_opus":0.022117794658010108,"score_gpt":0.2903933627755822,"score_spread":0.2682755681175721,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083196805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99161565,0.0023710933,0.0000058954897,0.002901043,0.00004548215,0.00022526966,0.000032774446,0.000026880614,0.0027759175],"genre_scores_gemma":[0.9955335,0.00008208171,0.00011793133,0.0032276749,0.00013411172,0.00007117373,0.000026510641,0.000014544357,0.00079241936],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99922806,0.000025292095,0.00021264158,0.00016640028,0.00019059087,0.00017701079],"domain_scores_gemma":[0.9997379,0.000028786892,0.000035505276,0.000086735265,0.0000061196015,0.000104946],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005446331,0.00009695246,0.00019892685,0.000062751315,0.000017736653,0.000008165845,0.000048824524,0.000035312634,0.00047562845],"category_scores_gemma":[0.000028340617,0.00008706477,0.000040139872,0.00017937543,0.000028648617,0.00011586963,0.000028216265,0.00008931367,0.000051461768],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011283797,0.0000387642,0.948396,0.0005592997,0.000019799758,0.00011298519,0.0015596176,0.00045116726,0.04746188,0.000066336834,0.00090062537,0.00032063376],"study_design_scores_gemma":[0.0009224275,0.00004759922,0.9937961,0.0005326576,0.000036791935,0.0000050607464,0.00055486226,0.0013342181,0.0018874977,0.00016136884,0.00059639016,0.0001250352],"about_ca_topic_score_codex":0.0003208067,"about_ca_topic_score_gemma":0.00016006191,"teacher_disagreement_score":0.045574382,"about_ca_system_score_codex":0.0003772658,"about_ca_system_score_gemma":0.00007563875,"threshold_uncertainty_score":0.5207798},"labels":[],"label_agreement":null},{"id":"W3093890556","doi":"10.1016/j.lungcan.2020.10.008","title":"Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study","year":2020,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Biotech; Associazione Italiana per la Ricerca sul Cancro; MedImmune; Merck Sharp and Dohme; Bristol-Myers Squibb Canada; Eisai; Seattle Genetics; Merck KGaA; Daiichi Sankyo Europe; Sanofi; Novartis; Ipsen; British Mycological Society; Daiichi-Sankyo; United Therapeutics Corporation; MSD Life Science Foundation, Public Interest Incorporated Foundation; Bayer; Celgene; AstraZeneca; Roche; Astellas Pharma US; Pfizer; Boehringer Ingelheim","keywords":"Medicine; Internal medicine; Oncology; Lung cancer; Clinical endpoint; Chemotherapy; Immunotherapy; Retrospective cohort study; Confidence interval; Gemcitabine; Hazard ratio; Cancer; Clinical trial","score_opus":0.007440933025061391,"score_gpt":0.3071473753137865,"score_spread":0.2997064422887251,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3093890556","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867907,0.0037216893,0.000042863216,0.003988696,0.00043246182,0.0041674767,0.00009353767,0.000045342047,0.0007172263],"genre_scores_gemma":[0.98904914,0.00053247553,0.000081766055,0.0071524023,0.00030339477,0.0019974695,0.000013512653,0.00006736803,0.0008024879],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984388,0.00005917315,0.00032334382,0.0005034401,0.00031369377,0.0003615734],"domain_scores_gemma":[0.9992293,0.000027432727,0.00012978156,0.00032445867,0.00016802823,0.00012096466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007707952,0.00028096457,0.00038388622,0.00005152036,0.00011452938,0.000043232998,0.00015444122,0.00008848199,0.00081036496],"category_scores_gemma":[0.000009305838,0.00018890334,0.00012337974,0.00033621376,0.000045119818,0.00010528935,0.00004493342,0.00038638926,0.000007821972],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001095517,0.0010594643,0.96449727,0.000105808846,0.00054484134,0.000018032622,0.029253747,0.000030705658,0.00022687532,0.0000010495821,0.0012662577,0.0019004293],"study_design_scores_gemma":[0.013490081,0.00034288265,0.9813786,0.00014323245,0.0004506616,1.5395105e-7,0.0005607091,0.0015823324,0.00042038204,0.0000020309571,0.0014247717,0.0002041239],"about_ca_topic_score_codex":0.0032499097,"about_ca_topic_score_gemma":0.001738284,"teacher_disagreement_score":0.028693037,"about_ca_system_score_codex":0.001121484,"about_ca_system_score_gemma":0.00024248063,"threshold_uncertainty_score":0.8872928},"labels":[],"label_agreement":null},{"id":"W3096141323","doi":"10.1183/13993003.congress-2020.2925","title":"Performance and safety of endoscopic procedures in superior vena cava syndrome","year":2020,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Airway Management and Intubation Techniques","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut universitaire de cardiologie et de pneumologie de Québec","funders":"","keywords":"Medicine; Superior vena cava syndrome; Surgery; Pneumothorax; Superior vena cava; Malignancy; Bronchoscopy; Airway; Radiology; Airway obstruction; Fistula; Internal medicine","score_opus":0.01011679245102978,"score_gpt":0.2730615732906085,"score_spread":0.26294478083957873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096141323","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991032,0.0012202483,0.000019973324,0.0016475011,0.000024245948,0.00033974554,0.0000030334063,0.00003858329,0.0056746695],"genre_scores_gemma":[0.99466425,0.0038995154,0.00009838602,0.00022473893,0.00002760797,0.000042589505,0.0000027262665,0.0000074670374,0.0010327235],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996003,0.0000049623923,0.00013203228,0.00010402559,0.00008132126,0.00007736889],"domain_scores_gemma":[0.99985754,0.00000530073,0.000028744815,0.00005596937,0.000019334431,0.000033117387],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000031884727,0.000054921446,0.00014537777,0.00004098161,0.000012906935,0.0000027799877,0.000032548276,0.000025816802,0.0004972818],"category_scores_gemma":[0.000021203494,0.000047875677,0.000012973801,0.00011678865,0.000028756302,0.00006950904,0.000023667775,0.00006158789,0.0000011721694],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020307818,0.000024329413,0.9723008,0.0029964957,0.00003698979,0.0000035381263,0.0014994474,0.000013796403,0.0016749754,0.00013203606,0.007322215,0.013792289],"study_design_scores_gemma":[0.001692188,0.0014043761,0.9564234,0.0012525133,0.00007984677,0.000002178177,0.00014712545,0.0074296817,0.013930675,0.000008422828,0.017486576,0.00014300665],"about_ca_topic_score_codex":0.00004401116,"about_ca_topic_score_gemma":0.000013447669,"teacher_disagreement_score":0.015877398,"about_ca_system_score_codex":0.00003260159,"about_ca_system_score_gemma":0.00004716845,"threshold_uncertainty_score":0.54448867},"labels":[],"label_agreement":null},{"id":"W3096173347","doi":"10.1016/j.lungcan.2020.10.023","title":"Tobacco exposure and immunotherapy response in PD-L1 positive lung cancer patients","year":2020,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Lung cancer; Internal medicine; Oncology; Immunotherapy; Logistic regression; Odds ratio; Cancer; Cohort; PD-L1","score_opus":0.008505465539782077,"score_gpt":0.2914343701218268,"score_spread":0.2829289045820447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096173347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.952895,0.03705026,0.000012230888,0.008475234,0.00034375006,0.00078730955,0.00012031317,0.00004590226,0.00027004373],"genre_scores_gemma":[0.9834477,0.004998225,0.000051081694,0.010539042,0.00021439523,0.00019606952,0.000018707688,0.00004766594,0.0004871486],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99861884,0.00010703232,0.00031790492,0.000403399,0.00022788317,0.00032494575],"domain_scores_gemma":[0.99940956,0.00007324973,0.000104174316,0.00018430692,0.00009464847,0.00013405859],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015735957,0.00023091922,0.0003584046,0.000089231115,0.00007099648,0.000030790492,0.00009649062,0.00012868487,0.000693212],"category_scores_gemma":[0.000030764553,0.0002029784,0.00009254754,0.0003809584,0.0000828247,0.00013263004,0.000035178506,0.00024368745,0.0000021633807],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07423256,0.000120840945,0.8390375,0.00013436397,0.0004421159,0.000037900434,0.0069214003,0.000013188361,0.041768,0.000007005205,0.0061507653,0.031134402],"study_design_scores_gemma":[0.009700057,0.0007024789,0.9748072,0.0005894706,0.000084889005,0.0000031587526,0.00017279881,0.0003130349,0.004425848,0.000002472349,0.0089009125,0.00029768908],"about_ca_topic_score_codex":0.0015547662,"about_ca_topic_score_gemma":0.00025207343,"teacher_disagreement_score":0.13576974,"about_ca_system_score_codex":0.00050986,"about_ca_system_score_gemma":0.00027727798,"threshold_uncertainty_score":0.8277219},"labels":[],"label_agreement":null},{"id":"W3097246853","doi":"10.1016/j.lungcan.2020.10.015","title":"Pulmonary neuroendocrine neoplasms with well differentiated morphology and high proliferative activity: illustrated by a case series and review of the literature","year":2020,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Takeda Canada; British Microcirculation Society; Boehringer Ingelheim; Roche","keywords":"Medicine; Series (stratigraphy); Morphology (biology); Pathology; Neuroendocrine differentiation; Internal medicine; Biology; Zoology; Cancer; Paleontology","score_opus":0.014150203855641454,"score_gpt":0.3237106748629496,"score_spread":0.3095604710073081,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097246853","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005085943,0.98695135,5.2736607e-7,0.0035024323,0.000098029945,0.0035038856,0.00076155254,0.000041805837,0.000054486056],"genre_scores_gemma":[0.0026109125,0.9943998,0.000017839573,0.0004199189,0.000076945085,0.00056149333,0.00012716552,0.00008847166,0.0016974888],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976225,0.00048818855,0.0004171912,0.0007402047,0.00033145078,0.00040049863],"domain_scores_gemma":[0.9985948,0.00013859104,0.00041801608,0.00043355822,0.00017264721,0.00024238157],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0000350949,0.0006013198,0.0022173906,0.00008756186,0.00009541471,0.000037791597,0.00014308788,0.000031919823,0.000089575544],"category_scores_gemma":[0.00011331125,0.00031910837,0.00013210066,0.00082360633,0.00041963274,0.0001579604,0.0002460804,0.0012246718,6.8373873e-7],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011465419,0.00018786547,0.00038314346,0.6503233,0.0010641451,0.17396237,0.0000502206,2.0837426e-7,0.00022411448,0.000022743981,0.006350413,0.16628495],"study_design_scores_gemma":[0.0007644212,0.00080968376,0.000029234656,0.13622382,0.002378301,0.36779898,0.000010035944,0.000013148535,0.00030062007,0.000002992191,0.49134412,0.00032464167],"about_ca_topic_score_codex":0.00008832286,"about_ca_topic_score_gemma":0.00004472865,"teacher_disagreement_score":0.5140995,"about_ca_system_score_codex":0.00007593178,"about_ca_system_score_gemma":0.00041180087,"threshold_uncertainty_score":0.9999261},"labels":[],"label_agreement":null},{"id":"W3107615104","doi":"10.1016/j.lungcan.2020.11.029","title":"The relationship between body-mass index and overall survival in non-small cell lung cancer by sex, smoking status, and race: A pooled analysis of 20,937 International lung Cancer consortium (ILCCO) patients","year":2020,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Public Health Ontario; University of Toronto; Sinai Health System; Princess Margaret Cancer Centre","funders":"National Cancer Institute; Norges Idrettshøgskole","keywords":"Medicine; Underweight; Body mass index; Overweight; Internal medicine; Lung cancer; Hazard ratio; Obesity; Obesity paradox; Demography; Oncology; Proportional hazards model; Confidence interval","score_opus":0.014965659577513226,"score_gpt":0.3041517916218181,"score_spread":0.2891861320443049,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3107615104","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98584133,0.010197557,0.00018209015,0.0011238741,0.00039739176,0.0006728875,0.0013198318,0.00002302304,0.00024203034],"genre_scores_gemma":[0.9944457,0.0039684153,0.00001403203,0.00038931295,0.00023337537,0.00015793415,0.00021742223,0.000041970914,0.00053188286],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99777466,0.000087568194,0.00062354194,0.0005394901,0.0005385966,0.00043612218],"domain_scores_gemma":[0.99847716,0.00045663584,0.00040617728,0.00021079117,0.00018380898,0.0002654064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022933185,0.00028781279,0.00068395154,0.00020765206,0.00013439542,0.00006992873,0.00015087762,0.00016612712,0.00019185504],"category_scores_gemma":[0.000091638874,0.00024052808,0.000121305144,0.0006269726,0.00011868727,0.00016159246,0.000111539644,0.0005109166,1.3292198e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031931436,0.0000315955,0.9922744,0.00023683987,0.0017442851,0.0000026591993,0.0017100255,0.0009323471,0.00025039175,0.000012277183,0.0016001883,0.00088566693],"study_design_scores_gemma":[0.0034361093,0.00003528116,0.95927936,0.00020209918,0.0024505884,8.177034e-8,0.0001556141,0.03287042,0.00011211334,0.0000050299263,0.0012157364,0.00023755738],"about_ca_topic_score_codex":0.019235792,"about_ca_topic_score_gemma":0.0072972607,"teacher_disagreement_score":0.032995038,"about_ca_system_score_codex":0.0007101303,"about_ca_system_score_gemma":0.00036686726,"threshold_uncertainty_score":0.9872952},"labels":[],"label_agreement":null},{"id":"W3108642522","doi":"10.1016/j.lungcan.2020.11.015","title":"A reply to “Correspondence Re: Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model”","year":2020,"lang":"en","type":"letter","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada); Saskatchewan Cancer Agency; Mount Sinai Hospital; McMaster University; Alberta Cancer Foundation; William Osler Health System; AstraZeneca (Canada)","funders":"AstraZeneca Canada","keywords":"Medicine; Lung cancer; Cancer; Oncology; Internal medicine; Intensive care medicine","score_opus":0.024112624666970464,"score_gpt":0.3370667255501405,"score_spread":0.31295410088317005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3108642522","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.526874,0.013362877,0.0020654963,0.4417519,0.00088044116,0.007681878,0.0059005907,0.00011259037,0.0013702203],"genre_scores_gemma":[0.73343664,0.0034409086,0.0036722443,0.22852558,0.0033803496,0.005200163,0.004596149,0.00029133688,0.01745662],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99764794,0.00007865847,0.00071228156,0.0008303256,0.00033601117,0.00039477393],"domain_scores_gemma":[0.99850535,0.00019804892,0.00043681238,0.00054075825,0.00017883074,0.0001402071],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00010797695,0.00046114114,0.0006309439,0.00018437872,0.00010839388,0.000042378928,0.00016084405,0.00025207648,0.000082250175],"category_scores_gemma":[0.000057093825,0.00030666933,0.00015650882,0.0004517896,0.00004115574,0.000105781626,0.00006593382,0.00047172603,0.000004721686],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017616579,0.00011927392,0.07097944,0.0003700995,0.0013311248,0.00010905654,0.021695856,0.017945819,0.0012283083,9.4695747e-7,0.8821323,0.0023261448],"study_design_scores_gemma":[0.047064282,0.003371051,0.4555808,0.020600447,0.016133929,0.000028340108,0.0010464718,0.22007743,0.009154912,0.00024412428,0.22256534,0.004132859],"about_ca_topic_score_codex":0.06714196,"about_ca_topic_score_gemma":0.0019905732,"teacher_disagreement_score":0.65956694,"about_ca_system_score_codex":0.0062622502,"about_ca_system_score_gemma":0.0034169767,"threshold_uncertainty_score":0.99993855},"labels":[],"label_agreement":null},{"id":"W3116093824","doi":"10.1016/j.lungcan.2020.12.026","title":"Definitions, outcomes, and management of hyperprogression in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors","year":2020,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Takeda Canada; AstraZeneca France; Pfizer; British Microcirculation Society; Boehringer Ingelheim; AbbVie; Roche","keywords":"Medicine; Lung cancer; Incidence (geometry); Internal medicine; Cancer; Response Evaluation Criteria in Solid Tumors; Medical record; Oncology; Retrospective cohort study; Disease; Progressive disease","score_opus":0.010774719639024865,"score_gpt":0.25192111033758624,"score_spread":0.24114639069856136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3116093824","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98902804,0.008258328,0.000013673604,0.000910818,0.000057913934,0.0011671224,0.000037221358,0.00002637399,0.0005005339],"genre_scores_gemma":[0.993877,0.004758012,0.00047358088,0.00039897277,0.000024425106,0.00028678516,0.000041426993,0.000036817833,0.00010298999],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988883,0.000017364066,0.0003340645,0.0002989318,0.0002449325,0.00021640255],"domain_scores_gemma":[0.9994904,0.000010027994,0.00017047703,0.00017292866,0.00006732784,0.00008883646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000054633376,0.00020953108,0.00037846089,0.00007562299,0.000041961284,0.000010663854,0.000058082584,0.000059676597,0.00010039368],"category_scores_gemma":[0.0000012699674,0.0001365671,0.000053396845,0.00038570393,0.0000720439,0.000060343886,0.00003585314,0.00012961333,4.331017e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004776345,0.000207796,0.9867896,0.0013657504,0.00043759332,0.000021662552,0.00047544797,0.000017898734,0.001143642,0.000002857486,0.00019365984,0.004567739],"study_design_scores_gemma":[0.015472959,0.0004887024,0.97247726,0.0031769557,0.00045243482,8.284753e-7,0.00017339553,0.00018693318,0.0071298,3.86046e-7,0.0002279131,0.0002124534],"about_ca_topic_score_codex":0.0013834923,"about_ca_topic_score_gemma":0.00016587976,"teacher_disagreement_score":0.014312369,"about_ca_system_score_codex":0.00020909651,"about_ca_system_score_gemma":0.000094265735,"threshold_uncertainty_score":0.5569045},"labels":[],"label_agreement":null},{"id":"W3118230868","doi":"10.1016/j.lungcan.2020.12.029","title":"Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study","year":2020,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Roche; Merck; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb Canada; Boehringer Ingelheim","keywords":"SABR volatility model; Medicine; Radiation therapy; Clinical endpoint; Lung cancer; Oncology; Internal medicine; Randomized controlled trial","score_opus":0.020383404452767706,"score_gpt":0.3443107984212012,"score_spread":0.3239273939684335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3118230868","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860019,0.00078997377,0.00004778263,0.0051594917,0.0001181057,0.00719182,0.00037037916,0.0000674271,0.00025312515],"genre_scores_gemma":[0.9960213,0.0001419278,0.00018102552,0.0012675108,0.0000751798,0.00212941,0.000044230015,0.00006432282,0.00007513096],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974719,0.0002763714,0.00039115793,0.00078956713,0.0006463137,0.0004246854],"domain_scores_gemma":[0.9985174,0.00029995447,0.00021872616,0.000302383,0.00028966786,0.0003718764],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018032666,0.00039747125,0.00085779896,0.00013669164,0.00011683041,0.000050937684,0.00011944225,0.00006792088,0.00017521917],"category_scores_gemma":[0.00020754895,0.0002849264,0.00005849619,0.00068105035,0.00010025417,0.00020209291,0.00008420769,0.00031428554,0.0000018306862],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0072831414,0.0056009428,0.9516981,0.00010148339,0.0027024038,0.0002615337,0.028851401,0.000012963977,0.000045885932,0.0000310448,0.0006686775,0.0027424127],"study_design_scores_gemma":[0.046843138,0.012032266,0.9361725,0.0010299088,0.00076699286,0.0000025047902,0.0019059936,0.00049914484,0.00024553604,0.000028724478,0.0000768354,0.00039648442],"about_ca_topic_score_codex":0.00039802917,"about_ca_topic_score_gemma":0.00070455606,"teacher_disagreement_score":0.039559998,"about_ca_system_score_codex":0.0011487029,"about_ca_system_score_gemma":0.00034278113,"threshold_uncertainty_score":0.9999603},"labels":[],"label_agreement":null},{"id":"W3126845260","doi":"10.1016/j.lungcan.2021.01.025","title":"Safety of G-CSF with concurrent chemo-radiotherapy in limited-stage small cell lung cancer - Secondary analysis of the randomised phase 3 CONVERT trial","year":2021,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Canadian Cancer Society Research Institute; National Institute for Health and Care Research; Cancer Research UK","keywords":"Medicine; Neutropenia; Internal medicine; Regimen; Incidence (geometry); Febrile neutropenia; Granulocyte colony-stimulating factor; Gastroenterology; Randomized controlled trial; Radiation therapy; Lung cancer; Chemotherapy; Surgery; Oncology","score_opus":0.01929891310890295,"score_gpt":0.36019842857951406,"score_spread":0.3408995154706111,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3126845260","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94377536,0.048537012,0.00017991629,0.0015645116,0.000566116,0.0027455548,0.0006809172,0.000021151156,0.0019294759],"genre_scores_gemma":[0.98072207,0.013005395,0.00007836732,0.0006508095,0.00026155481,0.00068902393,0.000064678585,0.000050587598,0.00447753],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99751806,0.0002264101,0.00070839777,0.00047978226,0.0006476099,0.00041976565],"domain_scores_gemma":[0.998084,0.000318731,0.00039316056,0.00061071565,0.00046390182,0.00012950404],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004165567,0.00027817782,0.0014069718,0.00024111924,0.00006536509,0.000013488875,0.00022195028,0.000098815595,0.002747197],"category_scores_gemma":[0.00009844604,0.00018181879,0.00044144932,0.001786138,0.00029088164,0.000065332584,0.00008749346,0.00045464025,1.7372061e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.46554333,0.0028400098,0.37656277,0.0071864217,0.03586258,0.00018395808,0.013993928,0.0041820286,0.069482684,0.0000642368,0.0112377945,0.012860261],"study_design_scores_gemma":[0.8056142,0.00061071815,0.022510394,0.0015084473,0.00826824,0.0000024746832,0.00070958043,0.026498161,0.12127092,0.0000011588154,0.012521936,0.0004838058],"about_ca_topic_score_codex":0.0019482492,"about_ca_topic_score_gemma":0.005051947,"teacher_disagreement_score":0.3540524,"about_ca_system_score_codex":0.0010063222,"about_ca_system_score_gemma":0.0025795652,"threshold_uncertainty_score":0.9981644},"labels":[],"label_agreement":null},{"id":"W3130089277","doi":"10.1016/j.lungcan.2021.02.030","title":"MET exon 14 skipping mutation positive non-small cell lung cancer: Response to systemic therapy","year":2021,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia; BC Cancer Agency","funders":"Roche; Merck; AstraZeneca","keywords":"Medicine; Discontinuation; Crizotinib; Internal medicine; Oncology; Lung cancer; Targeted therapy; Population; Chemotherapy; Cancer","score_opus":0.01069406291528424,"score_gpt":0.3345778876241834,"score_spread":0.32388382470889915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3130089277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9621422,0.029079473,0.0016088272,0.0024750293,0.0010629832,0.0016050155,0.00020034106,0.00009145179,0.0017346581],"genre_scores_gemma":[0.98323655,0.0016059225,0.0009789951,0.0026610524,0.00041746182,0.0012571283,0.000111599235,0.00007016514,0.009661112],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99830663,0.00013731091,0.00032017299,0.00053853495,0.000307774,0.0003896022],"domain_scores_gemma":[0.9986948,0.00013623173,0.00013357901,0.0003609688,0.00044690585,0.00022754338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017058045,0.00025390205,0.00040092066,0.00015861235,0.00015671631,0.000059640457,0.00008574213,0.00010981319,0.00033723592],"category_scores_gemma":[0.00003352548,0.00023496101,0.00013857835,0.0005403137,0.00002017619,0.000113120775,0.00003432471,0.00017202202,0.000016738064],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00884637,0.0008979917,0.1279715,0.0020147816,0.0050714863,0.0026479745,0.073571354,0.010150293,0.6741454,0.00013459177,0.024163539,0.07038471],"study_design_scores_gemma":[0.034320705,0.0019017432,0.45948452,0.013322861,0.0071064197,0.000495427,0.008414216,0.006959187,0.4401981,0.000041125986,0.025453713,0.0023020068],"about_ca_topic_score_codex":0.0017358592,"about_ca_topic_score_gemma":0.00037870213,"teacher_disagreement_score":0.331513,"about_ca_system_score_codex":0.0017704939,"about_ca_system_score_gemma":0.0014846198,"threshold_uncertainty_score":0.95814323},"labels":[],"label_agreement":null},{"id":"W3134321408","doi":"10.1016/j.lungcan.2021.02.019","title":"A reply to “Lung cancer outcomes: Are BMI and race clinically relevant?”","year":2021,"lang":"en","type":"letter","venue":"Lung Cancer","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Sinai Health System; Princess Margaret Cancer Centre; Public Health Ontario; University of Toronto","funders":"","keywords":"Medicine; Race (biology); Lung cancer; Oncology; Internal medicine","score_opus":0.02857701456576859,"score_gpt":0.3799848214228085,"score_spread":0.3514078068570399,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134321408","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.020060906,0.03110739,0.00007533804,0.94087964,0.0044330903,0.0015537797,0.00083034177,0.00019054441,0.0008689823],"genre_scores_gemma":[0.0015880687,0.0135793965,0.00028574053,0.91555023,0.008142972,0.00075186533,0.00015323657,0.00022620388,0.059722293],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958982,0.000090778645,0.00094747555,0.0014480564,0.0008020584,0.0008134199],"domain_scores_gemma":[0.9971846,0.00032315476,0.00051523664,0.0011920759,0.00039414622,0.0003907971],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00024230222,0.0006901601,0.0018399487,0.00019958732,0.00012058216,0.000120820856,0.0002509715,0.0008854638,0.0019762046],"category_scores_gemma":[0.00034700663,0.00057256775,0.00044820574,0.00037850352,0.00011622158,0.00009080788,0.00023021176,0.002642966,0.000016484655],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014199714,0.000020088231,0.32594252,0.0011361963,0.0005838062,0.000701613,0.00028918913,0.000008763248,0.00001679459,0.000001116184,0.66896194,0.0021959743],"study_design_scores_gemma":[0.0014981224,0.00009191242,0.075657055,0.0036746091,0.0012726142,0.000034860674,0.000059040907,0.0000746778,0.0000109228995,0.000005288362,0.9169689,0.00065200933],"about_ca_topic_score_codex":0.009470835,"about_ca_topic_score_gemma":0.0020233423,"teacher_disagreement_score":0.25028545,"about_ca_system_score_codex":0.0011496638,"about_ca_system_score_gemma":0.0012048186,"threshold_uncertainty_score":0.9996726},"labels":[],"label_agreement":null},{"id":"W3135006396","doi":"10.1016/j.lungcan.2021.02.036","title":"Impact of EGFR mutation on outcomes following SRS for brain metastases in non-small cell lung cancer","year":2021,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Kingston Health Sciences Centre; Toronto Western Hospital; Southlake Regional Health Center; Princess Margaret Cancer Centre; University Health Network; University of Toronto; Queen's University","funders":"","keywords":"Medicine; Radiosurgery; Incidence (geometry); Lung cancer; Internal medicine; Proportional hazards model; Oncology; Concomitant; Toxicity; Radiation therapy","score_opus":0.01833466819261894,"score_gpt":0.3719808780207105,"score_spread":0.3536462098280916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135006396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99001074,0.0059065456,0.0006357133,0.0014278783,0.00036722224,0.0009446378,0.00043158312,0.00001675806,0.00025889784],"genre_scores_gemma":[0.99515074,0.000108760534,0.0021028551,0.00073376804,0.0000725382,0.0004578979,0.00016417375,0.000040789302,0.00116849],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99876547,0.000060226903,0.00032055195,0.0003292346,0.00021076146,0.0003137747],"domain_scores_gemma":[0.9991063,0.0003243289,0.000127667,0.00025251182,0.00009031808,0.000098906625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020336793,0.00021707542,0.00055628136,0.00012418421,0.000040988667,0.000014429735,0.000050628772,0.00006137348,0.00028458596],"category_scores_gemma":[0.00009319423,0.0001651894,0.00050110504,0.0002587436,0.0000145934655,0.0000605765,0.00001941095,0.00010655948,0.0000011030081],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034610782,0.0006850735,0.9645564,0.0008978814,0.0021129695,0.0003362181,0.001051126,0.006270093,0.0049815825,0.000069778886,0.0051342654,0.013558532],"study_design_scores_gemma":[0.018498676,0.0008436212,0.9296463,0.0014638227,0.0029835857,0.000007950419,0.00050266937,0.0051999907,0.0393373,0.0000551345,0.0009811664,0.00047978183],"about_ca_topic_score_codex":0.0038055168,"about_ca_topic_score_gemma":0.0017654303,"teacher_disagreement_score":0.03491007,"about_ca_system_score_codex":0.0006436566,"about_ca_system_score_gemma":0.00050015654,"threshold_uncertainty_score":0.6736228},"labels":[],"label_agreement":null},{"id":"W3143892312","doi":"10.1016/j.lungcan.2021.03.017","title":"Non-small cell lung cancer stage migration as a function of wait times from diagnostic imaging: A pooled analysis from five international centres","year":2021,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Stage (stratigraphy); Adenocarcinoma; Lung cancer; Radiology; Confidence interval; Radiation therapy; Cancer; Nuclear medicine; Internal medicine","score_opus":0.005371146779315362,"score_gpt":0.26998970909895226,"score_spread":0.2646185623196369,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3143892312","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9637682,0.028124437,0.00047646093,0.0035005012,0.001006305,0.00045751967,0.0014539518,0.000040871193,0.0011717837],"genre_scores_gemma":[0.9861102,0.005592486,0.00021126574,0.0008746925,0.0005528976,0.00040796364,0.0017840986,0.00003319532,0.0044331793],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99830335,0.00004393385,0.00038739588,0.00059544476,0.00042858918,0.00024125865],"domain_scores_gemma":[0.99855125,0.00029225808,0.00026821744,0.00036816747,0.00038083683,0.00013924457],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00004245557,0.0002516752,0.0005084872,0.00016166906,0.000057096204,0.00005640162,0.00010326298,0.00008175716,0.010465166],"category_scores_gemma":[0.000055700395,0.00022593306,0.000314826,0.00042322764,0.000032532273,0.00012822448,0.00006313869,0.00013939764,0.00001380675],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027123466,0.0004202711,0.9705799,0.00011364032,0.0075241243,0.000109550274,0.0014307627,0.0020087822,0.0031180142,0.00002506815,0.012228831,0.0021697844],"study_design_scores_gemma":[0.0039600036,0.00005917949,0.89205205,0.0008491958,0.021284673,6.006779e-7,0.0005675226,0.042643864,0.034392428,0.000046216566,0.0038504165,0.0002938307],"about_ca_topic_score_codex":0.07332035,"about_ca_topic_score_gemma":0.02227934,"teacher_disagreement_score":0.07852787,"about_ca_system_score_codex":0.0009491565,"about_ca_system_score_gemma":0.0005227462,"threshold_uncertainty_score":0.99556154},"labels":[],"label_agreement":null},{"id":"W3153040841","doi":"10.1016/j.lungcan.2021.04.005","title":"Selection of individuals for lung cancer screening based on risk prediction model performance and economic factors – The Ontario experience","year":2021,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Public Health Ontario; Toronto General Hospital; University of Toronto; University Health Network; Women's College Hospital; Cancer Care Ontario; Princess Margaret Cancer Centre; Brock University","funders":"","keywords":"Medicine; Lung cancer screening; Lung cancer; Population; Cancer registry; Cancer; Risk assessment; Categorical variable; Environmental health; Internal medicine; Statistics","score_opus":0.01835187791511211,"score_gpt":0.3005128474192939,"score_spread":0.2821609695041818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3153040841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99613076,0.0008888957,0.0012551913,0.00037135533,0.000281179,0.000645521,0.0002541248,0.00002217185,0.00015080867],"genre_scores_gemma":[0.9965473,0.0010409903,0.0006126086,0.00021711558,0.00012407881,0.00096765865,0.000035072473,0.00002068694,0.00043452394],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99908096,0.000019565767,0.00021709476,0.00032501662,0.00016521342,0.00019213614],"domain_scores_gemma":[0.99942654,0.00008976565,0.00015620247,0.00018105592,0.00008187935,0.00006454369],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000958852,0.00015377378,0.00023459,0.00004768472,0.00019215973,0.00002222899,0.000043965534,0.000066069515,0.00019290483],"category_scores_gemma":[0.000011703061,0.00010965499,0.00008014244,0.000077983226,0.000040627565,0.00011147917,0.000016910753,0.00013517673,1.0788782e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013309116,0.000045477682,0.9019835,0.00012645531,0.00019960076,2.1617788e-7,0.0023088094,0.092590034,0.00007107224,0.000009261187,0.00088782504,0.0016446395],"study_design_scores_gemma":[0.0011699644,0.000114716975,0.46671852,0.00033864268,0.00041403028,8.1623233e-7,0.00006691055,0.5194888,0.011090551,0.0000017536637,0.00052311935,0.00007214824],"about_ca_topic_score_codex":0.016011387,"about_ca_topic_score_gemma":0.02040437,"teacher_disagreement_score":0.435265,"about_ca_system_score_codex":0.0012111934,"about_ca_system_score_gemma":0.00054252,"threshold_uncertainty_score":0.9974707},"labels":[],"label_agreement":null},{"id":"W3155565607","doi":"10.1016/j.lungcan.2021.04.006","title":"Durability of CNS disease control in NSCLC patients with brain metastases treated with immune checkpoint inhibitors plus cranial radiotherapy","year":2021,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Radiation therapy; Oncology; Immune checkpoint; Internal medicine; Disease; Prophylactic cranial irradiation; Immune system; Immunotherapy; Cancer; Immunology","score_opus":0.005355088471290016,"score_gpt":0.25745019468544217,"score_spread":0.25209510621415215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3155565607","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908152,0.004927715,0.00025075188,0.002189164,0.00006347016,0.0011436124,0.000541074,0.00002633552,0.00004265414],"genre_scores_gemma":[0.9984886,0.00007209591,0.00040462456,0.00042485187,0.000060015464,0.00018835283,0.00020390374,0.00003782032,0.00011973768],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983935,0.0001689227,0.00039903034,0.00039583698,0.0003647373,0.00027802112],"domain_scores_gemma":[0.9989281,0.000103747276,0.00015786315,0.00041914123,0.00019963103,0.00019149312],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015028889,0.00025215093,0.00067288824,0.000074323,0.00003893455,0.000012309676,0.000046345678,0.000041418538,0.00054841343],"category_scores_gemma":[0.00005513328,0.00016053945,0.00014489911,0.0003702423,0.00012986107,0.00007468734,0.0000121295025,0.0001272364,5.543288e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014197309,0.0017204265,0.97581565,0.00031249804,0.0012568056,0.0003973191,0.00033526076,0.000540881,0.0016990989,0.000020433545,0.00017382432,0.0035304925],"study_design_scores_gemma":[0.045440666,0.00089378306,0.9463981,0.0006573975,0.00083541445,0.0000067610276,0.000081856095,0.0005016401,0.004593362,0.0000048262327,0.00035560736,0.0002305978],"about_ca_topic_score_codex":0.0015002806,"about_ca_topic_score_gemma":0.00058612536,"teacher_disagreement_score":0.031243358,"about_ca_system_score_codex":0.0004852506,"about_ca_system_score_gemma":0.0005896367,"threshold_uncertainty_score":0.6546609},"labels":[],"label_agreement":null},{"id":"W3157516959","doi":"10.1016/j.lungcan.2021.04.022","title":"Two-year survival with nivolumab in previously treated advanced non–small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and Canada","year":2021,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Bristol-Myers Squibb (Canada); McMaster University; Institut universitaire de cardiologie et de pneumologie de Québec; Juravinski Cancer Centre","funders":"Bristol-Myers Squibb","keywords":"Medicine; Nivolumab; Lung cancer; Pooled analysis; Oncology; Internal medicine; Cancer; Demography; Intensive care medicine; Immunotherapy; Meta-analysis","score_opus":0.004109893966680977,"score_gpt":0.2502025030859512,"score_spread":0.24609260911927022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157516959","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884713,0.008316259,0.0000074581276,0.00014639631,0.00022067688,0.0006450438,0.0005090442,0.000019650744,0.0016641166],"genre_scores_gemma":[0.99220365,0.004277118,0.00014698668,0.00033541804,0.000061987885,0.0001599822,0.00025679008,0.00004354354,0.0025144988],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981003,0.00007322777,0.00047955607,0.0005533093,0.00040246703,0.00039115016],"domain_scores_gemma":[0.99884033,0.00007046602,0.00026288713,0.00042682418,0.00025971184,0.00013978984],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000080290585,0.00028109842,0.0009065498,0.00023032655,0.000053253363,0.000016776994,0.000105736326,0.00007063415,0.0005928391],"category_scores_gemma":[0.0000050723957,0.0002476393,0.00011627185,0.0016101998,0.00006111136,0.00007329998,0.000037857037,0.00019133372,1.5661516e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025411458,0.00013445491,0.9867733,0.00023965177,0.003595307,0.000062703395,0.0004483482,0.0003791028,0.0034059796,0.0000013012601,0.00034604792,0.0020726253],"study_design_scores_gemma":[0.012663965,0.00008957078,0.9747495,0.0006800956,0.0045218472,3.499011e-7,0.00019632898,0.002009957,0.004060362,3.7853314e-7,0.00072032714,0.00030732818],"about_ca_topic_score_codex":0.9298399,"about_ca_topic_score_gemma":0.9886659,"teacher_disagreement_score":0.058826007,"about_ca_system_score_codex":0.00090673467,"about_ca_system_score_gemma":0.0015850574,"threshold_uncertainty_score":0.99999756},"labels":[],"label_agreement":null},{"id":"W3159640992","doi":"10.1016/j.lungcan.2021.04.025","title":"Malignant pleural mesothelioma: Comparison of surgery-based trimodality therapy to medical therapy at two tertiary academic institutions","year":2021,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Institut universitaire de cardiologie et de pneumologie de Québec","funders":"","keywords":"Medicine; Cohort; Radiation therapy; Systemic therapy; Chemotherapy; Hazard ratio; Mesothelioma; Surgery; Internal medicine; Cancer; Breast cancer; Pathology","score_opus":0.08764534016131116,"score_gpt":0.4213575770566978,"score_spread":0.33371223689538665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3159640992","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9810252,0.010966694,0.00014714818,0.006937677,0.0002594417,0.00028407798,0.00016651793,0.000035598827,0.00017761416],"genre_scores_gemma":[0.99164903,0.0009004957,0.00006239392,0.0065811304,0.00019212342,0.00011001788,0.00018888114,0.000016710408,0.00029923904],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984226,0.00008223843,0.0003805881,0.0002726839,0.0006293271,0.00021254327],"domain_scores_gemma":[0.9991582,0.00014066575,0.000082583,0.00022941429,0.000046210243,0.00034291274],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00013363632,0.00014856098,0.0003667824,0.000068322275,0.00008623217,0.000004672723,0.0000869549,0.00009340387,0.0031817274],"category_scores_gemma":[0.00006763621,0.00011296058,0.0001828119,0.0002336198,0.00013085999,0.000048835354,0.00004108834,0.00014941003,0.000015900278],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009876591,0.000459296,0.958137,0.000051581486,0.00011653577,0.000030785137,0.00011956519,0.00026696702,0.028549042,0.00007886099,0.0055519426,0.005650782],"study_design_scores_gemma":[0.002199563,0.000049853792,0.87881726,0.0002863476,0.000060696282,0.000007967553,0.000026668089,0.0009318657,0.10740439,0.000014634397,0.010050629,0.00015012147],"about_ca_topic_score_codex":0.00052907906,"about_ca_topic_score_gemma":0.000111148795,"teacher_disagreement_score":0.079319715,"about_ca_system_score_codex":0.00025993228,"about_ca_system_score_gemma":0.0010000861,"threshold_uncertainty_score":0.9977295},"labels":[],"label_agreement":null},{"id":"W3165571064","doi":"10.1016/j.lungcan.2021.05.021","title":"A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer","year":2021,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lakeridge Health; Trillium Health Centre; University Health Network; University of Toronto; St Joseph's Health Centre; Princess Margaret Cancer Centre; Markham Stouffville Hospital; Queen's University","funders":"Novartis Pharmaceuticals Canada; Princess Margaret Cancer Foundation; Array BioPharma","keywords":"Medicine; Pemetrexed; Carboplatin; KRAS; Internal medicine; Oncology; MEK inhibitor; Lung cancer; Neuroblastoma RAS viral oncogene homolog; Adverse effect; Rash; Trametinib; Chemotherapy; Cancer; Colorectal cancer; MAPK/ERK pathway; Kinase; Cisplatin","score_opus":0.012106317204449145,"score_gpt":0.34483031731766367,"score_spread":0.3327240001132145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165571064","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97969794,0.015517574,0.00005120791,0.000507157,0.00044345803,0.002098161,0.000116859956,0.000033729357,0.001533902],"genre_scores_gemma":[0.9943527,0.0010808754,0.00040215734,0.00042064526,0.00023877391,0.00092992955,0.000043070435,0.00007760711,0.0024542648],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99796146,0.000063786116,0.00055645185,0.00064292044,0.0003564654,0.00041888686],"domain_scores_gemma":[0.9988285,0.00011074499,0.00022758127,0.00040539607,0.0002287868,0.00019901259],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00013232711,0.00034653378,0.0007739692,0.00024263139,0.00008311241,0.000030452331,0.00008771785,0.00012076451,0.00037790716],"category_scores_gemma":[0.000024698116,0.00031073063,0.00010453746,0.0008072027,0.000054298263,0.00008611718,0.0000571278,0.0002641953,0.0000012011143],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030612927,0.012954227,0.7555379,0.0030393791,0.0025076051,0.00089979585,0.10167263,0.0009540032,0.07995285,0.000009284215,0.006820273,0.032590743],"study_design_scores_gemma":[0.38869253,0.0068129343,0.3434603,0.003996994,0.009121327,0.000063694904,0.027418341,0.03712397,0.17764743,0.00002107738,0.0033767885,0.0022646256],"about_ca_topic_score_codex":0.011574871,"about_ca_topic_score_gemma":0.0076195854,"teacher_disagreement_score":0.41207764,"about_ca_system_score_codex":0.0007308167,"about_ca_system_score_gemma":0.0011721896,"threshold_uncertainty_score":0.9999345},"labels":[],"label_agreement":null},{"id":"W3169556370","doi":"10.1016/j.lungcan.2021.06.002","title":"The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer","year":2021,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Queen Elizabeth II Health Sciences Centre; William Osler Health System; Humber Polytechnic; Dalhousie University; University of Toronto; Juravinski Cancer Centre; Princess Margaret Cancer Centre; BC Cancer Agency; Ottawa Hospital; University of Ottawa; McMaster University","funders":"","keywords":"Medicine; Lung cancer; Oncology; Intensive care medicine","score_opus":0.017649542354702362,"score_gpt":0.3591299504094271,"score_spread":0.34148040805472474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3169556370","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00037501886,0.9935294,0.00006989514,0.00021382257,0.0011284123,0.0022760087,0.00030499193,0.000033973432,0.0020684826],"genre_scores_gemma":[0.00063921534,0.9907337,0.0005877428,0.000117998534,0.00035205655,0.002471549,0.00020554216,0.00012468855,0.0047675506],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99763244,0.00008073192,0.000834118,0.0005936616,0.00033486515,0.0005241652],"domain_scores_gemma":[0.99805754,0.000312295,0.00059037504,0.00063047546,0.00029252283,0.00011679414],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018448371,0.00053939386,0.0018319862,0.00019748698,0.00015070567,0.000046859102,0.00026506078,0.00026104067,0.0004564782],"category_scores_gemma":[0.00003883509,0.00034029712,0.00052927516,0.0007948669,0.000065171596,0.00008627549,0.00007860466,0.00051077636,0.0000016634452],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000088591754,0.0005827879,0.010384829,0.047222935,0.005195775,0.000070520364,0.0036337834,0.00033852822,0.00013896957,0.00007026233,0.011316962,0.9209561],"study_design_scores_gemma":[0.004147048,0.00007821248,0.0010990965,0.05483792,0.00677981,0.000010474027,0.00048764568,0.00081752246,0.000056245535,0.0000018638957,0.9310977,0.00058648473],"about_ca_topic_score_codex":0.0010525004,"about_ca_topic_score_gemma":0.0013873931,"teacher_disagreement_score":0.92036957,"about_ca_system_score_codex":0.0009262536,"about_ca_system_score_gemma":0.003140051,"threshold_uncertainty_score":0.99990493},"labels":[],"label_agreement":null},{"id":"W3183328865","doi":"10.1016/j.lungcan.2021.07.007","title":"Stereotactic ablative radiotherapy in T1-2N0M0 small cell lung cancer: A systematic review and meta-analysis","year":2021,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; London Health Sciences Centre; University of Toronto","funders":"","keywords":"Medicine; SABR volatility model; Meta-analysis; Confidence interval; Radiation therapy; Internal medicine; Lung cancer; Observational study; Systematic review; Surgery; Oncology; MEDLINE","score_opus":0.09116733073286165,"score_gpt":0.45274710486949943,"score_spread":0.3615797741366378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3183328865","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000019005633,0.98689616,0.000026304951,0.0009753446,0.00012431019,0.011185535,0.0003445065,0.000051316496,0.00039461913],"genre_scores_gemma":[0.000006809941,0.9714981,0.00012752712,0.0012381375,0.00013804725,0.015967509,0.000064311476,0.00015791999,0.010801656],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99354476,0.0014694405,0.0018371361,0.0014208967,0.00088352413,0.00084423943],"domain_scores_gemma":[0.99586123,0.00086221535,0.0011750521,0.0013617,0.00041848578,0.00032134395],"candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001212838,0.0011282545,0.020358426,0.000801509,0.00011279872,0.000103213766,0.00039933855,0.00029836883,0.0021295599],"category_scores_gemma":[0.00025555378,0.00073413114,0.0032954395,0.0033158709,0.00012590605,0.00012022935,0.00021375457,0.0011923616,0.000004532061],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000069709804,0.000043721633,0.00011190674,0.6872714,0.30973318,0.00013379942,0.0003463564,0.0000028830234,1.09978245e-7,0.0000040945642,0.0015849344,0.0007606314],"study_design_scores_gemma":[0.00044358795,0.000038930288,0.000007072205,0.20238355,0.7523504,0.000026689,0.000033402906,0.00006858387,4.976898e-7,3.9642904e-7,0.044140246,0.00050665083],"about_ca_topic_score_codex":0.0025970482,"about_ca_topic_score_gemma":0.0023686702,"teacher_disagreement_score":0.48488787,"about_ca_system_score_codex":0.0037106154,"about_ca_system_score_gemma":0.002018897,"threshold_uncertainty_score":0.999511},"labels":[],"label_agreement":null},{"id":"W3192563092","doi":"10.1016/j.lungcan.2021.08.003","title":"Canadian ROS proto-oncogene 1 study (CROS) for multi-institutional implementation of ROS1 testing in non-small cell lung cancer","year":2021,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saskatchewan Health Authority; University of Saskatchewan; Dalhousie University; Queen Elizabeth II Health Sciences Centre; McGill University Health Centre; University of Ottawa; Calgary Laboratory Services; University of Manitoba; University of Calgary; Spinal Cord Injury BC; Canada's Michael Smith Genome Sciences Centre; Sunnybrook Health Science Centre; Ottawa Hospital; University Health Network; McMaster University Medical Centre; Health Sciences Centre; London Health Sciences Centre; Health Sciences North; Institut Universitaire de Cardiologie et de Pneumologie de Québec; Centre Hospitalier de l’Université de Montréal; Université Laval; University of Alberta; University of Toronto","funders":"Pfizer Canada","keywords":"ROS1; Immunohistochemistry; Medicine; Crizotinib; Lung cancer; Fluorescence in situ hybridization; Cancer research; Pathology; Cancer; Oncogene; Adenocarcinoma; Internal medicine; Biology; Gene; Cell cycle; Genetics","score_opus":0.03611358999379091,"score_gpt":0.40586751162549994,"score_spread":0.36975392163170906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3192563092","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98623514,0.002594941,0.0009989415,0.00045310348,0.00048263816,0.007517115,0.0011231373,0.000023247703,0.00057174277],"genre_scores_gemma":[0.9868777,0.000055889726,0.004494937,0.0002790933,0.0001942491,0.0066882856,0.00023254521,0.00003574511,0.0011415788],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99863636,0.000023586272,0.00040361503,0.00037873548,0.00018591531,0.00037179305],"domain_scores_gemma":[0.9990263,0.000040083116,0.0001324989,0.00018808703,0.00043918213,0.00017384434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011094204,0.0001864582,0.00031484783,0.00014494952,0.00017594516,0.000023101376,0.00006518278,0.000060229322,0.00026574818],"category_scores_gemma":[0.00003097362,0.00017079122,0.00007362403,0.0004138016,0.000022424303,0.00008821404,0.000023295788,0.000103116436,8.3354587e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000053255808,0.0003532754,0.97725403,0.00051651656,0.00028266563,0.00005445787,0.0028681997,0.001818839,0.009285533,0.000013363117,0.00036356013,0.0071362783],"study_design_scores_gemma":[0.02177883,0.00033513777,0.90888983,0.0008040974,0.0016336098,0.000010786157,0.004075506,0.018105952,0.041793372,0.0000053031613,0.0021473723,0.00042020783],"about_ca_topic_score_codex":0.4392027,"about_ca_topic_score_gemma":0.81931096,"teacher_disagreement_score":0.38010827,"about_ca_system_score_codex":0.0025689865,"about_ca_system_score_gemma":0.0064952485,"threshold_uncertainty_score":0.999137},"labels":[],"label_agreement":null},{"id":"W3198449529","doi":"10.1016/j.lungcan.2021.08.014","title":"ALK inhibitor-induced bradycardia: A systematic-review and meta-analysis","year":2021,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Impact; Population Health Research Institute; University of Toronto; McMaster University; Hamilton Health Sciences","funders":"","keywords":"Crizotinib; Medicine; Alectinib; Bradycardia; Anaplastic lymphoma kinase; Internal medicine; Oncology; Adverse effect; Lung cancer; Heart rate","score_opus":0.07416902445756512,"score_gpt":0.44421100264302055,"score_spread":0.3700419781854554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3198449529","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[1.4883882e-7,0.9927166,0.000011950593,0.00061084493,0.0001695358,0.004822605,0.00040758075,0.000050236646,0.0012105095],"genre_scores_gemma":[0.0000061335663,0.9838793,0.00008654299,0.0012499145,0.0001583548,0.0061942744,0.00039506625,0.00007423064,0.007956167],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9973113,0.00028412737,0.000985034,0.0007231985,0.0004098269,0.00028654825],"domain_scores_gemma":[0.99790627,0.00014992474,0.00055465073,0.00093531876,0.00022232394,0.00023153746],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00022932998,0.0006114439,0.012988111,0.00025077182,0.000087610424,0.00006608128,0.00010848474,0.0002358756,0.0010975956],"category_scores_gemma":[0.00007422857,0.0003647647,0.004578057,0.001269359,0.000026243739,0.00006593095,0.00007165325,0.0003087832,0.000017569837],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[2.7902337e-7,0.000022749535,0.0000010856553,0.55748117,0.43754378,0.00004819098,0.000025399777,8.555962e-8,2.1579297e-8,0.000025116227,0.0019300837,0.0029220707],"study_design_scores_gemma":[0.00012791,0.000013719392,5.624383e-7,0.075237125,0.7261137,0.00005466247,0.0000065739837,0.0000010216862,2.11049e-7,3.8119907e-7,0.19822466,0.00021951266],"about_ca_topic_score_codex":0.00021220582,"about_ca_topic_score_gemma":0.00007096872,"teacher_disagreement_score":0.482244,"about_ca_system_score_codex":0.0005207663,"about_ca_system_score_gemma":0.0009151846,"threshold_uncertainty_score":0.99988043},"labels":[],"label_agreement":null},{"id":"W3201631634","doi":"10.1016/j.lungcan.2021.09.003","title":"Molecular testing in stage I–III non-small cell lung cancer: Approaches and challenges","year":2021,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"AstraZeneca","keywords":"Medicine; Stage (stratigraphy); Lung cancer; Oncology; Internal medicine; Computational biology; Cancer research; Biology","score_opus":0.09481768416690141,"score_gpt":0.3480119460773508,"score_spread":0.2531942619104494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201631634","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00070855604,0.9917315,0.0000069253,0.000438071,0.00035888804,0.0024017515,0.00010854243,0.000050228657,0.0041954964],"genre_scores_gemma":[0.0004670883,0.9931222,0.0003829206,0.00012921295,0.00041214476,0.004404416,0.00008741444,0.00016310872,0.0008314809],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971177,0.000113992406,0.00064397766,0.0011855111,0.00032136624,0.00061746646],"domain_scores_gemma":[0.9984661,0.00021314263,0.00036357733,0.00061991444,0.000088327055,0.00024896977],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002087886,0.0007455047,0.0025821438,0.00021780387,0.00006787518,0.0000572305,0.00016702281,0.00039676853,0.00010414189],"category_scores_gemma":[0.000025124753,0.000610085,0.00033846896,0.00045527885,0.000055691533,0.00005429479,0.00017999983,0.00061929977,0.0000018293201],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010288337,0.00026584836,0.006289409,0.16691585,0.0010291636,0.00078710454,0.0005452404,0.000062745334,0.0000014557937,0.00007041278,0.0003964892,0.823626],"study_design_scores_gemma":[0.0032984253,0.00014981048,0.00064605864,0.1835635,0.009704362,0.000048703823,0.00024035026,0.00086277677,0.00007673474,0.0000020363163,0.80021703,0.0011902242],"about_ca_topic_score_codex":0.002297024,"about_ca_topic_score_gemma":0.0010910352,"teacher_disagreement_score":0.8224358,"about_ca_system_score_codex":0.0018504607,"about_ca_system_score_gemma":0.0016493256,"threshold_uncertainty_score":0.99963504},"labels":[],"label_agreement":null},{"id":"W3215059890","doi":"10.1016/j.lungcan.2021.11.011","title":"A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer","year":2021,"lang":"en","type":"article","venue":"Lung Cancer","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"EMD Serono; Sierra Oncology; MacroGenics; BeiGene; Janssen Pharmaceuticals; Merck KGaA; Sanofi; TG Therapeutics; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; GlaxoSmithKline","keywords":"Medicine; Gemcitabine; Tolerability; Internal medicine; Lung cancer; Nausea; Adverse effect; Oncology; Gastroenterology; Cancer","score_opus":0.006218265558364029,"score_gpt":0.29263375914906253,"score_spread":0.2864154935906985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3215059890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966689,0.0016739276,0.00014691049,0.000048437865,0.000057294757,0.0013143445,0.000018133736,0.0000044945327,0.000067593195],"genre_scores_gemma":[0.99899614,0.00009565291,0.00039756205,0.000052400243,0.000016035441,0.00024881848,0.00005001171,0.000025257918,0.00011813346],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99890536,0.000108362176,0.00023270414,0.0003740052,0.00019172509,0.00018783336],"domain_scores_gemma":[0.9993553,0.000026780408,0.00014038954,0.0002759441,0.00016938383,0.000032156335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019155422,0.00015043616,0.00019137036,0.000034779252,0.000041553947,0.000009298574,0.000097124,0.00005244653,0.000009831788],"category_scores_gemma":[0.000027116044,0.00010955863,0.000019055058,0.00021164799,0.000029145418,0.000008765152,0.00009495268,0.000106071406,4.9524374e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0087956805,0.0049881632,0.83947206,0.0002620718,0.0001528091,0.000012850272,0.002558059,0.007965997,0.11912741,0.000005785414,0.000013899626,0.016645238],"study_design_scores_gemma":[0.06581877,0.0099250935,0.7860883,0.00054949726,0.00023349107,0.0000012817867,0.0008265323,0.011880845,0.12427082,0.0000034230854,0.00002492926,0.00037704126],"about_ca_topic_score_codex":0.00021181477,"about_ca_topic_score_gemma":0.0016021307,"teacher_disagreement_score":0.05702309,"about_ca_system_score_codex":0.00007918669,"about_ca_system_score_gemma":0.00024467576,"threshold_uncertainty_score":0.44676712},"labels":[],"label_agreement":null},{"id":"W4205367336","doi":"10.1016/j.lungcan.2021.12.019","title":"Short communication: The activity of brigatinib in patients with disease progression after next generation anaplastic lymphoma tyrosine kinase inhibitors and an exploratory analysis of circulating tumor DNA","year":2022,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Takeda Pharmaceuticals U.S.A.","keywords":"Medicine; Anaplastic lymphoma kinase; Internal medicine; Cohort; Oncology; Clinical endpoint; Alectinib; Progressive disease; Lung cancer; Chemotherapy; Clinical trial","score_opus":0.016814873006195555,"score_gpt":0.3132456634977558,"score_spread":0.29643079049156024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205367336","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978791,0.0012939267,0.000013532017,0.00010489512,0.00003541131,0.00054804294,0.00010721192,0.00000764266,0.000010271238],"genre_scores_gemma":[0.9990275,0.0000131118195,0.00007185177,0.000057747642,0.000022699101,0.0005719386,0.00021850344,0.000012264679,0.0000044126423],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991635,0.00011131061,0.00019069602,0.00017364435,0.00027549695,0.000085339394],"domain_scores_gemma":[0.9993711,0.0000288218,0.00013975907,0.0002989861,0.000097684046,0.00006360905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008866602,0.000089872694,0.00019566774,0.00012432925,0.0001233219,0.000010765188,0.00004404811,0.000011867842,0.000039098373],"category_scores_gemma":[0.000011081878,0.00006247812,0.00003549116,0.00057654135,0.00007507948,0.00017454538,0.00004826871,0.00005596633,2.0268613e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006815458,0.00049630285,0.98258734,0.000063261105,0.0002981067,0.000005123975,0.0018518895,0.002239119,0.0007556445,0.0000076279966,0.000011046086,0.011002966],"study_design_scores_gemma":[0.001258066,0.00019140558,0.979507,0.00012810905,0.0015471259,2.5867462e-7,0.0002357627,0.016542427,0.0005139158,0.0000014778674,0.000008148955,0.000066273606],"about_ca_topic_score_codex":0.000172568,"about_ca_topic_score_gemma":0.0005158548,"teacher_disagreement_score":0.014303309,"about_ca_system_score_codex":0.00024333179,"about_ca_system_score_gemma":0.00017635853,"threshold_uncertainty_score":0.2547784},"labels":[],"label_agreement":null},{"id":"W4210511187","doi":"10.1016/j.lungcan.2022.01.020","title":"Treatment patterns and outcomes in early-stage ALK-rearranged non-small cell lung cancer","year":2022,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Princess Margaret Cancer Centre; Takeda (Canada); University Health Network","funders":"Swiss Cancer Research Foundation","keywords":"Durvalumab; Medicine; Stage (stratigraphy); Internal medicine; Lung cancer; Oncology; Cancer; Surgery; Nivolumab; Immunotherapy","score_opus":0.012730693498659464,"score_gpt":0.3251160578730218,"score_spread":0.3123853643743623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210511187","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874824,0.0049581607,0.00002555721,0.0019057426,0.0004985491,0.0013939416,0.0006149768,0.00004827914,0.003072361],"genre_scores_gemma":[0.96961325,0.0012438514,0.00007794853,0.0006574339,0.00010715248,0.0030854235,0.00006420858,0.000051365336,0.025099367],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986736,0.00004156468,0.00024178902,0.0004294146,0.00023666197,0.00037698037],"domain_scores_gemma":[0.99940664,0.000042340744,0.000090656446,0.00027773544,0.000032206026,0.00015043496],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000049875962,0.00025417886,0.00041446695,0.00014495988,0.00018596044,0.000026615226,0.00007375099,0.000048869937,0.0011934614],"category_scores_gemma":[0.000002581958,0.00020678152,0.00010136228,0.00018149568,0.000023967847,0.0000669645,0.00006560946,0.00018482385,0.0000023528914],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010513381,0.00030940337,0.98842573,0.00016577178,0.00040257446,0.00015176403,0.0059736436,0.00035187675,0.00024732045,0.000010973114,0.00048767604,0.003368144],"study_design_scores_gemma":[0.008610901,0.00034831013,0.97358805,0.00010305381,0.0009397719,0.000006528216,0.0007573093,0.0014138486,0.0005579993,0.0000030489707,0.01339,0.00028118808],"about_ca_topic_score_codex":0.054740973,"about_ca_topic_score_gemma":0.009691427,"teacher_disagreement_score":0.045049544,"about_ca_system_score_codex":0.0017818111,"about_ca_system_score_gemma":0.00036637118,"threshold_uncertainty_score":0.99971956},"labels":[],"label_agreement":null},{"id":"W4210525122","doi":"10.1016/j.lungcan.2022.01.013","title":"Exploitation of treatment induced tumor lysis to enhance the sensitivity of ctDNA analysis: A first-in-human pilot study","year":2022,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Internal medicine; Prospective cohort study; Lung cancer; Chemotherapy; Cohort; Oncology; Gastroenterology; Radiation therapy; Cancer; Circulating tumor DNA","score_opus":0.015472865041570472,"score_gpt":0.3147946030324561,"score_spread":0.29932173799088563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210525122","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99867696,0.0003645452,0.00020379078,0.00011367289,0.000073019626,0.00043587555,0.00008946304,0.0000019513172,0.00004075072],"genre_scores_gemma":[0.99924666,0.00004202163,0.000022027518,0.00009857158,0.00004509679,0.0004525969,0.000020936353,0.000009199466,0.00006291216],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99922436,0.000105756735,0.00020948828,0.0002362243,0.0001134655,0.00011067495],"domain_scores_gemma":[0.99941844,0.000041835694,0.00012823546,0.00031813618,0.00006705681,0.000026277468],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022238826,0.00009012364,0.00020308736,0.00008080605,0.00007851178,0.0000051049974,0.00009031999,0.000009870432,0.00003268514],"category_scores_gemma":[0.000033609274,0.00007802567,0.00006773005,0.00045644288,0.00001503549,0.0000014823139,0.00010098162,0.000036863246,1.4934922e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037804226,0.0009433968,0.10544422,0.000024569132,0.0010707555,0.0000058656283,0.002935903,0.13140045,0.7564333,0.00002333962,0.00022589556,0.0011142668],"study_design_scores_gemma":[0.001912759,0.01244094,0.33493087,0.000029713763,0.0019230762,0.0000014881019,0.005324011,0.003049387,0.6385456,0.000029882085,0.0013286727,0.00048362196],"about_ca_topic_score_codex":0.009639654,"about_ca_topic_score_gemma":0.04583184,"teacher_disagreement_score":0.22948664,"about_ca_system_score_codex":0.00017707505,"about_ca_system_score_gemma":0.00010674459,"threshold_uncertainty_score":0.9969552},"labels":[],"label_agreement":null},{"id":"W4210665852","doi":"10.1016/j.lungcan.2022.01.023","title":"Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO)","year":2022,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Afatinib; Medicine; Pembrolizumab; Internal medicine; Lung cancer; Clinical endpoint; Oncology; Adverse effect; Population; Carcinoma; Epidermal growth factor receptor; Surgery; Gastroenterology; Cancer; Gefitinib; Immunotherapy; Clinical trial","score_opus":0.0071702449301228755,"score_gpt":0.3156310337756659,"score_spread":0.30846078884554307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210665852","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99460095,0.0015279381,0.0000032803762,0.00013915599,0.00026482058,0.003226876,0.00008124062,0.00001898661,0.00013674935],"genre_scores_gemma":[0.99744064,0.0000067960086,0.000037078877,0.00007228192,0.000048007656,0.0014386108,0.00002404923,0.00005335897,0.0008791524],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983096,0.000059826736,0.00040642053,0.00033775548,0.0006159849,0.00027037645],"domain_scores_gemma":[0.9991418,0.000028532326,0.00026818056,0.000413405,0.000084886306,0.00006320477],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006732862,0.00021803107,0.00041424038,0.0001221024,0.0002525032,0.000006445708,0.00013897795,0.00003704992,0.00038982692],"category_scores_gemma":[0.000008041724,0.00013269001,0.00010453042,0.0004947203,0.000031527772,0.000079169105,0.0001265342,0.00019808116,1.02196736e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011338295,0.0070526227,0.9597656,0.0004925965,0.0001978111,0.000056649216,0.018927783,0.0012806313,0.00010786167,4.4406056e-7,0.00013112892,0.00064856355],"study_design_scores_gemma":[0.12849575,0.007587841,0.857193,0.00044019998,0.0011115943,0.000003066068,0.0013065232,0.0015416874,0.0019945719,7.425653e-7,0.000092634415,0.00023236366],"about_ca_topic_score_codex":0.00067005004,"about_ca_topic_score_gemma":0.00049736805,"teacher_disagreement_score":0.11715746,"about_ca_system_score_codex":0.00092053914,"about_ca_system_score_gemma":0.00038181114,"threshold_uncertainty_score":0.5410941},"labels":[],"label_agreement":null},{"id":"W4214550380","doi":"10.1016/j.lungcan.2022.02.009","title":"Applying utility values in cost-effectiveness analyses of lung cancer screening: A review of methods","year":2022,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University","funders":"Australian Government","keywords":"Medicine; Lung cancer; Quality-adjusted life year; Quality of life (healthcare); Lung cancer screening; Cost effectiveness; Intensive care medicine; Cost–benefit analysis; Baseline (sea); Actuarial science; Risk analysis (engineering); Oncology","score_opus":0.2596218530954964,"score_gpt":0.5800838968781026,"score_spread":0.3204620437826062,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214550380","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000012466376,0.9881542,0.00026096898,0.00005069495,0.0004338031,0.010020985,0.00044893226,0.00002960718,0.0005883672],"genre_scores_gemma":[0.00004697857,0.96116203,0.0010413849,0.00014457743,0.00012445245,0.037139587,0.00018066472,0.000090537,0.00006978737],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9949768,0.0016124481,0.0014993295,0.000884457,0.000601356,0.00042560857],"domain_scores_gemma":[0.9961179,0.0013590187,0.0012693851,0.0009075855,0.00020307259,0.00014302091],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020517234,0.0006381501,0.005650453,0.0003958134,0.00006279204,0.000007982692,0.0003113045,0.00020854255,0.002661896],"category_scores_gemma":[0.00025549828,0.00048535818,0.0013566338,0.0016796591,0.000112960246,0.00007092238,0.00021489672,0.0006114038,3.6324766e-7],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000050068127,0.00017911731,0.0075351866,0.39301696,0.0022642526,0.000012353468,0.000030663752,0.000013141021,0.0000011746795,0.0000065714453,0.0007303733,0.5961601],"study_design_scores_gemma":[0.00078818394,0.00006717855,0.0011763289,0.4062814,0.01683212,0.000006572536,0.000009943751,0.00012892838,0.00007921056,0.0000028030454,0.57434374,0.00028360504],"about_ca_topic_score_codex":0.0062877564,"about_ca_topic_score_gemma":0.00011089917,"teacher_disagreement_score":0.5958765,"about_ca_system_score_codex":0.0026316845,"about_ca_system_score_gemma":0.001741948,"threshold_uncertainty_score":0.9997598},"labels":[],"label_agreement":null},{"id":"W4221131077","doi":"10.1016/j.lungcan.2022.03.003","title":"Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer","year":2022,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"United Therapeutics Corporation","keywords":"Irinotecan; Topotecan; Medicine; Tolerability; Internal medicine; Clinical endpoint; Oncology; Lung cancer; Randomized controlled trial; Chemotherapy; Cancer; Adverse effect; Colorectal cancer","score_opus":0.032677582691871036,"score_gpt":0.39410300744961657,"score_spread":0.36142542475774553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221131077","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9732829,0.013736107,0.000065526416,0.0014295587,0.0006059198,0.009573987,0.0010587018,0.00004444187,0.00020290239],"genre_scores_gemma":[0.98998547,0.0017309657,0.000073929354,0.0001737691,0.0002994715,0.004509821,0.000026235786,0.000076164004,0.0031241863],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9969347,0.0003406995,0.0008042318,0.00066404865,0.0006637274,0.00059260015],"domain_scores_gemma":[0.99780464,0.0004929677,0.00051862485,0.00071997184,0.00029797017,0.00016583786],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005338402,0.00042052873,0.0018311926,0.00024312832,0.0004122495,0.00001889783,0.00031793147,0.000067065805,0.0006472266],"category_scores_gemma":[0.00012012393,0.000263915,0.00036352183,0.00059360114,0.00034113112,0.000058571262,0.0003550519,0.0002784633,1.0224571e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6317653,0.026007425,0.16271584,0.0105741555,0.013138425,0.00027835826,0.050806496,0.0032204045,0.077971295,0.00011121961,0.0066639087,0.016747156],"study_design_scores_gemma":[0.86732405,0.015410961,0.008309178,0.00049748854,0.0060693626,0.000027334598,0.0042364546,0.0087162675,0.083262205,0.000026862139,0.005433198,0.0006866227],"about_ca_topic_score_codex":0.008114841,"about_ca_topic_score_gemma":0.005460285,"teacher_disagreement_score":0.23555875,"about_ca_system_score_codex":0.0011352669,"about_ca_system_score_gemma":0.001034108,"threshold_uncertainty_score":0.9999813},"labels":[],"label_agreement":null},{"id":"W4235340419","doi":"10.1016/s0169-5002(04)00142-4","title":"Docetaxel and Gemcitabine administered on days 1 and 8 for metastatic non-small cell lung carcinoma (NSCLC): a phase II multicenter trial*1","year":2004,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital","funders":"","keywords":"Docetaxel; Medicine; Gemcitabine; Internal medicine; Regimen; Toxicity; Oncology; Phases of clinical research; Chemotherapy; Performance status; Progressive disease; Gastroenterology; Surgery","score_opus":0.0281149032536593,"score_gpt":0.36894898323737196,"score_spread":0.3408340799837127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235340419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867392,0.004866891,0.0008708942,0.0018395733,0.00039742058,0.003833067,0.00033976167,0.00003528716,0.0010779058],"genre_scores_gemma":[0.991754,0.00018913294,0.0028620884,0.0010627998,0.00022611528,0.0011573595,0.00009356141,0.000048509235,0.0026064184],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9987917,0.000015732841,0.00028692244,0.00043972037,0.00014411025,0.0003217963],"domain_scores_gemma":[0.99924445,0.000072783376,0.00011814792,0.00024492134,0.00008445664,0.00023525987],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008101343,0.00025589726,0.0004096607,0.000104090286,0.00020063852,0.00003924285,0.00004807723,0.000054300366,0.000058574846],"category_scores_gemma":[0.000024766065,0.00020043532,0.00009331036,0.00009264968,0.000054850752,0.00008767408,0.000033753546,0.00010325001,0.0000016596659],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45166454,0.049333997,0.073222175,0.029159186,0.016949218,0.0018729824,0.11844413,0.0007147642,0.06509186,0.003930245,0.045339745,0.14427716],"study_design_scores_gemma":[0.935697,0.014296389,0.008936347,0.0013128427,0.010355301,0.00004816298,0.0008011236,0.0055086496,0.011027482,0.0001289756,0.011064996,0.0008226946],"about_ca_topic_score_codex":0.00030298452,"about_ca_topic_score_gemma":0.00013388667,"teacher_disagreement_score":0.48403248,"about_ca_system_score_codex":0.00027662283,"about_ca_system_score_gemma":0.0003010906,"threshold_uncertainty_score":0.8173515},"labels":[],"label_agreement":null},{"id":"W4238393566","doi":"10.1016/s0169-5002(12)00159-6","title":"Contents","year":2012,"lang":"de","type":"paratext","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine","score_opus":0.026331870780195915,"score_gpt":0.3486145025486761,"score_spread":0.32228263176848015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4238393566","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00449333,0.85310155,0.000019010582,0.0030612142,0.042404093,0.002239149,0.0013987533,0.00007059547,0.093212314],"genre_scores_gemma":[0.26224083,0.25323707,0.00004645771,0.0044214795,0.021755707,0.0027925943,0.0016090564,0.00030614753,0.45359066],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99600434,0.000105198975,0.00072133326,0.0009828276,0.00081052526,0.0013757942],"domain_scores_gemma":[0.9972634,0.00012971544,0.00049512443,0.0010224265,0.00029223898,0.00079709286],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00014383161,0.00096215954,0.0015440959,0.00017717962,0.00019683327,0.00008266053,0.0003038159,0.000742051,0.07245256],"category_scores_gemma":[0.000022062357,0.0007841677,0.0005589036,0.0002742719,0.00015174605,0.00013031773,0.00014817453,0.0008045173,0.036079083],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002636078,0.0006712246,0.16059743,0.002311462,0.0065838676,0.00007344106,0.0005190146,0.00001524185,0.000019011894,0.00009194205,0.8193131,0.009540669],"study_design_scores_gemma":[0.0046859575,0.00021395234,0.018370854,0.006776846,0.010679811,0.0000065116715,0.000041118314,0.000086154745,0.0005888056,0.0000032117857,0.95777184,0.00077494833],"about_ca_topic_score_codex":0.0030443354,"about_ca_topic_score_gemma":0.00018192771,"teacher_disagreement_score":0.5998645,"about_ca_system_score_codex":0.004349925,"about_ca_system_score_gemma":0.0007570448,"threshold_uncertainty_score":0.9994722},"labels":[],"label_agreement":null},{"id":"W4246311091","doi":"10.1016/s0169-5002(00)80318-9","title":"Population-based outcome for small cell lung cancer (SCLC): Impact of standard management policies in British Columbia (BC)","year":2000,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Global Cancer Incidence and Screening","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Oncology; Outcome (game theory); Lung cancer; Population; Internal medicine; Demography; Environmental health","score_opus":0.03030715759910746,"score_gpt":0.3688329795743873,"score_spread":0.33852582197527986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4246311091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992457,0.0033714944,0.00011554589,0.00023639407,0.00015320786,0.0012512761,0.0005502632,0.00004024254,0.0018245755],"genre_scores_gemma":[0.99267703,0.000425137,0.0008754085,0.00072268717,0.00015167746,0.00036168465,0.000058178408,0.00003581087,0.004692386],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983547,0.000022554865,0.00049639,0.00031502376,0.00034647956,0.00046486987],"domain_scores_gemma":[0.9993325,0.0000370043,0.0001340004,0.00024247538,0.00012790033,0.0001261133],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00017773945,0.00015269406,0.0005038778,0.000080173544,0.000078796365,0.00007328822,0.00013298166,0.00009113302,0.0027993508],"category_scores_gemma":[0.000012930366,0.00019817511,0.00023354514,0.00033200742,0.00003406451,0.000088952256,0.000017636552,0.00012822647,9.627513e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042812963,0.000040244675,0.96694064,0.0007296091,0.000094364026,0.000021937194,0.00010867467,0.008980118,0.00003100212,0.0000036220115,0.009620201,0.013001464],"study_design_scores_gemma":[0.0033109523,0.00021275306,0.98845166,0.0011853072,0.00026234624,0.0000020779544,0.0000686943,0.0048781927,0.000054095093,0.00002178149,0.0013351836,0.00021697088],"about_ca_topic_score_codex":0.61725783,"about_ca_topic_score_gemma":0.4315471,"teacher_disagreement_score":0.1857107,"about_ca_system_score_codex":0.001542334,"about_ca_system_score_gemma":0.00031459687,"threshold_uncertainty_score":0.9981122},"labels":[],"label_agreement":null},{"id":"W4280569448","doi":"10.1016/j.lungcan.2022.05.008","title":"Race &amp; sex disparities related to low-dose computed tomography lung cancer screening eligibility criteria: A lung cancer cases review","year":2022,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brock University","funders":"National Cancer Institute","keywords":"Medicine; Lung cancer; Race (biology); Lung cancer screening; Computed tomography; Cancer; Internal medicine; Lung; Oncology; Radiology","score_opus":0.020984149981019433,"score_gpt":0.3855254398027715,"score_spread":0.36454128982175205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280569448","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.37954202,0.587635,0.00011402578,0.023285132,0.0023014708,0.0046163136,0.0017162625,0.00040715953,0.0003826064],"genre_scores_gemma":[0.87345743,0.083211936,0.000728983,0.019882983,0.0007189571,0.016489863,0.00051496807,0.00022549069,0.004769393],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950896,0.00033884466,0.0010122323,0.0014464904,0.0010593935,0.0010534663],"domain_scores_gemma":[0.9972388,0.00027406003,0.00036846127,0.0011466619,0.0003762371,0.00059575983],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005528608,0.0007256719,0.0015156653,0.00029903185,0.0007269195,0.00009722547,0.00037593735,0.00014159986,0.007041405],"category_scores_gemma":[0.000084515734,0.0006705511,0.0005410716,0.0017440233,0.00013040433,0.00023367899,0.00046909245,0.0007498338,0.0000056656104],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00059581763,0.0005073843,0.5865303,0.008511507,0.0022575685,0.0002794692,0.0012201745,0.0027179304,0.00016039603,0.000039964212,0.39054346,0.006636037],"study_design_scores_gemma":[0.016904784,0.00097412814,0.49419573,0.079710566,0.017757256,0.00044066246,0.00043144778,0.020898685,0.0014807292,0.000055751123,0.36270455,0.004445743],"about_ca_topic_score_codex":0.028927809,"about_ca_topic_score_gemma":0.0046795285,"teacher_disagreement_score":0.5044231,"about_ca_system_score_codex":0.003728542,"about_ca_system_score_gemma":0.00087110273,"threshold_uncertainty_score":0.99957454},"labels":[],"label_agreement":null},{"id":"W4280617886","doi":"10.1016/j.lungcan.2022.05.003","title":"Health utilities for participants in a population-based sample who meet eligibility criteria for lung cancer screening","year":2022,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brock University; Simon Fraser University","funders":"","keywords":"Medicine; Lung cancer screening; Population; Lung cancer; Cohort; Demography; Metric (unit); Risk assessment; Quality-adjusted life year; Cost effectiveness; Environmental health; Internal medicine; Risk analysis (engineering)","score_opus":0.06972541836701968,"score_gpt":0.457082574985871,"score_spread":0.38735715661885134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280617886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9417383,0.018089622,0.0034942492,0.023046548,0.0010190004,0.006058911,0.0064141825,0.00010706872,0.00003208714],"genre_scores_gemma":[0.9728045,0.00014453703,0.002125996,0.0036672507,0.00026275183,0.020349415,0.00043618854,0.00005013409,0.00015922134],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979018,0.000087839195,0.0004947029,0.0005506729,0.00029851013,0.0006664997],"domain_scores_gemma":[0.9987734,0.0004495231,0.0001712652,0.000330693,0.000100453624,0.00017465021],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050505623,0.00021518803,0.00061655056,0.00011517187,0.0003518524,0.000027724675,0.0000903343,0.000043918233,0.00060394895],"category_scores_gemma":[0.00011253456,0.0002060926,0.00017729566,0.00022511059,0.000024600835,0.000076265314,0.000039956587,0.00010382162,7.040205e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012075319,0.00023986428,0.96258485,0.001611331,0.00018681516,0.0000015621836,0.00101955,0.0046756407,0.0000134003885,0.0002315315,0.0236234,0.004604535],"study_design_scores_gemma":[0.009119043,0.0005942324,0.7173433,0.0011217006,0.0004524006,7.053643e-7,0.00031779383,0.25909662,0.0002360278,0.00031320428,0.011042816,0.00036215896],"about_ca_topic_score_codex":0.054216,"about_ca_topic_score_gemma":0.018618159,"teacher_disagreement_score":0.25442097,"about_ca_system_score_codex":0.0032252958,"about_ca_system_score_gemma":0.00090066285,"threshold_uncertainty_score":0.9992895},"labels":[],"label_agreement":null},{"id":"W4281390999","doi":"10.1016/j.lungcan.2022.05.012","title":"Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial","year":2022,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Crizotinib; Lung cancer; Hazard ratio; Confidence interval; Clinical endpoint; Oncology; Population; ALK inhibitor; Adverse effect; Cancer; Gastroenterology; Clinical trial","score_opus":0.0043017809103495,"score_gpt":0.3100869242154153,"score_spread":0.3057851433050658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281390999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924351,0.0014499244,0.00011249186,0.00024769854,0.00013851223,0.00227842,0.0015026256,0.000009372957,0.0018258416],"genre_scores_gemma":[0.99861157,0.00016209442,0.00029908054,0.00007899583,0.000034985256,0.0004267851,0.00026812506,0.000020757672,0.00009758182],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998546,0.00005148988,0.0004282151,0.00041500718,0.0003091975,0.00025011072],"domain_scores_gemma":[0.99916995,0.000046931353,0.00032136706,0.0002153406,0.00011073726,0.00013568813],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007851393,0.00021359701,0.00069323234,0.00018159537,0.000103696606,0.000008274983,0.00006638013,0.00004699943,0.0001177393],"category_scores_gemma":[0.0000073755045,0.00018257236,0.00008795595,0.001025918,0.00008013693,0.0000811519,0.00005936286,0.00013937514,4.2936602e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050164927,0.0015850622,0.9173263,0.00026436776,0.0029320861,0.000022190297,0.0056516645,0.0018176892,0.00017404131,0.000021477828,0.000058420937,0.019981792],"study_design_scores_gemma":[0.16647786,0.002044858,0.8204494,0.00026485755,0.0072377245,9.0148706e-7,0.0006543531,0.0023825497,0.00015898646,0.0000018634034,0.00012399339,0.00020261071],"about_ca_topic_score_codex":0.0030317188,"about_ca_topic_score_gemma":0.003480371,"teacher_disagreement_score":0.116312936,"about_ca_system_score_codex":0.00075280946,"about_ca_system_score_gemma":0.00042755177,"threshold_uncertainty_score":0.74450845},"labels":[],"label_agreement":null},{"id":"W4282933212","doi":"10.1016/j.lungcan.2022.06.009","title":"Correlations between objective response rate and survival-based endpoints in first-line advanced non-small cell lung Cancer: A systematic review and meta-analysis","year":2022,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Broadcom (Canada); Prevention of Organ Failure","funders":"Bristol-Myers Squibb","keywords":"Medicine; Chemotherapy; Lung cancer; Internal medicine; Oncology; Randomized controlled trial; Meta-analysis; Confidence interval; Surrogate endpoint","score_opus":0.0538948238228783,"score_gpt":0.37835719499216597,"score_spread":0.32446237116928767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282933212","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009429238,0.9859028,0.000059033435,0.001056408,0.0001465341,0.010637264,0.0019701333,0.000041742718,0.000091806534],"genre_scores_gemma":[0.00067406293,0.9712435,0.00008293482,0.00047952286,0.000054016087,0.025416655,0.00039596044,0.00011609693,0.0015372678],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9944674,0.001748083,0.0015952196,0.0012576159,0.00044663282,0.0004850904],"domain_scores_gemma":[0.9935092,0.0038367137,0.0012540015,0.0009700963,0.00014416596,0.00028584755],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019799261,0.0009211613,0.01076057,0.00069581595,0.00020657216,0.000046284593,0.00019947317,0.00022236539,0.001097124],"category_scores_gemma":[0.00028440938,0.0006596807,0.0016595859,0.0019919525,0.000063495274,0.00008427756,0.00013852876,0.0006499852,0.0000030663618],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013485436,0.00014320915,0.0034451983,0.89178264,0.10255304,0.000089528854,0.00022643027,0.00024323078,4.9702756e-8,0.0000020889631,0.00020069539,0.0011790344],"study_design_scores_gemma":[0.0015474732,0.00013726248,0.0008259607,0.09041456,0.8865061,0.000004293107,0.000020940404,0.00023354028,0.000001211277,0.0000010032575,0.019756332,0.0005513428],"about_ca_topic_score_codex":0.0015373868,"about_ca_topic_score_gemma":0.0032739413,"teacher_disagreement_score":0.80136806,"about_ca_system_score_codex":0.0029804595,"about_ca_system_score_gemma":0.0013449349,"threshold_uncertainty_score":0.999816},"labels":[],"label_agreement":null},{"id":"W4283714926","doi":"10.1016/j.lungcan.2022.06.014","title":"Practical considerations of single-fraction stereotactic ablative radiotherapy to the lung","year":2022,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; University of Toronto","funders":"Varian Medical Systems","keywords":"SABR volatility model; Medicine; Ablative case; Radiation therapy; Lung cancer; Concomitant; Radiology; Internal medicine","score_opus":0.0944734411297645,"score_gpt":0.4420928949961969,"score_spread":0.34761945386643245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283714926","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000010147365,0.9887004,0.00016707357,0.005625963,0.0009090531,0.0030925476,0.00014041383,0.00003325116,0.0013211386],"genre_scores_gemma":[0.00020980845,0.9938901,0.00054852426,0.0010636426,0.0005001746,0.0029214881,0.00006436503,0.0000746414,0.0007272499],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99807477,0.00026496514,0.00053880515,0.0004399755,0.00044006368,0.00024141996],"domain_scores_gemma":[0.99742603,0.0013021271,0.00048159953,0.00056702195,0.00010000002,0.00012319755],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00019619061,0.00033018403,0.0012569986,0.00014349369,0.00018445429,0.000041565174,0.00006233976,0.00011953833,0.0056007747],"category_scores_gemma":[0.00016673747,0.00020857852,0.00040412202,0.00038096646,0.00004850146,0.000090841604,0.000046873072,0.0004737917,0.0000092476375],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023324868,0.001548147,0.0007431061,0.01975327,0.014568622,0.00026758102,0.0017075199,0.00006617862,0.0000042831102,0.0014442886,0.47458425,0.4850795],"study_design_scores_gemma":[0.00049611507,0.0002863014,0.00005442852,0.0047307685,0.0062650964,0.00018253633,0.000041240975,0.000045226505,0.0000061792643,0.000005786484,0.9877007,0.00018561911],"about_ca_topic_score_codex":0.00032749324,"about_ca_topic_score_gemma":0.000120667224,"teacher_disagreement_score":0.5131165,"about_ca_system_score_codex":0.0042990665,"about_ca_system_score_gemma":0.0014106422,"threshold_uncertainty_score":0.9995233},"labels":[],"label_agreement":null},{"id":"W4285403511","doi":"10.1016/j.lungcan.2022.07.008","title":"The changing landscape of pneumonitis in non-small cell lung cancer","year":2022,"lang":"en","type":"editorial","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Ontario Institute for Cancer Research","keywords":"Medicine; Lung cancer; Pneumonitis; Radiation Pneumonitis; Hypersensitivity pneumonitis; Lung; Oncology; Internal medicine","score_opus":0.005636140618514189,"score_gpt":0.3081479833239252,"score_spread":0.302511842705411,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285403511","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0142932255,0.10332436,0.000013857065,0.001070166,0.8650495,0.0022980236,0.0019404334,0.00006236559,0.011948095],"genre_scores_gemma":[0.064199574,0.060715728,0.000083145314,0.00031995485,0.78454906,0.009899129,0.0015800034,0.00037344455,0.07827995],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99777377,0.000052584495,0.00045035876,0.00047887655,0.0006755492,0.0005688735],"domain_scores_gemma":[0.9985172,0.0003687417,0.00034981742,0.00046150808,0.00020182777,0.00010091078],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00021354058,0.00034375524,0.00062165566,0.00028605564,0.00025648726,0.000035650643,0.00026313594,0.000280281,0.0009409041],"category_scores_gemma":[0.000041505526,0.0002585205,0.00019732345,0.00056501286,0.000048147063,0.00004908032,0.00014020044,0.00083668914,0.000001899623],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014986517,0.00010196567,0.020965192,0.0013705489,0.0006268227,0.0000805932,0.00346493,0.00034164224,0.000062440056,0.0000074371683,0.9698923,0.0029362612],"study_design_scores_gemma":[0.0038963305,0.00014146723,0.002360262,0.0017305386,0.002341991,0.000002200827,0.0009898256,0.0011407717,0.00017977499,0.0000059270774,0.9868093,0.00040159846],"about_ca_topic_score_codex":0.006609898,"about_ca_topic_score_gemma":0.0037648287,"teacher_disagreement_score":0.080500394,"about_ca_system_score_codex":0.0014963895,"about_ca_system_score_gemma":0.0021556169,"threshold_uncertainty_score":0.9999867},"labels":[],"label_agreement":null},{"id":"W4287448591","doi":"10.1016/j.lungcan.2022.07.018","title":"PD-L1 assessment in cytology samples predicts treatment response to checkpoint inhibitors in NSCLC","year":2022,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre; University Health Network; University of Toronto; Toronto General Hospital; Princess Margaret Cancer Centre; Queen's University","funders":"","keywords":"Cytology; Medicine; Histology; Internal medicine; Lung cancer; PD-L1; Biomarker; Oncology; Cancer; Pathology; Gastroenterology; Immunotherapy; Biology","score_opus":0.05902054763603569,"score_gpt":0.4145764070750323,"score_spread":0.3555558594389966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4287448591","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0032213184,0.99000865,0.000003546806,0.0012059415,0.0011662641,0.0034370655,0.00023741096,0.00004742345,0.0006723987],"genre_scores_gemma":[0.00036981993,0.99156344,0.00013396422,0.0004546495,0.00027836635,0.0054787565,0.00018029849,0.00008760263,0.0014530831],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99664474,0.00059285376,0.0010637086,0.00076702045,0.0003784405,0.00055322715],"domain_scores_gemma":[0.99858767,0.00038372926,0.00027134304,0.0005829003,0.000020601898,0.00015375725],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008385322,0.00053786236,0.0020224813,0.0008453213,0.000054888693,0.000018897614,0.00019651855,0.00030135424,0.0019612925],"category_scores_gemma":[0.00007305023,0.0004280033,0.00049730175,0.0010328545,0.000059769518,0.000037503585,0.000112479844,0.0005929915,0.0000067485794],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058586327,0.00035572168,0.0017555153,0.0038111839,0.00053547916,0.00038032254,0.00077032566,0.000008578735,0.000059624454,0.000006346434,0.0021868711,0.9842714],"study_design_scores_gemma":[0.0030884135,0.0009171822,0.005351533,0.01231027,0.00047026423,0.00005843697,0.00010443372,0.000006175551,0.000013275075,0.000001835956,0.9773208,0.00035736107],"about_ca_topic_score_codex":0.004614522,"about_ca_topic_score_gemma":0.0034348825,"teacher_disagreement_score":0.983914,"about_ca_system_score_codex":0.012139352,"about_ca_system_score_gemma":0.0037553788,"threshold_uncertainty_score":0.9998172},"labels":[],"label_agreement":null},{"id":"W4296676807","doi":"10.1016/j.lungcan.2022.08.023","title":"EGFR mutation prevalence, real-world treatment patterns, and outcomes among patients with resected, early-stage, non-small cell lung cancer in Canada","year":2022,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; William Osler Health System; AstraZeneca (Canada); London Health Sciences Centre; Natural Sciences and Engineering Research Council of Canada; Princess Margaret Cancer Centre; Canada Research Chairs; Western University","funders":"","keywords":"Medicine; Osimertinib; Internal medicine; Cohort; Adjuvant therapy; Oncology; Population; Lung cancer; Stage (stratigraphy); Retrospective cohort study; Disease; Cancer; Epidermal growth factor receptor; Erlotinib","score_opus":0.006545336997180896,"score_gpt":0.2823730039069236,"score_spread":0.2758276669097427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296676807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941906,0.00074010046,0.0000069116386,0.00029963237,0.00036110907,0.0020500608,0.001170718,0.000029059685,0.0011518137],"genre_scores_gemma":[0.9785897,0.0006918175,0.000046435583,0.00023996463,0.00004780107,0.0026935178,0.00018973314,0.000054210275,0.017446788],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982462,0.00006126438,0.00031041654,0.0005043357,0.0004660209,0.00041174126],"domain_scores_gemma":[0.99919194,0.000057822923,0.00018848694,0.00028430257,0.00009949608,0.00017796518],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004640286,0.00028917546,0.00037982222,0.00019413479,0.00021095973,0.000026599702,0.000083180516,0.000030800027,0.00075797964],"category_scores_gemma":[0.000003006881,0.00020689334,0.000044247092,0.00038425197,0.000028303082,0.00012335424,0.000051582636,0.00019588199,3.388131e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020420049,0.00018946333,0.9921605,0.0003944443,0.0003373944,0.00012747452,0.0016748258,0.0023849893,0.000003236648,0.0000029266942,0.00048063407,0.0020399261],"study_design_scores_gemma":[0.0063438592,0.00026846334,0.99013776,0.00025145878,0.000716727,8.42291e-7,0.00034453324,0.0011077798,0.0000848754,7.608197e-7,0.0004999154,0.00024301304],"about_ca_topic_score_codex":0.9829921,"about_ca_topic_score_gemma":0.98982865,"teacher_disagreement_score":0.016294973,"about_ca_system_score_codex":0.007578899,"about_ca_system_score_gemma":0.0020779413,"threshold_uncertainty_score":0.99623084},"labels":[],"label_agreement":null},{"id":"W4308432482","doi":"10.1016/j.lungcan.2022.11.004","title":"Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer","year":2022,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Pfizer","keywords":"Crizotinib; Medicine; Lung cancer; Nausea; Internal medicine; Quality of life (healthcare); ALK inhibitor; Oncology; Nursing","score_opus":0.017987614608198272,"score_gpt":0.3551372383528579,"score_spread":0.3371496237446596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308432482","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98343444,0.0049329037,0.000062423125,0.0012041385,0.0017147582,0.006446377,0.00077148486,0.000044468226,0.0013890006],"genre_scores_gemma":[0.9920279,0.00024603822,0.00012501597,0.0004910494,0.00011469552,0.0059405295,0.00024251886,0.000060127153,0.0007521538],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973383,0.00022796424,0.00091761426,0.0005744918,0.00056338555,0.00037824796],"domain_scores_gemma":[0.9975278,0.00095881574,0.0006335441,0.0005516968,0.00021437075,0.00011381302],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00022812893,0.00035295478,0.0010732498,0.00012836276,0.00030268615,0.00001888894,0.00017484723,0.000053634154,0.0014885071],"category_scores_gemma":[0.000113203736,0.00024538525,0.0002552858,0.00051057566,0.00008051431,0.00009624384,0.0001421969,0.0003813469,9.055489e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22920753,0.0081852535,0.64187783,0.000177962,0.007702257,0.00033453273,0.07593995,0.02282652,0.0006264787,0.000009714109,0.0024510245,0.010660941],"study_design_scores_gemma":[0.90053695,0.0019152764,0.06575382,0.0003531648,0.008257173,0.0000022869049,0.011437334,0.008668427,0.0013691457,0.000011706965,0.0011917596,0.0005029679],"about_ca_topic_score_codex":0.026770907,"about_ca_topic_score_gemma":0.008638781,"teacher_disagreement_score":0.67132944,"about_ca_system_score_codex":0.0008898286,"about_ca_system_score_gemma":0.0005123926,"threshold_uncertainty_score":0.9999998},"labels":[],"label_agreement":null},{"id":"W4309342023","doi":"10.1016/j.lungcan.2022.11.009","title":"Usage of epidermal growth factor mutation testing and impact on treatment patterns in non-small cell lung cancer: An international observational study","year":2022,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Medical Research Council; AstraZeneca","keywords":"Medicine; Lung cancer; Internal medicine; Oncology; Observational study; Epidermal growth factor receptor; Chemotherapy; Medical record; Cancer","score_opus":0.05358302492849484,"score_gpt":0.38799351964314566,"score_spread":0.3344104947146508,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309342023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99668694,0.00024395861,0.000038042414,0.00027870666,0.00028210907,0.0012819465,0.0008978035,0.000020379875,0.00027010735],"genre_scores_gemma":[0.9978877,0.00006360546,0.0001780471,0.0001674826,0.00013714525,0.0010842264,0.00019452606,0.000026904017,0.00026038665],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987825,0.000064350206,0.00030451763,0.00033883762,0.00031714325,0.00019264522],"domain_scores_gemma":[0.999328,0.00014441986,0.00017800703,0.00014303115,0.0001148123,0.000091685295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008289433,0.00019409393,0.00027202742,0.00018466687,0.00011423298,0.000019380153,0.00007590789,0.000026464668,0.0004671644],"category_scores_gemma":[0.000019059804,0.00015569667,0.000056744782,0.0002144472,0.00001430051,0.00015889328,0.000037194673,0.00012448704,2.5040248e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019795526,0.0011316137,0.9795763,0.000068583075,0.00032955818,0.00006110893,0.0052175806,0.007480046,0.00051739684,0.0000062164563,0.000029342407,0.0053842976],"study_design_scores_gemma":[0.004417781,0.0013296291,0.9743119,0.00009053687,0.00030022257,0.0000067546016,0.00067845976,0.018309692,0.0004110145,0.00000641978,0.000011257694,0.00012636198],"about_ca_topic_score_codex":0.027236069,"about_ca_topic_score_gemma":0.0016124661,"teacher_disagreement_score":0.025623603,"about_ca_system_score_codex":0.0021049867,"about_ca_system_score_gemma":0.00043650897,"threshold_uncertainty_score":0.97924167},"labels":[],"label_agreement":null},{"id":"W4309942201","doi":"10.1016/j.lungcan.2022.11.017","title":"The impact of population-based EGFR testing in non-squamous metastatic non-small cell lung cancer in Alberta, Canada","year":2022,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Oncology; Lung cancer; Population; Proportional hazards model; Epidermal growth factor receptor; Clinical trial; Cancer","score_opus":0.010252541598297648,"score_gpt":0.318615882465887,"score_spread":0.3083633408675894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309942201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993327,0.002670179,0.000015710055,0.0008647021,0.00034089384,0.001249809,0.00023080422,0.000008734254,0.0012921633],"genre_scores_gemma":[0.9970521,0.000023340897,0.000114283896,0.00025931146,0.000049359496,0.0011978677,0.000078087556,0.000040055907,0.001185645],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99848187,0.00006641443,0.00043803232,0.00028042006,0.00032399478,0.0004092913],"domain_scores_gemma":[0.99874896,0.00056253956,0.00022231646,0.00027930687,0.000087957924,0.000098941346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015139024,0.00020347425,0.00035888003,0.00013774107,0.00019483414,0.000013699123,0.00013545179,0.00002530551,0.0003325602],"category_scores_gemma":[0.00006374565,0.00015080874,0.00008990567,0.00076901325,0.00001942933,0.000045334575,0.00003581116,0.00026445228,2.5841342e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008058449,0.00010194427,0.7400124,0.00015828224,0.000105462575,0.000033151173,0.0006284652,0.2565457,0.00014989916,0.0000033895542,0.0010873349,0.0010933965],"study_design_scores_gemma":[0.0032870672,0.00011864558,0.8255101,0.00020315105,0.00034959085,0.0000028459517,0.00028991312,0.16977723,0.00014018302,0.000008416844,0.00013601332,0.00017686628],"about_ca_topic_score_codex":0.99356985,"about_ca_topic_score_gemma":0.9748308,"teacher_disagreement_score":0.08676847,"about_ca_system_score_codex":0.005729288,"about_ca_system_score_gemma":0.005110833,"threshold_uncertainty_score":0.9980875},"labels":[],"label_agreement":null},{"id":"W4313398502","doi":"10.1016/j.lungcan.2022.12.011","title":"Economic impact of using risk models for eligibility selection to the International lung screening Trial","year":2022,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; Brock University; Simon Fraser University; BC Cancer Agency; University of British Columbia; University of Calgary; Vancouver Coastal Health","funders":"Terry Fox Research Institute","keywords":"Medicine; Socioeconomic status; Quality-adjusted life year; Demography; Lung cancer screening; Cost effectiveness; Risk assessment; Environmental health; Internal medicine; Population; Lung cancer","score_opus":0.036244475782754484,"score_gpt":0.4078666064544207,"score_spread":0.3716221306716662,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313398502","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895847,0.00052675576,0.0060776514,0.0007247942,0.0008388244,0.0016168159,0.00048276366,0.00001624025,0.0001314609],"genre_scores_gemma":[0.9975007,0.00006467522,0.0007090568,0.00013808702,0.0006068124,0.00085937046,0.00002331509,0.000016751159,0.00008121405],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99921227,0.000032912038,0.00021360902,0.00023223773,0.00016515738,0.00014383547],"domain_scores_gemma":[0.9995116,0.000076559656,0.0001418288,0.00016016058,0.000059903487,0.00004994632],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003053579,0.00009164481,0.000190215,0.000060609545,0.00016815556,0.000014869853,0.00009097528,0.00001987299,0.00039346569],"category_scores_gemma":[0.000018443943,0.000066217704,0.00022344258,0.00008307956,0.000009851381,0.00006226691,0.000057495687,0.000095588664,2.8960883e-7],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012305066,0.00008559682,0.16381195,0.000022003895,0.0008075124,3.1377257e-7,0.00032798835,0.80989105,0.00009617919,0.00006146545,0.009676773,0.0029141025],"study_design_scores_gemma":[0.01585096,0.0005939737,0.014209392,0.00004965633,0.0005938703,0.0000044176845,0.00005186525,0.9667029,0.0004802239,0.000104514285,0.0012611339,0.000097132826],"about_ca_topic_score_codex":0.010923118,"about_ca_topic_score_gemma":0.0006127377,"teacher_disagreement_score":0.15681182,"about_ca_system_score_codex":0.0046905642,"about_ca_system_score_gemma":0.0004968559,"threshold_uncertainty_score":0.99913025},"labels":[],"label_agreement":null},{"id":"W4315650998","doi":"10.1016/j.lungcan.2023.01.006","title":"Long-term comparative efficacy and safety of nivolumab plus ipilimumab relative to other first-line therapies for advanced non-small-cell lung cancer: A systematic literature review and network meta-analysis","year":2023,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; Prevention of Organ Failure","funders":"Bristol-Myers Squibb","keywords":"Medicine; Nivolumab; Ipilimumab; Pembrolizumab; Internal medicine; Oncology; Population; Lung cancer; Hazard ratio; Atezolizumab; Docetaxel; Cancer; Confidence interval; Immunotherapy","score_opus":0.07048827422576923,"score_gpt":0.39530272533794564,"score_spread":0.32481445111217644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4315650998","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000045828903,0.97945905,0.0007732292,0.00039404008,0.00021592752,0.01772302,0.00129214,0.000052729592,0.000044006847],"genre_scores_gemma":[0.00007023825,0.9857399,0.00039038018,0.000578719,0.00021086053,0.0076194815,0.00020655518,0.00014404136,0.0050398638],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9959074,0.00034642228,0.0018293296,0.0010431107,0.00035427872,0.000519451],"domain_scores_gemma":[0.99585676,0.0011328526,0.0015803823,0.0008412773,0.00039540988,0.00019329163],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006992984,0.0009943541,0.011432534,0.00035795386,0.00019686868,0.00006142533,0.0002769402,0.0003537143,0.00018927675],"category_scores_gemma":[0.000042031417,0.0006465807,0.0022496227,0.002406717,0.00012943853,0.000109599365,0.00010437036,0.00044937758,0.0000013799738],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011899151,0.000049555252,0.000046817477,0.756201,0.23265398,0.000008014299,0.0021297708,0.00015290092,0.0000015298448,0.000008653949,0.0008305613,0.0067272694],"study_design_scores_gemma":[0.0033396615,0.00026753402,0.000088042914,0.40141267,0.56480354,0.0000112005255,0.000029129817,0.00016720171,0.0000016436737,0.0000015787489,0.029263131,0.0006146551],"about_ca_topic_score_codex":0.00013895995,"about_ca_topic_score_gemma":0.0013939688,"teacher_disagreement_score":0.35478836,"about_ca_system_score_codex":0.0006599808,"about_ca_system_score_gemma":0.00044368595,"threshold_uncertainty_score":0.99959856},"labels":[],"label_agreement":null},{"id":"W4319240035","doi":"10.1016/j.lungcan.2023.02.002","title":"Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer","year":2023,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Centre Hospitalier de l’Université de Montréal","funders":"Institute of Cancer Research; Instituto de Salud Carlos III; Institut Du Cancer de Montréal; Sociedad Española de Oncología Médica; Terry Fox Foundation","keywords":"Medicine; Taxane; Chemotherapy; Internal medicine; Immunotherapy; Oncology; Lung cancer; Progression-free survival; Cancer; Surgery; Gastroenterology; Breast cancer","score_opus":0.007287272378358274,"score_gpt":0.3189931669307253,"score_spread":0.311705894552367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319240035","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876469,0.0062724403,0.00005566144,0.0015339312,0.00052348187,0.002979551,0.0005431631,0.00014629854,0.00029856994],"genre_scores_gemma":[0.98193145,0.0034953132,0.00069624436,0.0011075087,0.00020370194,0.0049491315,0.00057672936,0.00014286919,0.0068970565],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980784,0.000022087555,0.00040005014,0.00062837754,0.00033787484,0.00053318904],"domain_scores_gemma":[0.9989992,0.00005749649,0.00018280899,0.00048042735,0.00012651188,0.00015357044],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00003965137,0.00046713487,0.00066396315,0.00018734367,0.000107331485,0.00003071402,0.000106200474,0.0001313438,0.0016286209],"category_scores_gemma":[0.0000025142324,0.00030572733,0.00014138689,0.00047039587,0.000042013042,0.00014536943,0.000025962614,0.00016188232,0.000014668139],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002888605,0.00069622346,0.95904785,0.0001669872,0.00082135573,0.00004891261,0.0034937558,0.0013601144,0.00015114759,5.7370113e-7,0.00046526603,0.030859178],"study_design_scores_gemma":[0.037764635,0.00078124803,0.9505459,0.00094580906,0.0004314715,2.9215872e-7,0.000070132075,0.0018334154,0.0018173209,0.0000060904345,0.005412092,0.00039161576],"about_ca_topic_score_codex":0.0020781711,"about_ca_topic_score_gemma":0.0056563932,"teacher_disagreement_score":0.03487603,"about_ca_system_score_codex":0.0019725547,"about_ca_system_score_gemma":0.00048366617,"threshold_uncertainty_score":0.9999395},"labels":[],"label_agreement":null},{"id":"W4323664765","doi":"10.1016/j.lungcan.2023.03.002","title":"Use of radiation therapy among patients with Extensive-stage Small-cell lung cancer receiving Immunotherapy: Canadian consensus recommendations","year":2023,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University; Surrey Memorial Hospital; Sunnybrook Health Science Centre; Surrey Place Centre; Centre Hospitalier de l’Université de Montréal; McGill University Health Centre; McGill University; University Health Network; Health Sciences Centre; St. John’s Health Sciences Centre; BC Cancer Agency; Princess Margaret Cancer Centre","funders":"AstraZeneca Canada; AstraZeneca","keywords":"Medicine; Radiation therapy; Lung cancer; Immunotherapy; Oncology; Stage (stratigraphy); Intensive care medicine; Consensus conference; Internal medicine; Cancer","score_opus":0.0804489223633583,"score_gpt":0.39027321538339904,"score_spread":0.3098242930200408,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323664765","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0068768677,0.9830237,0.0000053237977,0.00055210455,0.00089743984,0.005842522,0.0024929796,0.00010940546,0.00019964247],"genre_scores_gemma":[0.00021450354,0.99076974,0.00009170769,0.00030398145,0.0002802654,0.0023616834,0.0006706436,0.00030867357,0.0049987794],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964821,0.00030086638,0.00091073784,0.00079779554,0.0006202268,0.00088829093],"domain_scores_gemma":[0.9963547,0.00061063614,0.00090130337,0.0008219622,0.0009274868,0.0003839304],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003032968,0.0006998093,0.0020338371,0.00081678206,0.00030722868,0.00007848311,0.00026443478,0.00032691812,0.00045780806],"category_scores_gemma":[0.00016930177,0.0005411789,0.00036771497,0.0012624876,0.00022482392,0.00013601297,0.00007345793,0.000821551,0.000006816382],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002051064,0.00010536564,0.096775666,0.02108012,0.005353594,0.000043084397,0.0009547382,0.00006263258,0.0000059268577,0.000004893465,0.044052888,0.831356],"study_design_scores_gemma":[0.0025423386,0.00016939655,0.024683101,0.037783895,0.0017515089,0.0000016879877,0.000054750457,0.00013329087,0.000027653254,6.115431e-7,0.9321093,0.0007424649],"about_ca_topic_score_codex":0.26343778,"about_ca_topic_score_gemma":0.20456366,"teacher_disagreement_score":0.8880564,"about_ca_system_score_codex":0.0040905173,"about_ca_system_score_gemma":0.0053953133,"threshold_uncertainty_score":0.9997326},"labels":[],"label_agreement":null},{"id":"W4353095460","doi":"10.1016/j.lungcan.2023.107176","title":"Clinical presentation and outcome of patients with enteric-type adenocarcinoma of the lung: A pooled analysis of published cases","year":2023,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada)","funders":"Fondazione Internazionale di Ricerca in Medicina Onlus","keywords":"Medicine; Presentation (obstetrics); Adenocarcinoma; Pooled analysis; Internal medicine; Lung; Oncology; General surgery; Meta-analysis; Surgery; Cancer","score_opus":0.06036838018464324,"score_gpt":0.45720151292088185,"score_spread":0.3968331327362386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4353095460","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.049804248,0.947004,0.000007509674,0.000053002706,0.0003718627,0.0018179844,0.0008376549,0.000013124579,0.000090608824],"genre_scores_gemma":[0.10720677,0.8902658,0.00009123285,0.000041347826,0.00007407883,0.00020467464,0.0007862255,0.00005785104,0.0012719725],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980644,0.000118029944,0.0010111702,0.00031199565,0.0003686699,0.00012576376],"domain_scores_gemma":[0.9976957,0.00026916506,0.0011068251,0.0004683632,0.00039304953,0.00006689772],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012270332,0.00020526502,0.0018367837,0.00030129583,0.000025830626,0.000008924423,0.00011976814,0.00012138427,0.00009857339],"category_scores_gemma":[0.00017601035,0.0001092523,0.00047503476,0.001529994,0.00012355695,0.00006255057,0.00006998087,0.00013939796,2.6851941e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000101285084,0.00016224492,0.9506719,0.01171441,0.016714234,0.0000035505082,0.00014341362,0.000004799861,5.54431e-8,0.000009886965,0.0006098651,0.01986435],"study_design_scores_gemma":[0.0013999509,0.00024987588,0.84040296,0.0051280544,0.14616436,0.0000014230802,0.000034354434,0.000060034046,6.9833703e-7,0.0000010927942,0.006445453,0.00011175808],"about_ca_topic_score_codex":0.0009585802,"about_ca_topic_score_gemma":0.000245412,"teacher_disagreement_score":0.12945011,"about_ca_system_score_codex":0.00014253045,"about_ca_system_score_gemma":0.00045588976,"threshold_uncertainty_score":0.44551796},"labels":[],"label_agreement":null},{"id":"W4362716531","doi":"10.1016/j.lungcan.2023.107191","title":"Indirect comparison of mobocertinib and real-world therapies for pre-treated non-small cell lung cancer with EGFR exon 20 insertion mutations","year":2023,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVRAZ (Canada)","funders":"Viropharma","keywords":"Medicine; Internal medicine; Hazard ratio; Lung cancer; Oncology; Confidence interval; Vinorelbine; Discontinuation; Population; Response Evaluation Criteria in Solid Tumors; Clinical trial; Gastroenterology; Chemotherapy; Surgery; Phases of clinical research; Cisplatin","score_opus":0.024040701422515128,"score_gpt":0.3758878505984089,"score_spread":0.35184714917589377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362716531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906023,0.0038436297,0.00020887125,0.0009788059,0.00017446156,0.0020844177,0.00028629086,0.00014383612,0.0016773909],"genre_scores_gemma":[0.98775345,0.0010325814,0.0005549272,0.00010234246,0.00011778243,0.0022072096,0.0003679774,0.000057475376,0.0078062387],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988483,0.00002352518,0.00031752183,0.00033672983,0.00018782676,0.000286093],"domain_scores_gemma":[0.9991468,0.00011422348,0.00021841512,0.00019740766,0.00021967005,0.00010345277],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000672755,0.00021460261,0.00044059457,0.00024276422,0.00016601554,0.000023133658,0.00005466713,0.000072508934,0.00007746891],"category_scores_gemma":[0.000006739427,0.00016278954,0.00006689624,0.0006491437,0.000070025155,0.000100133744,0.000016717615,0.00009744491,0.0000011402192],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00064072694,0.00019049794,0.96830875,0.0010030692,0.0009412955,0.000004236842,0.009983368,0.0017814641,0.007322791,0.00002256448,0.005283659,0.004517606],"study_design_scores_gemma":[0.0062018586,0.0005101992,0.9286594,0.001088178,0.0030226542,0.0000016015342,0.0010645754,0.022617757,0.034311343,0.000024952978,0.0021865768,0.0003109205],"about_ca_topic_score_codex":0.008266066,"about_ca_topic_score_gemma":0.016156144,"teacher_disagreement_score":0.039649338,"about_ca_system_score_codex":0.0003296114,"about_ca_system_score_gemma":0.00035782444,"threshold_uncertainty_score":0.998338},"labels":[],"label_agreement":null},{"id":"W4376619319","doi":"10.1016/j.lungcan.2023.107247","title":"Germline EGFR c.2527G &gt; A (p.V843I) variant and familial lung cancer","year":2023,"lang":"de","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill Genome Centre; McGill University Health Centre; Jewish General Hospital; McGill University","funders":"Canadian Institutes of Health Research","keywords":"Germline; Epidermal growth factor receptor; Lung cancer; Proband; Medicine; Germline mutation; Missense mutation; Adenocarcinoma; Exon; Gefitinib; Somatic cell; Oncology; Cancer research; Internal medicine; Cancer; Mutation; Genetics; Biology; Gene","score_opus":0.012307176042524784,"score_gpt":0.3530358392758478,"score_spread":0.340728663233323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376619319","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2950373,0.6384362,0.00034404884,0.027712423,0.022334456,0.0043060547,0.0042672623,0.00077698304,0.006785282],"genre_scores_gemma":[0.6978476,0.18474264,0.00029545865,0.0047804224,0.014175729,0.003124841,0.00088992034,0.0003922016,0.09375116],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963398,0.0000970713,0.00067484536,0.0010687361,0.00067327695,0.0011462921],"domain_scores_gemma":[0.998102,0.00017108898,0.00025803404,0.00063602114,0.00025656997,0.0005762657],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00025815345,0.0006375313,0.0008552378,0.00032802776,0.00046705006,0.00012974007,0.00020514529,0.00033279593,0.0022017206],"category_scores_gemma":[0.000065893044,0.00055909826,0.00022321506,0.0011108995,0.00021256387,0.00022861871,0.0001885456,0.00048041917,0.00021216217],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012741499,0.0007010022,0.2655368,0.004927031,0.01806991,0.0027285875,0.017499609,0.002082379,0.0026027344,0.0025857447,0.61786765,0.064124435],"study_design_scores_gemma":[0.020759901,0.0005447661,0.23852116,0.0059725796,0.030949833,0.000044772303,0.0008130495,0.11313703,0.0004683942,0.00023369354,0.5864835,0.0020713473],"about_ca_topic_score_codex":0.009397855,"about_ca_topic_score_gemma":0.0018449427,"teacher_disagreement_score":0.45369354,"about_ca_system_score_codex":0.001574729,"about_ca_system_score_gemma":0.0016987796,"threshold_uncertainty_score":0.99968606},"labels":[],"label_agreement":null},{"id":"W4379141408","doi":"10.1016/j.lungcan.2023.107259","title":"Stereotactic body radiation therapy and thermal ablation for treatment of NSCLC: A systematic literature review and meta-analysis","year":2023,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"AstraZeneca; Johnson and Johnson; Pfizer","keywords":"Medicine; Meta-analysis; Radiofrequency ablation; Microwave ablation; Lung cancer; Radiosurgery; Stage (stratigraphy); Subgroup analysis; Internal medicine; Randomized controlled trial; Oncology; Systematic review; Radiation therapy; non-small cell lung cancer (NSCLC); Radiology; Nuclear medicine; Ablation; MEDLINE","score_opus":0.18104766197304406,"score_gpt":0.39147298220618093,"score_spread":0.21042532023313687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379141408","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000061911844,0.9906152,0.0000046034625,0.00015339117,0.000028327673,0.008821219,0.00028026447,0.000022240736,0.000012837517],"genre_scores_gemma":[0.00027542084,0.9915269,0.00003224373,0.000056495064,0.00006351464,0.006289039,0.00057552825,0.00004749497,0.0011333862],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.998484,0.00023084864,0.00063103397,0.00035796055,0.00015649054,0.0001396754],"domain_scores_gemma":[0.99866265,0.00028449288,0.0005619158,0.00032170126,0.00009792614,0.00007133407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002383282,0.00037735046,0.0049552643,0.00026222167,0.00004127617,0.000035003366,0.000033785444,0.00016523994,0.00006417193],"category_scores_gemma":[0.000019898538,0.00020350431,0.0015836121,0.0005992704,0.00001553099,0.000058446334,0.0000069042294,0.00004748795,0.0000010415072],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016595865,0.00004512902,0.00046965346,0.70725346,0.24883766,0.000010045635,0.00020279715,3.1844134e-8,2.8426584e-7,0.000009973367,0.000033125674,0.04312126],"study_design_scores_gemma":[0.00052263675,0.00024537675,0.00007279287,0.03560795,0.9461449,0.000011289681,0.0000016007131,0.00018239698,0.0000015207265,0.0000010601897,0.0170551,0.0001533899],"about_ca_topic_score_codex":0.000030670584,"about_ca_topic_score_gemma":0.0000070610527,"teacher_disagreement_score":0.6973072,"about_ca_system_score_codex":0.00014389108,"about_ca_system_score_gemma":0.00009310156,"threshold_uncertainty_score":0.8298665},"labels":[],"label_agreement":null},{"id":"W4381547499","doi":"10.1016/j.lungcan.2023.107281","title":"Stereotactic body radiotherapy for Ultra-Central lung Tumors: A systematic review and Meta-Analysis and International Stereotactic Radiosurgery Society practice guidelines","year":2023,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto","funders":"Department of Health and Social Care; Cancer Research UK; National Institute for Health and Care Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; Royal Marsden NHS Foundation Trust","keywords":"Medicine; Radiosurgery; Meta-analysis; Lung cancer; Radiation therapy; Incidence (geometry); Pneumonitis; Dose fractionation; Oncology; Internal medicine; Radiology; Lung","score_opus":0.1080639109713676,"score_gpt":0.45644371223217445,"score_spread":0.34837980126080687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381547499","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000014084437,0.9825345,0.00012070306,0.007459389,0.0003831059,0.008709116,0.0006753155,0.00009166192,0.000024763263],"genre_scores_gemma":[0.0000064818378,0.9798263,0.0008063644,0.0053934287,0.00045464977,0.010123725,0.00029915894,0.0001650275,0.0029249052],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99539447,0.00032549247,0.0020518077,0.0011153782,0.00057256885,0.0005402624],"domain_scores_gemma":[0.9944033,0.0020986805,0.0017800726,0.0007633524,0.0006502018,0.0003044173],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012318383,0.0008852187,0.009030988,0.0002837367,0.000128496,0.00021589981,0.00020772892,0.00022510922,0.00025211662],"category_scores_gemma":[0.0008636174,0.0005702466,0.0039586765,0.0007643445,0.000066253706,0.000310958,0.000046629786,0.00034373466,0.0000025750255],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000017194587,0.00007748393,0.000070354305,0.5652627,0.4197067,0.00003179973,0.00008321837,4.832825e-7,5.378872e-8,0.000010389304,0.013667869,0.0010717778],"study_design_scores_gemma":[0.00063646166,0.000053839758,0.000011200877,0.09383528,0.7938714,0.00028293193,0.00002370433,0.00019995433,2.1262353e-7,0.0000012526027,0.11067603,0.0004077098],"about_ca_topic_score_codex":0.00021845187,"about_ca_topic_score_gemma":0.000030912703,"teacher_disagreement_score":0.4714274,"about_ca_system_score_codex":0.0016402258,"about_ca_system_score_gemma":0.000639328,"threshold_uncertainty_score":0.9996749},"labels":[],"label_agreement":null},{"id":"W4381953305","doi":"10.1016/j.lungcan.2023.107284","title":"Stereotactic Body Radiotherapy for Lung Oligo-metastases: Systematic Review and International Stereotactic Radiosurgery Society Practice Guidelines","year":2023,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Radiosurgery; Randomized controlled trial; Guideline; Radiation therapy; Radiology; Lung cancer; Stereotactic radiotherapy; Dose fractionation; Oncology; Internal medicine","score_opus":0.14962560740118783,"score_gpt":0.4413805635659144,"score_spread":0.2917549561647266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381953305","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000034293937,0.98377997,0.00014301683,0.0029013543,0.0010588226,0.011437663,0.00046400243,0.00015673538,0.0000550314],"genre_scores_gemma":[0.000002418204,0.9805241,0.0015638263,0.0036523263,0.00094643945,0.0077418727,0.0006859381,0.0002481016,0.004634931],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958776,0.0003869681,0.0018965831,0.00084290706,0.00050292973,0.0004929604],"domain_scores_gemma":[0.99504465,0.0018270344,0.0014189904,0.0007123652,0.00074913737,0.0002478164],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016465407,0.0008099352,0.0044964775,0.0002211169,0.0001348282,0.000158185,0.0002548453,0.00030234765,0.00018461476],"category_scores_gemma":[0.001551237,0.00058630237,0.0016682218,0.00048939406,0.0000520624,0.0003237804,0.00007527029,0.0003951318,0.000014421941],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003035431,0.0000754585,0.00028556096,0.9114808,0.015370876,0.000097001444,0.00007388061,4.179825e-8,2.5903105e-7,0.000012579966,0.054174405,0.018398803],"study_design_scores_gemma":[0.00069170445,0.00006265486,0.0000013549443,0.4075548,0.075347625,0.00051474985,0.000022117058,0.0009487333,2.653559e-7,8.6100164e-7,0.5144545,0.00040061687],"about_ca_topic_score_codex":0.000060735492,"about_ca_topic_score_gemma":0.0000029772996,"teacher_disagreement_score":0.503926,"about_ca_system_score_codex":0.0010775327,"about_ca_system_score_gemma":0.00082019705,"threshold_uncertainty_score":0.9996588},"labels":[],"label_agreement":null},{"id":"W4387981858","doi":"10.1183/13993003.congress-2023.pa3887","title":"Impact of COPD on lung cancer symptom burden: A population-based study","year":2023,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; McMaster University; Sunnybrook Hospital; University of Toronto","funders":"","keywords":"COPD; Medicine; Lung cancer; Internal medicine; Stage (stratigraphy); Population; Cancer; Retrospective cohort study; Cohort; Poisson regression; Physical therapy","score_opus":0.01939794815664339,"score_gpt":0.3946958386500647,"score_spread":0.3752978904934213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387981858","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99393535,0.002008166,0.000005330062,0.00073049986,0.000356016,0.0018602211,0.00037298203,0.00014166019,0.00058980763],"genre_scores_gemma":[0.9963239,0.00007389247,0.0000069439175,0.00008778293,0.0005422294,0.0005702553,0.00012490743,0.00007325802,0.0021968752],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99757344,0.00009815708,0.00034203127,0.00050826644,0.00093675207,0.0005413377],"domain_scores_gemma":[0.9985791,0.0001595391,0.00012773814,0.00059327745,0.0002560819,0.00028428456],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00017831054,0.00026063004,0.0004811748,0.0003659872,0.00010345772,0.00001921658,0.00017453807,0.00008620381,0.0033799028],"category_scores_gemma":[0.0000842114,0.00021846149,0.00024868827,0.001043845,0.000054750166,0.00007524595,0.00006570998,0.00028646816,0.000029811257],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00076214905,0.0003083982,0.97189647,0.00066844374,0.0006142124,0.000096792515,0.0003982689,0.014748386,0.0004850498,0.000016126412,0.006471036,0.003534676],"study_design_scores_gemma":[0.0030902366,0.00024682653,0.94053185,0.00051367696,0.00029512995,8.8851385e-7,0.00015483572,0.05480308,0.000071980314,0.000007715207,0.000096958625,0.00018679307],"about_ca_topic_score_codex":0.019238718,"about_ca_topic_score_gemma":0.00053681165,"teacher_disagreement_score":0.040054694,"about_ca_system_score_codex":0.0028828168,"about_ca_system_score_gemma":0.0014374814,"threshold_uncertainty_score":0.9975311},"labels":[],"label_agreement":null},{"id":"W4388185745","doi":"10.1183/13993003.congress-2023.pa3890","title":"Has the covid pandemic influenced the diagnosis of patients with lung cancer?","year":2023,"lang":"en","type":"article","venue":"Lung Cancer","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Lung cancer; Medicine; Pandemic; Coronavirus disease 2019 (COVID-19); Referral; Retrospective cohort study; Stage (stratigraphy); Quarter (Canadian coin); Cancer; Pediatrics; Disease; Internal medicine; Family medicine; Infectious disease (medical specialty)","score_opus":0.05877271174007154,"score_gpt":0.40868309182035584,"score_spread":0.3499103800802843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388185745","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95787275,0.0028819705,0.000009294872,0.03761574,0.00031348626,0.0010263526,0.00012094701,0.00008489714,0.00007457157],"genre_scores_gemma":[0.98397464,0.0023103352,0.0000032571006,0.01255462,0.0002064623,0.0006314414,0.000015460184,0.000025557847,0.00027820776],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99870974,0.00005540326,0.00022978333,0.00020745936,0.0004461274,0.0003514917],"domain_scores_gemma":[0.9986741,0.00044548698,0.0001449942,0.00039721216,0.00019217136,0.00014601894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022563241,0.00014041175,0.00025071175,0.00006590981,0.00022964388,0.000018576637,0.00017178069,0.000067511275,0.000264439],"category_scores_gemma":[0.00021611311,0.00006728132,0.000059662187,0.00065483677,0.00017464634,0.000059295635,0.000052688058,0.0002550861,0.0000049007035],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024359243,0.0000208376,0.96100026,0.0004140113,0.00011878237,0.0000032865873,0.002660837,0.00035020552,0.000027788179,0.000015905942,0.03000852,0.005135961],"study_design_scores_gemma":[0.0013334637,0.000109103246,0.9644113,0.00044864675,0.00023823504,6.8686387e-7,0.00010655218,0.00040859194,0.00012250118,0.000013822572,0.032714993,0.000092113834],"about_ca_topic_score_codex":0.014172928,"about_ca_topic_score_gemma":0.0063038566,"teacher_disagreement_score":0.026101915,"about_ca_system_score_codex":0.00045668063,"about_ca_system_score_gemma":0.001359092,"threshold_uncertainty_score":0.99239177},"labels":[],"label_agreement":null},{"id":"W4388563714","doi":"10.1016/j.lungcan.2023.107419","title":"Understanding health-related quality of life measures used in early-stage non-small cell lung cancer clinical trials: A review","year":2023,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"AstraZeneca España; AstraZeneca","keywords":"Medicine; Quality of life (healthcare); Disease; Stage (stratigraphy); Lung cancer; Clinical trial; Intensive care medicine; Scope (computer science); Physical therapy; Oncology; Internal medicine; Nursing","score_opus":0.6041392632226493,"score_gpt":0.5597146177118956,"score_spread":0.04442464551075376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388563714","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002963234,0.98546857,0.00004029195,0.0014769755,0.0018429271,0.009761059,0.0007589553,0.00011111905,0.00024376716],"genre_scores_gemma":[0.00047375984,0.99293834,0.000031324667,0.0007816911,0.00053703954,0.0036038135,0.00017033971,0.00022785166,0.0012358571],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.98542327,0.0037862102,0.007638378,0.0013241236,0.00097136036,0.0008566401],"domain_scores_gemma":[0.99003595,0.003245206,0.004791303,0.0011013104,0.00018034969,0.00064587797],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.013515579,0.0009178986,0.012997922,0.00040885966,0.00009392772,0.000034522964,0.00036722,0.0007648499,0.00046135887],"category_scores_gemma":[0.0014275967,0.00067782233,0.0025715728,0.0014970799,0.00012522476,0.00007155151,0.00013337423,0.0014107252,0.00001911723],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0002500819,0.00065877003,0.08394763,0.79149044,0.006187912,0.000082107355,0.00051739864,0.000018562621,1.8092777e-7,0.00010876171,0.039726548,0.077011615],"study_design_scores_gemma":[0.008127182,0.0003011139,0.0035047177,0.7468541,0.013214148,0.000002051539,0.000072887284,0.00005450293,0.00000115287,0.000010679399,0.22693114,0.0009263248],"about_ca_topic_score_codex":0.02675575,"about_ca_topic_score_gemma":0.010347629,"teacher_disagreement_score":0.18720458,"about_ca_system_score_codex":0.00716026,"about_ca_system_score_gemma":0.009064081,"threshold_uncertainty_score":0.9995673},"labels":[],"label_agreement":null},{"id":"W4391818063","doi":"10.1016/j.lungcan.2024.107504","title":"Response to letter: Microwave ablation for Early-Stage Non-Small cell Lung Cancer: Don’t Put the Cart before the stereotactic Horse","year":2024,"lang":"en","type":"letter","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Johnson and Johnson","keywords":"Cart; Microwave ablation; Medicine; Stage (stratigraphy); Ablation; Horse; Lung cancer; Oncology; Internal medicine; Nuclear medicine; Biology; History","score_opus":0.012961014427310983,"score_gpt":0.29490520646762397,"score_spread":0.281944192040313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391818063","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10577773,0.014737083,0.000116867595,0.86488664,0.00459484,0.0077887373,0.0014702759,0.00011132482,0.0005164819],"genre_scores_gemma":[0.09324533,0.0013193568,0.0001741909,0.76377404,0.01770687,0.017602867,0.0004047456,0.0005048595,0.105267756],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99632484,0.00019843862,0.00061724725,0.0011766193,0.00067941565,0.0010034598],"domain_scores_gemma":[0.99728775,0.000514717,0.000336124,0.0014302495,0.00025526053,0.0001758736],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005152668,0.00082732376,0.00082546554,0.00022633966,0.00035916452,0.0003169771,0.000501731,0.0005841161,0.00029068175],"category_scores_gemma":[0.000028513494,0.0004756302,0.00062742806,0.00039968383,0.00010577702,0.00009511505,0.00017430073,0.0016257344,0.000054330012],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00077319145,0.000045206965,0.012916121,0.0024762533,0.0013850547,0.0003334508,0.0041224076,0.00008447892,0.0002368648,0.0000040873074,0.9764396,0.0011832868],"study_design_scores_gemma":[0.0017594526,0.00042236262,0.007027504,0.0023850617,0.0048641837,0.000016135786,0.0000893562,0.00046422763,0.001564124,0.000009944355,0.9809389,0.00045875317],"about_ca_topic_score_codex":0.0059043677,"about_ca_topic_score_gemma":0.0047847605,"teacher_disagreement_score":0.104751274,"about_ca_system_score_codex":0.003734625,"about_ca_system_score_gemma":0.0009877195,"threshold_uncertainty_score":0.99976957},"labels":[],"label_agreement":null},{"id":"W4391896363","doi":"10.1016/j.lungcan.2024.107506","title":"Blood tumor mutational burden and response to pembrolizumab plus chemotherapy in non–small cell lung cancer: KEYNOTE-782","year":2024,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke; Queen's University","funders":"","keywords":"Medicine; Pemetrexed; Pembrolizumab; Lung cancer; Carboplatin; Internal medicine; Oncology; Response Evaluation Criteria in Solid Tumors; Chemotherapy; Surrogate endpoint; Cancer; Immunotherapy; Cisplatin; Progressive disease","score_opus":0.0039897269361011825,"score_gpt":0.26341521555037406,"score_spread":0.2594254886142729,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391896363","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9675472,0.028795479,0.00028805618,0.001886249,0.00046190602,0.00045203354,0.00025170052,0.000015884714,0.00030149185],"genre_scores_gemma":[0.99197394,0.0031311898,0.0003251255,0.0012976046,0.0009778248,0.00035530943,0.00003765044,0.000059006343,0.0018423283],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987943,0.00002997122,0.000212414,0.0005275295,0.0001198476,0.00031593203],"domain_scores_gemma":[0.9994947,0.000057515914,0.000039756935,0.0002167749,0.000057520418,0.00013376442],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014279236,0.00020593051,0.0001847092,0.00010075497,0.000050690433,0.000087163535,0.0001496961,0.00010566428,0.00009484745],"category_scores_gemma":[0.000029896119,0.00021712956,0.00006212894,0.00016857593,0.000036157584,0.0000047839835,0.00009446759,0.00012772002,0.0000033080207],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049817963,0.00007609605,0.010256156,0.0007202014,0.00032792654,0.00025798756,0.0037708017,0.023535712,0.92690754,0.00009521608,0.01965017,0.00942038],"study_design_scores_gemma":[0.01959541,0.0012327557,0.059611544,0.0014436058,0.0007101221,0.00014806991,0.0005338499,0.06889182,0.49976882,0.00019347665,0.3449684,0.0029020957],"about_ca_topic_score_codex":0.0014774965,"about_ca_topic_score_gemma":0.0012568719,"teacher_disagreement_score":0.42713875,"about_ca_system_score_codex":0.00022393145,"about_ca_system_score_gemma":0.0008805997,"threshold_uncertainty_score":0.88542867},"labels":[],"label_agreement":null},{"id":"W4392382353","doi":"10.1016/j.lungcan.2024.107529","title":"Outcomes of patients with advanced epithelial growth factor receptor mutant lung cancer treated with first-line osimertinib who would not have met the eligibility criteria for the FLAURA clinical trial","year":2024,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Osimertinib; Internal medicine; Lung cancer; Population; T790M; Clinical trial; Oncology; Cohort; Cancer; Surgery; Epidermal growth factor receptor; Gefitinib; Erlotinib","score_opus":0.0368810711503858,"score_gpt":0.4325912659763442,"score_spread":0.3957101948259584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392382353","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9762674,0.0024937156,0.0005247763,0.0067966217,0.0016833595,0.006533071,0.0055415174,0.000099307494,0.00006023159],"genre_scores_gemma":[0.99311274,0.0009019828,0.0002906962,0.000822081,0.0006591063,0.0029311476,0.00017666913,0.00009106418,0.0010145061],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99747556,0.00009495615,0.0008096524,0.0006704695,0.0005259269,0.0004234271],"domain_scores_gemma":[0.9972558,0.0011518968,0.00030944176,0.0005837162,0.00055080367,0.00014831717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026585747,0.0004171921,0.00084568386,0.00006650031,0.00025121946,0.00006445659,0.00021025712,0.00018298574,0.0005156966],"category_scores_gemma":[0.00020905837,0.0001733203,0.00032230435,0.00031154483,0.0002868985,0.00017138026,0.000039371174,0.00042001743,0.000001483033],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13294338,0.0009247332,0.81655383,0.0011003352,0.010810952,0.000010233176,0.0033693144,0.00020502304,0.00027366818,0.00011096426,0.0061483877,0.027549203],"study_design_scores_gemma":[0.17396401,0.009808813,0.735677,0.002881878,0.018761046,0.0000030397405,0.0004282691,0.008198888,0.011329702,0.000034636432,0.037804384,0.0011083555],"about_ca_topic_score_codex":0.0013918519,"about_ca_topic_score_gemma":0.0014345659,"teacher_disagreement_score":0.08087683,"about_ca_system_score_codex":0.00056431297,"about_ca_system_score_gemma":0.0008533167,"threshold_uncertainty_score":0.7067796},"labels":[],"label_agreement":null},{"id":"W4392859966","doi":"10.1016/j.lungcan.2024.107535","title":"A pragmatic guide for management of adverse events associated with lorlatinib","year":2024,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Pfizer","keywords":"Medicine; Adverse effect; Clinical trial; Anaplastic lymphoma kinase; Concomitant; Tyrosine-kinase inhibitor; Intensive care medicine; Oncology; Internal medicine; Lung cancer; Cancer","score_opus":0.027980821829533785,"score_gpt":0.4324065033874051,"score_spread":0.40442568155787134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392859966","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000006093679,0.98753595,0.00011677538,0.000068144276,0.00037154276,0.0045977985,0.0007091852,0.000054909542,0.006539574],"genre_scores_gemma":[0.000020867003,0.94982797,0.0012924062,0.00004215591,0.00009156249,0.0039205956,0.00077141303,0.00009468507,0.043938324],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986625,0.000023211556,0.00049862236,0.00033385033,0.00026339316,0.00021846141],"domain_scores_gemma":[0.99911624,0.0000610642,0.00035603793,0.000286566,0.000108651555,0.0000714121],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009800148,0.00030641974,0.0011228865,0.00012784581,0.00003439592,0.0000031648703,0.0000812529,0.000111042085,0.00011329664],"category_scores_gemma":[0.0000129693,0.00018865771,0.0003772709,0.00035469388,0.000022299957,0.000031826152,0.000030413872,0.0001229149,0.000010519616],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000066605426,0.000359321,0.00015008706,0.37374055,0.042542886,0.00012625514,0.000351934,0.000019687915,9.705187e-8,0.00074532186,0.034264788,0.54763246],"study_design_scores_gemma":[0.0013684055,0.00012723255,0.000047058034,0.15715244,0.06786069,0.000006172059,0.00003308222,0.000045222318,1.676656e-7,0.000021428941,0.7731697,0.00016841751],"about_ca_topic_score_codex":0.00004430204,"about_ca_topic_score_gemma":0.00004802627,"teacher_disagreement_score":0.7389049,"about_ca_system_score_codex":0.001023546,"about_ca_system_score_gemma":0.00067613815,"threshold_uncertainty_score":0.7693238},"labels":[],"label_agreement":null},{"id":"W4393340184","doi":"10.1016/j.lungcan.2024.107557","title":"Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: Results from the multicenter, phase 2 REMORA trial","year":2024,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eisai Canada; Eisai; Center for Clinical Trials, Japan Medical Association","keywords":"Lenvatinib; Medicine; Hazard ratio; Internal medicine; Adverse effect; Confidence interval; Oncology; Clinical trial; Gastroenterology; Cancer; Thyroid cancer","score_opus":0.03466082282414185,"score_gpt":0.3378925740177667,"score_spread":0.30323175119362483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393340184","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99306023,0.0043310896,0.00002323218,0.00021849108,0.0005430831,0.0009798263,0.0008114554,0.000016678885,0.000015919131],"genre_scores_gemma":[0.998996,0.00016836896,0.00006884557,0.00008516313,0.0001047115,0.00008589897,0.00034584373,0.000022972936,0.00012218984],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998513,0.000106246516,0.00048050587,0.00038860156,0.00033016969,0.00018148612],"domain_scores_gemma":[0.99908984,0.0002446598,0.00014431383,0.00036253425,0.00008025748,0.00007839141],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022770489,0.00017678106,0.00051771395,0.00019128625,0.00003230325,0.000029420862,0.000085542844,0.00003553996,0.00012459974],"category_scores_gemma":[0.00008892719,0.0000932759,0.000108651184,0.0006957155,0.000064805165,0.00008783736,0.000034596498,0.0001777506,0.0000011479656],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31866404,0.0009830798,0.6252081,0.00037735232,0.003932882,0.0001894908,0.009569576,0.000008591713,0.00011277163,0.000012579845,0.0010745595,0.039866973],"study_design_scores_gemma":[0.23327848,0.0023168807,0.7459307,0.0017143915,0.0097592715,8.5701777e-7,0.00038640125,0.0058129886,0.000191037,0.0000051646152,0.00034532475,0.0002585262],"about_ca_topic_score_codex":0.0006551829,"about_ca_topic_score_gemma":0.002478935,"teacher_disagreement_score":0.120722584,"about_ca_system_score_codex":0.00010238085,"about_ca_system_score_gemma":0.0001622896,"threshold_uncertainty_score":0.38036808},"labels":[],"label_agreement":null},{"id":"W4394878299","doi":"10.1016/j.lungcan.2024.107733","title":"172 Stage and Survival of Screen Detected Small Cell Lung Cancer from the SUMMIT Study","year":2024,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Summit; Medicine; Stage (stratigraphy); Lung cancer; Oncology; Internal medicine; Cartography","score_opus":0.028990671029437663,"score_gpt":0.36243275310084566,"score_spread":0.333442082071408,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394878299","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8753208,0.11886697,0.000057281883,0.001652732,0.0006239833,0.0015935516,0.0006925554,0.00010751117,0.0010846481],"genre_scores_gemma":[0.9880759,0.0045768972,0.000045574703,0.0001464028,0.00067403796,0.00040604034,0.00001343435,0.00006273648,0.00599899],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979517,0.00014065648,0.0003104496,0.000537021,0.0006297707,0.00043042467],"domain_scores_gemma":[0.9986489,0.00047360233,0.000070238595,0.0004734589,0.00019316998,0.00014062674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036750507,0.00025500383,0.00047446068,0.00008793427,0.00013043203,0.00006532959,0.00022441638,0.00007125714,0.0007016214],"category_scores_gemma":[0.00007341807,0.0001637333,0.00009278133,0.00044484952,0.00017976384,0.00007532392,0.00027193263,0.00047335256,0.0000035409698],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038583376,0.000097132346,0.9713852,0.0010603683,0.0017240128,0.000091549715,0.004594421,0.00002886934,0.0035875496,0.00002005214,0.013059995,0.003965052],"study_design_scores_gemma":[0.0040489207,0.0004476863,0.96078813,0.0016883055,0.0022744446,8.90766e-7,0.004590035,0.0052133324,0.006025269,0.00001662654,0.014471533,0.00043484272],"about_ca_topic_score_codex":0.0512693,"about_ca_topic_score_gemma":0.04595522,"teacher_disagreement_score":0.11429007,"about_ca_system_score_codex":0.00040934217,"about_ca_system_score_gemma":0.00054282905,"threshold_uncertainty_score":0.9714536},"labels":[],"label_agreement":null},{"id":"W4394879017","doi":"10.1016/j.lungcan.2024.107603","title":"42 Evaluation of a novel simulator for linear and radial EBUS at University College London: The Lung Phantom","year":2024,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Ultrasound in Clinical Applications","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Imaging phantom; Medicine; Simulation; Nuclear medicine; Computer science","score_opus":0.05356015067535775,"score_gpt":0.40550049936074173,"score_spread":0.351940348685384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394879017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855904,0.005196542,0.0025476487,0.0034226887,0.00032222975,0.0015870666,0.0010015805,0.00003681118,0.0002950423],"genre_scores_gemma":[0.9958481,0.00018513383,0.0005360316,0.00017826866,0.00037599634,0.00004991111,0.000024855688,0.000012847098,0.0027888531],"study_design_codex":"not_applicable","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9993385,0.000018999232,0.00013856227,0.000190174,0.00021858381,0.00009517483],"domain_scores_gemma":[0.99872977,0.00083490176,0.000042813066,0.00015596637,0.00018376048,0.00005277622],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036452795,0.00006556907,0.00013485651,0.000029215911,0.00008278288,0.000004125156,0.000056153236,0.00006314789,0.00018788944],"category_scores_gemma":[0.00015113145,0.000048182003,0.00006540787,0.0001903019,0.000096297095,0.00003884383,0.000026743157,0.00008520142,0.0000018354505],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010925328,0.0027324422,0.13754529,0.009016822,0.007194201,0.00002053593,0.01197084,0.025569947,0.17739984,0.07989434,0.49974144,0.037988983],"study_design_scores_gemma":[0.0033808597,0.0000742559,0.0072246147,0.00015866032,0.0014321872,0.000004892511,0.000056708952,0.90355796,0.0008254309,0.00007755766,0.08312863,0.0000782544],"about_ca_topic_score_codex":0.000068830384,"about_ca_topic_score_gemma":0.00008790692,"teacher_disagreement_score":0.877988,"about_ca_system_score_codex":0.0003131078,"about_ca_system_score_gemma":0.00029257266,"threshold_uncertainty_score":0.20572577},"labels":[],"label_agreement":null},{"id":"W4394879899","doi":"10.1016/j.lungcan.2024.107562","title":"1 Fast-tracking NSCLC Standard of Care Genomic Testing with a Formalin-free Fresh EBUS Pathway","year":2024,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Genomics and Rare Diseases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Medicine; Tracking (education); Oncology; Radiology; Internal medicine","score_opus":0.0064031601652497615,"score_gpt":0.24919803156432999,"score_spread":0.24279487139908024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394879899","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9514298,0.04526323,0.0006066859,0.00005935468,0.00024172054,0.00018649735,0.00088773045,0.000024200051,0.0013007896],"genre_scores_gemma":[0.9980241,0.00019910077,0.0011367565,0.00007283133,0.00029308695,0.000034971665,0.00007413556,0.000038601425,0.00012641578],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99924105,0.0000111331465,0.00014867289,0.00027391943,0.00011311769,0.00021209371],"domain_scores_gemma":[0.9994393,0.000010170387,0.00005181525,0.000284626,0.00015203132,0.00006204784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000045206423,0.0001361887,0.00013700497,0.000034065397,0.000059080652,0.000043937554,0.00017356245,0.00006733656,0.00002131905],"category_scores_gemma":[0.00002081523,0.00011084542,0.0000738818,0.00008551154,0.00004382448,0.0000045881416,0.00010434573,0.00006887107,8.396113e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008213816,0.00003842029,0.037765678,0.0021178492,0.0005886829,0.00014877321,0.001725921,0.0044645118,0.8940596,0.00047388815,0.0036404298,0.05415489],"study_design_scores_gemma":[0.0040920163,0.003031831,0.021605145,0.0031509132,0.0007996798,0.00014852386,0.0032978447,0.0022088862,0.8328751,0.00030190634,0.12642756,0.002060626],"about_ca_topic_score_codex":0.00011810278,"about_ca_topic_score_gemma":0.0006041254,"teacher_disagreement_score":0.122787125,"about_ca_system_score_codex":0.000051379306,"about_ca_system_score_gemma":0.00043734777,"threshold_uncertainty_score":0.4520145},"labels":[],"label_agreement":null},{"id":"W4396769086","doi":"10.1016/j.lungcan.2024.107819","title":"Natural history of SCLC patients treated in third-line and beyond: A retrospective real world study","year":2024,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Amgen","keywords":"Medicine; Natural history; Retrospective cohort study; Real world evidence; Natural (archaeology); Internal medicine; Archaeology; History","score_opus":0.015157342278014005,"score_gpt":0.35070606231962614,"score_spread":0.3355487200416121,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396769086","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9509573,0.029910825,2.509416e-7,0.0005041886,0.00071396626,0.001444386,0.00003854097,0.00006143927,0.016369134],"genre_scores_gemma":[0.9779339,0.0008315454,0.000016201731,0.00009784657,0.000111407906,0.00021820229,0.000009280017,0.000025419704,0.020756224],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99869144,0.000051095238,0.00024179321,0.00038661348,0.00039319767,0.00023587927],"domain_scores_gemma":[0.99947155,0.000059295297,0.00004600981,0.00019213528,0.0001636382,0.000067357665],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019074911,0.0001479459,0.0004173953,0.00030648097,0.000023307572,0.000013877761,0.00009217077,0.00003179046,0.00008190275],"category_scores_gemma":[0.000065017324,0.00011304336,0.00003935049,0.0004943239,0.0001276305,0.00012376966,0.00016840875,0.00035782208,0.0000013279852],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007020875,0.0002861059,0.9623972,0.00035479444,0.0003909687,0.00007759943,0.006757646,7.778186e-7,0.00017776607,0.00008278592,0.026021983,0.0027502906],"study_design_scores_gemma":[0.0030888712,0.0006479396,0.9924068,0.00057526847,0.00017949595,6.616928e-7,0.00022183637,0.00044617202,0.000096133204,0.000032217293,0.0021864052,0.00011819937],"about_ca_topic_score_codex":0.011582856,"about_ca_topic_score_gemma":0.020079555,"teacher_disagreement_score":0.030009605,"about_ca_system_score_codex":0.0043409565,"about_ca_system_score_gemma":0.00033679637,"threshold_uncertainty_score":0.9994812},"labels":[],"label_agreement":null},{"id":"W4396774318","doi":"10.1016/j.lungcan.2024.107816","title":"Efficacy and safety of crizotinib in the treatment of advanced non-small cell lung cancer with ROS1 gene fusion: a systematic literature review and meta-analysis of real-world evidence","year":2024,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Pfizer","keywords":"Crizotinib; Medicine; ROS1; Meta-analysis; Oncology; Lung cancer; Fusion gene; Internal medicine; Cancer; Gene; Adenocarcinoma; Genetics","score_opus":0.04719019416161372,"score_gpt":0.4142573196791078,"score_spread":0.36706712551749404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396774318","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022324748,0.99004436,0.000005473642,0.00025396605,0.00005319474,0.008352465,0.0009008709,0.000008968914,0.00015743621],"genre_scores_gemma":[0.0007154772,0.99312913,0.00027816513,0.00008524995,0.000029634206,0.003812855,0.00012093921,0.00004863228,0.0017798934],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9971217,0.00025907645,0.0013885131,0.00063065655,0.0003829606,0.00021711757],"domain_scores_gemma":[0.9972314,0.00050347147,0.0011168101,0.0008108412,0.0002479337,0.00008953658],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031755565,0.00059022405,0.0069305208,0.0004670296,0.00003955528,0.000021096881,0.0001529122,0.000117249925,0.00008375243],"category_scores_gemma":[0.00001920619,0.00026055114,0.0009789137,0.0025346726,0.000084687446,0.000063582906,0.000035280143,0.00019643601,1.833608e-7],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009336191,0.00021935077,0.00016346996,0.8865599,0.104878716,0.000047629488,0.0026813422,0.0000472315,0.0000042736997,0.000015847329,0.00009779046,0.005191075],"study_design_scores_gemma":[0.00069141365,0.00024143612,0.00018933893,0.27715728,0.7177125,0.000011306581,0.000032812834,0.00002817871,0.0000066445423,2.7424113e-7,0.0037714583,0.0001573214],"about_ca_topic_score_codex":0.0009034814,"about_ca_topic_score_gemma":0.0020609968,"teacher_disagreement_score":0.6128338,"about_ca_system_score_codex":0.00046778613,"about_ca_system_score_gemma":0.00068493705,"threshold_uncertainty_score":0.9999847},"labels":[],"label_agreement":null},{"id":"W4396901941","doi":"10.1016/j.lungcan.2024.107822","title":"Optimal management of radiation pneumonitis: Findings of an international Delphi consensus study","year":2024,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Effects of Radiation Exposure","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto; London Health Sciences Centre; Health Sciences Centre; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Pulmonologists; Hypersensitivity pneumonitis; Radiation therapy; Pneumonitis; Prednisone; Internal medicine; Intensive care medicine; Lung","score_opus":0.009975424873616748,"score_gpt":0.3474710461159723,"score_spread":0.33749562124235555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396901941","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995721,0.0011711837,0.0000709044,0.0005635165,0.0006397858,0.00054725155,0.00003958063,0.000042847507,0.0012039721],"genre_scores_gemma":[0.9985301,0.000135639,0.0006540436,0.00003595804,0.000118988355,0.000042093172,0.000023605986,0.000015379488,0.00044418714],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99921876,0.000024020508,0.00021933841,0.00016449545,0.00029305852,0.00008034499],"domain_scores_gemma":[0.9996525,0.000041806055,0.000055229368,0.00013757139,0.00007286335,0.0000400452],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016114826,0.0000726723,0.00014040201,0.00014352746,0.000011723358,0.0000111208155,0.000069816626,0.000031755004,0.00017333066],"category_scores_gemma":[0.000013673309,0.00006945173,0.000042095435,0.00014618665,0.000025480049,0.000078085446,0.000019064715,0.00007339943,0.0000034394798],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011202128,0.0015396255,0.7673062,0.0042447187,0.006164367,0.0009876853,0.010392137,0.013735702,0.01276738,0.0045867246,0.008067579,0.16908766],"study_design_scores_gemma":[0.0032283114,0.001021417,0.9338718,0.00096235704,0.0008636236,0.000030523635,0.0012761478,0.046701714,0.009960487,0.000017158418,0.0018870409,0.00017939371],"about_ca_topic_score_codex":0.000084418745,"about_ca_topic_score_gemma":0.00000820099,"teacher_disagreement_score":0.16890827,"about_ca_system_score_codex":0.00012922112,"about_ca_system_score_gemma":0.000055625453,"threshold_uncertainty_score":0.28321594},"labels":[],"label_agreement":null},{"id":"W4396979303","doi":"10.1016/j.lungcan.2024.107823","title":"Single organ metastatic sites in non-small cell lung cancer: Patient characteristics, treatment patterns and outcomes from a large retrospective Canadian cohort","year":2024,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Retrospective cohort study; Internal medicine; Cohort; Brain metastasis; Metastasis; Proportional hazards model; Lung cancer; Stage (stratigraphy); Cancer; Oncology","score_opus":0.009659942565585887,"score_gpt":0.2731270567589191,"score_spread":0.2634671141933332,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396979303","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9778942,0.013407692,0.000012073269,0.0018286726,0.00075677637,0.0015399397,0.00419342,0.000054922282,0.00031230363],"genre_scores_gemma":[0.9923734,0.0044947267,0.00007738712,0.0007463867,0.00018749223,0.0011830904,0.00037841575,0.00007405173,0.0004850684],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99813104,0.000035074394,0.0003557285,0.0007023743,0.0002224866,0.00055332715],"domain_scores_gemma":[0.9990879,0.00008896331,0.00008176013,0.00030217614,0.000070997834,0.00036815973],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00006077448,0.00038465252,0.00070857623,0.00020945445,0.00008468188,0.00010363828,0.000057715184,0.00008129461,0.0010199976],"category_scores_gemma":[0.000011468264,0.00029637915,0.000115034505,0.00020541456,0.000026648746,0.00008179143,0.000034306187,0.00017371682,0.00000877638],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003290816,0.00034623744,0.98847157,0.0003573733,0.0011508942,0.0006450439,0.004023718,0.0000029538894,0.00012147807,0.000010836246,0.0010801728,0.0037568186],"study_design_scores_gemma":[0.0019748437,0.00030975905,0.98920286,0.0011299549,0.0018038456,0.0000034726731,0.00019711729,0.0015566371,0.0016391143,0.0000071438953,0.0018784573,0.0002967939],"about_ca_topic_score_codex":0.5422125,"about_ca_topic_score_gemma":0.6819495,"teacher_disagreement_score":0.13973701,"about_ca_system_score_codex":0.007614888,"about_ca_system_score_gemma":0.0006485228,"threshold_uncertainty_score":0.99994886},"labels":[],"label_agreement":null},{"id":"W4399565974","doi":"10.1016/j.lungcan.2024.107848","title":"Evaluation of chest CT-scans following lung stereotactic ablative radiotherapy: Challenges and new insights","year":2024,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto; London Health Sciences Centre","funders":"Amsterdam University Medical Centers","keywords":"Ablative case; Medicine; Radiology; Lung; Stereotactic radiotherapy; Radiation therapy; SABR volatility model; Radiosurgery; Medical physics; Nuclear medicine; Internal medicine","score_opus":0.050608393796494566,"score_gpt":0.369057012862431,"score_spread":0.3184486190659364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399565974","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.38726917,0.6050704,0.000038482518,0.0029592954,0.0006263649,0.0006638874,0.0000058716037,0.000044686476,0.0033218018],"genre_scores_gemma":[0.9645976,0.03420701,0.00010677815,0.00010776806,0.00029637953,0.00017347858,0.0000058674987,0.000033149314,0.00047199786],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987732,0.00006071138,0.0001825015,0.00032839758,0.0005033248,0.00015183495],"domain_scores_gemma":[0.9994714,0.000097899385,0.00005279644,0.00018469393,0.000086259606,0.00010689804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023512647,0.00016113042,0.0003030867,0.0001017593,0.00003335143,0.00002343113,0.00003315668,0.00004042815,0.00018393056],"category_scores_gemma":[0.000018409106,0.0001228031,0.000090565474,0.00014406291,0.000025052082,0.00015491556,0.000012654365,0.0000977733,0.0000013016185],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019211287,0.0003322131,0.04925233,0.0032504671,0.015516236,0.00020502416,0.044481725,0.00025321456,0.0015904712,0.0022691872,0.0077724243,0.8748846],"study_design_scores_gemma":[0.024292953,0.0016303693,0.6507433,0.022985006,0.038182486,0.00012561568,0.0019096005,0.16385433,0.01491695,0.001952809,0.07798395,0.0014226472],"about_ca_topic_score_codex":0.0005633963,"about_ca_topic_score_gemma":0.0005054675,"teacher_disagreement_score":0.87346196,"about_ca_system_score_codex":0.0011200609,"about_ca_system_score_gemma":0.00066483347,"threshold_uncertainty_score":0.5007765},"labels":[],"label_agreement":null},{"id":"W4400112296","doi":"10.1016/j.lungcan.2024.107863","title":"Clinical and pathological predictors of engraftment for patient-derived xenografts in lung adenocarcinoma","year":2024,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer Cells and Metastasis","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; Toronto General Hospital; University Health Network","funders":"","keywords":"Medicine; Pathological; Adenocarcinoma; Lung; Oncology; Internal medicine; Adenocarcinoma of the lung; Pathology; Cancer","score_opus":0.02446286563237558,"score_gpt":0.35464468166086716,"score_spread":0.33018181602849156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400112296","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9426928,0.054439873,0.00016347354,0.0004901739,0.0010881388,0.00083884393,0.00011559671,0.00003439493,0.00013670554],"genre_scores_gemma":[0.99499464,0.0032893715,0.0007183173,0.0002455463,0.00034481505,0.0002644156,0.000016653285,0.000020368345,0.00010587915],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988434,0.000038558475,0.0004128776,0.00034103543,0.0001494859,0.00021468771],"domain_scores_gemma":[0.9995335,0.000114592855,0.000048557227,0.00014232364,0.000042060623,0.00011899453],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021614654,0.00012442977,0.00037522518,0.000088206674,0.00001809709,0.000011039289,0.00003706322,0.00010148624,0.00010109955],"category_scores_gemma":[0.00004118948,0.000093323026,0.00014486192,0.00014282308,0.000110328336,0.000036162444,0.000043156153,0.00016220556,4.9235894e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00068996643,0.00020128477,0.900544,0.001831339,0.00029583444,0.00011689233,0.0015569546,0.000008986092,0.004982657,0.00014223733,0.008432228,0.08119766],"study_design_scores_gemma":[0.0062259287,0.0021154478,0.90571713,0.0019476302,0.0014426882,0.00003876147,0.00043541176,0.003552082,0.011974435,0.000092167225,0.066066965,0.00039134422],"about_ca_topic_score_codex":0.00008674348,"about_ca_topic_score_gemma":0.00005718964,"teacher_disagreement_score":0.080806315,"about_ca_system_score_codex":0.000090895875,"about_ca_system_score_gemma":0.00013826265,"threshold_uncertainty_score":0.38056025},"labels":[],"label_agreement":null},{"id":"W4400485995","doi":"10.1016/j.lungcan.2024.107861","title":"Asbestos-Related lung Cancer: An underappreciated oncological issue","year":2024,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"University of Sydney; Sydney Local Health District","keywords":"Asbestos; Lung cancer; Mesothelioma; Medicine; Asbestosis; Incidence (geometry); Environmental health; Cancer; Oncology; Pathology; Internal medicine; Lung","score_opus":0.03920343235166781,"score_gpt":0.43045564897653765,"score_spread":0.39125221662486986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400485995","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000258375,0.99226,0.0000016757991,0.00032933685,0.0016044561,0.0013991067,0.0006511846,0.0002576744,0.0032381946],"genre_scores_gemma":[0.00017763383,0.9769285,0.00002974465,0.0004972798,0.0012747548,0.001007432,0.0015993087,0.00012515795,0.018360198],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99755967,0.00011196771,0.0006292046,0.00081107207,0.00047048484,0.00041762725],"domain_scores_gemma":[0.9989423,0.000062604566,0.00019881404,0.00037120297,0.000031380732,0.00039369636],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00009289778,0.000588575,0.0015263236,0.00015553282,0.00010189635,0.000044108278,0.00019611661,0.00057614146,0.009385129],"category_scores_gemma":[0.0000151322265,0.00040586607,0.00056347996,0.0004551472,0.00011954707,0.00009533044,0.00010319906,0.0007365262,0.00031680107],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011051228,0.0005085157,0.0031475187,0.038088597,0.002763029,0.00031776266,0.000077893805,0.00005312208,0.0000019960125,0.00012486335,0.101311006,0.8534952],"study_design_scores_gemma":[0.0003786624,0.00014972496,0.0014320196,0.022206586,0.013937051,0.000037281672,0.000008363077,0.0004890208,4.9900575e-7,0.000022207376,0.960864,0.00047455533],"about_ca_topic_score_codex":0.0004431838,"about_ca_topic_score_gemma":0.00008520528,"teacher_disagreement_score":0.85955304,"about_ca_system_score_codex":0.0020480747,"about_ca_system_score_gemma":0.00094966707,"threshold_uncertainty_score":0.9998393},"labels":[],"label_agreement":null},{"id":"W4401029773","doi":"10.1016/j.lungcan.2024.107900","title":"Trajectory of PD-L1 expression in a patient underwent neoadjuvant chemo-immunotherapy for resectable NSCLC","year":2024,"lang":"en","type":"letter","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Immunotherapy; Oncology; Internal medicine; Neoadjuvant therapy; Chemotherapy; Cancer","score_opus":0.017030840922792504,"score_gpt":0.30625259375077823,"score_spread":0.28922175282798573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401029773","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.060766146,0.43961066,0.00041140107,0.4718026,0.010191202,0.010179677,0.001319503,0.00028750525,0.005431306],"genre_scores_gemma":[0.0417027,0.027260173,0.001863531,0.8606778,0.00948222,0.007963058,0.0014619491,0.0010644171,0.0485242],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974615,0.000060062208,0.00074120064,0.00064196024,0.00054168154,0.00055359537],"domain_scores_gemma":[0.99883354,0.00012612517,0.00028678248,0.00059548963,0.000110798246,0.0000472498],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020762434,0.00043764253,0.00086751865,0.00037841263,0.000044027027,0.000027316537,0.00020020909,0.0007090655,0.0008118925],"category_scores_gemma":[0.000012863174,0.00035056076,0.0004968507,0.00033791657,0.000101384205,0.00005814934,0.000041814106,0.0010413678,0.0000031131442],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005331671,0.00010082731,0.00012065108,0.003404315,0.00049279083,0.00011000458,0.0012586813,0.000010703679,0.07511333,0.0000012989468,0.8963619,0.01769383],"study_design_scores_gemma":[0.0043780874,0.00055985106,0.00028260265,0.008867143,0.00018539952,0.000016418766,0.00009729455,0.00015095352,0.04279099,0.00004240838,0.9422214,0.00040746032],"about_ca_topic_score_codex":0.0010265748,"about_ca_topic_score_gemma":0.00015094462,"teacher_disagreement_score":0.41235048,"about_ca_system_score_codex":0.0013093001,"about_ca_system_score_gemma":0.00074816536,"threshold_uncertainty_score":0.9998946},"labels":[],"label_agreement":null},{"id":"W4401029882","doi":"10.1016/j.lungcan.2024.107898","title":"Treatment patterns and outcomes in KRAS‐positive advanced NSCLC patients previously treated with immune checkpoint inhibitors: A Canada-wide real-world, multi-center, retrospective cohort study","year":2024,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"William Osler Health System; London Health Sciences Centre; Brampton Civic Hospital; CancerCare Manitoba; Ottawa Hospital; University Health Network; Occupational Cancer Research Centre; Juravinski Cancer Centre; University of Ottawa; Jewish General Hospital; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; University of Calgary; Centre Hospitalier de l’Université de Montréal; Hamilton Health Sciences","funders":"Canadian Institutes of Health Research; Amgen Canada; Amgen","keywords":"Medicine; Oncology; Retrospective cohort study; Internal medicine; Cohort; KRAS; Center (category theory); Cancer","score_opus":0.005912470398139684,"score_gpt":0.28135253948923683,"score_spread":0.27544006909109714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401029882","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925798,0.0020761422,0.000005281336,0.00041012253,0.0003319274,0.0040476583,0.00025584674,0.00007483136,0.00021835687],"genre_scores_gemma":[0.9954332,0.001472125,0.000022499646,0.0001209394,0.000045184937,0.0009999828,0.00010323261,0.00006148259,0.0017413138],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980298,0.000068356756,0.00048141295,0.0006583812,0.00036900022,0.00039302488],"domain_scores_gemma":[0.9993056,0.000056971516,0.00011870676,0.00029429732,0.00010672956,0.00011771616],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000097041906,0.00039433036,0.0007091919,0.00017937463,0.000069509326,0.000042523396,0.000057377176,0.00005162208,0.000045789493],"category_scores_gemma":[0.0000118373455,0.0002681023,0.00009741121,0.0003927668,0.000054729306,0.00011891342,0.000029900615,0.00018626494,5.5917945e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026951951,0.0012508779,0.9853532,0.00010028522,0.0017313958,0.00027118248,0.0020951966,0.0000022877969,0.00014290922,5.3149563e-7,0.00006163556,0.00629533],"study_design_scores_gemma":[0.018392898,0.0015664328,0.97589505,0.0014687255,0.00040374897,0.0000052605137,0.00037356018,0.00010148577,0.0013063547,2.2381457e-7,0.00020174091,0.0002844928],"about_ca_topic_score_codex":0.8132924,"about_ca_topic_score_gemma":0.90820587,"teacher_disagreement_score":0.09491344,"about_ca_system_score_codex":0.0061438344,"about_ca_system_score_gemma":0.0004957684,"threshold_uncertainty_score":0.9999771},"labels":[],"label_agreement":null},{"id":"W4401281322","doi":"10.1016/j.lungcan.2024.107919","title":"Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer","year":2024,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Pfizer (Canada); Princess Margaret Cancer Centre","funders":"National Cancer Institute; EMD Serono; International Society for Pharmacoepidemiology; Gilead Sciences; Sanofi; Genentech; AstraZeneca; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Anaplastic lymphoma kinase; ALK inhibitor; Lung cancer; Tyrosine kinase; Tyrosine-kinase inhibitor; Cancer research; Ceritinib; Oncology; Internal medicine; Cancer; Receptor","score_opus":0.01174501105919376,"score_gpt":0.329370564327469,"score_spread":0.31762555326827524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401281322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96276575,0.031218609,0.0004183728,0.0002343944,0.0007152627,0.0025498695,0.000550588,0.00005538755,0.0014917479],"genre_scores_gemma":[0.9909567,0.0029758008,0.0007743773,0.00008096417,0.00038082257,0.0018690563,0.00017532591,0.00005704203,0.0027298995],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99883586,0.000040287807,0.00025588373,0.00050106854,0.000118848206,0.00024802357],"domain_scores_gemma":[0.9992997,0.0001801057,0.00009094273,0.00015394554,0.00014833186,0.00012698324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010945043,0.00026943814,0.00041595596,0.00015687595,0.00012856018,0.000042333206,0.000025524663,0.00007669001,0.00003264681],"category_scores_gemma":[0.0000059059525,0.0002136152,0.00008979639,0.00022274631,0.000057134166,0.00016564244,0.000019635841,0.00008474037,2.9461242e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009280513,0.0001882197,0.058537364,0.009327388,0.0020753772,0.00008076459,0.0076976297,0.0017995227,0.8895034,0.0005846127,0.0014761045,0.027801564],"study_design_scores_gemma":[0.008726851,0.0011110273,0.048268072,0.0052528116,0.004600759,0.000012796791,0.00029308294,0.027300386,0.9017388,0.000052030904,0.0021487859,0.00049456407],"about_ca_topic_score_codex":0.0052821217,"about_ca_topic_score_gemma":0.005854609,"teacher_disagreement_score":0.028242808,"about_ca_system_score_codex":0.002100112,"about_ca_system_score_gemma":0.00075320655,"threshold_uncertainty_score":0.8710975},"labels":[],"label_agreement":null},{"id":"W4401344824","doi":"10.1016/j.lungcan.2024.107916","title":"Exomic and epigenomic analysis of pulmonary blastoma","year":2024,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Congenital Diaphragmatic Hernia Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Montreal Neurological Institute and Hospital; Université de Montréal; McGill University; University of British Columbia; University of British Columbia Hospital; Jewish General Hospital","funders":"","keywords":"Somatic cell; Medicine; Pulmonary Blastoma; Lung cancer; Germline; Missense mutation; Genetics; Cancer research; Lung; Pathology; Biology; Gene; Mutation; Internal medicine","score_opus":0.008681207880618616,"score_gpt":0.3146348541837301,"score_spread":0.3059536463031115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401344824","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9472837,0.04873343,0.000042616855,0.000529848,0.00012360195,0.00013510723,0.000044813358,0.00003821335,0.0030686597],"genre_scores_gemma":[0.9965095,0.0012814633,0.000046751287,0.00007470727,0.000062650346,0.000030898518,0.0000048773704,0.000012652231,0.0019765326],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99945265,0.000009636612,0.00015906904,0.00016776906,0.00010168234,0.000109201705],"domain_scores_gemma":[0.99970424,0.000072880604,0.000020514666,0.00012758953,0.000026922313,0.000047872887],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006243366,0.00007961842,0.00029638998,0.00022480267,0.000017102975,0.000007869812,0.00002623883,0.00002916958,0.00045790113],"category_scores_gemma":[0.000015632895,0.00006520568,0.00010023587,0.00042958924,0.00005580179,0.000027546368,0.000036867124,0.00006093808,0.000009670402],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018804912,0.000084283754,0.6734326,0.0030430015,0.02235493,0.00034226011,0.005189664,0.00010462679,0.058225166,0.0002853346,0.0035836229,0.23316647],"study_design_scores_gemma":[0.00022338165,0.000035632343,0.8880995,0.00032252228,0.009800268,0.000016019445,0.00016618946,0.09513292,0.00064825715,0.00003520711,0.005376134,0.0001439891],"about_ca_topic_score_codex":0.00018947499,"about_ca_topic_score_gemma":0.00017645014,"teacher_disagreement_score":0.23302248,"about_ca_system_score_codex":0.000084811654,"about_ca_system_score_gemma":0.00006227154,"threshold_uncertainty_score":0.5013696},"labels":[],"label_agreement":null},{"id":"W4401351374","doi":"10.1016/j.lungcan.2024.107921","title":"Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation","year":2024,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"UCLH Biomedical Research Centre; University College London Hospitals NHS Foundation Trust; National Institute for Health and Care Research; University College London; Amgen","keywords":"Docetaxel; Medicine; KRAS; Oncology; Internal medicine; Mutation; Chemotherapy; Cancer; Genetics","score_opus":0.013747274052184733,"score_gpt":0.36173386110479955,"score_spread":0.3479865870526148,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401351374","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9831912,0.006761623,0.00072009326,0.0013893481,0.0010410883,0.0039731064,0.0001769933,0.00028471995,0.0024618558],"genre_scores_gemma":[0.99162924,0.00015323557,0.0009307707,0.00021817788,0.00008408601,0.0027774754,0.00046915634,0.000070295675,0.0036675767],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99858415,0.000017321807,0.00035273822,0.0004545936,0.00024826883,0.0003429374],"domain_scores_gemma":[0.99925005,0.00012366749,0.000104772625,0.00023799122,0.00016787896,0.000115633695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000044476317,0.00025534784,0.00038789798,0.00017187143,0.000068136906,0.00004465166,0.000040658422,0.000080357415,0.000120711346],"category_scores_gemma":[0.000044043245,0.00017845775,0.00010938246,0.000397667,0.000038514037,0.00021230716,0.000009301528,0.00011651535,0.000006641142],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025955796,0.0018291242,0.6684627,0.0032235517,0.012459179,0.0021175756,0.015722597,0.004693426,0.0025642335,0.00097248086,0.011830345,0.25016898],"study_design_scores_gemma":[0.19570786,0.013221861,0.5707992,0.013136951,0.027240165,0.0003565217,0.0044201887,0.03541197,0.011817966,0.00037006923,0.12388917,0.0036281247],"about_ca_topic_score_codex":0.001097048,"about_ca_topic_score_gemma":0.0017072336,"teacher_disagreement_score":0.24654084,"about_ca_system_score_codex":0.0009245301,"about_ca_system_score_gemma":0.0005641909,"threshold_uncertainty_score":0.72772956},"labels":[],"label_agreement":null},{"id":"W4401481084","doi":"10.1016/j.lungcan.2024.107927","title":"Predictive value and molecular correlates of MYC immunohistochemistry and copy number gain in non-small cell lung carcinomas treated with immunotherapy","year":2024,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; BC Cancer Agency","funders":"Association of Pathology Chairs; Mayo Foundation for Medical Education and Research; Department of Pathology and Laboratory Medicine, School of Medicine and Public Health, University of Wisconsin-Madison; Mayo Clinic","keywords":"Immunotherapy; Medicine; Immunohistochemistry; Oncology; Predictive value; Lung cancer; Lung; Internal medicine; Copy-number variation; Value (mathematics); Cancer research; Cancer; Gene; Biology; Genome","score_opus":0.0033432570704485676,"score_gpt":0.28164715645814914,"score_spread":0.27830389938770056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401481084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.943583,0.050827272,0.0002394327,0.00009765376,0.000060817132,0.0006076221,0.000060999944,0.00003062322,0.0044925846],"genre_scores_gemma":[0.9966337,0.0012689554,0.00025064204,0.00006090888,0.000023381564,0.00020501885,0.000039400038,0.000040137453,0.0014778222],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992352,0.00001571794,0.00017795549,0.00029282382,0.00011016164,0.00016811129],"domain_scores_gemma":[0.99963456,0.000042112333,0.000048822298,0.0001573882,0.000054948527,0.000062192245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000042112384,0.00017810919,0.00026875196,0.00005956066,0.000032309195,0.000018046834,0.000031686308,0.00008521441,0.00006492924],"category_scores_gemma":[0.0000023080047,0.00013825066,0.000037065638,0.0001864219,0.000096241165,0.000050880946,0.00001463736,0.00015429284,6.026469e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005159117,0.00011500462,0.92306936,0.0010370038,0.0008356988,0.000207698,0.0046529323,0.00019863989,0.06837048,0.00006676247,0.0003009729,0.0006295354],"study_design_scores_gemma":[0.02349299,0.0013608042,0.5804187,0.00908418,0.00565766,0.00032094077,0.002080863,0.04956746,0.32623857,0.0001450107,0.0005387694,0.0010940753],"about_ca_topic_score_codex":0.0018190627,"about_ca_topic_score_gemma":0.000016007263,"teacher_disagreement_score":0.34265068,"about_ca_system_score_codex":0.00032474255,"about_ca_system_score_gemma":0.00024060954,"threshold_uncertainty_score":0.5637698},"labels":[],"label_agreement":null},{"id":"W4401539643","doi":"10.1016/j.lungcan.2024.107928","title":"Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma","year":2024,"lang":"id","type":"article","venue":"Lung Cancer","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Foundation Medicine; Sanofi Genzyme; Genentech; Regeneron Pharmaceuticals; National Institutes of Health; Jazz Pharmaceuticals; European School of Oncology; AstraZeneca; Novocure; Invitae; Silverback Therapeutics; Verily Life Sciences; Boston Pharmaceuticals; Takeda Oncology; Mirati Therapeutics; Chugai Pharmaceutical; Lung Cancer Research Foundation; Revolution Medicines; International Association for the Study of Lung Cancer; U.S. Department of Defense; Sanofi; Bristol-Myers Squibb; Pfizer; University of Miami; National Cancer Institute; Bayer; Mesothelioma Applied Research Foundation","keywords":"Pembrolizumab; Medicine; Randomized controlled trial; Mesothelioma; Internal medicine; Oncology; Pathology; Immunotherapy; Cancer","score_opus":0.014904383084671374,"score_gpt":0.3307358708547637,"score_spread":0.3158314877700923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401539643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8856318,0.094752595,0.00051091984,0.0036754224,0.0026544733,0.0081126075,0.0020436456,0.00010110126,0.002517409],"genre_scores_gemma":[0.98391694,0.0022150117,0.00019722401,0.00044921262,0.0013789401,0.0009721011,0.00021004486,0.000083456245,0.0105770435],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99759823,0.00012515075,0.0007484585,0.0005999343,0.0005185544,0.00040969023],"domain_scores_gemma":[0.9985376,0.0006293395,0.00013389924,0.00027935035,0.00007580871,0.00034402436],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00031753923,0.00038759437,0.0012962855,0.00024297833,0.000091310794,0.00006154842,0.0001209568,0.0001355587,0.0012212583],"category_scores_gemma":[0.000118254764,0.00031508046,0.0004307619,0.00026986623,0.00028717107,0.00010457557,0.00007487352,0.00013660277,0.000034580436],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9723349,0.00031446503,0.00031604592,0.003077222,0.0012339071,0.000022937524,0.0006557233,0.00007354927,0.0014425411,0.00080802274,0.015723966,0.003996683],"study_design_scores_gemma":[0.952919,0.0009378141,0.0025204897,0.0019658064,0.0039648376,0.000018245104,0.00007323479,0.014685186,0.0009439322,0.00020887174,0.021370953,0.00039160362],"about_ca_topic_score_codex":0.00035211063,"about_ca_topic_score_gemma":0.000036388232,"teacher_disagreement_score":0.09828514,"about_ca_system_score_codex":0.0003146171,"about_ca_system_score_gemma":0.00036618017,"threshold_uncertainty_score":0.99993014},"labels":[],"label_agreement":null},{"id":"W4402105865","doi":"10.1016/j.lungcan.2024.107952","title":"New diagnostic and nonsurgical local treatment modalities for early stage lung cancer","year":2024,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Stage (stratigraphy); Modalities; Treatment modality; Lung cancer; Cancer; Radiology; Lung; Oncology; Internal medicine","score_opus":0.03839558299077461,"score_gpt":0.40817030628290907,"score_spread":0.36977472329213446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402105865","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011310622,0.9893809,0.00018940945,0.0008937887,0.0015848133,0.0049792132,0.0023432465,0.00013662454,0.0003789263],"genre_scores_gemma":[0.00020986944,0.9497008,0.00013568642,0.00013542015,0.0018857864,0.013536759,0.00021962039,0.00021094999,0.03396514],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971488,0.0000542961,0.0006585255,0.0010972599,0.00036439014,0.0006767397],"domain_scores_gemma":[0.9979334,0.0007557096,0.0001951424,0.0005001719,0.00007941619,0.00053615856],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000084787425,0.0009446957,0.0026033467,0.00019363363,0.00011431735,0.00013937554,0.00012044491,0.00041109548,0.0007352892],"category_scores_gemma":[0.000025582684,0.000606865,0.0008853046,0.0002501426,0.000109464454,0.000077446624,0.00008212955,0.00031612266,0.00001898219],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009740652,0.00015401295,0.0018377184,0.06763902,0.0057608904,0.00028513075,0.00046241313,0.000010590036,2.3330665e-8,0.00064714765,0.03840472,0.88470095],"study_design_scores_gemma":[0.002264618,0.00044047865,0.000141435,0.049437318,0.032553755,0.00003122634,0.00002162731,0.0001940087,0.0000028526147,0.00001931282,0.91435313,0.0005402228],"about_ca_topic_score_codex":0.010756581,"about_ca_topic_score_gemma":0.001374916,"teacher_disagreement_score":0.8841607,"about_ca_system_score_codex":0.004876876,"about_ca_system_score_gemma":0.0027716144,"threshold_uncertainty_score":0.99963826},"labels":[],"label_agreement":null},{"id":"W4403992066","doi":"10.1016/j.lungcan.2024.108000","title":"Corrigendum to “Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK -positive advanced non-small cell lung cancer” [Lung Cancer 195 (2024) 107919]","year":2024,"lang":"en","type":"erratum","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Pfizer (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Tyrosine kinase; Cancer research; Tyrosine-kinase inhibitor; Cancer; Lung; Anaplastic lymphoma kinase; Oncology; Internal medicine; Receptor","score_opus":0.014557669215704791,"score_gpt":0.32902184021540215,"score_spread":0.31446417099969737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403992066","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.402049,0.42062667,0.00085405685,0.0017763696,0.10417074,0.027975773,0.021186015,0.00035026425,0.021011101],"genre_scores_gemma":[0.33153507,0.04423705,0.0012476874,0.00089207443,0.008502805,0.027489614,0.004428338,0.00073742465,0.58092993],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99627197,0.00010939321,0.0007807102,0.001612282,0.00042688867,0.0007987284],"domain_scores_gemma":[0.99777424,0.00016924345,0.00048312653,0.00050114555,0.00058378006,0.0004884751],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021332197,0.0010793534,0.0016403642,0.00059287,0.00033730187,0.00012290668,0.00012620859,0.0004606668,0.00018422151],"category_scores_gemma":[0.00001905427,0.00092438655,0.0003034964,0.0006668433,0.00011903758,0.00022170825,0.00011178396,0.00054924726,0.0000013195917],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025323508,0.00045696762,0.029330745,0.044589397,0.009610688,0.00029507236,0.011928797,0.0033912768,0.101586565,0.00018837483,0.77923715,0.01685264],"study_design_scores_gemma":[0.038808487,0.0067449026,0.049274936,0.091769956,0.07295882,0.00006930694,0.0016093722,0.065573774,0.36731124,0.00010789883,0.29902643,0.006744885],"about_ca_topic_score_codex":0.03897498,"about_ca_topic_score_gemma":0.07812919,"teacher_disagreement_score":0.5599188,"about_ca_system_score_codex":0.010006388,"about_ca_system_score_gemma":0.004557934,"threshold_uncertainty_score":0.9993207},"labels":[],"label_agreement":null},{"id":"W4404512668","doi":"10.1016/j.lungcan.2024.108034","title":"Lorlatinib-associated weight gain and dyslipidaemia: A retrospective analysis and implications for future care","year":2024,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Medicine; Weight gain; Intensive care medicine; Internal medicine; Body weight","score_opus":0.005804123158632089,"score_gpt":0.3434996721612806,"score_spread":0.3376955490026485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404512668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7583408,0.18079658,0.005841244,0.038432777,0.0011815807,0.0032909263,0.0042070914,0.00046032618,0.0074487342],"genre_scores_gemma":[0.99561757,0.0010399595,0.00043908472,0.00021072038,0.00042801257,0.0005526487,0.00027778494,0.000022513615,0.0014117187],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99932647,0.000011508987,0.0001201614,0.00032050474,0.00007039825,0.00015097386],"domain_scores_gemma":[0.9995619,0.000050657494,0.000034937842,0.00012601829,0.00013966706,0.00008679269],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000042258005,0.000115558345,0.00023427913,0.00013646159,0.00014263773,0.00004735663,0.00001981715,0.000082339655,0.000050596504],"category_scores_gemma":[0.0000145569065,0.00009102985,0.00008967977,0.0005481767,0.000031430445,0.000064805274,0.000012899922,0.00009553887,4.5411127e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002739738,0.000033183474,0.95175546,0.00037991008,0.006091923,0.0000050556164,0.0068962537,0.000010387427,0.00033418956,0.003093353,0.006801504,0.024571365],"study_design_scores_gemma":[0.0010769204,0.00009064695,0.9771663,0.00015519133,0.0109415455,0.000003863821,0.0006977128,0.0015007799,0.00008979707,0.00032429682,0.007813239,0.0001397009],"about_ca_topic_score_codex":0.0001816622,"about_ca_topic_score_gemma":0.0010931077,"teacher_disagreement_score":0.2372768,"about_ca_system_score_codex":0.00054092176,"about_ca_system_score_gemma":0.00014908866,"threshold_uncertainty_score":0.37120894},"labels":[],"label_agreement":null},{"id":"W4404704376","doi":"10.1016/j.lungcan.2024.108040","title":"The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in patients with metastatic non-small cell lung cancer harboring sensitizing EGFR mutations","year":2024,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Center for Advancing Translational Sciences; Cancer Center, University of Colorado; National Institutes of Health; National Cancer Institute; Georgia Clinical and Translational Science Alliance","keywords":"Medicine; Osimertinib; Pemetrexed; Lung cancer; Oncology; Chemotherapy; Internal medicine; Cancer research; Cancer; Epidermal growth factor receptor; Cisplatin; Erlotinib","score_opus":0.0069943952562110025,"score_gpt":0.3123541077166042,"score_spread":0.30535971246039323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404704376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98985326,0.0065167984,0.0003511497,0.00050957303,0.00025699587,0.0019960243,0.000044760018,0.00006739563,0.00040403238],"genre_scores_gemma":[0.99689525,0.00018915015,0.0016611033,0.00006573309,0.00008916827,0.00051399844,0.000049289774,0.00007975576,0.00045652094],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99846274,0.00003932388,0.0003681848,0.00038455767,0.00037479008,0.00037042075],"domain_scores_gemma":[0.9990391,0.0002393678,0.00019146352,0.00024024861,0.00019904802,0.00009073704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012707608,0.00025867595,0.00035915483,0.00016154203,0.00013851417,0.00007063542,0.000071508504,0.000043013653,0.0000453321],"category_scores_gemma":[0.000014634218,0.00014989499,0.000069227906,0.00063501776,0.000064436026,0.00013618196,0.000018166045,0.00023302059,9.338193e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024275598,0.0006419562,0.87200284,0.0020027321,0.0023662965,0.00012128675,0.03165256,0.0056434865,0.0033864037,0.000048265392,0.000341217,0.07936541],"study_design_scores_gemma":[0.033922907,0.0011575401,0.8430605,0.024019066,0.005971591,0.000009765603,0.0026571897,0.057284664,0.0296991,0.000008873176,0.0013294355,0.00087939965],"about_ca_topic_score_codex":0.0006480073,"about_ca_topic_score_gemma":0.0006745646,"teacher_disagreement_score":0.07848601,"about_ca_system_score_codex":0.0005080671,"about_ca_system_score_gemma":0.00042870568,"threshold_uncertainty_score":0.611254},"labels":[],"label_agreement":null},{"id":"W4405861407","doi":"10.1016/j.lungcan.2024.108066","title":"FURVENT: Phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004)","year":2024,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Exon; Oncology; Internal medicine; Chemotherapy; Mutation; Cancer research; Gene; Genetics; Biology","score_opus":0.04779677523494436,"score_gpt":0.46264716297713754,"score_spread":0.4148503877421932,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405861407","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009969791,0.983407,0.00028799448,0.0010970759,0.00094238424,0.01082733,0.0016425746,0.00012621346,0.000672416],"genre_scores_gemma":[0.0010154418,0.97066647,0.0005464706,0.000113954906,0.00082855514,0.013981346,0.0035592145,0.00019860636,0.009089946],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976166,0.000043141663,0.0009092269,0.00071666547,0.00034226774,0.00037209474],"domain_scores_gemma":[0.99833995,0.0001572209,0.0005901653,0.000518619,0.00021098102,0.00018307474],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00008655113,0.0006698259,0.0019226485,0.00028195654,0.00013794142,0.00003351109,0.00010826564,0.00025449673,0.0002647304],"category_scores_gemma":[0.000028394108,0.00042717744,0.0008361348,0.00054272666,0.00007341672,0.000103119695,0.000013823108,0.00018471536,0.000016359158],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028388096,0.002093132,0.0000033423219,0.015504558,0.0053706993,0.000033725675,0.0007427498,0.00007079105,0.000007155865,0.00007087733,0.0015198237,0.94619507],"study_design_scores_gemma":[0.10721159,0.0087474035,0.0000020165703,0.01846473,0.02341985,0.000024407193,0.00003366571,0.00013676981,0.00007429755,0.000035495224,0.8414756,0.0003741567],"about_ca_topic_score_codex":0.0003700403,"about_ca_topic_score_gemma":0.00047166998,"teacher_disagreement_score":0.94582087,"about_ca_system_score_codex":0.0018009127,"about_ca_system_score_gemma":0.0018802829,"threshold_uncertainty_score":0.999818},"labels":[],"label_agreement":null},{"id":"W4406061941","doi":"10.1016/j.lungcan.2025.108080","title":"Assessing the feasibility and external validity of natural language processing-extracted data for advanced lung cancer patients","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); University Health Network; Systems, Applications & Products in Data Processing (Canada); Princess Margaret Cancer Centre","funders":"Princess Margaret Cancer Foundation; F. Hoffmann-La Roche","keywords":"Medicine; Lung cancer; Intensive care medicine; Natural language processing; Medical physics; Oncology; Computer science","score_opus":0.060318550680282884,"score_gpt":0.48930471986458773,"score_spread":0.4289861691843049,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406061941","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9102039,0.084753,0.00048598665,0.0016038824,0.000538203,0.0017913503,0.00038116908,0.000042607386,0.00019991903],"genre_scores_gemma":[0.9970297,0.0007677796,0.0005521806,0.00032673802,0.00018571911,0.00031743725,0.00007119414,0.000019884073,0.0007293359],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983646,0.000069648595,0.00030835462,0.0005007716,0.00041070647,0.00034590694],"domain_scores_gemma":[0.9984044,0.00026085906,0.00018406459,0.00059552136,0.00049080857,0.000064346736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000422873,0.00018212409,0.0003801832,0.00006267449,0.00023388612,0.00006956852,0.00031573218,0.00005809402,0.000028739798],"category_scores_gemma":[0.0007006282,0.00011848507,0.00005560672,0.00028561743,0.00021656347,0.00044274013,0.00033321508,0.00031369456,6.276658e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054690783,0.00014104813,0.90096164,0.004004566,0.0002499328,0.0000022703546,0.0007247851,0.000007969536,0.0058593396,0.000009175076,0.0051359693,0.08235639],"study_design_scores_gemma":[0.0040284735,0.000071977454,0.9661036,0.0025257003,0.00061331375,9.793739e-7,0.0003730268,0.021822453,0.0031057585,0.000023850645,0.0011542356,0.00017660994],"about_ca_topic_score_codex":0.0007290661,"about_ca_topic_score_gemma":0.00064984005,"teacher_disagreement_score":0.08682585,"about_ca_system_score_codex":0.0005356801,"about_ca_system_score_gemma":0.0006971786,"threshold_uncertainty_score":0.4831681},"labels":[],"label_agreement":null},{"id":"W4406834303","doi":"10.1016/j.lungcan.2025.108107","title":"Proposal of real-world solutions for the implementation of predictive biomarker testing in patients with operable non-small cell lung cancer","year":2025,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Biomarker; Oncology; Lung cancer; Cancer; Internal medicine; Predictive value","score_opus":0.029400893027625805,"score_gpt":0.3756929050328241,"score_spread":0.34629201200519827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406834303","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011010997,0.98395395,0.00009130347,0.00013281191,0.00037572414,0.011495788,0.001999902,0.00001606874,0.0008333414],"genre_scores_gemma":[0.0055573555,0.9803482,0.0005129846,0.00003319801,0.00010943711,0.012421241,0.00031798537,0.000059939164,0.000639604],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981618,0.00005661614,0.00070385356,0.0004285395,0.00026538537,0.00038380135],"domain_scores_gemma":[0.9981024,0.000426369,0.0006140131,0.00035111513,0.00045278933,0.00005330133],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002073219,0.00033670207,0.0011603379,0.00024377808,0.000104524275,0.000011098533,0.00014517737,0.000098247714,0.00007566887],"category_scores_gemma":[0.000016789027,0.00019782882,0.00021051055,0.0008339626,0.00006214363,0.000056869478,0.00007451374,0.00016954188,1.4009505e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023551114,0.00052534346,0.62447196,0.09413743,0.0023736116,0.0000016726985,0.00039808342,0.00018788925,0.0000013175534,0.000038291964,0.005101897,0.272527],"study_design_scores_gemma":[0.021586534,0.0019026835,0.51466,0.34513313,0.057012126,0.0000011359576,0.0003719,0.002439838,0.00025922817,0.000009337097,0.055504445,0.0011196331],"about_ca_topic_score_codex":0.01967464,"about_ca_topic_score_gemma":0.014203403,"teacher_disagreement_score":0.27140737,"about_ca_system_score_codex":0.0018194139,"about_ca_system_score_gemma":0.0040542143,"threshold_uncertainty_score":0.9868534},"labels":[],"label_agreement":null},{"id":"W4407001040","doi":"10.1016/j.lungcan.2025.108412","title":"EGFR testing practices, treatment choice and clinical outcomes in advanced NSCLC in a real-world setting: A retrospective analysis of a US-based electronic health records database","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"AstraZeneca","keywords":"Medicine; Health records; Electronic database; Retrospective cohort study; Electronic health record; Real world evidence; Medical record; Database; Internal medicine; Health care","score_opus":0.0344460277777888,"score_gpt":0.48366972175411665,"score_spread":0.44922369397632783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407001040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98883146,0.0027365366,0.000062284445,0.0051543573,0.00011647268,0.0013857757,0.0001622871,0.00003995448,0.0015108504],"genre_scores_gemma":[0.9933328,0.0015561858,0.002382532,0.0009363362,0.00003102175,0.00039771188,0.00013020403,0.000017602966,0.0012156058],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980854,0.00015173183,0.0006852026,0.0005442632,0.00016434243,0.0003690955],"domain_scores_gemma":[0.99785405,0.000978006,0.0006066616,0.00036046814,0.0001052956,0.00009552369],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004246942,0.00019553398,0.00089811924,0.00073373463,0.00005620385,0.000012227215,0.00005271518,0.000051337665,0.000031186762],"category_scores_gemma":[0.0007515946,0.00014799455,0.00012403034,0.0025061176,0.00004668802,0.00011480842,0.000023269566,0.00025233225,2.2343214e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002918675,0.0006962586,0.9739769,0.00012976672,0.0019508782,0.000011397226,0.00018413707,0.00029383152,0.000019929244,0.000076137796,0.000052705156,0.022316195],"study_design_scores_gemma":[0.0066400864,0.000547927,0.9778215,0.0006658723,0.0029771968,3.5345042e-7,0.00008424412,0.010249475,0.000017539964,0.000013142721,0.00087789673,0.00010473625],"about_ca_topic_score_codex":0.111749396,"about_ca_topic_score_gemma":0.4696345,"teacher_disagreement_score":0.3578851,"about_ca_system_score_codex":0.0041824295,"about_ca_system_score_gemma":0.0027732507,"threshold_uncertainty_score":0.99964035},"labels":[],"label_agreement":null},{"id":"W4407100100","doi":"10.1016/j.lungcan.2025.108418","title":"Mitigation of decline with virtual exercise with lung cancer (MoVE with lung cancer) − A promising approach to enhance physiological strength, improve body composition, and build upon current evidence","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer survivorship and care","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of British Columbia Hospital; BC Cancer Agency","funders":"BC Cancer Foundation; University of British Columbia; Coordenação de Aperfeiçoamento de Pessoal de Nível Superior; British Columbia Lung Association","keywords":"Medicine; Lung cancer; Cancer; Current (fluid); Lung; Composition (language); Intensive care medicine; Physical medicine and rehabilitation; Physical therapy; Oncology; Internal medicine; Engineering","score_opus":0.008952557718701293,"score_gpt":0.3242286696104168,"score_spread":0.3152761118917155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407100100","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.955903,0.03180491,0.008028607,0.0010340374,0.0003654308,0.0024843048,0.00015868353,0.00008368784,0.00013735864],"genre_scores_gemma":[0.99284637,0.0031282897,0.0008129232,0.00044531014,0.0003128394,0.002098817,0.000057522295,0.00004854692,0.00024938036],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973551,0.0000742689,0.0004496217,0.0009852906,0.0006374199,0.00049829413],"domain_scores_gemma":[0.9981791,0.00009195626,0.00030894962,0.00045106406,0.0007127948,0.00025614494],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016919029,0.00046896262,0.00082492735,0.00015768399,0.00016989747,0.00006121019,0.00018947542,0.00013107917,0.00004163528],"category_scores_gemma":[0.000022566697,0.00032454202,0.00006527037,0.0009005631,0.00021340555,0.0002800952,0.000109876455,0.00045750017,1.772497e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04883908,0.0019082568,0.50973237,0.024277467,0.0026032268,0.000048857673,0.013416649,0.016807735,0.21658093,0.0009112893,0.0050816196,0.1597925],"study_design_scores_gemma":[0.015283675,0.0054228785,0.27515417,0.16360562,0.010403894,0.000046206613,0.0028911398,0.113820575,0.4086743,0.000044422413,0.0010693582,0.003583759],"about_ca_topic_score_codex":0.004631308,"about_ca_topic_score_gemma":0.0042496333,"teacher_disagreement_score":0.2345782,"about_ca_system_score_codex":0.0007514784,"about_ca_system_score_gemma":0.0011167997,"threshold_uncertainty_score":0.99992067},"labels":[],"label_agreement":null},{"id":"W4407607529","doi":"10.1016/j.lungcan.2025.108452","title":"Prognostic and predictive effects of TP53 co-mutation in patients with non-small cell lung cancer with rare treatable driver mutations","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Mutation; Lung cancer; Oncology; Internal medicine; Lung; Cancer; Cancer research; Genetics; Gene; Biology","score_opus":0.002382273752439514,"score_gpt":0.26599251725522083,"score_spread":0.26361024350278134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407607529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912849,0.002405786,0.0009878257,0.00012437314,0.00010281221,0.003009709,0.00020693969,0.000026025204,0.0018516169],"genre_scores_gemma":[0.9961599,0.000114612056,0.00040867488,0.0001080973,0.000023096374,0.0015649594,0.00025560838,0.000026611877,0.0013384374],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99904287,0.000025381349,0.00019114366,0.0003268328,0.00019222382,0.00022152154],"domain_scores_gemma":[0.9992811,0.000115080926,0.00012108214,0.00015755858,0.00024849633,0.00007664586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000023386598,0.00019452457,0.00031071887,0.000194558,0.00008311821,0.000015860165,0.000039721417,0.000062621315,0.000029609158],"category_scores_gemma":[0.000013217922,0.00013999858,0.000025648775,0.00044217586,0.00008217433,0.00014959632,0.000013491878,0.00011426424,3.9380947e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005852144,0.0003554725,0.99050623,0.001629436,0.00057026424,0.000023738601,0.0027809201,0.0017678157,0.00006849393,0.000014536607,0.0003992913,0.0012986062],"study_design_scores_gemma":[0.011591042,0.00061717763,0.9770827,0.0027879043,0.0029422902,9.145903e-7,0.00019871184,0.0022765594,0.002308786,0.000007650928,0.00004554845,0.00014067255],"about_ca_topic_score_codex":0.00137191,"about_ca_topic_score_gemma":0.0008656167,"teacher_disagreement_score":0.013423469,"about_ca_system_score_codex":0.00048198132,"about_ca_system_score_gemma":0.0006700148,"threshold_uncertainty_score":0.57089764},"labels":[],"label_agreement":null},{"id":"W4407856069","doi":"10.1016/j.lungcan.2025.108441","title":"Corrigendum to “Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer” [Lung Cancer 195 (2024) 107919]","year":2025,"lang":"en","type":"erratum","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Pfizer (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Anaplastic lymphoma kinase; Cancer research; ALK inhibitor; Tyrosine kinase; Tyrosine-kinase inhibitor; Kinase; Oncology; Internal medicine; Cancer; Genetics; Biology","score_opus":0.01313441767526678,"score_gpt":0.32763194866333406,"score_spread":0.31449753098806726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407856069","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.42077702,0.36238635,0.0021136033,0.002272842,0.10700576,0.040471096,0.02663476,0.0003622592,0.03797633],"genre_scores_gemma":[0.23577559,0.043189697,0.00156484,0.0011941901,0.0056987307,0.027543664,0.004816278,0.00046949016,0.6797475],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9964253,0.00012782919,0.0007825213,0.0015014806,0.0003853336,0.00077753514],"domain_scores_gemma":[0.997541,0.00021076058,0.00057279255,0.00053045363,0.00071392674,0.00043105616],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020224533,0.0010322982,0.0017104881,0.000600359,0.00040452092,0.000089730165,0.00013627483,0.00046379925,0.00015491244],"category_scores_gemma":[0.00002658094,0.00091293216,0.00028007242,0.0006747323,0.00011305279,0.0002125474,0.00010939251,0.00046599726,4.6756975e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003551069,0.000604429,0.06378875,0.04004525,0.009526702,0.00016607327,0.009018812,0.004426174,0.084048524,0.0001956722,0.7616221,0.023006493],"study_design_scores_gemma":[0.053509682,0.005766353,0.09487419,0.08587744,0.061655227,0.000033135057,0.0014137436,0.047485884,0.41324964,0.00007154066,0.22980317,0.0062599783],"about_ca_topic_score_codex":0.046810348,"about_ca_topic_score_gemma":0.08569126,"teacher_disagreement_score":0.6417712,"about_ca_system_score_codex":0.009830162,"about_ca_system_score_gemma":0.005527881,"threshold_uncertainty_score":0.99933213},"labels":[],"label_agreement":null},{"id":"W4408032112","doi":"10.1016/j.lungcan.2025.108175","title":"65 Referral Trends for Peripheral Nodule Biopsy Using Navigational Bronchoscopy at a Tertiary Centre in London","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Bronchoscopy; Tertiary referral centre; Tertiary care; Nodule (geology); Referral; General surgery; Radiology; Peripheral; Biopsy; Surgery; Internal medicine; Family medicine","score_opus":0.015100993089419092,"score_gpt":0.3564217013608297,"score_spread":0.3413207082714106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408032112","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98507845,0.0059056785,0.00007089362,0.006635345,0.0007314746,0.00048189468,0.00013304983,0.000036462705,0.0009267724],"genre_scores_gemma":[0.98542607,0.0001482778,0.0017119853,0.0014760885,0.00030569278,0.00034896677,0.00023551381,0.000028636397,0.010318769],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989459,0.000016960128,0.000227726,0.00035356783,0.00015383783,0.00030203868],"domain_scores_gemma":[0.9995882,0.00003126659,0.000053402884,0.00019052267,0.00006345651,0.00007315126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000047859558,0.00016810886,0.00026136026,0.00011624286,0.00008439665,0.000018647896,0.000053328306,0.00008810338,0.00063416065],"category_scores_gemma":[0.000007643726,0.00014438735,0.00012044043,0.0002535138,0.000034766486,0.0000737677,0.000034526962,0.00009315645,0.0000018205108],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060307543,0.00024134952,0.96601063,0.00033574377,0.00024207027,0.000030590392,0.00035282376,0.0002108158,0.0037571536,0.00018186176,0.02212223,0.005911646],"study_design_scores_gemma":[0.01632135,0.00015963532,0.89563686,0.0036992116,0.0008436763,0.000029535959,0.00009300806,0.024563912,0.015515801,0.000099607336,0.042574827,0.00046255699],"about_ca_topic_score_codex":0.0011068556,"about_ca_topic_score_gemma":0.00097072264,"teacher_disagreement_score":0.07037376,"about_ca_system_score_codex":0.0030826903,"about_ca_system_score_gemma":0.00023508967,"threshold_uncertainty_score":0.8061128},"labels":[],"label_agreement":null},{"id":"W4408032342","doi":"10.1016/j.lungcan.2025.108168","title":"58 Operator outcomes and learning for robotic-assisted bronchoscopic biopsies of pulmonary nodules","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Operator (biology); Radiology; Artificial intelligence; Computer science","score_opus":0.01189381326130011,"score_gpt":0.3310439689725905,"score_spread":0.31915015571129035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408032342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9696796,0.022684133,0.00023508228,0.004634931,0.00049797713,0.0008428788,0.000016392152,0.00005021123,0.0013588261],"genre_scores_gemma":[0.9909527,0.0010324741,0.00075410755,0.00042154593,0.000052580086,0.00035060983,0.000015952566,0.00001555602,0.0064045317],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993159,0.000017432969,0.00018934383,0.00022929275,0.00009104107,0.0001569482],"domain_scores_gemma":[0.99953073,0.00013079104,0.000055669916,0.00014668347,0.00008652117,0.000049594644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005149395,0.00012787126,0.00037188412,0.000074767304,0.00008631573,0.0000150492315,0.000039930073,0.000057047815,0.00006627118],"category_scores_gemma":[0.00004964371,0.00009542594,0.000076095865,0.00011433588,0.00005337046,0.000041190808,0.000030861247,0.0000799508,8.138612e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010260934,0.00015266023,0.9780039,0.0011819159,0.00048565667,0.0000047875674,0.00013701942,0.00016934656,0.0011467738,0.00027572163,0.002184691,0.0161549],"study_design_scores_gemma":[0.0022756495,0.000116546835,0.9845657,0.0011646756,0.0007539436,0.0000026955177,0.00012093186,0.0021512306,0.004415678,0.000016361579,0.004305871,0.0001107244],"about_ca_topic_score_codex":0.00034626544,"about_ca_topic_score_gemma":0.00007720196,"teacher_disagreement_score":0.02165166,"about_ca_system_score_codex":0.00018873051,"about_ca_system_score_gemma":0.00010149121,"threshold_uncertainty_score":0.38913566},"labels":[],"label_agreement":null},{"id":"W4408064743","doi":"10.1016/j.lungcan.2025.108309","title":"200 Stage shift in lung cancers found during a screening study: Early detection is only half the battle","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Stage (stratigraphy); Battle; Oncology; Internal medicine; Ancient history; History","score_opus":0.011095965016378002,"score_gpt":0.34747468509005724,"score_spread":0.33637872007367925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408064743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895851,0.0032116259,0.0006553667,0.0018570325,0.000848154,0.00128322,0.000032246324,0.000066803026,0.0024604602],"genre_scores_gemma":[0.9897301,0.000084695486,0.000041656986,0.00043409906,0.0001692053,0.00052043557,0.0000045440447,0.0000273154,0.008987954],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987522,0.000045531397,0.00025638053,0.00036602747,0.00025015356,0.0003297564],"domain_scores_gemma":[0.99938226,0.00008285979,0.00007658073,0.00033389594,0.00005959126,0.00006478775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011461338,0.00018244423,0.00024199618,0.00018263947,0.00028251536,0.00006436435,0.00010155354,0.000061741885,0.00030054693],"category_scores_gemma":[0.00002668811,0.00013874428,0.000076459764,0.00059290254,0.00004339479,0.000150519,0.000045242177,0.00026778982,0.0000040555947],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038640917,0.00012989405,0.9798746,0.00021792679,0.0009494249,0.000053571446,0.009433311,0.0010183166,0.00027065448,0.00006625286,0.0007269929,0.0068726134],"study_design_scores_gemma":[0.004226248,0.00010074035,0.9869807,0.0004675665,0.000686984,0.0000024876808,0.0017925045,0.0015137086,0.000501676,0.00001297014,0.0035588183,0.00015560427],"about_ca_topic_score_codex":0.05295892,"about_ca_topic_score_gemma":0.050911024,"teacher_disagreement_score":0.007640807,"about_ca_system_score_codex":0.0017507955,"about_ca_system_score_gemma":0.0005897158,"threshold_uncertainty_score":0.96640736},"labels":[],"label_agreement":null},{"id":"W4408065122","doi":"10.1016/j.lungcan.2025.108334","title":"225 Durvalumab (D) as consolidation therapy in limited-stage SCLC (LS-SCLC): Outcomes by prior concurrent chemoradiotherapy (cCRT) regimen and prophylactic cranial irradiation (PCI) use in the ADRIATIC trial","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Prophylactic cranial irradiation; Durvalumab; Regimen; Oncology; Chemoradiotherapy; Conventional PCI; Internal medicine; Radiation therapy; Cancer; Immunotherapy","score_opus":0.03159646343939662,"score_gpt":0.39573207681587,"score_spread":0.3641356133764734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408065122","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96941984,0.009463832,0.00002564602,0.014556226,0.0006074504,0.00545332,0.000037016933,0.000047355767,0.0003893374],"genre_scores_gemma":[0.9868101,0.006381015,0.00004380031,0.0025410368,0.00019361514,0.0014071959,0.00003254533,0.000032935804,0.0025577466],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99759525,0.00036929,0.00051304116,0.00049701316,0.0006002321,0.0004251611],"domain_scores_gemma":[0.9986192,0.0006008627,0.00018840203,0.0003962417,0.00012268127,0.00007263058],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006779208,0.00028822178,0.00063559547,0.00024225542,0.00013114589,0.00014542643,0.00017530397,0.00012771769,0.00009997866],"category_scores_gemma":[0.0005926988,0.00020025176,0.00008183118,0.00063196925,0.00017343098,0.00028260695,0.000038186106,0.00045714653,0.0000027343478],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06056965,0.0017371725,0.8010295,0.0015798536,0.0012996031,0.00008574666,0.017678171,0.000053436055,0.006723846,0.0011847168,0.026586924,0.08147138],"study_design_scores_gemma":[0.23828743,0.0021272,0.7152907,0.0010169403,0.00029959265,0.000008474107,0.0010144586,0.0043075597,0.0012478492,0.00013353858,0.035589408,0.0006768376],"about_ca_topic_score_codex":0.0025803281,"about_ca_topic_score_gemma":0.0012101721,"teacher_disagreement_score":0.17771778,"about_ca_system_score_codex":0.0011415407,"about_ca_system_score_gemma":0.00079073897,"threshold_uncertainty_score":0.81660295},"labels":[],"label_agreement":null},{"id":"W4408067390","doi":"10.1016/j.lungcan.2025.108178","title":"68 First year experience of Robotic-assisted bronchoscopy implementation for lung cancer","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Lung cancer; Flexible bronchoscopy; General surgery; Bronchoscopy; Radiology; Oncology","score_opus":0.01628290795756007,"score_gpt":0.40431128137201017,"score_spread":0.3880283734144501,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408067390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92438793,0.040689133,0.0071910666,0.0142665235,0.004078002,0.0059040105,0.00044313926,0.00015730789,0.0028829102],"genre_scores_gemma":[0.9894793,0.0022760823,0.001631318,0.00065192283,0.00019166403,0.003568094,0.00005409741,0.000026616171,0.0021209298],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989083,0.00001131545,0.0003043023,0.00032326378,0.00019023784,0.00026261614],"domain_scores_gemma":[0.9993075,0.000068075635,0.00012497514,0.00026553395,0.00016250741,0.00007136573],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00005144346,0.00015727697,0.0003317703,0.000083285864,0.000093861156,0.00001634606,0.000084675274,0.000061318126,0.0010869422],"category_scores_gemma":[0.000013069499,0.00013597826,0.0001222952,0.00025092417,0.00004541186,0.000075807904,0.000028787528,0.00005829851,0.0000010630564],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030732926,0.00018622655,0.9025386,0.0015375271,0.0006910335,0.000002576083,0.0015469276,0.00031162545,0.0010292799,0.0006855927,0.08360708,0.00755619],"study_design_scores_gemma":[0.01569173,0.00045188036,0.814304,0.0047827708,0.0034330913,0.0000021254834,0.0016730812,0.00583867,0.09458253,0.00004382538,0.058677655,0.0005186183],"about_ca_topic_score_codex":0.0038213485,"about_ca_topic_score_gemma":0.0022616775,"teacher_disagreement_score":0.09355325,"about_ca_system_score_codex":0.0010879751,"about_ca_system_score_gemma":0.00038477746,"threshold_uncertainty_score":0.9998262},"labels":[],"label_agreement":null},{"id":"W4408266096","doi":"10.1016/j.lungcan.2025.108491","title":"Establishing survival benchmarks in the era of peri-operative immunotherapy","year":2025,"lang":"en","type":"letter","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Immunotherapy; Peri; Internal medicine; Oncology; Intensive care medicine; Cancer","score_opus":0.012279643713661387,"score_gpt":0.3195714229083646,"score_spread":0.3072917791947032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408266096","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01232941,0.044455927,0.000035632474,0.91302687,0.0031963289,0.0018087658,0.0003039997,0.000032571836,0.024810478],"genre_scores_gemma":[0.01440424,0.011861465,0.00013097255,0.9596183,0.0038249334,0.00057705643,0.0007471418,0.000084480824,0.008751445],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977402,0.0002701798,0.00055999396,0.0004339307,0.0005883319,0.0004073581],"domain_scores_gemma":[0.998538,0.00040412307,0.00022572874,0.00067072955,0.00014309336,0.000018337681],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00054581685,0.00037560108,0.00077381136,0.00018480695,0.00008403963,0.000077716635,0.0004658052,0.0005797918,0.0021542066],"category_scores_gemma":[0.00003873047,0.00025196775,0.00032088195,0.00060887047,0.0001799376,0.00011367413,0.000038189464,0.0025882868,7.5050383e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009904554,0.00005690012,0.0033651097,0.0006523042,0.00074849534,0.00011950661,0.004152991,0.0000063328907,0.0010831526,0.000020333833,0.97389686,0.014907573],"study_design_scores_gemma":[0.0026616945,0.00013937529,0.008295172,0.002582905,0.00019522164,0.000011467765,0.0005164428,0.00005943401,0.00039012887,0.00001641585,0.9848089,0.00032279312],"about_ca_topic_score_codex":0.006940096,"about_ca_topic_score_gemma":0.000670472,"teacher_disagreement_score":0.04659138,"about_ca_system_score_codex":0.00050214084,"about_ca_system_score_gemma":0.0009764457,"threshold_uncertainty_score":0.99999326},"labels":[],"label_agreement":null},{"id":"W4408914861","doi":"10.1016/j.lungcan.2025.108495","title":"Natural history models for lung Cancer: A scoping review","year":2025,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brock University; University of British Columbia","funders":"National Cancer Institute","keywords":"Medicine; Lung cancer; Natural history; Intensive care medicine; Oncology; Internal medicine","score_opus":0.050988583829570826,"score_gpt":0.42904347260279624,"score_spread":0.3780548887732254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408914861","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[6.8598546e-8,0.9798122,0.00008331944,0.0009204585,0.004227839,0.012666984,0.00033096888,0.00012552686,0.001832621],"genre_scores_gemma":[5.2195685e-7,0.9482768,0.00025496268,0.0032166992,0.0010217425,0.034139477,0.00033825994,0.00012527524,0.012626222],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.996927,0.00007803615,0.0009544504,0.0010338118,0.00039304022,0.00061363104],"domain_scores_gemma":[0.9978776,0.00031002256,0.00055922696,0.00079764466,0.0002563476,0.00019918242],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002001122,0.0007826806,0.003965638,0.00021187976,0.000101177204,0.000020028565,0.00027606767,0.00030590786,0.0005834418],"category_scores_gemma":[0.000057390007,0.00059216394,0.0014844697,0.0003245336,0.00005258606,0.00011933557,0.00009711189,0.00048753803,0.0000030848257],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000012693519,0.000036482175,0.0000090217845,0.5001929,0.0009857884,0.000010313071,0.00001774197,0.000004680763,1.4076938e-8,0.00008097437,0.19280997,0.30583945],"study_design_scores_gemma":[0.00050456444,0.000020837377,3.2475114e-7,0.50785875,0.013876971,0.000005732391,4.2270318e-7,0.00024414732,2.5718478e-7,0.0000023212306,0.47721177,0.00027390476],"about_ca_topic_score_codex":0.00061217695,"about_ca_topic_score_gemma":0.00040392883,"teacher_disagreement_score":0.30556554,"about_ca_system_score_codex":0.013697554,"about_ca_system_score_gemma":0.009218895,"threshold_uncertainty_score":0.999653},"labels":[],"label_agreement":null},{"id":"W4409210105","doi":"10.1016/j.lungcan.2025.108530","title":"Frequency of targetable genetic alterations in resectable lung adenocarcinoma: Results from the LORD project","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"RNA modifications and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval; Institut universitaire de cardiologie et de pneumologie de Québec","funders":"Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval; Fonds de Recherche du Québec - Santé; Québec Consortium for Drug Discovery; Fondation Institut Universitaire de Cardiologie et de Pneumologie de Québec","keywords":"Medicine; Adenocarcinoma; Oncology; Lung; Internal medicine; Adenocarcinoma of the lung; General surgery; Cancer","score_opus":0.011483084744082344,"score_gpt":0.29671027015768725,"score_spread":0.2852271854136049,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409210105","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93155056,0.05980006,0.001525653,0.00096804625,0.00031847955,0.000549044,0.000414838,0.00000759057,0.0048657],"genre_scores_gemma":[0.99379486,0.0012443515,0.0007004754,0.00021998753,0.00016822216,0.00029515233,0.00014845909,0.000010707573,0.0034177843],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9990614,0.000065679465,0.00028734174,0.0003159498,0.000087372726,0.00018222164],"domain_scores_gemma":[0.999267,0.000026088002,0.00008180325,0.0005138488,0.0000944717,0.000016808677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011611935,0.000099837605,0.00011699278,0.000044761633,0.00008632644,0.000022880977,0.00024374171,0.000082928644,0.000038353886],"category_scores_gemma":[0.000059215334,0.00007892193,0.00004824057,0.0002974022,0.00005018157,0.000005965268,0.000057080673,0.00009398178,7.711339e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002927679,0.00013135912,0.393,0.00008757352,0.0002569641,0.0000026817227,0.0008575608,0.0046639,0.47707328,0.00091409223,0.1211547,0.0015651024],"study_design_scores_gemma":[0.0042359163,0.00010423787,0.6754778,0.00044091523,0.00024379113,0.0000017553356,0.00057566015,0.0094911605,0.26369685,0.0009800778,0.04414754,0.0006043039],"about_ca_topic_score_codex":0.011248334,"about_ca_topic_score_gemma":0.006009289,"teacher_disagreement_score":0.28247777,"about_ca_system_score_codex":0.00006212322,"about_ca_system_score_gemma":0.0004657978,"threshold_uncertainty_score":0.9953359},"labels":[],"label_agreement":null},{"id":"W4409251436","doi":"10.1016/j.lungcan.2025.108535","title":"Tumour dimension is a prognostic factor in thymic epithelial tumours: An update analysis from the ESTS thymic database: Tumour dimension in thymic tumours","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Dimension (graph theory); Thymic carcinoma; Pathology; Thymoma; Thymus Neoplasm; Oncology","score_opus":0.01155893071936104,"score_gpt":0.3063515068251497,"score_spread":0.2947925761057887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409251436","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98516536,0.0059733,0.000099012774,0.005511586,0.0006244366,0.0015293066,0.00088123465,0.000115115516,0.00010066452],"genre_scores_gemma":[0.9945955,0.00069347897,0.00024855667,0.002793778,0.00030793683,0.00021845089,0.0007228384,0.0000837571,0.00033565197],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99553454,0.00043066245,0.0009714616,0.0013435269,0.00076669635,0.0009531067],"domain_scores_gemma":[0.9976858,0.00033583093,0.00031837786,0.0012272834,0.00015712126,0.00027559407],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00059426867,0.00066682394,0.0012125098,0.0008618522,0.00020268194,0.00011402915,0.0005764867,0.00022499586,0.00086449325],"category_scores_gemma":[0.0001838152,0.00047557428,0.0003361146,0.0024807085,0.0001392163,0.00035197134,0.00029604742,0.0009907376,0.00007626276],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00076818274,0.00043593673,0.9212593,0.0001001538,0.00038620553,0.00030733252,0.0017137179,0.00020250637,0.07127604,0.00016701913,0.002070339,0.0013132826],"study_design_scores_gemma":[0.003495597,0.00014314978,0.96014893,0.0019832992,0.0018555368,0.000013413671,0.00039086604,0.019795448,0.010924936,0.00026088374,0.00044792,0.00054001936],"about_ca_topic_score_codex":0.014283886,"about_ca_topic_score_gemma":0.014047073,"teacher_disagreement_score":0.060351104,"about_ca_system_score_codex":0.00060802477,"about_ca_system_score_gemma":0.0006219555,"threshold_uncertainty_score":0.99976957},"labels":[],"label_agreement":null},{"id":"W4409595460","doi":"10.1016/j.lungcan.2025.108551","title":"Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival analysis","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Takeda Pharmaceutical Company; Takeda Pharmaceuticals U.S.A.; AstraZeneca; LUNGevity Foundation","keywords":"Medicine; Afatinib; Osimertinib; Oncology; Lung cancer; Internal medicine; Cancer; Erlotinib; Epidermal growth factor receptor","score_opus":0.021994936969514413,"score_gpt":0.38232338040072067,"score_spread":0.36032844343120624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409595460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97545165,0.010216524,0.004194464,0.0016683458,0.00088752835,0.0022944012,0.00025542095,0.0001001901,0.004931472],"genre_scores_gemma":[0.9878675,0.0036553657,0.0014406447,0.0005389342,0.000079699115,0.0009371788,0.00017074248,0.000038013364,0.0052719507],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976521,0.0001241807,0.00080814125,0.0006040891,0.00033971644,0.0004717536],"domain_scores_gemma":[0.99860066,0.00014756378,0.00028189676,0.0004783938,0.00033349867,0.00015800071],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022676801,0.000358125,0.0010093268,0.00077306875,0.00011830413,0.000025853731,0.00017355595,0.00010353411,0.0005491671],"category_scores_gemma":[0.000031014893,0.00029524317,0.00033075467,0.0030952862,0.00012989934,0.00010679854,0.000042358057,0.00028240157,0.000002994864],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013411188,0.0012689362,0.9741476,0.00054050575,0.006350388,0.00004537794,0.0019974858,0.0073646866,0.0023871155,0.00027688438,0.0011634298,0.003116464],"study_design_scores_gemma":[0.016228411,0.00012091406,0.9255587,0.00085089775,0.008285303,6.641388e-7,0.00023482284,0.037850477,0.008631467,0.000016819913,0.0018386033,0.0003829436],"about_ca_topic_score_codex":0.03468835,"about_ca_topic_score_gemma":0.048068352,"teacher_disagreement_score":0.04858893,"about_ca_system_score_codex":0.0010476633,"about_ca_system_score_gemma":0.001640715,"threshold_uncertainty_score":0.99995},"labels":[],"label_agreement":null},{"id":"W4410255805","doi":"10.1016/j.lungcan.2025.108579","title":"Intracranial and systemic progression on amivantamab in platinum-treated epidermal growth factor receptor exon 20 insertion-mutated advanced non-small cell lung cancer","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Epidermal growth factor receptor; Exon; Lung cancer; Cancer research; Oncology; Epidermal growth factor; Receptor; Mutation; Internal medicine; Gene; Genetics; Biology","score_opus":0.006628700707250518,"score_gpt":0.31542100738779666,"score_spread":0.30879230668054614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410255805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874089,0.00648165,0.00010267242,0.0010069428,0.0008112155,0.0025323085,0.00021857991,0.00013013244,0.0013076151],"genre_scores_gemma":[0.99413127,0.0015118775,0.0003231056,0.00037554774,0.00016177475,0.0012379872,0.00016808348,0.000054526598,0.0020358237],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980571,0.00007387275,0.00051605026,0.0006393761,0.00024405764,0.00046951335],"domain_scores_gemma":[0.9990871,0.000111734684,0.00020303708,0.00024560423,0.0001853852,0.00016715951],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0000662616,0.00038375746,0.0005623733,0.00030492878,0.00015874425,0.000039988994,0.0000928151,0.00020898956,0.00018980158],"category_scores_gemma":[0.000033851065,0.00031073892,0.00007758379,0.0005682771,0.00005164682,0.00017379051,0.00004150543,0.0003477458,0.000005359302],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001880495,0.00038803185,0.9155286,0.001902998,0.00039997132,0.00008911682,0.0016595728,0.00043231246,0.055321217,0.000028063527,0.0014287336,0.02094088],"study_design_scores_gemma":[0.030804802,0.00075680885,0.8564128,0.020050233,0.0016848805,0.00002953485,0.0006150527,0.01974231,0.06805807,0.00002336712,0.0007909039,0.0010312079],"about_ca_topic_score_codex":0.0024463376,"about_ca_topic_score_gemma":0.0013263648,"teacher_disagreement_score":0.059115782,"about_ca_system_score_codex":0.0015410201,"about_ca_system_score_gemma":0.0006142019,"threshold_uncertainty_score":0.9999345},"labels":[],"label_agreement":null},{"id":"W4410349213","doi":"10.1016/j.lungcan.2025.108583","title":"Real-world survival outcomes, treatment patterns, and impact of PD-L1 expression among patients with unresectable, stage III NSCLC treated with CRT → durvalumab in Canada: The RELEVANCE study","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Public Health Ontario; AstraZeneca (Canada); Institut universitaire de cardiologie et de pneumologie de Québec; Dalhousie University; Université Laval; Queen Elizabeth II Health Sciences Centre; Université de Montréal; University of Calgary; Centre Hospitalier de l’Université de Montréal; BC Cancer Agency; Ottawa Hospital","funders":"AstraZeneca","keywords":"Durvalumab; Medicine; Stage (stratigraphy); Oncology; Internal medicine; Overall survival; Relevance (law); Cancer; Immunotherapy; Nivolumab","score_opus":0.008585620769715262,"score_gpt":0.2952468966671313,"score_spread":0.286661275897416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410349213","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968266,0.00050269376,0.0000040820505,0.00009867973,0.00008843139,0.0017782126,0.00015589077,0.000014717273,0.0005307294],"genre_scores_gemma":[0.99533397,0.0004524716,0.000005130778,0.000051055198,0.000012298692,0.00021696437,0.000028771778,0.000025209889,0.0038741338],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99850595,0.00011218452,0.00032808766,0.0003447804,0.00041077536,0.00029821417],"domain_scores_gemma":[0.9990933,0.00012928099,0.00017752856,0.0004390495,0.00009426596,0.00006658649],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012458916,0.00027620053,0.0005637563,0.000121036,0.00008299531,0.00001611952,0.00009999404,0.00003362347,0.00009761658],"category_scores_gemma":[0.0000073694255,0.00013174959,0.000050430917,0.0004978275,0.00007188913,0.00007745242,0.000029514948,0.00013324474,3.2694167e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012812487,0.0003486591,0.98230517,0.0000757433,0.0008575045,0.00002860864,0.00042527923,0.00009941343,0.00009484534,6.62494e-7,0.00020545664,0.0027461788],"study_design_scores_gemma":[0.017688114,0.0009878989,0.9788708,0.00089570944,0.00021215517,2.4843314e-7,0.0005631728,0.00006779981,0.00050012954,1.494282e-7,0.00007006136,0.00014377311],"about_ca_topic_score_codex":0.988673,"about_ca_topic_score_gemma":0.9918272,"teacher_disagreement_score":0.004875628,"about_ca_system_score_codex":0.0028573396,"about_ca_system_score_gemma":0.0014605793,"threshold_uncertainty_score":0.74718434},"labels":[],"label_agreement":null},{"id":"W4410764962","doi":"10.1016/j.lungcan.2025.108596","title":"Clinicopathologic characteristics, co-mutation landscape, and survival outcomes of KRAS-G12D mutant lung adenocarcinoma in comparison to KRAS-G12C and EGFR-mutated subtypes","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Université Laval; Institut universitaire de cardiologie et de pneumologie de Québec","funders":"Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval; Fondation Institut Universitaire de Cardiologie et de Pneumologie de Québec","keywords":"KRAS; Medicine; Mutant; Adenocarcinoma; Mutation; Cancer research; Lung cancer; Oncology; Internal medicine; Cancer; Genetics; Gene; Biology; Colorectal cancer","score_opus":0.01598881384185044,"score_gpt":0.38761122630906397,"score_spread":0.3716224124672135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410764962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99099165,0.0051001376,0.00016328155,0.0013692483,0.00042646079,0.00081796333,0.00015755896,0.000041882482,0.00093182514],"genre_scores_gemma":[0.9981805,0.00041061745,0.0001994822,0.00044997095,0.000043497243,0.00011546967,0.00012398208,0.000018877961,0.00045756475],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985943,0.00006660252,0.0005374304,0.0003856913,0.00017091038,0.00024510437],"domain_scores_gemma":[0.99922204,0.00018265906,0.0001623021,0.0001955611,0.0001273054,0.000110107845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018908652,0.00021338984,0.0007298754,0.00025931303,0.00006738735,0.000027394039,0.000058233105,0.00010878831,0.000062040395],"category_scores_gemma":[0.000110307876,0.00017361724,0.00004757827,0.00031246117,0.000076906144,0.00007278121,0.00004345627,0.00015686445,0.0000021394133],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031118563,0.00013913577,0.99324167,0.00032886778,0.00024625132,0.000053135354,0.0014594396,0.000024922374,0.00072265783,0.00017510688,0.00037324513,0.0029243957],"study_design_scores_gemma":[0.0030919816,0.00017865398,0.99217105,0.00032045977,0.0006560639,0.000007653091,0.0005492815,0.0019361671,0.00073466665,0.0000321565,0.0001720619,0.00014978115],"about_ca_topic_score_codex":0.0005495171,"about_ca_topic_score_gemma":0.00049299095,"teacher_disagreement_score":0.007188896,"about_ca_system_score_codex":0.00019012454,"about_ca_system_score_gemma":0.0002132897,"threshold_uncertainty_score":0.7079906},"labels":[],"label_agreement":null},{"id":"W4411176534","doi":"10.1016/j.lungcan.2025.108621","title":"Efficacy of immune checkpoint inhibitors (ICIs) in PD-L1 negative Non-Small Cell Lung Cancer (NSCLC) – A meta-analysis based on reconstructed individual participant data","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada)","funders":"","keywords":"Medicine; Lung cancer; Oncology; Meta-analysis; non-small cell lung cancer (NSCLC); Internal medicine; Cancer; PD-L1; Immune system; Immunotherapy; Immunology; A549 cell","score_opus":0.07116806147672569,"score_gpt":0.35294685240541346,"score_spread":0.28177879092868774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411176534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9433658,0.044534378,0.00022351673,0.0041650645,0.0008670542,0.0031536557,0.0015611278,0.00007528323,0.0020541358],"genre_scores_gemma":[0.9959565,0.0006073572,0.00040285135,0.0012716679,0.00008754662,0.00069927156,0.0002607019,0.000039022038,0.0006750846],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9964291,0.00020722108,0.0014380526,0.0008801746,0.00050234457,0.00054314634],"domain_scores_gemma":[0.99727476,0.00040238784,0.0006122798,0.0014184907,0.00017464264,0.000117452895],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009936995,0.0004343378,0.001776044,0.0008358632,0.00008099677,0.000037250535,0.0005206285,0.00020576105,0.0019525422],"category_scores_gemma":[0.0001236071,0.00034618564,0.0010610034,0.0027950844,0.00021151928,0.00011536689,0.00017593158,0.00047028178,0.0000013634233],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043551374,0.0045048483,0.20639364,0.003765005,0.6139685,0.00013385457,0.009205577,0.01724226,0.051672965,0.00003457699,0.015939463,0.033587925],"study_design_scores_gemma":[0.02219162,0.00034651216,0.3397929,0.0014652231,0.41507396,0.0000014182332,0.00069724076,0.054859985,0.16313939,0.000010167801,0.0014862159,0.0009353694],"about_ca_topic_score_codex":0.016199451,"about_ca_topic_score_gemma":0.005448587,"teacher_disagreement_score":0.19889456,"about_ca_system_score_codex":0.0004081255,"about_ca_system_score_gemma":0.0012135776,"threshold_uncertainty_score":0.999899},"labels":[],"label_agreement":null},{"id":"W4411682439","doi":"10.1016/j.lungcan.2025.108644","title":"Acquired SMARCA4 alterations: An uncommon contributor to cancer progression in lung adenocarcinomas","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Chromatin Remodeling and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Fonds de recherche du Québec","keywords":"Medicine; Lung cancer; SMARCA4; Oncology; Adenocarcinoma; Lung; Internal medicine; Cancer; Pathology; Epigenetics","score_opus":0.008851246903555158,"score_gpt":0.3533905978112096,"score_spread":0.3445393509076544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411682439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96956336,0.025205465,0.0016934233,0.0015608629,0.00070100167,0.0006110816,0.000078589546,0.000032405755,0.00055379537],"genre_scores_gemma":[0.9948967,0.00051860925,0.0003619554,0.0014423938,0.0003759205,0.00079436565,0.00011571674,0.000022167173,0.0014721402],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987797,0.000067550136,0.00026190953,0.00045101167,0.00013170866,0.00030810444],"domain_scores_gemma":[0.99935853,0.000009072104,0.00005806613,0.0003630508,0.00011670378,0.00009459887],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013537964,0.00017267188,0.00018995955,0.00008036762,0.000099162244,0.000049045026,0.00020441158,0.00014424186,0.00006989725],"category_scores_gemma":[0.00003124529,0.00016300414,0.000054269734,0.00023897643,0.000027564718,0.0000096037065,0.00009645908,0.00007659856,0.0000013162282],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008260578,0.00022362969,0.28185746,0.0003743742,0.0001982865,0.000009112788,0.0006759471,0.01756612,0.59253085,0.0002877374,0.046294436,0.05915598],"study_design_scores_gemma":[0.0078439675,0.0005832136,0.114151165,0.0034479965,0.00030037365,0.000005960475,0.00035130337,0.12545152,0.6210677,0.00026090568,0.124711715,0.001824184],"about_ca_topic_score_codex":0.0009409579,"about_ca_topic_score_gemma":0.003984272,"teacher_disagreement_score":0.16770628,"about_ca_system_score_codex":0.0002537089,"about_ca_system_score_gemma":0.0003879264,"threshold_uncertainty_score":0.6647116},"labels":[],"label_agreement":null},{"id":"W4412434154","doi":"10.1016/j.lungcan.2025.108662","title":"Managing lorlatinib together: An overview and practical guide for patients by ALK-positive NSCLC patients and medical experts","year":2025,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Canadian Patient Safety Institute; Princess Margaret Cancer Centre","funders":"Pfizer","keywords":"Medicine; Internal medicine; Oncology; Intensive care medicine","score_opus":0.029684763254258697,"score_gpt":0.4571309382903152,"score_spread":0.42744617503605653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412434154","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004568209,0.99227494,0.00009895675,0.0006953597,0.00043492267,0.0029954868,0.0007552777,0.000034650493,0.00266471],"genre_scores_gemma":[0.000024827556,0.99249154,0.0005476961,0.0015766345,0.00016842052,0.001477535,0.0017271262,0.000064652224,0.0019215451],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979582,0.00010514814,0.00052591664,0.0006642041,0.0004216007,0.00032492162],"domain_scores_gemma":[0.9985701,0.00040555163,0.00023676586,0.00024948054,0.00018896557,0.0003491417],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00011858398,0.00040676945,0.0011000953,0.00010329461,0.000135974,0.000050641607,0.000066734916,0.00029353958,0.00016764211],"category_scores_gemma":[0.00023274454,0.00030754448,0.00015663107,0.00013903744,0.00008022988,0.00016268299,0.000096467855,0.00020032484,9.4075915e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000048635884,0.00031217176,0.001182112,0.013455893,0.0008494007,0.000010731451,0.0002769981,2.0432207e-8,2.7305369e-8,0.00009704554,0.050972607,0.93279433],"study_design_scores_gemma":[0.0028407539,0.00034581302,0.00021110973,0.030938625,0.0053354893,0.000008871776,0.00002995219,0.000042224838,4.88017e-7,0.00002113172,0.9599227,0.0003028479],"about_ca_topic_score_codex":0.00022496167,"about_ca_topic_score_gemma":0.00006086049,"teacher_disagreement_score":0.9324915,"about_ca_system_score_codex":0.00042223014,"about_ca_system_score_gemma":0.0007843774,"threshold_uncertainty_score":0.99993765},"labels":[],"label_agreement":null},{"id":"W4412653243","doi":"10.1016/j.lungcan.2025.108672","title":"Adjuvant therapy in pStage IA1–IIA lung adenocarcinoma (pN0): A multicenter study focusing on EGFR mutations and recurrence patterns (CReGYT-01 EGFR study)","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Aging","funders":"Society of Thoracic Surgeons","keywords":"Medicine; Oncology; Adenocarcinoma; Internal medicine; Adjuvant; Lung; Multicenter study; Cancer; Randomized controlled trial","score_opus":0.018883263490755635,"score_gpt":0.3849086370658569,"score_spread":0.36602537357510123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412653243","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872111,0.0056790086,0.00016848378,0.0013014231,0.0005681218,0.0041430737,0.00007896609,0.000064954846,0.00078486686],"genre_scores_gemma":[0.9963694,0.0004102552,0.00007550837,0.00071464473,0.000109342276,0.0011328282,0.000029781431,0.000037217305,0.0011209884],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99808997,0.0001321955,0.00042409112,0.0006593075,0.0003121547,0.000382283],"domain_scores_gemma":[0.99909955,0.00012566069,0.00011307301,0.00043277952,0.000109992376,0.0001189449],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015008799,0.0003136531,0.00044824253,0.0003474446,0.000216712,0.00007498389,0.000115312614,0.00006716444,0.00015672337],"category_scores_gemma":[0.000032127624,0.00025654677,0.0000705136,0.00046264246,0.00004954375,0.00015741424,0.0000626442,0.0003014008,0.0000034501154],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042565973,0.002066486,0.9620071,0.00011649362,0.00061409286,0.00016247202,0.015227911,0.00006733338,0.00007743072,0.000031071504,0.00031271414,0.018891258],"study_design_scores_gemma":[0.012400305,0.00084375,0.97639203,0.0009044941,0.0007031412,0.0000023744033,0.0069299424,0.0012056358,0.00011935371,0.000014594081,0.00026248998,0.00022187515],"about_ca_topic_score_codex":0.004473607,"about_ca_topic_score_gemma":0.005314496,"teacher_disagreement_score":0.018669384,"about_ca_system_score_codex":0.0008542875,"about_ca_system_score_gemma":0.00028967008,"threshold_uncertainty_score":0.9999887},"labels":[],"label_agreement":null},{"id":"W4413050186","doi":"10.1016/j.lungcan.2025.108683","title":"Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trial","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Amgen","keywords":"Docetaxel; Medicine; Internal medicine; Oncology; Lung cancer; Hazard ratio; KRAS; Chemotherapy; Adverse effect; Cancer; Population; Confidence interval","score_opus":0.006267195991771177,"score_gpt":0.3542312934856155,"score_spread":0.3479640974938443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413050186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96724975,0.009852195,0.000986988,0.0008555818,0.001914177,0.014784785,0.0007743996,0.00009946793,0.0034826614],"genre_scores_gemma":[0.988706,0.0013513432,0.00040274186,0.0002645946,0.00026111925,0.0070017725,0.00012805783,0.000040093302,0.0018442764],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9970307,0.0002826393,0.0010664605,0.00071250316,0.00037862276,0.00052909076],"domain_scores_gemma":[0.99788946,0.0005190673,0.0006113665,0.00045392077,0.00034101182,0.00018517526],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029946544,0.00052614044,0.0030211,0.00023930229,0.000099027224,0.00004025102,0.00017913793,0.0002670662,0.000666043],"category_scores_gemma":[0.00021329953,0.00040270793,0.00058785133,0.00087690627,0.00014663067,0.00018176917,0.000048981463,0.00032840183,0.0000018911592],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9617789,0.002308038,0.016360091,0.00036605264,0.0040923283,0.00006560143,0.00069949747,0.0006461077,0.00830628,0.00002110174,0.00075491256,0.0046011163],"study_design_scores_gemma":[0.9567437,0.00032852514,0.0033504532,0.0011804583,0.007927964,9.2623446e-7,0.00005493306,0.022388745,0.007568545,0.000050763145,0.00010176238,0.00030322297],"about_ca_topic_score_codex":0.019331817,"about_ca_topic_score_gemma":0.0040467368,"teacher_disagreement_score":0.021742638,"about_ca_system_score_codex":0.0017435695,"about_ca_system_score_gemma":0.002512169,"threshold_uncertainty_score":0.99984246},"labels":[],"label_agreement":null},{"id":"W4413365072","doi":"10.1016/j.lungcan.2025.108717","title":"Canadian Perspectives Revisited: Consensus on the management of ALK-rearranged NSCLC","year":2025,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University; Mount Sinai Hospital; Public Health Ontario; Jewish General Hospital; Centre Hospitalier de l’Université de Montréal; Dalhousie University; Juravinski Cancer Centre; William Osler Health System; University of Alberta; Princess Margaret Cancer Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Oncology; Intensive care medicine","score_opus":0.023430912474930395,"score_gpt":0.39245221475810704,"score_spread":0.36902130228317664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413365072","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000002367231,0.8271001,0.0000011415124,0.0025633997,0.00022531294,0.0022039025,0.00044866864,0.0000197133,0.1674354],"genre_scores_gemma":[0.00012811787,0.97234005,0.00007397777,0.00034184277,0.00012462225,0.00071208004,0.0000922506,0.000033894456,0.026153138],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987692,0.00007391269,0.00031252275,0.00036832105,0.00021720822,0.00025878206],"domain_scores_gemma":[0.99887466,0.00014159856,0.00016558729,0.0005692893,0.000121130615,0.0001277047],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009794714,0.00029607804,0.0009236956,0.00024314407,0.00012025484,0.000015850552,0.0001436387,0.00012377911,0.00065098895],"category_scores_gemma":[0.000017706823,0.00017582855,0.00036026843,0.00048082133,0.0000619316,0.000008672018,0.000023793456,0.00024689143,0.000017072463],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002707828,0.0000727904,0.000030043691,0.041762177,0.008491536,0.00012530344,0.00056405715,0.0000014788914,7.1699e-8,0.012723124,0.07013288,0.86606944],"study_design_scores_gemma":[0.00039128162,0.00003417,0.00004807767,0.07258315,0.010712874,0.000005869561,0.00038362388,0.0000015444908,3.6552035e-7,0.000010740172,0.91569275,0.0001355412],"about_ca_topic_score_codex":0.028370904,"about_ca_topic_score_gemma":0.0074837045,"teacher_disagreement_score":0.8659339,"about_ca_system_score_codex":0.0020107594,"about_ca_system_score_gemma":0.0019648548,"threshold_uncertainty_score":0.9780993},"labels":[],"label_agreement":null},{"id":"W4414062917","doi":"10.1016/j.lungcan.2025.108748","title":"Mutation testing, treatment patterns, and outcomes in patients with unresectable stage III EGFR-mutated non-small cell lung cancer treated with chemoradiotherapy: Final analysis of a global real–world study","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Lung cancer; Stage (stratigraphy); Mutation; Cancer; Lung","score_opus":0.010605903276625087,"score_gpt":0.32990914063305166,"score_spread":0.3193032373564266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414062917","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952923,0.00051078515,0.000106540785,0.00009454697,0.00004015697,0.0025492953,0.0004892411,0.00004346729,0.0008736482],"genre_scores_gemma":[0.9944931,0.00009499975,0.00022274432,0.00009238436,0.000012027108,0.00084642257,0.00020100911,0.000028009876,0.0040092818],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99840915,0.0000464178,0.00039003737,0.00053468015,0.00029582452,0.00032388416],"domain_scores_gemma":[0.99901354,0.00006471721,0.00025322454,0.0003056463,0.00026364703,0.00009921104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000054988006,0.00035095564,0.00090175756,0.00038820013,0.000087772,0.00003554847,0.00006902531,0.00005176337,0.000095596304],"category_scores_gemma":[0.000004297473,0.00023180792,0.00006541789,0.0023137948,0.000043666627,0.0000935011,0.000017867158,0.00008447353,9.8984586e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016543977,0.0018340184,0.98049617,0.0002350039,0.007819653,0.000058027606,0.0014719095,0.0044335034,0.000019280676,0.000002621906,0.000025258716,0.0019501424],"study_design_scores_gemma":[0.025207996,0.0012791307,0.95605874,0.0004063235,0.011023182,2.5888687e-7,0.00039718507,0.0051806527,0.00023774986,4.1052814e-7,0.000008207172,0.00020019071],"about_ca_topic_score_codex":0.17742558,"about_ca_topic_score_gemma":0.18124385,"teacher_disagreement_score":0.024437472,"about_ca_system_score_codex":0.0024230226,"about_ca_system_score_gemma":0.0006699832,"threshold_uncertainty_score":0.94528526},"labels":[],"label_agreement":null},{"id":"W4414598684","doi":"10.1016/j.lungcan.2025.108765","title":"Letter to the editor: What is the target nodule for robotic-assisted bronchoscopy?","year":2025,"lang":"en","type":"letter","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Intuitive; Olympus","keywords":"Nodule (geology); Solitary pulmonary nodule; MEDLINE; Computed tomography","score_opus":0.01246357973591114,"score_gpt":0.3112382687688385,"score_spread":0.29877468903292737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414598684","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000008529843,0.017773518,0.00047261102,0.9455372,0.031553615,0.003699858,0.00027350758,0.000063954525,0.0006172041],"genre_scores_gemma":[0.000067335444,0.0015987045,0.00045143004,0.83995265,0.11034785,0.005952503,0.0003022913,0.0000931015,0.041234136],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974319,0.000072328,0.00038048107,0.0008024508,0.0006296148,0.00068326725],"domain_scores_gemma":[0.9976813,0.0004709764,0.00016970595,0.0013449368,0.00023971667,0.00009335169],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016421366,0.00052573124,0.0006996978,0.000093107476,0.00030512584,0.0002911196,0.0004918342,0.00053110434,0.0007485869],"category_scores_gemma":[0.00003124584,0.00027043707,0.0005057629,0.00026275657,0.000077082834,0.0001087212,0.000120025055,0.0010820987,0.0000669461],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007418754,0.000049326714,0.00041267765,0.00077668414,0.00125464,0.00002528629,0.00042859043,0.00007313855,0.0000032446999,0.000004952324,0.9944771,0.0024201602],"study_design_scores_gemma":[0.0010456827,0.00012650472,0.00046505127,0.0024119413,0.0020599642,0.0000033790695,0.000026437014,0.00016962197,0.00028605835,0.000015745674,0.99309665,0.00029296623],"about_ca_topic_score_codex":0.0005213208,"about_ca_topic_score_gemma":0.00016160881,"teacher_disagreement_score":0.105584554,"about_ca_system_score_codex":0.0014714552,"about_ca_system_score_gemma":0.0004952492,"threshold_uncertainty_score":0.9999748},"labels":[],"label_agreement":null},{"id":"W4415817108","doi":"10.1016/j.lungcan.2025.108812","title":"Systematic review and network meta-analysis: evaluation of systemic therapies for platinum refractory or resistant small cell lung cancer","year":2025,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Waterloo","funders":"","keywords":"Refractory (planetary science); Lung cancer; Platinum; Chemotherapy; Clinical trial","score_opus":0.15357206138554297,"score_gpt":0.4720203776983185,"score_spread":0.31844831631277554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415817108","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000014556248,0.97320765,0.000066808985,0.00019935405,0.00025376055,0.025126472,0.0008801341,0.000045737397,0.00021862364],"genre_scores_gemma":[0.00003678863,0.94524556,0.00013485012,0.0002187837,0.00025524964,0.045926753,0.00011407589,0.00008898758,0.007978963],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.993148,0.001584178,0.0023980357,0.0009753078,0.0012960386,0.00059840543],"domain_scores_gemma":[0.992786,0.001988283,0.0022992587,0.0012653178,0.0015170386,0.00014412755],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.005052025,0.00083147746,0.014210646,0.0004551036,0.00016883103,0.000041996933,0.00037572763,0.00030650062,0.0004232526],"category_scores_gemma":[0.0008802533,0.0004682196,0.002721283,0.0017254999,0.00009951355,0.000080197555,0.0001580532,0.0004595732,7.668896e-7],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006369257,0.00002155202,0.000010641561,0.7374313,0.25492832,0.0000023725029,0.00020332586,0.000028534929,4.7807913e-7,0.000010545157,0.005833631,0.0014656401],"study_design_scores_gemma":[0.0003825335,0.00005118619,0.0000014967266,0.4121821,0.57732207,0.000002446353,0.000055673394,0.00012958692,3.058864e-7,0.0000022213492,0.009635214,0.00023515588],"about_ca_topic_score_codex":0.00036921998,"about_ca_topic_score_gemma":0.0012614797,"teacher_disagreement_score":0.32524917,"about_ca_system_score_codex":0.0021620803,"about_ca_system_score_gemma":0.004086529,"threshold_uncertainty_score":0.99977696},"labels":[],"label_agreement":null},{"id":"W4416017497","doi":"10.1016/j.lungcan.2025.108834","title":"MAGELLAN arms B1 and B3: Durvalumab plus chemotherapy with and without oleclumab in treatment-naïve metastatic non-small-cell lung cancer","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Durvalumab; Chemotherapy; Lung cancer; Disease; Cancer","score_opus":0.009759950064900491,"score_gpt":0.3044476110311205,"score_spread":0.29468766096622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416017497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9511831,0.042738255,0.00015309348,0.0022924822,0.00019818661,0.0015052343,0.000038725128,0.000043514596,0.0018474414],"genre_scores_gemma":[0.9644739,0.020805202,0.00068932574,0.0018905582,0.00009973715,0.00059233594,0.000015398631,0.00006367453,0.011369836],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985496,0.000042947548,0.0002740668,0.00054430345,0.00017963296,0.00040948033],"domain_scores_gemma":[0.9993782,0.000036617144,0.000113085676,0.0003065473,0.000054467502,0.000111066365],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012255393,0.000365576,0.0006292503,0.00019434353,0.000087664346,0.000055461245,0.000077480414,0.000089637964,0.00022743864],"category_scores_gemma":[0.000002993572,0.0002667961,0.000067255154,0.00038582398,0.00015708643,0.000071794624,0.000023988485,0.00017291866,6.2140106e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0148504935,0.00040797633,0.84119064,0.0022517177,0.0029905648,0.000106293635,0.008132141,0.00009172468,0.019354638,0.000015743959,0.0021901075,0.108417965],"study_design_scores_gemma":[0.1735264,0.0025059823,0.71312046,0.0071639144,0.0045843883,0.00014182492,0.0030006198,0.0322195,0.043725837,0.000045580025,0.018044384,0.0019211338],"about_ca_topic_score_codex":0.010530213,"about_ca_topic_score_gemma":0.008200501,"teacher_disagreement_score":0.15867591,"about_ca_system_score_codex":0.000934607,"about_ca_system_score_gemma":0.0007475236,"threshold_uncertainty_score":0.9999784},"labels":[],"label_agreement":null},{"id":"W4416345611","doi":"10.1016/j.lungcan.2025.108840","title":"Treatment and outcomes of limited stage small cell lung cancer in the Canadian small cell lung cancer database (CASCADE)","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research; Western University; AstraZeneca (Canada); London Health Sciences Centre; Dalhousie University; University of Ottawa; McGill University; Princess Margaret Cancer Centre; University of Calgary; Jewish General Hospital; Occupational Cancer Research Centre; CancerCare Manitoba","funders":"Princess Margaret Cancer Foundation; AstraZeneca","keywords":"Immunotherapy; Small-cell carcinoma; Lung cancer; Overall survival; Stage (stratigraphy); Small Cell Lung Carcinoma","score_opus":0.028782662505763917,"score_gpt":0.3607694565274413,"score_spread":0.3319867940216774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416345611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8337967,0.13534658,0.000019008814,0.0138258375,0.0007193144,0.003871569,0.0023835811,0.000056298988,0.009981145],"genre_scores_gemma":[0.9295082,0.033111807,0.00013685024,0.0026610054,0.00023400539,0.0026926724,0.00007429101,0.000077477875,0.031503707],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99684435,0.00018479662,0.0005833313,0.00080563047,0.00047992187,0.0011019967],"domain_scores_gemma":[0.9979377,0.00035826306,0.00019160961,0.000880494,0.00025605,0.00037590324],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003704444,0.0005434937,0.00093726645,0.00056006864,0.00030465913,0.00007219169,0.00041336965,0.00018754674,0.00043010258],"category_scores_gemma":[0.00007440606,0.00037347645,0.0001693277,0.0008993579,0.00023812315,0.00011546132,0.00019246199,0.000597332,0.0000013918701],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026344712,0.00019714872,0.97331136,0.0031579353,0.0008826323,0.00015076014,0.004808792,0.00029520426,0.0013078711,0.00009354392,0.01342777,0.0021035431],"study_design_scores_gemma":[0.015435341,0.00034154803,0.87562054,0.0030333695,0.0037792553,0.000005573687,0.0026823487,0.012173404,0.015071206,0.000010296713,0.07074252,0.001104604],"about_ca_topic_score_codex":0.81089044,"about_ca_topic_score_gemma":0.93472254,"teacher_disagreement_score":0.123832084,"about_ca_system_score_codex":0.0048672827,"about_ca_system_score_gemma":0.0043879193,"threshold_uncertainty_score":0.99987173},"labels":[],"label_agreement":null},{"id":"W4416398904","doi":"10.1016/j.lungcan.2025.108844","title":"Tarlatamab population survival kinetics in extensive-stage small cell lung cancer: brief report","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Population; Lung; Survival analysis; Duration (music); Cell","score_opus":0.021190006092245132,"score_gpt":0.37352279612439293,"score_spread":0.3523327900321478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416398904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92928773,0.03916447,0.0004086234,0.0058382163,0.0024615729,0.0021501342,0.00013027666,0.00017487686,0.02038411],"genre_scores_gemma":[0.9501811,0.0037158944,0.00029865623,0.0009729493,0.00052005897,0.0005443812,0.00010859571,0.00005956508,0.043598767],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99739593,0.000075379285,0.0005949801,0.00070411275,0.000571287,0.00065828883],"domain_scores_gemma":[0.99848765,0.00011324239,0.0001819979,0.0006497374,0.0004210618,0.0001462836],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003340041,0.0002998217,0.00063894485,0.00030185518,0.00010654886,0.000040200546,0.00017598242,0.00015045976,0.0002812235],"category_scores_gemma":[0.0002562809,0.00028483276,0.00012021163,0.00079617195,0.0000886651,0.00010138574,0.00020931434,0.0005015148,0.0000023303699],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032585277,0.0001133326,0.97532517,0.0016433032,0.00021408798,0.0005972498,0.00032628287,0.0009593595,0.0022529725,0.00010653216,0.01570874,0.0024271184],"study_design_scores_gemma":[0.0032328097,0.00005942345,0.95647603,0.0011859167,0.00034155592,0.000009537582,0.0001544545,0.004485565,0.0021898702,0.000027374792,0.031511307,0.00032617175],"about_ca_topic_score_codex":0.033854555,"about_ca_topic_score_gemma":0.018028684,"teacher_disagreement_score":0.035448574,"about_ca_system_score_codex":0.0022073097,"about_ca_system_score_gemma":0.00070106704,"threshold_uncertainty_score":0.99996036},"labels":[],"label_agreement":null},{"id":"W4416507772","doi":"10.1016/j.lungcan.2025.108850","title":"Patient and oncologist preferences for ALK+ advanced non-small cell lung cancer tyrosine kinase inhibitor treatments: a discrete choice experiment in the United States","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Activation Laboratories","funders":"Pfizer","keywords":"Lung cancer; Tyrosine-kinase inhibitor; Tyrosine kinase; MEDLINE; Personalized medicine; Cancer","score_opus":0.01354000152627287,"score_gpt":0.35769011416939617,"score_spread":0.3441501126431233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416507772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9677285,0.02342905,0.00017873509,0.0029573508,0.0004417566,0.0037730176,0.00036046453,0.00003566626,0.0010954379],"genre_scores_gemma":[0.98158807,0.0032455462,0.0005947505,0.0019645295,0.00010466377,0.010061788,0.00035173204,0.00002530232,0.0020636362],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987094,0.000046752066,0.00031206667,0.00042800224,0.00015858466,0.00034521404],"domain_scores_gemma":[0.99921805,0.00019637785,0.00012555868,0.00025064143,0.00012386504,0.00008553201],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000058242487,0.0002707088,0.00033021648,0.00014742803,0.00017720343,0.00004998514,0.00008694493,0.00007341614,0.000040189665],"category_scores_gemma":[0.00002040853,0.0001686621,0.00006727936,0.0003899931,0.00007861583,0.00008930631,0.00004200625,0.000119845834,3.238359e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037379367,0.0039177956,0.80249673,0.00362066,0.0029260092,0.00008499719,0.05590619,0.006765471,0.010483074,0.00034438237,0.039665636,0.070051104],"study_design_scores_gemma":[0.088875584,0.0075841844,0.40939438,0.0113803875,0.012713664,0.000008069036,0.036985833,0.03391338,0.10454542,0.00034298646,0.2919716,0.002284515],"about_ca_topic_score_codex":0.009746783,"about_ca_topic_score_gemma":0.0036074936,"teacher_disagreement_score":0.39310235,"about_ca_system_score_codex":0.0009926945,"about_ca_system_score_gemma":0.00040433666,"threshold_uncertainty_score":0.9968474},"labels":[],"label_agreement":null},{"id":"W4416637135","doi":"10.1183/13993003.congress-2025.oa2354","title":"Late Breaking Abstract - Risk prediction for lung cancer screening: a systematic review","year":2025,"lang":"","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Institute of Cancer Research; University of British Columbia; Centre for Advancing Health Outcomes","funders":"","keywords":"Guideline; Lung cancer; Calibration; Predictive modelling; Selection (genetic algorithm); Biomarker; Data extraction; Risk assessment; Systematic review","score_opus":0.01470574262890578,"score_gpt":0.3546844643734007,"score_spread":0.3399787217444949,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416637135","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0036000274,0.9587709,0.0030459526,0.00778243,0.005331017,0.017353054,0.0023225234,0.00019596123,0.0015981568],"genre_scores_gemma":[0.28641725,0.6713975,0.00025228946,0.0044690804,0.0015871899,0.026314978,0.00014185536,0.000160132,0.009259692],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99467164,0.00018579818,0.0020080842,0.001315155,0.00074049056,0.00107883],"domain_scores_gemma":[0.99581313,0.0006486733,0.0014340462,0.0011489805,0.00061822037,0.00033696656],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011261635,0.00087075937,0.0024635782,0.0002756427,0.0006137202,0.00015676739,0.00034162524,0.00036072073,0.0011421893],"category_scores_gemma":[0.00036901646,0.0007223272,0.0009088435,0.0008630465,0.00009696375,0.0003058854,0.00010888998,0.00061323243,0.000008545625],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032651395,0.0003155303,0.09198559,0.7976434,0.010757261,0.000023572164,0.00040397362,0.0010315721,0.000017178209,0.00011553979,0.09197165,0.005408178],"study_design_scores_gemma":[0.0050720763,0.00016804514,0.021156171,0.8529848,0.07351993,0.0000068929635,0.00006142016,0.042471733,0.00019370213,0.000021293763,0.003797059,0.0005469121],"about_ca_topic_score_codex":0.0059368317,"about_ca_topic_score_gemma":0.000963977,"teacher_disagreement_score":0.28737336,"about_ca_system_score_codex":0.0044685774,"about_ca_system_score_gemma":0.0013608058,"threshold_uncertainty_score":0.9997709},"labels":[],"label_agreement":null},{"id":"W4416795272","doi":"10.1016/j.lungcan.2025.108858","title":"Real-world incidence, prevalence, and clinical impact of brain metastases in patients with ALK-positive metastatic non–small cell lung cancer treated with first-line ALK tyrosine kinase inhibitors","year":2025,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Pfizer","keywords":"Lung cancer; Brain metastasis; Anaplastic lymphoma kinase; Tyrosine kinase; Tyrosine-kinase inhibitor; ALK inhibitor; ROS1","score_opus":0.009281889041171434,"score_gpt":0.3533143530854521,"score_spread":0.3440324640442807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416795272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909982,0.0037866482,0.00007524427,0.00048666302,0.000100979814,0.0025589007,0.00093084347,0.00003330329,0.0010292177],"genre_scores_gemma":[0.993652,0.001654621,0.00074924197,0.0002467893,0.000054810364,0.00048133172,0.00021700324,0.000048974856,0.0028952197],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99781615,0.00012150017,0.00068720325,0.00062992127,0.000331679,0.0004135564],"domain_scores_gemma":[0.9982135,0.00039922463,0.00037225292,0.00035919066,0.0004495874,0.00020621603],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019259161,0.00042050116,0.00088618614,0.00044881538,0.00009708373,0.000027839282,0.00009675618,0.00007397971,0.00011154207],"category_scores_gemma":[0.000054400367,0.0002706899,0.00012690057,0.0013536885,0.00022573011,0.00020725919,0.00005453395,0.00025391785,4.6725293e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025710603,0.0010455097,0.98814905,0.001261717,0.0019952455,0.00006296432,0.0003641594,0.0008418554,0.000048959824,0.000011579145,0.002184727,0.0014631624],"study_design_scores_gemma":[0.014065578,0.0017541979,0.9707719,0.004846461,0.00592207,0.0000014790405,0.000036213438,0.0010325222,0.0012104898,0.0000037991038,0.00007881303,0.0002764701],"about_ca_topic_score_codex":0.029064799,"about_ca_topic_score_gemma":0.027046047,"teacher_disagreement_score":0.017377153,"about_ca_system_score_codex":0.0009423572,"about_ca_system_score_gemma":0.001523672,"threshold_uncertainty_score":0.99997455},"labels":[],"label_agreement":null},{"id":"W4417407062","doi":"10.1016/j.lungcan.2025.108875","title":"Corrigendum to “Treatment and outcomes of limited stage small cell lung cancer in the Canadian small cell lung cancer database (CASCADE)” [Lung Cancer 210 (2025) 108840]","year":2025,"lang":"en","type":"erratum","venue":"Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research; Western University; AstraZeneca (Canada); London Health Sciences Centre; Dalhousie University; University of Ottawa; McGill University; Princess Margaret Cancer Centre; University of Calgary; Jewish General Hospital; Occupational Cancer Research Centre; CancerCare Manitoba","funders":"","keywords":"Cancer; Lung cancer; Stage (stratigraphy); Cell; Small-cell carcinoma","score_opus":0.03818360186285828,"score_gpt":0.3594488226258624,"score_spread":0.3212652207630041,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417407062","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.050459046,0.77115524,0.000045959827,0.024492055,0.045647748,0.020970488,0.047166165,0.00027788477,0.03978542],"genre_scores_gemma":[0.01989698,0.20672485,0.00019370181,0.00742042,0.003242914,0.016283568,0.0013605581,0.0004911199,0.7443859],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9898021,0.0005128488,0.0017530603,0.0028080337,0.0017896838,0.003334266],"domain_scores_gemma":[0.9934653,0.0004631277,0.0008937765,0.002555329,0.0011023792,0.0015200698],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0008757085,0.0022048727,0.0034730416,0.0019264842,0.00078472466,0.00026663876,0.0016107088,0.0011641377,0.0025249575],"category_scores_gemma":[0.00022888208,0.0016803552,0.00061083946,0.0023511779,0.00044881608,0.00024065895,0.00086712296,0.0033919371,0.000006059233],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00043810086,0.00024416938,0.33752403,0.011775406,0.002612361,0.00042768902,0.005347894,0.0004079131,0.00019736767,0.000021617376,0.6394428,0.0015606359],"study_design_scores_gemma":[0.009308432,0.00045140038,0.11212971,0.015433428,0.00984486,0.0000079182655,0.0017761709,0.007834713,0.001628696,0.0000032805103,0.8386214,0.002960003],"about_ca_topic_score_codex":0.9196461,"about_ca_topic_score_gemma":0.9792813,"teacher_disagreement_score":0.70460045,"about_ca_system_score_codex":0.021151656,"about_ca_system_score_gemma":0.026096718,"threshold_uncertainty_score":0.99906915},"labels":[],"label_agreement":null}]}